{"9484b6c94fb966c2039455cf434cdc12cf0be9e9": [["79ARDS patients exhibit high serum levels of mucin-1/MUC1 (KL-6) (Nakashima et al., 80 2008).", [["serum", "ANATOMY", 29, 34], ["ARDS", "DISEASE", 2, 6], ["patients", "ORGANISM", 7, 15], ["serum", "ORGANISM_SUBSTANCE", 29, 34], ["mucin-1", "GENE_OR_GENE_PRODUCT", 45, 52], ["MUC1", "GENE_OR_GENE_PRODUCT", 53, 57], ["KL-6", "GENE_OR_GENE_PRODUCT", 59, 63], ["mucin", "PROTEIN", 45, 50], ["MUC1", "PROTEIN", 53, 57], ["KL", "PROTEIN", 59, 61], ["patients", "SPECIES", 7, 15], ["ARDS", "PROBLEM", 2, 6], ["high serum levels", "PROBLEM", 24, 41], ["mucin", "TEST", 45, 50], ["KL", "TEST", 59, 61]]], ["MUC1 is a transmembrane protein expressed on the apical membrane of most mucosal 81 epithelial cells and plays a critical role in lining the airway lumen (Kato et al., 2017) .", [["transmembrane", "ANATOMY", 10, 23], ["apical membrane", "ANATOMY", 49, 64], ["mucosal 81 epithelial cells", "ANATOMY", 73, 100], ["airway lumen", "ANATOMY", 141, 153], ["MUC1", "GENE_OR_GENE_PRODUCT", 0, 4], ["transmembrane", "CELLULAR_COMPONENT", 10, 23], ["apical membrane", "CELLULAR_COMPONENT", 49, 64], ["mucosal 81 epithelial cells", "CELL", 73, 100], ["airway lumen", "MULTI-TISSUE_STRUCTURE", 141, 153], ["MUC1", "PROTEIN", 0, 4], ["transmembrane protein", "PROTEIN", 10, 31], ["mucosal 81 epithelial cells", "CELL_TYPE", 73, 100], ["a transmembrane protein", "TEST", 8, 31], ["apical", "ANATOMY_MODIFIER", 49, 55], ["membrane", "ANATOMY_MODIFIER", 56, 64], ["epithelial cells", "OBSERVATION", 84, 100], ["airway", "ANATOMY", 141, 147], ["lumen", "ANATOMY_MODIFIER", 148, 153]]], ["Mucins are 82 glycoproteins that impart specific properties to mucus.", [["mucus", "ANATOMY", 63, 68], ["Mucins", "GENE_OR_GENE_PRODUCT", 0, 6], ["mucus", "TISSUE", 63, 68], ["82 glycoproteins", "PROTEIN", 11, 27], ["mucus", "OBSERVATION", 63, 68]]], ["In response to specific stimuli, goblet 83 cells can rapidly secrete mucus by exocytosis to form a mucus layer that lines the airways.", [["goblet 83 cells", "ANATOMY", 33, 48], ["mucus", "ANATOMY", 69, 74], ["mucus layer", "ANATOMY", 99, 110], ["airways", "ANATOMY", 126, 133], ["goblet 83 cells", "CELL", 33, 48], ["mucus", "ORGANISM_SUBSTANCE", 69, 74], ["airways", "MULTI-TISSUE_STRUCTURE", 126, 133], ["goblet 83 cells", "CELL_TYPE", 33, 48], ["specific stimuli", "TEST", 15, 31], ["a mucus layer that lines the airways", "PROBLEM", 97, 133], ["mucus layer", "OBSERVATION", 99, 110], ["airways", "ANATOMY", 126, 133]]], ["In 84 healthy individuals, mucus along the lumen serves as a major protective barrier against inhaled 85 pathogens, toxins, and other foreign particles.", [["mucus", "ANATOMY", 27, 32], ["lumen", "ANATOMY", 43, 48], ["mucus", "MULTI-TISSUE_STRUCTURE", 27, 32], ["lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 43, 48], ["a major protective barrier", "TREATMENT", 59, 85], ["toxins", "PROBLEM", 116, 122], ["other foreign particles", "PROBLEM", 128, 151], ["lumen", "ANATOMY", 43, 48], ["foreign particles", "OBSERVATION", 134, 151]]], ["However, excessive mucus in the airways has been 86 linked to increased frequency and duration of infections, decreased lung function, and increased 87 mortality from respiratory diseases (Vestbo, 2002) .", [["mucus", "ANATOMY", 19, 24], ["airways", "ANATOMY", 32, 39], ["lung", "ANATOMY", 120, 124], ["respiratory", "ANATOMY", 167, 178], ["infections", "DISEASE", 98, 108], ["respiratory diseases", "DISEASE", 167, 187], ["mucus", "ORGANISM_SUBSTANCE", 19, 24], ["airways", "MULTI-TISSUE_STRUCTURE", 32, 39], ["lung", "ORGAN", 120, 124], ["excessive mucus in the airways", "PROBLEM", 9, 39], ["infections", "PROBLEM", 98, 108], ["decreased lung function", "PROBLEM", 110, 133], ["respiratory diseases", "PROBLEM", 167, 187], ["excessive", "OBSERVATION_MODIFIER", 9, 18], ["mucus", "OBSERVATION", 19, 24], ["airways", "ANATOMY", 32, 39], ["increased", "OBSERVATION_MODIFIER", 62, 71], ["frequency", "OBSERVATION_MODIFIER", 72, 81], ["infections", "OBSERVATION", 98, 108], ["decreased", "OBSERVATION_MODIFIER", 110, 119], ["lung", "ANATOMY", 120, 124], ["function", "OBSERVATION_MODIFIER", 125, 133], ["increased", "OBSERVATION_MODIFIER", 139, 148], ["87 mortality", "OBSERVATION_MODIFIER", 149, 161], ["respiratory diseases", "OBSERVATION", 167, 187]]], ["Abnormalities in mucus production 88 contribute to severe pulmonary complications and death from respiratory failure in patients with 89 diseases such as cystic fibrosis, chronic obstructive pulmonary disease (COPD), and acute lung 90 injury due to viral pathogens, such as SARS-CoV2.", [["mucus", "ANATOMY", 17, 22], ["pulmonary", "ANATOMY", 58, 67], ["respiratory", "ANATOMY", 97, 108], ["cystic", "ANATOMY", 154, 160], ["pulmonary", "ANATOMY", 191, 200], ["lung", "ANATOMY", 227, 231], ["pulmonary complications", "DISEASE", 58, 81], ["death", "DISEASE", 86, 91], ["respiratory failure", "DISEASE", 97, 116], ["cystic fibrosis", "DISEASE", 154, 169], ["chronic obstructive pulmonary disease", "DISEASE", 171, 208], ["COPD", "DISEASE", 210, 214], ["acute lung 90 injury", "DISEASE", 221, 241], ["SARS-CoV2", "DISEASE", 274, 283], ["mucus", "ORGANISM_SUBSTANCE", 17, 22], ["pulmonary", "ORGAN", 58, 67], ["patients", "ORGANISM", 120, 128], ["pulmonary", "ORGAN", 191, 200], ["lung", "ORGAN", 227, 231], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 274, 283], ["patients", "SPECIES", 120, 128], ["Abnormalities in mucus production", "PROBLEM", 0, 33], ["severe pulmonary complications", "PROBLEM", 51, 81], ["death", "PROBLEM", 86, 91], ["respiratory failure", "PROBLEM", 97, 116], ["89 diseases", "PROBLEM", 134, 145], ["cystic fibrosis", "PROBLEM", 154, 169], ["chronic obstructive pulmonary disease", "PROBLEM", 171, 208], ["COPD)", "PROBLEM", 210, 215], ["acute lung 90 injury", "PROBLEM", 221, 241], ["viral pathogens", "PROBLEM", 249, 264], ["mucus production", "OBSERVATION", 17, 33], ["severe", "OBSERVATION_MODIFIER", 51, 57], ["pulmonary", "ANATOMY", 58, 67], ["complications", "OBSERVATION", 68, 81], ["respiratory failure", "OBSERVATION", 97, 116], ["cystic", "OBSERVATION_MODIFIER", 154, 160], ["fibrosis", "OBSERVATION", 161, 169], ["chronic", "OBSERVATION_MODIFIER", 171, 178], ["obstructive", "OBSERVATION_MODIFIER", 179, 190], ["pulmonary", "ANATOMY", 191, 200], ["disease", "OBSERVATION", 201, 208], ["COPD", "OBSERVATION", 210, 214], ["acute", "OBSERVATION_MODIFIER", 221, 226], ["lung", "ANATOMY", 227, 231], ["90 injury", "OBSERVATION", 232, 241], ["viral", "OBSERVATION_MODIFIER", 249, 254], ["pathogens", "OBSERVATION", 255, 264]]], ["In this context wildtype MUC1 (MUC1-wt) served as a control, as we sought compounds 104 that specifically reduced the mutant, but not the wildtype form of MUC1.", [["MUC1", "GENE_OR_GENE_PRODUCT", 25, 29], ["MUC1", "GENE_OR_GENE_PRODUCT", 31, 35], ["MUC1", "GENE_OR_GENE_PRODUCT", 155, 159], ["MUC1", "PROTEIN", 25, 29], ["MUC1", "PROTEIN", 31, 35], ["MUC1", "PROTEIN", 155, 159], ["MUC1", "TEST", 31, 35]]], ["As the number of 105 COVID-19 cases increased globally, we turned our attention to identifying MUC1-reducing 106 compounds and mined this dataset to identify approved drugs that reduce expression of MUC1-107 wt.", [["MUC1", "GENE_OR_GENE_PRODUCT", 95, 99], ["MUC1", "GENE_OR_GENE_PRODUCT", 199, 203], ["MUC1", "PROTEIN", 95, 99], ["MUC1", "PROTEIN", 199, 203], ["COVID", "TEST", 21, 26], ["MUC1", "TEST", 95, 99], ["drugs", "TREATMENT", 167, 172], ["MUC1", "TEST", 199, 203]]], ["We searched for MUC1-reducing compounds based on the following criteria: 1) a drug that 108 reduces MUC1-wt protein in a dose-dependent manner; 2) a drug with a favorable toxicity 109 profile; 3) a drug that reduces MUC1-wt by non-transcriptional mechanisms (Dvela-Levitt et al., approved.", [["toxicity", "DISEASE", 171, 179], ["MUC1", "GENE_OR_GENE_PRODUCT", 16, 20], ["MUC1", "GENE_OR_GENE_PRODUCT", 100, 104], ["MUC1", "GENE_OR_GENE_PRODUCT", 216, 220], ["MUC1", "PROTEIN", 16, 20], ["MUC1", "PROTEIN", 100, 104], ["MUC1", "PROTEIN", 216, 220], ["MUC1-reducing compounds", "TREATMENT", 16, 39], ["MUC1", "TEST", 100, 104], ["a favorable toxicity 109 profile", "PROBLEM", 159, 191], ["non-transcriptional mechanisms", "PROBLEM", 227, 257]]], ["Based on these criteria, our screen identified R406, the active metabolite of 11379Fostamatinib (R788, an oral prodrug rapidly converted to R406), as a repurposing candidate for 114 the treatment of ALI.", [["oral", "ANATOMY", 106, 110], ["11379Fostamatinib", "CHEMICAL", 78, 95], ["R788", "CHEMICAL", 97, 101], ["R406", "CHEMICAL", 140, 144], ["ALI", "DISEASE", 199, 202], ["Fostamatinib", "CHEMICAL", 83, 95], ["R788", "CHEMICAL", 97, 101], ["R406", "CHEMICAL", 140, 144], ["R406", "SIMPLE_CHEMICAL", 47, 51], ["Fostamatinib", "SIMPLE_CHEMICAL", 83, 95], ["R788", "SIMPLE_CHEMICAL", 97, 101], ["oral", "ORGANISM_SUBDIVISION", 106, 110], ["our screen", "TEST", 25, 35], ["an oral prodrug", "TREATMENT", 103, 118], ["ALI", "PROBLEM", 199, 202], ["ALI", "OBSERVATION", 199, 202]]], ["115 116 11779Results 118 11979The FDA approved SYK inhibitor R406 depletes MUC1 from epithelial cells without 120 affecting cell viability 121 12279To investigate the expression pattern of MUC1 in human tissue, we took advantage of the 123 openly available Human Protein Atlas (HPA)(www.proteinatlas.org) (Uhlen et al., 2015) .", [["epithelial cells", "ANATOMY", 85, 101], ["cell", "ANATOMY", 124, 128], ["tissue", "ANATOMY", 203, 209], ["SYK inhibitor", "CHEMICAL", 47, 60], ["R406", "CHEMICAL", 61, 65], ["SYK", "SIMPLE_CHEMICAL", 47, 50], ["R406", "SIMPLE_CHEMICAL", 61, 65], ["MUC1", "GENE_OR_GENE_PRODUCT", 75, 79], ["epithelial cells", "CELL", 85, 101], ["cell", "CELL", 124, 128], ["MUC1", "GENE_OR_GENE_PRODUCT", 189, 193], ["human", "ORGANISM", 197, 202], ["tissue", "TISSUE", 203, 209], ["Human", "ORGANISM", 257, 262], ["MUC1", "PROTEIN", 75, 79], ["epithelial cells", "CELL_TYPE", 85, 101], ["MUC1", "PROTEIN", 189, 193], ["human", "SPECIES", 197, 202], ["Human", "SPECIES", 257, 262], ["human", "SPECIES", 197, 202], ["The FDA", "TEST", 30, 37], ["SYK inhibitor", "TEST", 47, 60], ["MUC1 from epithelial cells", "TEST", 75, 101], ["cell viability", "TEST", 124, 138], ["MUC1 in human tissue", "PROBLEM", 189, 209], ["human tissue", "OBSERVATION_MODIFIER", 197, 209]]], ["CC-BY-NC-ND 4.0 International license (which was not certified by peer review) is the author/funder.", [["CC", "CHEMICAL", 0, 2]]], ["It is made available under a The copyright holder for this preprint this version posted June 30, 2020. . https://doi.org/10.1101/2020.06.30.180380 doi: bioRxiv preprint Immunoperoxidase staining of human lung showed MUC1 expression in alveolar epithelium.", [["lung", "ANATOMY", 204, 208], ["alveolar epithelium", "ANATOMY", 235, 254], ["Immunoperoxidase", "GENE_OR_GENE_PRODUCT", 169, 185], ["human", "ORGANISM", 198, 203], ["lung", "ORGAN", 204, 208], ["MUC1", "GENE_OR_GENE_PRODUCT", 216, 220], ["alveolar epithelium", "TISSUE", 235, 254], ["MUC1", "PROTEIN", 216, 220], ["human", "SPECIES", 198, 203], ["human", "SPECIES", 198, 203], ["MUC1 expression in alveolar epithelium", "PROBLEM", 216, 254], ["lung", "ANATOMY", 204, 208], ["MUC1 expression", "OBSERVATION", 216, 231], ["alveolar", "ANATOMY_MODIFIER", 235, 243], ["epithelium", "ANATOMY_MODIFIER", 244, 254]]], ["12579This finding confirmed multiple reports of MUC1 expression in normal and diseased human lung 126 ( Figure 1A ) (Ishizaka et al., 2004; Ohtsuki et al., 2007) .", [["lung", "ANATOMY", 93, 97], ["12579", "CHEMICAL", 0, 5], ["MUC1", "GENE_OR_GENE_PRODUCT", 48, 52], ["human", "ORGANISM", 87, 92], ["lung", "ORGAN", 93, 97], ["MUC1", "PROTEIN", 48, 52], ["human", "SPECIES", 87, 92], ["12579", "SPECIES", 0, 5], ["human", "SPECIES", 87, 92], ["MUC1 expression", "PROBLEM", 48, 63], ["multiple", "OBSERVATION_MODIFIER", 28, 36], ["MUC1 expression", "OBSERVATION", 48, 63], ["normal", "OBSERVATION", 67, 73], ["diseased", "OBSERVATION_MODIFIER", 78, 86], ["lung", "ANATOMY", 93, 97]]], ["These data were corroborated by the 127 expression of MUC1 mRNA in human lung reported by the HPA, GTEx and FANTOM5 128 databases ( Figure 1B ) and by the Human Lung Atlas project (Muus, 2020) 129 130 We screened 3,713 compounds of the Repurposing Library for their ability to reduce 131 MUC1 protein levels ( Figure 2A ).", [["lung", "ANATOMY", 73, 77], ["Lung", "ANATOMY", 161, 165], ["MUC1", "GENE_OR_GENE_PRODUCT", 54, 58], ["human", "ORGANISM", 67, 72], ["lung", "ORGAN", 73, 77], ["Human", "ORGANISM", 155, 160], ["Lung", "ORGAN", 161, 165], ["MUC1", "GENE_OR_GENE_PRODUCT", 288, 292], ["MUC1 mRNA", "RNA", 54, 63], ["MUC1", "PROTEIN", 288, 292], ["human", "SPECIES", 67, 72], ["Human", "SPECIES", 155, 160], ["human", "SPECIES", 67, 72], ["These data", "TEST", 0, 10], ["MUC1 mRNA in human lung", "PROBLEM", 54, 77], ["the Repurposing Library", "TREATMENT", 232, 255], ["MUC1 protein levels", "TEST", 288, 307], ["lung", "ANATOMY", 73, 77], ["Lung", "ANATOMY", 161, 165]]], ["The screen employed high-content immunofluorescence (IF) 132 imaging of an immortalized kidney tubular epithelial cell line ( Positive hits from the 5-dose screen were defined by two criteria: lack of cellular toxicity (less 139 than 20% reduction in cell number compared to the DMSO control); and reduction of MUC1 140 abundance by >30% (normalized to DMSO and JQ1 controls) at 2 or more consecutive non-toxic 14179concentrations of test compound.", [["kidney tubular epithelial cell line", "ANATOMY", 88, 123], ["cellular", "ANATOMY", 201, 209], ["cell", "ANATOMY", 251, 255], ["toxicity", "DISEASE", 210, 218], ["DMSO", "CHEMICAL", 279, 283], ["DMSO", "CHEMICAL", 353, 357], ["DMSO", "CHEMICAL", 279, 283], ["DMSO", "CHEMICAL", 353, 357], ["kidney tubular epithelial cell line", "CELL", 88, 123], ["cellular", "CELL", 201, 209], ["cell", "CELL", 251, 255], ["MUC1 140", "GENE_OR_GENE_PRODUCT", 311, 319], ["DMSO", "SIMPLE_CHEMICAL", 353, 357], ["immortalized kidney tubular epithelial cell line", "CELL_LINE", 75, 123], ["MUC1", "PROTEIN", 311, 315], ["The screen", "TEST", 0, 10], ["imaging", "TEST", 61, 68], ["the 5-dose screen", "TEST", 145, 162], ["cellular toxicity", "PROBLEM", 201, 218], ["the DMSO control", "TREATMENT", 275, 291], ["MUC1", "TEST", 311, 315], ["DMSO and JQ1 controls", "TREATMENT", 353, 374], ["kidney", "ANATOMY", 88, 94], ["tubular", "ANATOMY_MODIFIER", 95, 102], ["epithelial cell line", "OBSERVATION", 103, 123], ["cellular toxicity", "OBSERVATION", 201, 218]]], ["The compounds that met these criteria included two major 142 groups, bromodomain inhibitors (blue) and vitamin D receptor agonists (orange, Figure 2B ).", [["vitamin D", "CHEMICAL", 103, 112], ["vitamin D", "CHEMICAL", 103, 112], ["blue", "SIMPLE_CHEMICAL", 93, 97], ["vitamin D receptor agonists", "SIMPLE_CHEMICAL", 103, 130], ["bromodomain inhibitors (blue", "TREATMENT", 69, 97], ["vitamin D receptor agonists", "TREATMENT", 103, 130]]], ["Our 143 screen also identified drugs that increased MUC1 levels ( Figure 2B ), including glucocorticoid 144 receptor agonists.", [["MUC1", "GENE_OR_GENE_PRODUCT", 52, 56], ["glucocorticoid 144 receptor", "GENE_OR_GENE_PRODUCT", 89, 116], ["MUC1", "PROTEIN", 52, 56], ["glucocorticoid 144 receptor", "PROTEIN", 89, 116], ["Our 143 screen", "TEST", 0, 14], ["drugs", "TREATMENT", 31, 36], ["increased MUC1 levels", "PROBLEM", 42, 63], ["glucocorticoid 144 receptor agonists", "TREATMENT", 89, 125]]], ["Most compounds that increased MUC1, such as epidermal growth factor 145 receptor (EGFR) inhibitors (green), also reduced cell number, indicating an association between 146 cell toxicity and increased MUC1 levels ( Figure 2B ).", [["cell", "ANATOMY", 121, 125], ["cell", "ANATOMY", 172, 176], ["toxicity", "DISEASE", 177, 185], ["MUC1", "GENE_OR_GENE_PRODUCT", 30, 34], ["epidermal growth factor 145 receptor", "GENE_OR_GENE_PRODUCT", 44, 80], ["EGFR", "GENE_OR_GENE_PRODUCT", 82, 86], ["cell", "CELL", 121, 125], ["cell", "CELL", 172, 176], ["MUC1", "GENE_OR_GENE_PRODUCT", 200, 204], ["MUC1", "PROTEIN", 30, 34], ["epidermal growth factor 145 receptor", "PROTEIN", 44, 80], ["EGFR", "PROTEIN", 82, 86], ["MUC1", "PROTEIN", 200, 204], ["increased MUC1", "PROBLEM", 20, 34], ["epidermal growth factor", "TEST", 44, 67], ["receptor (EGFR) inhibitors", "TREATMENT", 72, 98], ["reduced cell number", "PROBLEM", 113, 132], ["146 cell toxicity", "PROBLEM", 168, 185], ["increased MUC1 levels", "PROBLEM", 190, 211], ["increased", "OBSERVATION_MODIFIER", 20, 29], ["MUC1", "OBSERVATION", 30, 34], ["reduced cell number", "OBSERVATION", 113, 132], ["146 cell", "OBSERVATION_MODIFIER", 168, 176]]], ["In this screen, any compound that reduced 150 MUC1 by >30% at 2 or more consecutive concentrations without evidence of toxicity (cell 151 numbers within 20% of the DMSO control) was considered a positive hit.", [["cell", "ANATOMY", 129, 133], ["toxicity", "DISEASE", 119, 127], ["DMSO", "CHEMICAL", 164, 168], ["DMSO", "CHEMICAL", 164, 168], ["MUC1", "GENE_OR_GENE_PRODUCT", 46, 50], ["cell", "CELL", 129, 133], ["150 MUC1", "PROTEIN", 42, 50], ["this screen", "TEST", 3, 14], ["MUC1", "TEST", 46, 50], ["toxicity (cell", "PROBLEM", 119, 133], ["numbers", "TEST", 138, 145], ["the DMSO control", "TREATMENT", 160, 176], ["a positive hit", "PROBLEM", 193, 207], ["without evidence of", "UNCERTAINTY", 99, 118], ["toxicity", "OBSERVATION", 119, 127], ["positive hit", "OBSERVATION", 195, 207]]], ["Thirteen hits from this 152 screen were analyzed further in secondary profiling assays, including quantitative PCR (qPCR) 15379and cell viability screens.", [["cell", "ANATOMY", 131, 135], ["cell", "CELL", 131, 135], ["Thirteen hits", "TEST", 0, 13], ["this 152 screen", "TEST", 19, 34], ["profiling assays", "TEST", 70, 86], ["quantitative PCR", "TEST", 98, 114], ["cell viability screens", "TEST", 131, 153]]], ["MUC1 qPCR ( Figure 2C ) showed that for most compounds, reduction 154 of MUC1 protein abundance (MUC1 IF) was highly correlated with parallel reductions in 155 mRNA abundance (MUC1 qPCR).", [["MUC1", "GENE_OR_GENE_PRODUCT", 0, 4], ["MUC1", "GENE_OR_GENE_PRODUCT", 73, 77], ["MUC1 IF", "GENE_OR_GENE_PRODUCT", 97, 104], ["MUC1", "GENE_OR_GENE_PRODUCT", 176, 180], ["MUC1", "PROTEIN", 0, 4], ["MUC1 protein", "PROTEIN", 73, 85], ["MUC1 IF", "PROTEIN", 97, 104], ["155 mRNA", "RNA", 156, 164], ["MUC1", "PROTEIN", 176, 180], ["MUC1 qPCR", "TEST", 0, 9], ["MUC1 protein abundance", "TEST", 73, 95], ["MUC1 qPCR", "TEST", 176, 185]]], ["Of interest, 4 compounds reduced MUC1 protein without 156 affecting MUC1 mRNA.", [["MUC1", "GENE_OR_GENE_PRODUCT", 33, 37], ["MUC1", "GENE_OR_GENE_PRODUCT", 68, 72], ["MUC1 protein", "PROTEIN", 33, 45], ["MUC1 mRNA", "RNA", 68, 77], ["MUC1 protein", "TEST", 33, 45]]], ["These included the SYK inhibitor R406 (red, Figure 2C ); the RAF 157 inhibitor LGX818 (violet, Figure 2C ); the mannosidase inhibitor Kifunensine (green, Figure 2C ), 158 and the IKK inhibitor TPCA-1 (turquoise, Figure 2C ).", [["R406", "CHEMICAL", 33, 37], ["LGX818", "CHEMICAL", 79, 85], ["Kifunensine", "CHEMICAL", 134, 145], ["R406", "CHEMICAL", 33, 37], ["LGX818", "CHEMICAL", 79, 85], ["violet", "CHEMICAL", 87, 93], ["Kifunensine", "CHEMICAL", 134, 145], ["TPCA-1", "CHEMICAL", 193, 199], ["SYK", "GENE_OR_GENE_PRODUCT", 19, 22], ["R406", "SIMPLE_CHEMICAL", 33, 37], ["RAF 157", "SIMPLE_CHEMICAL", 61, 68], ["LGX818", "SIMPLE_CHEMICAL", 79, 85], ["violet", "SIMPLE_CHEMICAL", 87, 93], ["mannosidase", "GENE_OR_GENE_PRODUCT", 112, 123], ["Kifunensine", "SIMPLE_CHEMICAL", 134, 145], ["green", "SIMPLE_CHEMICAL", 147, 152], ["IKK", "GENE_OR_GENE_PRODUCT", 179, 182], ["TPCA-1", "SIMPLE_CHEMICAL", 193, 199], ["IKK", "PROTEIN", 179, 182], ["the SYK inhibitor", "TEST", 15, 32], ["the RAF", "TEST", 57, 64], ["the mannosidase inhibitor Kifunensine", "TREATMENT", 108, 145], ["the IKK inhibitor TPCA", "TEST", 175, 197]]], ["None of these four compounds exhibited 159 detectable toxicity (cell death or apoptosis) at any of the 10 tested concentrations.", [["cell", "ANATOMY", 64, 68], ["toxicity", "DISEASE", 54, 62], ["death", "DISEASE", 69, 74], ["cell", "CELL", 64, 68], ["detectable toxicity (cell death", "PROBLEM", 43, 74], ["apoptosis", "PROBLEM", 78, 87]]], ["Importantly, 16079only the SYK inhibitor R406 is FDA-approved (Figure 2A and D protein to the intracellular compartment with a perinuclear distribution pattern ( Figure 3A ).", [["intracellular compartment", "ANATOMY", 94, 119], ["perinuclear", "ANATOMY", 127, 138], ["R406", "CHEMICAL", 41, 45], ["R406", "CHEMICAL", 41, 45], ["SYK", "GENE_OR_GENE_PRODUCT", 27, 30], ["D protein", "GENE_OR_GENE_PRODUCT", 77, 86], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 94, 107], ["compartment", "IMMATERIAL_ANATOMICAL_ENTITY", 108, 119], ["D protein", "PROTEIN", 77, 86], ["the SYK inhibitor", "TREATMENT", 23, 40], ["intracellular compartment", "ANATOMY", 94, 119], ["perinuclear distribution", "OBSERVATION", 127, 151]]], ["We 174 quantified this relocalization using a STAR morphology \"Profile\" Module (Star Methods) that 175 allowed selective measurement of MUC1 signal distribution in cellular sub-compartments.", [["cellular sub-compartments", "ANATOMY", 164, 189], ["MUC1", "GENE_OR_GENE_PRODUCT", 136, 140], ["cellular", "CELL", 164, 172], ["MUC1", "PROTEIN", 136, 140], ["this relocalization", "TEST", 18, 37], ["a STAR morphology", "TEST", 44, 61], ["MUC1 signal", "OBSERVATION", 136, 147], ["distribution", "OBSERVATION_MODIFIER", 148, 160], ["cellular", "OBSERVATION_MODIFIER", 164, 172], ["sub", "OBSERVATION_MODIFIER", 173, 176]]], ["176 Figure 3B shows an analysis sequence for the sub-compartment corresponding to the cell region 17779closest to the plasma membrane.", [["cell", "ANATOMY", 86, 90], ["plasma membrane", "ANATOMY", 118, 133], ["cell region 17779", "CELLULAR_COMPONENT", 86, 103], ["plasma membrane", "CELLULAR_COMPONENT", 118, 133], ["cell region 17779", "DNA", 86, 103], ["Figure 3B", "TEST", 4, 13], ["an analysis sequence", "TEST", 20, 40], ["plasma membrane", "OBSERVATION", 118, 133]]], ["Within each cell, the nucleus border was identified based on 17879Hoechst staining (blue, second panel, Figure 3B ) and the plasma membrane (orange, second 179 panel, Figure 3B ) was identified based on the MUC1 signal.", [["cell", "ANATOMY", 12, 16], ["nucleus border", "ANATOMY", 22, 36], ["plasma membrane", "ANATOMY", 124, 139], ["cell", "CELL", 12, 16], ["nucleus border", "CELLULAR_COMPONENT", 22, 36], ["Hoechst", "SIMPLE_CHEMICAL", 66, 73], ["plasma membrane", "CELLULAR_COMPONENT", 124, 139], ["MUC1", "GENE_OR_GENE_PRODUCT", 207, 211], ["MUC1", "PROTEIN", 207, 211], ["Hoechst staining", "TEST", 66, 82], ["second panel", "TEST", 90, 102], ["Figure 3B", "TEST", 104, 113], ["the plasma membrane", "TEST", 120, 139], ["nucleus", "ANATOMY_MODIFIER", 22, 29], ["border", "ANATOMY_MODIFIER", 30, 36], ["plasma membrane", "ANATOMY", 124, 139]]], ["The calculated STAR morphology 180 \"Membrane Profile\" image was generated as illustrated in Figure 3B , panel 3 (STAR Methods).", [["Membrane", "CELLULAR_COMPONENT", 36, 44], ["The calculated STAR morphology", "TEST", 0, 30], ["Membrane Profile\" image", "TEST", 36, 59]]], ["18179The calculated STAR Membrane Profile values for MUC1 in each well were compared with total 182 cell MUC1 intensity ( Figure 3C) Importantly, MUC1 was significantly reduced by treatment with R788 ( Figure 4A ).", [["cell", "ANATOMY", 100, 104], ["18179", "CHEMICAL", 0, 5], ["R788", "CHEMICAL", 195, 199], ["MUC1", "GENE_OR_GENE_PRODUCT", 53, 57], ["MUC1", "GENE_OR_GENE_PRODUCT", 105, 109], ["MUC1", "GENE_OR_GENE_PRODUCT", 146, 150], ["MUC1", "PROTEIN", 53, 57], ["MUC1", "PROTEIN", 105, 109], ["MUC1", "PROTEIN", 146, 150], ["18179", "SPECIES", 0, 5], ["The calculated STAR Membrane Profile values", "TEST", 5, 48], ["MUC1", "PROBLEM", 53, 57], ["MUC1", "TEST", 146, 150]]], ["Quantitative 198 image analysis confirmed the in vivo efficacy of R788 in reducing MUC1 in injured lung 199 epithelium ( Figure 4B and C).", [["lung 199 epithelium", "ANATOMY", 99, 118], ["R788", "CHEMICAL", 66, 70], ["R788", "CHEMICAL", 66, 70], ["R788", "SIMPLE_CHEMICAL", 66, 70], ["MUC1", "GENE_OR_GENE_PRODUCT", 83, 87], ["lung 199 epithelium", "TISSUE", 99, 118], ["MUC1", "PROTEIN", 83, 87], ["image analysis", "TEST", 17, 31], ["lung", "ANATOMY", 99, 103]]], ["Our finding that R406 preferentially depletes MUC1 abundance in or near the plasma 232 membrane is consistent with a previously described mechanism by which SYK inhibition results 233 in dephosphorylation of integral membrane proteins followed by their endocytic removal from 234 the plasma membrane. of whom were critically ill, to 28 critically ill patients with ARDS or sepsis found no statistically 249 significant difference in circulating levels of IL-1b, IL-1RA, IL-6, IL-8 and TNF-alpha among 250 these conditions (Wilson, 2020) .", [["plasma 232 membrane", "ANATOMY", 76, 95], ["membrane", "ANATOMY", 217, 225], ["plasma membrane", "ANATOMY", 284, 299], ["R406", "CHEMICAL", 17, 21], ["critically ill", "DISEASE", 314, 328], ["critically ill", "DISEASE", 336, 350], ["ARDS", "DISEASE", 365, 369], ["sepsis", "DISEASE", 373, 379], ["R406", "SIMPLE_CHEMICAL", 17, 21], ["MUC1", "GENE_OR_GENE_PRODUCT", 46, 50], ["plasma 232 membrane", "CELLULAR_COMPONENT", 76, 95], ["SYK", "GENE_OR_GENE_PRODUCT", 157, 160], ["membrane", "CELLULAR_COMPONENT", 217, 225], ["plasma membrane", "CELLULAR_COMPONENT", 284, 299], ["patients", "ORGANISM", 351, 359], ["IL-1b", "GENE_OR_GENE_PRODUCT", 455, 460], ["IL-1RA", "GENE_OR_GENE_PRODUCT", 462, 468], ["IL-6", "GENE_OR_GENE_PRODUCT", 470, 474], ["IL-8", "GENE_OR_GENE_PRODUCT", 476, 480], ["TNF-alpha", "GENE_OR_GENE_PRODUCT", 485, 494], ["R406", "PROTEIN", 17, 21], ["MUC1", "PROTEIN", 46, 50], ["SYK", "PROTEIN", 157, 160], ["integral membrane proteins", "PROTEIN", 208, 234], ["IL", "PROTEIN", 455, 457], ["IL-1RA, IL-6, IL-8", "PROTEIN", 462, 480], ["TNF", "PROTEIN", 485, 488], ["patients", "SPECIES", 351, 359], ["MUC1 abundance", "PROBLEM", 46, 60], ["SYK inhibition", "TEST", 157, 171], ["integral membrane proteins", "TREATMENT", 208, 234], ["their endocytic removal", "TREATMENT", 247, 270], ["critically ill", "PROBLEM", 314, 328], ["ARDS", "PROBLEM", 365, 369], ["sepsis", "PROBLEM", 373, 379], ["circulating levels", "TEST", 433, 451], ["IL", "TEST", 455, 457], ["IL", "TEST", 462, 464], ["IL", "TEST", 470, 472], ["IL", "TEST", 476, 478], ["TNF", "TEST", 485, 488], ["depletes", "OBSERVATION_MODIFIER", 37, 45], ["MUC1", "OBSERVATION_MODIFIER", 46, 50], ["abundance", "OBSERVATION_MODIFIER", 51, 60], ["plasma", "ANATOMY", 76, 82], ["232 membrane", "OBSERVATION", 83, 95], ["consistent with", "UNCERTAINTY", 99, 114], ["ARDS", "OBSERVATION", 365, 369], ["sepsis", "OBSERVATION", 373, 379]]], ["These results indicate that COVID19-related ARDS is 251 associated with inflammatory cytokine levels no higher than in ARDS due to other critical 25279illnesses (Wilson, 2020 Image acquisition and analysis was as described in the Fluorescence image acquisition and 460 analysis section.", [["COVID19", "CHEMICAL", 28, 35], ["ARDS", "DISEASE", 44, 48], ["ARDS", "DISEASE", 119, 123], ["COVID19", "GENE_OR_GENE_PRODUCT", 28, 35], ["COVID19", "PROTEIN", 28, 35], ["inflammatory cytokine", "PROTEIN", 72, 93], ["COVID19", "TEST", 28, 35], ["ARDS", "PROBLEM", 44, 48], ["inflammatory cytokine levels", "PROBLEM", 72, 100], ["ARDS", "PROBLEM", 119, 123], ["Image acquisition", "TEST", 175, 192], ["analysis", "TEST", 197, 205], ["the Fluorescence image acquisition", "TEST", 226, 260], ["analysis section", "TEST", 269, 285], ["ARDS", "OBSERVATION", 44, 48], ["inflammatory", "OBSERVATION_MODIFIER", 72, 84], ["higher", "OBSERVATION_MODIFIER", 104, 110]]], ["Upon image analysis, two parameters were selected, i) total MUC1 cytoplasmic 46179intensity and ii) cell number as was detected by Hoechst 33342 stained nuclei.", [["cytoplasmic", "ANATOMY", 65, 76], ["cell", "ANATOMY", 100, 104], ["nuclei", "ANATOMY", 153, 159], ["Hoechst 33342", "CHEMICAL", 131, 144], ["Hoechst 33342", "CHEMICAL", 131, 144], ["MUC1", "GENE_OR_GENE_PRODUCT", 60, 64], ["cytoplasmic", "ORGANISM_SUBSTANCE", 65, 76], ["cell", "CELL", 100, 104], ["Hoechst 33342", "SIMPLE_CHEMICAL", 131, 144], ["nuclei", "CELLULAR_COMPONENT", 153, 159], ["MUC1", "PROTEIN", 60, 64], ["image analysis", "TEST", 5, 19]]], ["MUC1 levels in 462 the presence of DMSO or of JQ1 were defined, respectively as 0 and \u2212100% activity.", [["DMSO", "CHEMICAL", 35, 39], ["DMSO", "CHEMICAL", 35, 39], ["MUC1", "GENE_OR_GENE_PRODUCT", 0, 4], ["DMSO", "SIMPLE_CHEMICAL", 35, 39], ["JQ1", "GENE_OR_GENE_PRODUCT", 46, 49], ["MUC1", "PROTEIN", 0, 4], ["MUC1 levels", "TEST", 0, 11], ["DMSO", "TREATMENT", 35, 39], ["JQ1", "PROBLEM", 46, 49]]], ["Values for 463 test compounds were normalized accordingly.", [["Values", "TEST", 0, 6], ["test compounds", "TEST", 15, 29]]], ["Cell number was normalized to DMSO control.", [["Cell", "ANATOMY", 0, 4], ["DMSO", "CHEMICAL", 30, 34], ["DMSO", "CHEMICAL", 30, 34], ["Cell", "CELL", 0, 4], ["DMSO", "SIMPLE_CHEMICAL", 30, 34], ["Cell number", "TEST", 0, 11], ["DMSO control", "TREATMENT", 30, 42]]], ["46479All compound concentrations showing > \u221220% reduction in cell number were masked out.", [["cell", "ANATOMY", 61, 65], ["reduction in cell number", "DISEASE", 48, 72], ["cell", "CELL", 61, 65], ["All compound concentrations", "TEST", 5, 32], ["concentrations", "OBSERVATION_MODIFIER", 18, 32], ["cell number", "OBSERVATION", 61, 72]]], ["Based 465 on \u00b1 3 median absolute deviation value, hit calling criteria for the initial 5 doses screen were 466 chosen as MUC1 reduction > 30% in 2 or more consecutive concentrations for both replicates.", [["MUC1", "GENE_OR_GENE_PRODUCT", 121, 125], ["MUC1", "PROTEIN", 121, 125], ["MUC1 reduction", "TREATMENT", 121, 135]]], ["46779For the initial 10 doses screen, dose response curves were generated for each parameter using 46879Genedata Screener (Genedata AG), and positive hits for the profiling screens were selected based 469 on the compound's activity in reducing MUC1 abundance without cell toxicity.", [["cell", "ANATOMY", 267, 271], ["46779", "CHEMICAL", 0, 5], ["toxicity", "DISEASE", 272, 280], ["MUC1", "GENE_OR_GENE_PRODUCT", 244, 248], ["cell", "CELL", 267, 271], ["MUC1", "PROTEIN", 244, 248], ["46779", "SPECIES", 0, 5], ["dose response curves", "TEST", 38, 58], ["the profiling screens", "TEST", 159, 180], ["cell toxicity", "PROBLEM", 267, 280], ["without", "UNCERTAINTY", 259, 266], ["cell toxicity", "OBSERVATION", 267, 280]]], ["47079For the RT-PCR-based screen (Bittker, 2012), P cells seeded at 2000 cells/well in 384-well, clear 471 bottom, white wall plates were grown for 24 h, then treated with profiling compounds transferred 472 by pinning to duplicate plates.", [["P cells", "ANATOMY", 50, 57], ["cells", "ANATOMY", 73, 78], ["cells", "CELL", 52, 57], ["cells", "CELL", 73, 78], ["P cells", "CELL_LINE", 50, 57], ["the RT-PCR", "TEST", 9, 19], ["Bittker", "TEST", 34, 41], ["P cells", "TEST", 50, 57], ["white wall plates", "TEST", 115, 132], ["profiling compounds", "TREATMENT", 172, 191]]], ["JQ1 (250 nM) and DMSO were used for controls as above.", [["JQ1", "CHEMICAL", 0, 3], ["DMSO", "CHEMICAL", 17, 21], ["DMSO", "CHEMICAL", 17, 21], ["JQ1", "SIMPLE_CHEMICAL", 0, 3], ["DMSO", "SIMPLE_CHEMICAL", 17, 21], ["JQ1 (250 nM)", "TREATMENT", 0, 12], ["DMSO", "TREATMENT", 17, 21]]], ["After 473 24 h, cells were washed and cDNAs generated using ABI Cells-to-Ct kit (Thermo Fisher 474 Scientific, Waltham, MA).", [["cells", "ANATOMY", 16, 21], ["cells", "CELL", 16, 21], ["Cells", "CELL", 64, 69], ["cDNAs", "DNA", 38, 43], ["cells", "TEST", 16, 21], ["cDNAs", "TEST", 38, 43], ["ABI Cells", "TEST", 60, 69], ["Ct kit", "TEST", 73, 79]]], ["MUC1 and HMBS delta Cp values were determined using a Roche 47579LightCycler 480 Instrument in 5\u00b5L reactions using TaqMan probes for MUC1 FAM (4351368 476 assay ID Hs00159357_m1) and HMBS VIC (4448486-assay ID Hs00609297_m1) (Thermo 47779Fisher Scientific).", [["MUC1", "GENE_OR_GENE_PRODUCT", 0, 4], ["HMBS delta", "GENE_OR_GENE_PRODUCT", 9, 19], ["MUC1", "GENE_OR_GENE_PRODUCT", 133, 137], ["MUC1", "PROTEIN", 0, 4], ["Cp", "DNA", 20, 22], ["MUC1", "PROTEIN", 133, 137], ["MUC1", "TEST", 0, 4], ["HMBS delta Cp values", "TEST", 9, 29], ["MUC1 FAM", "TREATMENT", 133, 141], ["Hs", "TEST", 164, 166], ["HMBS VIC", "TEST", 183, 191]]], ["The fold change effect of the compounds on total MUC1 mRNA was 478 normalized to JQ1 and DMSO controls, as described above.", [["DMSO", "CHEMICAL", 89, 93], ["DMSO", "CHEMICAL", 89, 93], ["MUC1", "GENE_OR_GENE_PRODUCT", 49, 53], ["MUC1 mRNA", "RNA", 49, 58], ["The fold change effect", "PROBLEM", 0, 22], ["total MUC1 mRNA", "TEST", 43, 58], ["JQ1 and DMSO controls", "TREATMENT", 81, 102], ["fold", "OBSERVATION_MODIFIER", 4, 8], ["change", "OBSERVATION", 9, 15], ["compounds", "OBSERVATION_MODIFIER", 30, 39]]], ["479 48079For the viability profiling screen, P cells were seeded 12 h prior to profiling compound treatment 481 at a density of 12,000 cells/well in 384 well Cell Carrier Ultra plates (Perkin Elmer), pre-coated 482 with 0.25 mg/mL Synthemax II SC Substrate (Corning).", [["P cells", "ANATOMY", 45, 52], ["cells", "ANATOMY", 135, 140], ["479 48079", "CHEMICAL", 0, 9], ["Synthemax II", "CHEMICAL", 231, 243], ["P cells", "CELL", 45, 52], ["cells", "CELL", 135, 140], ["P cells", "CELL_LINE", 45, 52], ["479 48079", "SPECIES", 0, 9], ["the viability profiling screen", "TEST", 13, 43], ["P cells", "TREATMENT", 45, 52], ["profiling compound treatment", "TREATMENT", 79, 107]]], ["After 24 h, CellEvent Caspase-3/7 483 Green Detection Reagent (Thermo Fisher Scientific) and DRAQ7 (Biostatus) were added at 484 .", [["Caspase-3/7", "GENE_OR_GENE_PRODUCT", 22, 33], ["CellEvent Caspase", "TREATMENT", 12, 29], ["DRAQ7 (Biostatus)", "TREATMENT", 93, 110]]], ["CC-BY-NC-ND 4.0 International license (which was not certified by peer review) is the author/funder.", [["CC", "CHEMICAL", 0, 2]]], ["Mice were randomly 506 assigned to sham or I/R groups and were anesthetized by intraperitoneal injection of 72 mg/kg 507 pentobarbital.", [["intraperitoneal", "ANATOMY", 79, 94], ["pentobarbital", "CHEMICAL", 121, 134], ["pentobarbital", "CHEMICAL", 121, 134], ["Mice", "ORGANISM", 0, 4], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 79, 94], ["pentobarbital", "SIMPLE_CHEMICAL", 121, 134], ["Mice", "SPECIES", 0, 4], ["I/R groups", "TREATMENT", 43, 53], ["pentobarbital", "TREATMENT", 121, 134]]], ["Animals were subjected to I/R, as previously described (Pamuk et al., 2010) .", [["Animals", "ORGANISM", 0, 7], ["I/R", "GENE_OR_GENE_PRODUCT", 26, 29]]], ["Mice 50879were anesthetized with 72 mg/kg nembutal (Butler Schein Animal Health) given i.p.", [["Mice", "ORGANISM", 0, 4], ["Mice", "SPECIES", 0, 4]]], ["50979Additionally, 36 mg/kg nembuttal was given s.c. during the experiment as needed to maintain 510 anesthesia.", [["50979Additionally", "CHEMICAL", 0, 17], ["nembuttal", "TREATMENT", 28, 37], ["anesthesia", "TREATMENT", 101, 111]]], ["All procedures were performed on anesthetized, spontaneously breathing animals 511 with body temperature maintained at 37\u02daC with a controlled heating pad.", [["body", "ANATOMY", 88, 92], ["body", "ORGANISM_SUBDIVISION", 88, 92], ["All procedures", "TREATMENT", 0, 14], ["body temperature", "TEST", 88, 104], ["a controlled heating pad", "TREATMENT", 129, 153]]], ["A midline laparotomy 512 was performed, and the superior mesenteric artery was identified and isolated.", [["superior mesenteric artery", "ANATOMY", 48, 74], ["superior mesenteric artery", "MULTI-TISSUE_STRUCTURE", 48, 74], ["A midline laparotomy", "TREATMENT", 0, 20], ["midline", "ANATOMY", 2, 9], ["laparotomy", "OBSERVATION", 10, 20], ["superior mesenteric artery", "ANATOMY", 48, 74]]], ["Ischemia was 513 induced by application of \u223c 85 g of pressure fir 30 min via a small nontraumatic vascular clamp 514 (Roboz Surgical Instruments, Gaithersburg, MD).", [["vascular", "ANATOMY", 98, 106], ["Ischemia", "DISEASE", 0, 8], ["vascular", "MULTI-TISSUE_STRUCTURE", 98, 106], ["Ischemia", "PROBLEM", 0, 8], ["pressure fir", "TREATMENT", 53, 65], ["a small nontraumatic vascular clamp", "TREATMENT", 77, 112], ["small", "OBSERVATION_MODIFIER", 79, 84], ["nontraumatic", "OBSERVATION", 85, 97], ["vascular", "ANATOMY", 98, 106]]], ["After 30 min of ischemia, the clamp was 515 removed, the laparotomy incision was repaired with 4-0 Sofsilk (Covidien, Mansfield, MA), the 516 mice were resuscitated with 1.0 ml of prewarmed sterile PBS s.c., and the intestine was allowed 51779to reperfuse for 180 min.", [["intestine", "ANATOMY", 216, 225], ["ischemia", "DISEASE", 16, 24], ["mice", "ORGANISM", 142, 146], ["intestine", "ORGAN", 216, 225], ["mice", "SPECIES", 142, 146], ["mice", "SPECIES", 142, 146], ["ischemia", "PROBLEM", 16, 24], ["the clamp", "TREATMENT", 26, 35], ["the laparotomy incision", "TREATMENT", 53, 76], ["prewarmed sterile PBS s.c.", "TREATMENT", 180, 206], ["ischemia", "OBSERVATION", 16, 24], ["laparotomy", "OBSERVATION_MODIFIER", 57, 67], ["incision", "OBSERVATION", 68, 76], ["intestine", "ANATOMY", 216, 225]]], ["Sham-operated mice were subjected to the same operative procedure as 518 the experimental group except that clamping of the superior mesenteric artery was not 51979performed.", [["superior mesenteric artery", "ANATOMY", 124, 150], ["mice", "ORGANISM", 14, 18], ["superior mesenteric artery", "MULTI-TISSUE_STRUCTURE", 124, 150], ["mice", "SPECIES", 14, 18], ["mice", "SPECIES", 14, 18], ["the same operative procedure", "TREATMENT", 37, 65], ["superior mesenteric artery", "ANATOMY", 124, 150]]], ["At the conclusion of the reperfusion period, mice were euthanized by carbon dioxide 520 asphyxiation, following the IACUC Guidelines of the BIDMC.", [["carbon dioxide", "CHEMICAL", 69, 83], ["carbon dioxide", "CHEMICAL", 69, 83], ["mice", "ORGANISM", 45, 49], ["mice", "SPECIES", 45, 49], ["mice", "SPECIES", 45, 49], ["carbon dioxide", "TREATMENT", 69, 83]]], ["LGX818 Kifunensine TPCA-1 .", [["TPCA-1", "CHEMICAL", 19, 25], ["TPCA-1", "GENE_OR_GENE_PRODUCT", 19, 25], ["Kifunensine TPCA", "TREATMENT", 7, 23]]], ["CC-BY-NC-ND 4.0 International license (which was not certified by peer review) is the author/funder.", [["CC", "CHEMICAL", 0, 2]]], ["It is made available under a The copyright holder for this preprint this version posted June 30, 2020. . https://doi.org/10.1101/2020.06.30.180380 doi: bioRxiv preprint .", [["bioRxiv preprint", "TREATMENT", 152, 168]]], ["CC-BY-NC-ND 4.0 International license (which was not certified by peer review) is the author/funder.", [["CC", "CHEMICAL", 0, 2]]], ["It is made available under a The copyright holder for this preprint this version posted June 30, 2020. . https://doi.org/10.1101/2020.06.30.180380 doi: bioRxiv preprint", [["bioRxiv", "TREATMENT", 152, 159]]]], "6ceb4ffe07b5880b17ad034b4918b4b878bafd1f": [["IntroductionSialic acids are a family of approximately 50 naturally occurring 2-keto-3-deoxy-nononic acids that are involved in a wide range of biological processes.", [["IntroductionSialic acids", "CHEMICAL", 0, 24], ["2-keto-3-deoxy-nononic acids", "CHEMICAL", 78, 106], ["2-keto-3-deoxy-nononic acids", "CHEMICAL", 78, 106], ["IntroductionSialic acids", "SIMPLE_CHEMICAL", 0, 24], ["2-keto-3-deoxy-nononic acids", "SIMPLE_CHEMICAL", 78, 106], ["deoxy-nononic acids", "TREATMENT", 87, 106]]], ["[1] [2] [3] The C-5-amino derivative represents the long-known neuraminic acid and its amino function can either be acetylated (Neu5Ac) or glycolylated (Neu5Gc).", [["C-5-amino", "CHEMICAL", 16, 25], ["neuraminic acid", "CHEMICAL", 63, 78], ["Neu5Gc", "CHEMICAL", 153, 159], ["C-5-amino", "CHEMICAL", 16, 25], ["neuraminic acid", "CHEMICAL", 63, 78], ["amino", "CHEMICAL", 87, 92], ["Neu5Ac", "CHEMICAL", 128, 134], ["Neu5Gc", "CHEMICAL", 153, 159], ["[1] [2] [3]", "SIMPLE_CHEMICAL", 0, 11], ["C-5-amino derivative", "SIMPLE_CHEMICAL", 16, 36], ["neuraminic acid", "SIMPLE_CHEMICAL", 63, 78], ["amino", "AMINO_ACID", 87, 92], ["Neu5Ac", "SIMPLE_CHEMICAL", 128, 134], ["glycolylated", "SIMPLE_CHEMICAL", 139, 151], ["Neu5Gc", "SIMPLE_CHEMICAL", 153, 159], ["Neu5Gc", "PROTEIN", 153, 159], ["The C", "TEST", 12, 17], ["amino derivative", "TREATMENT", 20, 36], ["the long-known neuraminic acid", "TREATMENT", 48, 78], ["glycolylated (Neu5Gc", "TREATMENT", 139, 159]]], ["As terminal components of glycoproteins and glycolipids, neuraminic acids are a-(2?3)-or a-(2?6)-linked to galactosides or a-(2?6)-linked to 2-acetamido-galactosides.", [["neuraminic acids", "CHEMICAL", 57, 73], ["galactosides", "CHEMICAL", 107, 119], ["2-acetamido-galactosides", "CHEMICAL", 141, 165], ["neuraminic acids", "CHEMICAL", 57, 73], ["galactosides", "CHEMICAL", 107, 119], ["2-acetamido-galactosides", "CHEMICAL", 141, 165], ["neuraminic acids", "SIMPLE_CHEMICAL", 57, 73], ["a-(2?3)", "SIMPLE_CHEMICAL", 78, 85], ["a-(2?6)", "SIMPLE_CHEMICAL", 89, 96], ["galactosides", "SIMPLE_CHEMICAL", 107, 119], ["a-(2?6)", "SIMPLE_CHEMICAL", 123, 130], ["2-acetamido-galactosides", "SIMPLE_CHEMICAL", 141, 165], ["glycoproteins", "PROTEIN", 26, 39], ["glycoproteins and glycolipids", "TREATMENT", 26, 55], ["neuraminic acids", "TEST", 57, 73], ["galactosides", "TEST", 107, 119], ["acetamido", "TREATMENT", 143, 152], ["galactosides", "TREATMENT", 153, 165]]], ["[4] [5] [6] Enzymatic acetylation, lactylation, sulfation, methylation and phosphorylation of free hydroxyls give a large structural diversity of sialic acids.", [["sialic acids", "CHEMICAL", 146, 158], ["hydroxyls", "CHEMICAL", 99, 108], ["sialic acids", "CHEMICAL", 146, 158], ["[4] [5] [6] Enzymatic", "SIMPLE_CHEMICAL", 0, 21], ["lactylation", "SIMPLE_CHEMICAL", 35, 46], ["free hydroxyls", "SIMPLE_CHEMICAL", 94, 108], ["sialic acids", "SIMPLE_CHEMICAL", 146, 158], ["Enzymatic acetylation", "TREATMENT", 12, 33], ["lactylation", "TREATMENT", 35, 46], ["sulfation", "TREATMENT", 48, 57], ["methylation and phosphorylation of free hydroxyls", "TREATMENT", 59, 108], ["sialic acids", "TREATMENT", 146, 158], ["sialic acids", "OBSERVATION", 146, 158]]], ["3, 7 O-Acetylation of sialic acids takes place in the Golgi apparatus by membrane bound O-acetyltransferases.", [["Golgi apparatus", "ANATOMY", 54, 69], ["membrane", "ANATOMY", 73, 81], ["sialic acids", "CHEMICAL", 22, 34], ["3, 7 O", "CHEMICAL", 0, 6], ["sialic acids", "CHEMICAL", 22, 34], ["7 O-Acetylation", "SIMPLE_CHEMICAL", 3, 18], ["sialic acids", "SIMPLE_CHEMICAL", 22, 34], ["Golgi apparatus", "CELLULAR_COMPONENT", 54, 69], ["membrane", "CELLULAR_COMPONENT", 73, 81], ["O-acetyltransferases", "GENE_OR_GENE_PRODUCT", 88, 108], ["membrane bound O-acetyltransferases", "PROTEIN", 73, 108], ["sialic acids", "TREATMENT", 22, 34], ["sialic acids", "OBSERVATION", 22, 34], ["membrane", "OBSERVATION", 73, 81], ["bound O-acetyltransferases", "OBSERVATION", 82, 108]]], ["Interestingly, different cell types show different substrate selectivity for acetylation of sialic acid indicating that there are different classes of acetyltransfereases.", [["cell", "ANATOMY", 25, 29], ["sialic acid", "CHEMICAL", 92, 103], ["sialic acid", "CHEMICAL", 92, 103], ["cell", "CELL", 25, 29], ["sialic acid", "SIMPLE_CHEMICAL", 92, 103], ["acetyltransfereases", "GENE_OR_GENE_PRODUCT", 151, 170], ["acetyltransfereases", "PROTEIN", 151, 170], ["acetylation of sialic acid", "TREATMENT", 77, 103], ["acetyltransfereases", "TREATMENT", 151, 170], ["different cell types", "OBSERVATION", 15, 35], ["different", "OBSERVATION_MODIFIER", 41, 50], ["substrate selectivity", "OBSERVATION", 51, 72]]], ["2, 3, 8 Alternatively, it may be possible that adaptor proteins control the sub-strate specificity.", [["adaptor proteins", "PROTEIN", 47, 63], ["adaptor proteins", "TREATMENT", 47, 63], ["may be possible", "UNCERTAINTY", 26, 41]]], ["Initially, acetyl transferases introduce an acetyl ester at C-7 or C-9 of sialic acid and under physiological conditions, the C-7 acetyl ester can migrate to C-8 or C-9 making C-9 acetylation (Neu5,9Ac 2 ) the most prevalent sialic acid modification of cell surface glycoconjugates.", [["cell surface", "ANATOMY", 253, 265], ["acetyl", "CHEMICAL", 11, 17], ["acetyl ester", "CHEMICAL", 44, 56], ["C-7 or C-9 of sialic acid", "CHEMICAL", 60, 85], ["C-7 acetyl ester", "CHEMICAL", 126, 142], ["C-8 or C-9", "CHEMICAL", 158, 168], ["C-9", "CHEMICAL", 176, 179], ["sialic acid", "CHEMICAL", 225, 236], ["acetyl", "CHEMICAL", 11, 17], ["acetyl ester", "CHEMICAL", 44, 56], ["sialic acid", "CHEMICAL", 74, 85], ["C-7 acetyl ester", "CHEMICAL", 126, 142], ["sialic acid", "CHEMICAL", 225, 236], ["acetyl transferases", "GENE_OR_GENE_PRODUCT", 11, 30], ["acetyl ester", "SIMPLE_CHEMICAL", 44, 56], ["C-7", "SIMPLE_CHEMICAL", 60, 63], ["C-9", "SIMPLE_CHEMICAL", 67, 70], ["sialic acid", "SIMPLE_CHEMICAL", 74, 85], ["C-7 acetyl ester", "SIMPLE_CHEMICAL", 126, 142], ["C-8", "SIMPLE_CHEMICAL", 158, 161], ["C-9", "SIMPLE_CHEMICAL", 165, 168], ["C-9", "SIMPLE_CHEMICAL", 176, 179], ["Neu5", "SIMPLE_CHEMICAL", 193, 197], ["sialic acid", "SIMPLE_CHEMICAL", 225, 236], ["cell", "CELL", 253, 257], ["acetyl transferases", "PROTEIN", 11, 30], ["acetyl transferases", "TREATMENT", 11, 30], ["an acetyl ester", "TREATMENT", 41, 56], ["sialic acid", "TEST", 74, 85], ["the C", "TEST", 122, 127], ["C", "TEST", 158, 159], ["C", "TEST", 165, 166], ["C", "TEST", 176, 177], ["Neu5", "TEST", 193, 197], ["cell surface glycoconjugates", "TREATMENT", 253, 281]]], ["2, 7 Acetylation of the C-4 hydroxyl of sialosides has also been observed.", [["C-4 hydroxyl", "CHEMICAL", 24, 36], ["sialosides", "CHEMICAL", 40, 50], ["hydroxyl", "CHEMICAL", 28, 36], ["sialosides", "CHEMICAL", 40, 50], ["C-4 hydroxyl", "SIMPLE_CHEMICAL", 24, 36], ["sialosides", "SIMPLE_CHEMICAL", 40, 50], ["the C-4 hydroxyl of sialosides", "TREATMENT", 20, 50]]], ["9 It has been shown that 9-O-acetylation of sialic acids can dramatically influence biological properties of glycoconjugates.", [["9-O", "CHEMICAL", 25, 28], ["sialic acids", "CHEMICAL", 44, 56], ["9-O", "CHEMICAL", 25, 28], ["sialic acids", "CHEMICAL", 44, 56], ["9-O", "SIMPLE_CHEMICAL", 25, 28], ["sialic acids", "SIMPLE_CHEMICAL", 44, 56], ["sialic acids", "TREATMENT", 44, 56]]], ["2, 7, 10 For example, O-acetylation of sialosides on the surface of thymocytes results in loss of binding to Siglec-2 (CD22b) on B-cells.", [["surface", "ANATOMY", 57, 64], ["thymocytes", "ANATOMY", 68, 78], ["B-cells", "ANATOMY", 129, 136], ["sialosides", "CHEMICAL", 39, 49], ["sialosides", "CHEMICAL", 39, 49], ["sialosides", "GENE_OR_GENE_PRODUCT", 39, 49], ["surface", "CELLULAR_COMPONENT", 57, 64], ["thymocytes", "CELL", 68, 78], ["Siglec-2", "GENE_OR_GENE_PRODUCT", 109, 117], ["CD22b", "GENE_OR_GENE_PRODUCT", 119, 124], ["B-cells", "CELL", 129, 136], ["sialosides", "PROTEIN", 39, 49], ["thymocytes", "CELL_TYPE", 68, 78], ["Siglec-2", "PROTEIN", 109, 117], ["CD22b", "PROTEIN", 119, 124], ["B-cells", "CELL_TYPE", 129, 136], ["O-acetylation of sialosides", "TREATMENT", 22, 49], ["loss of binding", "PROBLEM", 90, 105], ["Siglec", "TEST", 109, 115], ["thymocytes", "ANATOMY", 68, 78]]], ["11 Abrogation of 9-O-acetylated deleteriously affects development of transgenic mice.", [["9-O", "CHEMICAL", 17, 20], ["9-O", "CHEMICAL", 17, 20], ["9-O-acetylated", "SIMPLE_CHEMICAL", 17, 31], ["mice", "ORGANISM", 80, 84], ["mice", "SPECIES", 80, 84], ["mice", "SPECIES", 80, 84], ["Abrogation", "TEST", 3, 13], ["transgenic mice", "OBSERVATION", 69, 84]]], ["This modification is also involved in cell specific recognition by influenza C and corona viruses.", [["cell", "ANATOMY", 38, 42], ["cell", "CELL", 38, 42], ["influenza C", "ORGANISM", 67, 78], ["corona viruses", "ORGANISM", 83, 97], ["influenza C and corona viruses", "PROBLEM", 67, 97], ["corona viruses", "OBSERVATION", 83, 97]]], ["12, 13 It has also been demonstrated that sialoglycoproteins having 9-O-acetylation are expressed on lymphoblasts of children with acute lymphoblastic leukemia.", [["lymphoblasts", "ANATOMY", 101, 113], ["acute lymphoblastic leukemia", "ANATOMY", 131, 159], ["acute lymphoblastic leukemia", "DISEASE", 131, 159], ["9-O", "CHEMICAL", 68, 71], ["sialoglycoproteins", "GENE_OR_GENE_PRODUCT", 42, 60], ["lymphoblasts", "CELL", 101, 113], ["children", "ORGANISM", 117, 125], ["acute lymphoblastic leukemia", "CANCER", 131, 159], ["lymphoblasts", "CELL_TYPE", 101, 113], ["children", "SPECIES", 117, 125], ["sialoglycoproteins", "TEST", 42, 60], ["acute lymphoblastic leukemia", "PROBLEM", 131, 159], ["acute", "OBSERVATION_MODIFIER", 131, 136], ["lymphoblastic leukemia", "OBSERVATION", 137, 159]]], ["14 Glycoproteins and gangliosides from rat, mouse and chicken erythrocytes express Neu5,9Ac 2 -a-(2?3)-Galb-(1?3)-GalNAc, which serves as targets for the binding of naturally occurring antibodies.", [["erythrocytes", "ANATOMY", 62, 74], ["Neu5,9Ac 2 -a-(2?3)-Galb-(1?3)-GalNAc", "CHEMICAL", 83, 120], ["GalNAc", "CHEMICAL", 114, 120], ["Glycoproteins", "GENE_OR_GENE_PRODUCT", 3, 16], ["gangliosides", "GENE_OR_GENE_PRODUCT", 21, 33], ["rat", "ORGANISM", 39, 42], ["mouse", "ORGANISM", 44, 49], ["chicken", "ORGANISM", 54, 61], ["erythrocytes", "CELL", 62, 74], ["Neu5", "GENE_OR_GENE_PRODUCT", 83, 87], ["9Ac 2 -a-(2?3)-Galb-(1?3)-GalNAc", "GENE_OR_GENE_PRODUCT", 88, 120], ["rat, mouse and chicken erythrocytes", "CELL_TYPE", 39, 74], ["Neu5", "PROTEIN", 83, 87], ["antibodies", "PROTEIN", 185, 195], ["rat", "SPECIES", 39, 42], ["mouse", "SPECIES", 44, 49], ["chicken", "SPECIES", 54, 61], ["rat", "SPECIES", 39, 42], ["mouse", "SPECIES", 44, 49], ["chicken", "SPECIES", 54, 61], ["Glycoproteins and gangliosides", "TREATMENT", 3, 33], ["Neu5", "TEST", 83, 87]]], ["12, 15, 16 In microorganisms, such as the trypanosoma parasite Crithidia fasciculata and the pathogenic fungus Cryptococcus neoformans, Neu5,9Ac 2 can be glycosidically linked to Gal-b-(1?3)-GalNAc.", [["Cryptococcus neoformans", "DISEASE", 111, 134], ["Gal-b-(1?3)-GalNAc", "CHEMICAL", 179, 197], ["Gal-b-(1?3)-GalNAc", "CHEMICAL", 179, 197], ["trypanosoma parasite", "ORGANISM", 42, 62], ["Crithidia fasciculata", "ORGANISM", 63, 84], ["fungus Cryptococcus neoformans", "ORGANISM", 104, 134], ["Neu5", "GENE_OR_GENE_PRODUCT", 136, 140], ["9Ac 2", "GENE_OR_GENE_PRODUCT", 141, 146], ["Gal-b-(1?3)-GalNAc", "GENE_OR_GENE_PRODUCT", 179, 197], ["Gal-b", "PROTEIN", 179, 184], ["Crithidia fasciculata", "SPECIES", 63, 84], ["Cryptococcus neoformans", "SPECIES", 111, 134], ["Crithidia fasciculata", "SPECIES", 63, 84], ["Cryptococcus neoformans", "SPECIES", 111, 134], ["microorganisms", "PROBLEM", 14, 28], ["the trypanosoma parasite Crithidia fasciculata", "PROBLEM", 38, 84], ["the pathogenic fungus Cryptococcus neoformans", "PROBLEM", 89, 134], ["microorganisms", "OBSERVATION", 14, 28], ["trypanosoma", "OBSERVATION_MODIFIER", 42, 53], ["parasite", "OBSERVATION_MODIFIER", 54, 62], ["Crithidia fasciculata", "OBSERVATION", 63, 84], ["pathogenic", "OBSERVATION_MODIFIER", 93, 103], ["fungus", "OBSERVATION_MODIFIER", 104, 110], ["Cryptococcus neoformans", "OBSERVATION", 111, 134]]], ["17, 18 The potential impact of 9-O-acetylation of the GD 1a ganglioside on the overall conformation and recognition by a natural human antibody has been investigated by molecular dynamics simulations and NMR.", [["9-O-", "CHEMICAL", 31, 35], ["9-O-", "CHEMICAL", 31, 35], ["ganglioside", "CHEMICAL", 60, 71], ["9-O-", "SIMPLE_CHEMICAL", 31, 35], ["GD 1a ganglioside", "SIMPLE_CHEMICAL", 54, 71], ["human", "ORGANISM", 129, 134], ["natural human antibody", "PROTEIN", 121, 143], ["human", "SPECIES", 129, 134], ["human", "SPECIES", 129, 134], ["a natural human antibody", "TEST", 119, 143]]], ["It was found that acetylation did not affect the conformational properties of the oligosaccharide.", [["acetylation", "PROBLEM", 18, 29], ["the oligosaccharide", "TREATMENT", 78, 97]]], ["However, it was shown that an antibody specific for a 9-O-acetylated ganglioside can make direct interactions with the acetyl group rationalizing the selective recognition of acetylated derivatives.", [["9-O", "CHEMICAL", 54, 57], ["acetyl", "CHEMICAL", 119, 125], ["9-O-acetylated ganglioside", "CHEMICAL", 54, 80], ["acetyl", "CHEMICAL", 119, 125], ["9-O-acetylated ganglioside", "SIMPLE_CHEMICAL", 54, 80], ["acetyl", "SIMPLE_CHEMICAL", 119, 125], ["acetylated derivatives", "SIMPLE_CHEMICAL", 175, 197], ["an antibody", "TEST", 27, 38], ["acetylated ganglioside", "TREATMENT", 58, 80], ["the acetyl group", "TREATMENT", 115, 131], ["acetylated derivatives", "TREATMENT", 175, 197], ["acetylated derivatives", "OBSERVATION", 175, 197]]], ["16, 19 As part of a program to develop monoclonal antibodies against sialo-oligosaccharides bearing 9-O-acetyl esters, we report here an efficient chemo-enzymatic synthesis of Neu5,9Ac 2 -a-(2?3)-Gal-b-(1?3)-Gal-NAc-O-Ser (1) .", [["9-O-acetyl esters", "CHEMICAL", 100, 117], ["Neu5,9Ac 2 -a-(2?3)-Gal-b-(1?3)-Gal-NAc-O-Ser", "CHEMICAL", 176, 221], ["9-O-acetyl esters", "CHEMICAL", 100, 117], ["Neu5,9Ac 2 -a-(2?3)-Gal-b-(1?3)-Gal-NAc-O-Ser", "CHEMICAL", 176, 221], ["sialo-oligosaccharides", "SIMPLE_CHEMICAL", 69, 91], ["9-O-acetyl esters", "SIMPLE_CHEMICAL", 100, 117], ["Neu5,9Ac 2 -a-(2?3)-Gal-b-(1?3)-Gal-NAc-O-Ser (1)", "SIMPLE_CHEMICAL", 176, 225], ["monoclonal antibodies", "PROTEIN", 39, 60], ["monoclonal antibodies", "TEST", 39, 60], ["Neu5", "TEST", 176, 180]]], ["It is to be expected that this compound can be employed for the preparation of fully synthetic immunogens for the development of monoclonal antibodies.", [["monoclonal antibodies", "PROTEIN", 129, 150], ["fully synthetic immunogens", "TREATMENT", 79, 105], ["monoclonal antibodies", "PROBLEM", 129, 150], ["monoclonal antibodies", "OBSERVATION", 129, 150]]], ["20-22Results and discussionWhile relatively efficient methods have been developed for the introduction of sialosides, the preparation of acetylated analogues is less well developed.", [["sialosides", "CHEMICAL", 106, 116], ["sialosides", "CHEMICAL", 106, 116], ["20-22Results", "SIMPLE_CHEMICAL", 0, 12], ["sialosides", "SIMPLE_CHEMICAL", 106, 116], ["the introduction of sialosides", "TREATMENT", 86, 116], ["the preparation of acetylated analogues", "TREATMENT", 118, 157], ["acetylated analogues", "OBSERVATION", 137, 157]]], ["It was anticipated that compound 1 could be prepared by a regioselective chemical acetylation 23 of Neu5Ac (2) to give 9-O-acetylated sialic acid 3, which can then be enzymatically converted into CMP-Neu5,9Ac 2 (4) employing the recombinant CMP-sialic acid synthetase from Neisseria meningitis.", [["Neu5Ac (2)", "CHEMICAL", 100, 110], ["9-O", "CHEMICAL", 119, 122], ["sialic acid", "CHEMICAL", 134, 145], ["CMP-Neu5,9Ac 2 (4)", "CHEMICAL", 196, 214], ["CMP-sialic acid", "CHEMICAL", 241, 256], ["Neisseria meningitis", "DISEASE", 273, 293], ["Neu5Ac", "CHEMICAL", 100, 106], ["9-O-acetylated sialic acid", "CHEMICAL", 119, 145], ["CMP-Neu5,9Ac 2 (4)", "CHEMICAL", 196, 214], ["sialic acid", "CHEMICAL", 245, 256], ["Neu5Ac (2)", "SIMPLE_CHEMICAL", 100, 110], ["9-O-acetylated sialic acid 3", "SIMPLE_CHEMICAL", 119, 147], ["CMP-Neu5", "SIMPLE_CHEMICAL", 196, 204], ["9Ac 2 (4)", "SIMPLE_CHEMICAL", 205, 214], ["CMP-sialic acid", "SIMPLE_CHEMICAL", 241, 256], ["Neisseria meningitis", "ORGANISM", 273, 293], ["recombinant CMP-sialic acid synthetase", "PROTEIN", 229, 267], ["Neisseria meningitis", "SPECIES", 273, 293], ["a regioselective chemical acetylation", "TREATMENT", 56, 93], ["Neu5Ac", "TREATMENT", 100, 106], ["acetylated sialic acid", "TREATMENT", 123, 145], ["CMP", "TEST", 196, 199], ["the recombinant CMP", "TREATMENT", 225, 244], ["sialic acid synthetase", "TREATMENT", 245, 267], ["Neisseria meningitis", "PROBLEM", 273, 293], ["meningitis", "OBSERVATION", 283, 293]]], ["This enzyme possesses a flexible substrate specificity and has been employed for the synthesis of CMP-sialic acid analogues such as CMP-Neu5,9Ac 2 .", [["CMP-sialic acid", "CHEMICAL", 98, 113], ["CMP", "CHEMICAL", 132, 135], ["CMP-sialic acid", "CHEMICAL", 98, 113], ["CMP-Neu5,9Ac 2", "CHEMICAL", 132, 146], ["CMP-sialic acid", "SIMPLE_CHEMICAL", 98, 113], ["CMP-Neu5,9Ac 2", "SIMPLE_CHEMICAL", 132, 146], ["This enzyme", "TEST", 0, 11], ["a flexible substrate specificity", "TEST", 22, 54], ["CMP", "TEST", 98, 101], ["sialic acid analogues", "TREATMENT", 102, 123], ["CMP", "TEST", 132, 135]]], ["24, 25, 30 The resulting compound can then be used for the enzymatic glycosylation 26 of the C-3 0 hydroxyl of chemically prepared glycopeptide 10 using the recombinant rat a-(2?3)-sialyltransferase [EC 2.4.99.4] expressed in Spodooptera frugiperda to give, after removal of the N a -CBz protecting group of serine, target compound 1.Results and discussionSialyltransferases exhibit some flexibility with regard to the structure of their acceptors and are able to trans-fer modified sialic acids from corresponding CMP-derivatives.", [["C-3 0 hydroxyl", "CHEMICAL", 93, 107], ["sialic acids", "CHEMICAL", 483, 495], ["CMP", "CHEMICAL", 515, 518], ["hydroxyl", "CHEMICAL", 99, 107], ["N a -CBz", "CHEMICAL", 279, 287], ["serine", "CHEMICAL", 308, 314], ["sialic acids", "CHEMICAL", 483, 495], ["C-3 0 hydroxyl", "SIMPLE_CHEMICAL", 93, 107], ["rat", "ORGANISM", 169, 172], ["a-(2?3)-sialyltransferase", "GENE_OR_GENE_PRODUCT", 173, 198], ["Spodooptera frugiperda", "ORGANISM", 226, 248], ["serine", "AMINO_ACID", 308, 314], ["Sialyltransferases", "GENE_OR_GENE_PRODUCT", 356, 374], ["sialic acids", "SIMPLE_CHEMICAL", 483, 495], ["CMP-derivatives", "SIMPLE_CHEMICAL", 515, 530], ["sialyltransferase", "PROTEIN", 181, 198], ["rat", "SPECIES", 169, 172], ["Spodooptera frugiperda", "SPECIES", 226, 248], ["Spodooptera frugiperda", "SPECIES", 226, 248], ["the enzymatic glycosylation", "TREATMENT", 55, 82], ["the C-3 0 hydroxyl of chemically prepared glycopeptide", "TREATMENT", 89, 143], ["Spodooptera frugiperda", "TREATMENT", 226, 248], ["removal", "TREATMENT", 264, 271], ["the N a -CBz protecting group of serine", "TREATMENT", 275, 314], ["CMP-derivatives", "TREATMENT", 515, 530]]], ["24, 25, 27 For example, a rat liver a-(2?3)sialyltransferase has been used to transfer Neu5,9Ac 2 from the corresponding CMP-donor to various glycoproteins, 28 and a porcine liver a(2?6)-sialyltransferase has been employed for the chemo-enzymatic synthesis of Neu5,9Ac 2 -a-(2?6)-Gal-b-(1?4)-GlcNAc-a-OCH 3 .", [["liver", "ANATOMY", 30, 35], ["liver", "ANATOMY", 174, 179], ["Neu5,9Ac 2 -a-(2?6)-Gal-b-(1?4)-GlcNAc-a-OCH", "CHEMICAL", 260, 304], ["Neu5,9Ac 2", "CHEMICAL", 87, 97], ["Neu5,9Ac 2 -a-(2?6)-Gal-b-(1?4)-GlcNAc-a-OCH", "CHEMICAL", 260, 304], ["rat", "ORGANISM", 26, 29], ["liver", "ORGAN", 30, 35], ["2?3)sialyltransferase", "GENE_OR_GENE_PRODUCT", 39, 60], ["Neu5", "GENE_OR_GENE_PRODUCT", 87, 91], ["9Ac 2", "GENE_OR_GENE_PRODUCT", 92, 97], ["porcine", "ORGANISM", 166, 173], ["liver", "ORGAN", 174, 179], ["2?6)-sialyltransferase", "GENE_OR_GENE_PRODUCT", 182, 204], ["Neu5,9Ac 2 -a-(2?6)-Gal-b-(1?4)-GlcNAc-a-OCH 3", "SIMPLE_CHEMICAL", 260, 306], ["rat liver a-(2?3)sialyltransferase", "PROTEIN", 26, 60], ["Neu5", "PROTEIN", 87, 91], ["9Ac 2", "PROTEIN", 92, 97], ["CMP", "PROTEIN", 121, 124], ["sialyltransferase", "PROTEIN", 187, 204], ["rat", "SPECIES", 26, 29], ["porcine", "SPECIES", 166, 173], ["a porcine liver a", "TREATMENT", 164, 181], ["the chemo-enzymatic synthesis of Neu5,9Ac", "TREATMENT", 227, 268], ["liver", "ANATOMY", 30, 35], ["liver", "ANATOMY", 174, 179]]], ["24 Recently, a library of (2?6)-linked modified sialosides of Gal-b-(1?4)-GlcNAc-a-O-(CH 2 ) 3 N 3 , which includes four 9-O-acetylated sialoside derivatives, has been prepared using the flexible recombinant Photobacterium damsela [EC 2.4.99.1] a-(2?6)-sialyltransferase by a one-pot three-enzyme system.", [["sialosides", "CHEMICAL", 48, 58], ["Gal-b-(1?4)-GlcNAc-a-O-(CH 2 ) 3 N 3", "CHEMICAL", 62, 98], ["sialosides", "CHEMICAL", 48, 58], ["Gal-b-(1?4)-GlcNAc-a-O-(CH 2 ) 3 N 3", "CHEMICAL", 62, 98], ["9-O-acetylated sialoside", "CHEMICAL", 121, 145], ["(2?6)-linked modified sialosides", "SIMPLE_CHEMICAL", 26, 58], ["Gal-b-(1?4)-GlcNAc-a-O-(CH 2 ) 3 N 3", "SIMPLE_CHEMICAL", 62, 98], ["9-O-acetylated sialoside derivatives", "SIMPLE_CHEMICAL", 121, 157], ["-(2?6)-sialyltransferase", "GENE_OR_GENE_PRODUCT", 246, 270], ["sialyltransferase", "PROTEIN", 253, 270], ["Photobacterium damsela", "SPECIES", 208, 230], ["Photobacterium damsela", "SPECIES", 208, 230], ["Gal-b", "TEST", 62, 67], ["GlcNAc-a-O", "TEST", 74, 84], ["acetylated sialoside derivatives", "TREATMENT", 125, 157], ["the flexible recombinant Photobacterium damsela", "TREATMENT", 183, 230], ["EC", "TEST", 232, 234], ["Gal", "ANATOMY_MODIFIER", 62, 65], ["-b", "ANATOMY", 65, 67]]], ["29 The enzymatic synthesis of the Neu5,9Ac 2 -a-(2?3)-Gal-O-p-nitrophenyl glycoside has also been reported.", [["Neu5,9Ac 2 -a-(2?3)-Gal-O-p-nitrophenyl glycoside", "CHEMICAL", 34, 83], ["Neu5,9Ac 2 -a-(2?3)-Gal-O-p-nitrophenyl glycoside", "CHEMICAL", 34, 83], ["Neu5", "SIMPLE_CHEMICAL", 34, 38], ["9Ac 2 -a-(2?3)-Gal-O-p-nitrophenyl glycoside", "SIMPLE_CHEMICAL", 39, 83], ["O-p-nitrophenyl glycoside", "TREATMENT", 58, 83], ["enzymatic synthesis", "OBSERVATION", 7, 26]]], ["30 It was anticipated that C-9 derivatives of sialic acid (Neu5Ac) would be readily available from Neu5Ac by a chemical regioselective acetylation.", [["C-9", "CHEMICAL", 27, 30], ["sialic acid", "CHEMICAL", 46, 57], ["Neu5Ac", "CHEMICAL", 59, 65], ["Neu5Ac", "CHEMICAL", 99, 105], ["sialic acid", "CHEMICAL", 46, 57], ["Neu5Ac", "CHEMICAL", 59, 65], ["Neu5Ac", "CHEMICAL", 99, 105], ["C-9 derivatives", "SIMPLE_CHEMICAL", 27, 42], ["sialic acid", "SIMPLE_CHEMICAL", 46, 57], ["Neu5Ac", "SIMPLE_CHEMICAL", 59, 65], ["Neu5Ac", "SIMPLE_CHEMICAL", 99, 105], ["C-9 derivatives", "TREATMENT", 27, 42], ["sialic acid (Neu5Ac)", "TREATMENT", 46, 66], ["Neu5Ac", "TREATMENT", 99, 105], ["a chemical regioselective acetylation", "TREATMENT", 109, 146]]], ["The reported purification strategy 25 gave a compound 4 contaminated with phosphorylated nucleotides (CTP, CDP and CMP) and a small amount of CMP-Neu5Ac and Neu5Ac.", [["CTP", "CHEMICAL", 102, 105], ["CDP", "CHEMICAL", 107, 110], ["CMP", "CHEMICAL", 115, 118], ["nucleotides", "CHEMICAL", 89, 100], ["CTP", "CHEMICAL", 102, 105], ["CDP", "CHEMICAL", 107, 110], ["CMP", "CHEMICAL", 115, 118], ["Neu5Ac", "CHEMICAL", 146, 152], ["Neu5Ac", "CHEMICAL", 157, 163], ["CTP", "SIMPLE_CHEMICAL", 102, 105], ["CDP", "SIMPLE_CHEMICAL", 107, 110], ["CMP", "SIMPLE_CHEMICAL", 115, 118], ["CMP-Neu5Ac", "GENE_OR_GENE_PRODUCT", 142, 152], ["Neu5Ac", "GENE_OR_GENE_PRODUCT", 157, 163], ["phosphorylated nucleotides", "TREATMENT", 74, 100], ["CTP", "TEST", 102, 105], ["CDP", "TEST", 107, 110], ["CMP", "TEST", 115, 118], ["CMP", "TEST", 142, 145], ["Neu5Ac", "TREATMENT", 157, 163], ["small", "OBSERVATION_MODIFIER", 126, 131], ["amount", "OBSERVATION_MODIFIER", 132, 138]]], ["However, it was found that highly pure 4 could be obtained by removal of inorganic salts by selective precipitation 31 in an ethanol-H 2 O mixture (9:1, v:v, twice) followed by size exclusion chromatography over extra fine Biogel P-2 using ammonium bicarbonate buffer as eluent at 4\u00b0C.Results and discussionGlycosylation of thioglycoside 5 32 with properly protected serine derivative 6 26 in the presence of Ph 2 SO-Tf 2 O and DTBMP provided the a-linked glycopeptide 7 in 83% yield with excellent a-anomeric selectivityResults and discussion.", [["inorganic salts", "CHEMICAL", 73, 88], ["ethanol", "CHEMICAL", 125, 132], ["H", "CHEMICAL", 133, 134], ["ammonium bicarbonate", "CHEMICAL", 240, 260], ["thioglycoside 5 32", "CHEMICAL", 324, 342], ["serine derivative 6 26", "CHEMICAL", 367, 389], ["Ph 2 SO-Tf 2 O", "CHEMICAL", 409, 423], ["DTBMP", "CHEMICAL", 428, 433], ["ethanol", "CHEMICAL", 125, 132], ["H 2 O", "CHEMICAL", 133, 138], ["ammonium bicarbonate", "CHEMICAL", 240, 260], ["thioglycoside", "CHEMICAL", 324, 337], ["serine", "CHEMICAL", 367, 373], ["Ph 2 SO-Tf 2 O", "CHEMICAL", 409, 423], ["DTBMP", "CHEMICAL", 428, 433], ["inorganic salts", "SIMPLE_CHEMICAL", 73, 88], ["ethanol", "SIMPLE_CHEMICAL", 125, 132], ["H 2 O mixture", "SIMPLE_CHEMICAL", 133, 146], ["ammonium bicarbonate", "SIMPLE_CHEMICAL", 240, 260], ["thioglycoside 5 32", "SIMPLE_CHEMICAL", 324, 342], ["serine derivative 6 26", "SIMPLE_CHEMICAL", 367, 389], ["Ph 2 SO-Tf 2 O", "SIMPLE_CHEMICAL", 409, 423], ["DTBMP", "SIMPLE_CHEMICAL", 428, 433], ["removal of inorganic salts", "TREATMENT", 62, 88], ["ammonium bicarbonate buffer", "TREATMENT", 240, 267], ["Glycosylation of thioglycoside", "TREATMENT", 307, 337], ["properly protected serine derivative", "TREATMENT", 348, 384], ["DTBMP", "TREATMENT", 428, 433], ["the a-linked glycopeptide", "TREATMENT", 443, 468]]], ["Treatment of 7 with aqueous acetic acid removed the benzylidene acetal and acetylation of the resulting free hydroxyls gave compound 8 in excellent overall yield.", [["acetic acid", "CHEMICAL", 28, 39], ["benzylidene acetal", "CHEMICAL", 52, 70], ["acetic acid", "CHEMICAL", 28, 39], ["benzylidene acetal", "CHEMICAL", 52, 70], ["hydroxyls", "CHEMICAL", 109, 118], ["aqueous acetic acid", "SIMPLE_CHEMICAL", 20, 39], ["benzylidene acetal", "SIMPLE_CHEMICAL", 52, 70], ["free hydroxyls", "SIMPLE_CHEMICAL", 104, 118], ["Treatment", "TREATMENT", 0, 9], ["aqueous acetic acid", "TREATMENT", 20, 39], ["the benzylidene acetal", "TREATMENT", 48, 70], ["acetylation", "TREATMENT", 75, 86], ["the resulting free hydroxyls", "TREATMENT", 90, 118]]], ["Next, the azido moiety of 8 was converted into an acetamido derivative by reaction with thioacetic acid in pyridine [33] [34] [35] and the resulting compound 9 was treated with a mixture of TFA and water to remove the t-butyl ester, and then with NaOMe in methanol to cleave the acetyl esters to give glycopeptide 10.", [["azido", "CHEMICAL", 10, 15], ["acetamido", "CHEMICAL", 50, 59], ["thioacetic acid", "CHEMICAL", 88, 103], ["pyridine [33] [34] [35]", "CHEMICAL", 107, 130], ["compound 9", "CHEMICAL", 149, 159], ["TFA", "CHEMICAL", 190, 193], ["t-butyl ester", "CHEMICAL", 218, 231], ["NaOMe", "CHEMICAL", 247, 252], ["acetyl esters", "CHEMICAL", 279, 292], ["azido", "CHEMICAL", 10, 15], ["acetamido", "CHEMICAL", 50, 59], ["thioacetic acid", "CHEMICAL", 88, 103], ["pyridine", "CHEMICAL", 107, 115], ["TFA", "CHEMICAL", 190, 193], ["t-butyl ester", "CHEMICAL", 218, 231], ["NaOMe", "CHEMICAL", 247, 252], ["methanol", "CHEMICAL", 256, 264], ["acetyl esters", "CHEMICAL", 279, 292], ["acetamido derivative", "SIMPLE_CHEMICAL", 50, 70], ["thioacetic acid", "SIMPLE_CHEMICAL", 88, 103], ["pyridine [33] [34] [35]", "SIMPLE_CHEMICAL", 107, 130], ["TFA", "SIMPLE_CHEMICAL", 190, 193], ["water", "SIMPLE_CHEMICAL", 198, 203], ["t-butyl ester", "SIMPLE_CHEMICAL", 218, 231], ["NaOMe", "SIMPLE_CHEMICAL", 247, 252], ["methanol", "SIMPLE_CHEMICAL", 256, 264], ["acetyl esters", "SIMPLE_CHEMICAL", 279, 292], ["the azido moiety", "TREATMENT", 6, 22], ["an acetamido derivative", "TREATMENT", 47, 70], ["thioacetic acid in pyridine", "TREATMENT", 88, 115], ["a mixture of TFA", "TREATMENT", 177, 193], ["the t-butyl ester", "TREATMENT", 214, 231], ["methanol", "TREATMENT", 256, 264], ["the acetyl esters", "TREATMENT", 275, 292], ["glycopeptide", "TREATMENT", 301, 313]]], ["36 At this stage of the synthesis, the Cbz group was kept intact because protection of the amino group of serine is required for glycopeptide synthesis.Results and discussionNext, attention was focused on the enzymatic sialylation of 10 using a CMP-Neu5,9Ac 2 donor (4) (Scheme 3).", [["Cbz", "CHEMICAL", 39, 42], ["amino", "CHEMICAL", 91, 96], ["Cbz", "CHEMICAL", 39, 42], ["amino", "CHEMICAL", 91, 96], ["serine", "CHEMICAL", 106, 112], ["Cbz", "SIMPLE_CHEMICAL", 39, 42], ["amino", "AMINO_ACID", 91, 96], ["serine", "AMINO_ACID", 106, 112], ["glycopeptide", "SIMPLE_CHEMICAL", 129, 141], ["Cbz group", "PROTEIN", 39, 48], ["the synthesis", "TREATMENT", 20, 33], ["the Cbz group", "TREATMENT", 35, 48], ["the amino group of serine", "TREATMENT", 87, 112], ["glycopeptide synthesis", "TREATMENT", 129, 151], ["the enzymatic sialylation", "TEST", 205, 230], ["a CMP", "TREATMENT", 243, 248]]], ["Thus, the recombinant rat a-(2?3)-sialyltransferase [EC 2.4.99.4] expressed in S. frugiperda and a calf intestine alkaline phosphatase [EC 3.6.1.1] were added to a mixture of 4 and 10 dissolved in cacodylate buffer (50 mM; pH 6.2) containing Triton X-100 and BSA.", [["calf intestine", "ANATOMY", 99, 113], ["Triton X-100", "CHEMICAL", 242, 254], ["cacodylate", "CHEMICAL", 197, 207], ["Triton X-100", "CHEMICAL", 242, 254], ["rat", "ORGANISM", 22, 25], ["a-(2?3)-sialyltransferase", "GENE_OR_GENE_PRODUCT", 26, 51], ["S. frugiperda", "ORGANISM", 79, 92], ["intestine", "ORGAN", 104, 113], ["cacodylate buffer", "SIMPLE_CHEMICAL", 197, 214], ["Triton X-100", "SIMPLE_CHEMICAL", 242, 254], ["BSA", "SIMPLE_CHEMICAL", 259, 262], ["sialyltransferase", "PROTEIN", 34, 51], ["calf intestine alkaline phosphatase", "PROTEIN", 99, 134], ["rat", "SPECIES", 22, 25], ["S. frugiperda", "SPECIES", 79, 92], ["calf", "SPECIES", 99, 103], ["S. frugiperda", "SPECIES", 79, 92], ["calf", "SPECIES", 99, 103], ["EC", "TEST", 53, 55], ["a calf intestine alkaline phosphatase", "TEST", 97, 134], ["EC", "TEST", 136, 138], ["cacodylate buffer", "TREATMENT", 197, 214], ["pH", "TEST", 223, 225], ["Triton", "TREATMENT", 242, 248], ["calf intestine", "ANATOMY", 99, 113]]], ["37 After incubation at 37\u00b0C for 2 h, another portion of alkaline phosphatase and CMP-Neu5,9Ac 2 (4) was added and after occasional stirring for an additional 3.5 h, TLC analysis showed complete consumption of the starting material 4 and the formation of a new product.", [["CMP-Neu5,9Ac 2 (4)", "CHEMICAL", 81, 99], ["CMP-Neu5", "CHEMICAL", 81, 89], ["CMP-Neu5", "SIMPLE_CHEMICAL", 81, 89], ["9Ac 2 (4)", "SIMPLE_CHEMICAL", 90, 99], ["alkaline phosphatase", "PROTEIN", 56, 76], ["alkaline phosphatase", "TEST", 56, 76], ["CMP", "TEST", 81, 84], ["Neu5", "TREATMENT", 85, 89], ["TLC analysis", "TEST", 165, 177], ["new", "OBSERVATION_MODIFIER", 256, 259]]], ["Purification of the crude reaction mixture by a reverse-phase C 18 column chromatography followed by an ion exchange chromatography using Biorad AG 50W-X8 (100-200 mesh, Na + form) at 4\u00b0C, gave a pure trisaccharide 11 in a yield of 69%.", [["AG 50W-X8", "CHEMICAL", 145, 154], ["Na", "CHEMICAL", 170, 172], ["Na", "CHEMICAL", 170, 172], ["trisaccharide", "CHEMICAL", 201, 214], ["Na +", "SIMPLE_CHEMICAL", 170, 174], ["the crude reaction mixture", "PROBLEM", 16, 42], ["a reverse-phase C 18 column chromatography", "TREATMENT", 46, 88], ["an ion exchange chromatography", "TEST", 101, 131], ["Biorad AG", "TREATMENT", 138, 147], ["a pure trisaccharide", "TREATMENT", 194, 214]]], ["In addition, a small amount (<5%) of 9-O-deacetylated product was also isolated.Results and discussionCompound 11 is appropriately protected for glycopeptide synthesis.", [["9-O", "CHEMICAL", 37, 40], ["9-O", "CHEMICAL", 37, 40], ["9-O-deacetylated product", "SIMPLE_CHEMICAL", 37, 61], ["glycopeptide synthesis", "TREATMENT", 145, 167], ["small", "OBSERVATION_MODIFIER", 15, 20], ["amount", "OBSERVATION_MODIFIER", 21, 27]]], ["However, fully unprotected 1 could be obtained by catalytic hydrogenation over Pd-C to remove the N a -Cbz group followed by purification by a Biogel P-2 size exclusion column chromatography.", [["Pd-C", "CHEMICAL", 79, 83], ["Pd-C", "CHEMICAL", 79, 83], ["N a -Cbz", "CHEMICAL", 98, 106], ["Pd-C", "SIMPLE_CHEMICAL", 79, 83], ["N a -Cbz", "SIMPLE_CHEMICAL", 98, 106], ["the N a -Cbz group", "TREATMENT", 94, 112], ["a Biogel P-2 size exclusion column chromatography", "TREATMENT", 141, 190]]], ["The chemical shift of the C-9 protons clearly demonstrated the presence of the C-9 acetyl ester: 4.37 (dd, 1H, J 8 00 ;9 00 a \u00bc 2:2 Hz, J 9 00 a;9 00 b \u00bc 12:0 Hz, H-9 00 a) and 4.19 (dd, 1H, J 8 00 ;9 00 b \u00bc 5:8 Hz, J 9 00 a;9 00 b \u00bc 12:0 Hz, H-9 00 b).Results and discussionIn conclusion, we have developed an efficient chemoenzymatic synthesis of the trisaccharide 11, which is appropriately protected for glycopeptide synthesis.", [["C-9", "CHEMICAL", 26, 29], ["C-9 acetyl ester", "CHEMICAL", 79, 95], ["C-9 acetyl ester", "CHEMICAL", 79, 95], ["1H", "CHEMICAL", 107, 109], ["1H", "CHEMICAL", 187, 189], ["trisaccharide", "CHEMICAL", 353, 366], ["C-9 protons", "SIMPLE_CHEMICAL", 26, 37], ["C-9 acetyl ester", "SIMPLE_CHEMICAL", 79, 95], ["trisaccharide 11", "SIMPLE_CHEMICAL", 353, 369], ["the C", "TEST", 75, 80], ["acetyl ester", "TEST", 83, 95], ["dd", "TEST", 103, 105], ["J", "TEST", 111, 112], ["a \u00bc 2:2 Hz", "TEST", 124, 134], ["J", "TEST", 136, 137], ["Hz", "TEST", 159, 161], ["H", "TEST", 163, 164], ["dd", "TEST", 183, 185], ["1H", "TEST", 187, 189], ["J", "TEST", 191, 192], ["Hz", "TEST", 212, 214], ["J", "TEST", 216, 217], ["a", "TEST", 223, 224], ["Hz", "TEST", 239, 241], ["H", "TEST", 243, 244], ["an efficient chemoenzymatic synthesis of the trisaccharide", "TREATMENT", 308, 366], ["glycopeptide synthesis", "TREATMENT", 408, 430], ["efficient", "OBSERVATION_MODIFIER", 311, 320], ["chemoenzymatic synthesis", "OBSERVATION", 321, 345]]], ["It has been shown that the rat recombinant a-(2?3)-sialyltransferase expressed in S. frugiperda can accept CMP-Neu5,9Ac 2 as a donor.", [["rat", "ORGANISM", 27, 30], ["a-(2?3)-sialyltransferase", "GENE_OR_GENE_PRODUCT", 43, 68], ["S. frugiperda", "ORGANISM", 82, 95], ["9Ac 2", "GENE_OR_GENE_PRODUCT", 116, 121], ["rat recombinant a-(2?3)-sialyltransferase", "PROTEIN", 27, 68], ["rat", "SPECIES", 27, 30], ["S. frugiperda", "SPECIES", 82, 95], ["rat", "SPECIES", 27, 30], ["S. frugiperda", "SPECIES", 82, 95]]], ["The improved purification protocol for CMP-Neu5,9Ac 2 was essential for the successful transfer of CMP-Neu5,9Ac 2 to glycosyl acceptor Gal-b- and AG 50W-X8 (100-200 mesh) ion exchange resin were obtained from Bio-Rad; preparative C 18 silica gel (125 \u00c5 , 55-105 lm) was obtained from Waters and Iatrobeads 6RS-8060 (60 lm) were purchased from Bioscan.", [["CMP-Neu5", "CHEMICAL", 39, 47], ["Iatrobeads 6RS-8060", "CHEMICAL", 295, 314], ["CMP-Neu5,9Ac 2", "CHEMICAL", 39, 53], ["CMP-Neu5,9Ac 2", "CHEMICAL", 99, 113], ["glycosyl", "CHEMICAL", 117, 125], ["Gal-b- and AG 50W-X8", "CHEMICAL", 135, 155], ["silica", "CHEMICAL", 235, 241], ["6RS-8060", "CHEMICAL", 306, 314], ["CMP-Neu5", "SIMPLE_CHEMICAL", 39, 47], ["9Ac 2", "SIMPLE_CHEMICAL", 48, 53], ["CMP-Neu5", "SIMPLE_CHEMICAL", 99, 107], ["9Ac 2", "SIMPLE_CHEMICAL", 108, 113], ["glycosyl acceptor Gal-b", "SIMPLE_CHEMICAL", 117, 140], ["AG 50W-X8", "SIMPLE_CHEMICAL", 146, 155], ["C 18 silica", "SIMPLE_CHEMICAL", 230, 241], ["The improved purification protocol", "TREATMENT", 0, 34], ["CMP", "TEST", 39, 42], ["CMP", "TEST", 99, 102], ["Neu5", "TEST", 103, 107], ["Gal-b", "TEST", 135, 140], ["AG", "TEST", 146, 148], ["ion exchange resin", "TEST", 171, 189], ["preparative C 18 silica gel", "TREATMENT", 218, 245], ["Iatrobeads", "TEST", 295, 305], ["Rad", "ANATOMY", 213, 216]]], ["Thin layer chromatography (TLC) was performed using Kieselgel 60 F 254 (Merck) plates with detection by UV and/or by charring with 5% sulfuric acid in ethanol, cerium ammonium nitrate or p-anisaldehyde reagents.", [["sulfuric acid", "CHEMICAL", 134, 147], ["ethanol", "CHEMICAL", 151, 158], ["cerium ammonium nitrate", "CHEMICAL", 160, 183], ["p-anisaldehyde", "CHEMICAL", 187, 201], ["sulfuric acid", "CHEMICAL", 134, 147], ["ethanol", "CHEMICAL", 151, 158], ["cerium ammonium nitrate", "CHEMICAL", 160, 183], ["p-anisaldehyde", "CHEMICAL", 187, 201], ["sulfuric acid", "SIMPLE_CHEMICAL", 134, 147], ["ethanol", "SIMPLE_CHEMICAL", 151, 158], ["cerium ammonium nitrate", "SIMPLE_CHEMICAL", 160, 183], ["p-anisaldehyde reagents", "SIMPLE_CHEMICAL", 187, 210], ["Thin layer chromatography", "TEST", 0, 25], ["5% sulfuric acid in ethanol", "TREATMENT", 131, 158], ["cerium ammonium nitrate", "TREATMENT", 160, 183], ["p-anisaldehyde reagents", "TREATMENT", 187, 210]]], ["Solvent evaporations were done in vacuo with a bath temperature <25\u00b0C. Optical rotations were measured with a Jasco P-1020 polarimeter.", [["Jasco P-1020 polarimeter", "DNA", 110, 134], ["Solvent evaporations", "TREATMENT", 0, 20], ["a bath temperature", "TEST", 45, 63]]], ["Both positive and negative ion matrix-assisted laser desorption ionization time of flight (MALDI-TOF) mass spectra were recorded using an Applied Biosystems 4700 instrument with gentisic acid as matrix.", [["gentisic acid", "CHEMICAL", 178, 191], ["gentisic acid", "CHEMICAL", 178, 191], ["gentisic acid", "SIMPLE_CHEMICAL", 178, 191], ["matrix", "CELLULAR_COMPONENT", 195, 201], ["mass spectra", "PROBLEM", 102, 114], ["an Applied Biosystems", "TREATMENT", 135, 156], ["gentisic acid as matrix", "TREATMENT", 178, 201], ["positive", "OBSERVATION", 5, 13], ["negative", "OBSERVATION_MODIFIER", 18, 26], ["ion matrix", "OBSERVATION_MODIFIER", 27, 37]]], ["1D and 2D 1 H NMR and 13 C NMR spectra were recorded at 25\u00b0C on Varian Inova300, Varian Inova500, Varian Inova600 or Varian Inova900 spectrometers.", [["1 H", "CHEMICAL", 10, 13], ["C", "CHEMICAL", 25, 26], ["NMR", "TEST", 14, 17], ["C NMR spectra", "TEST", 25, 38], ["Varian Inova300", "TREATMENT", 64, 79], ["Varian Inova500", "TREATMENT", 81, 96], ["Varian Inova600", "TREATMENT", 98, 113], ["Varian Inova900 spectrometers", "TREATMENT", 117, 146]]], ["For 1 H spectra recorded in CDCl 3 , D 2 O and CH 3 OD and 13 C spectra recorded in CDCl 3 , chemical shifts are given in ppm relative to solvents peaks (CDCl 3 , 1 H 7.24; 13 C, 77.00; D 2 O, 1 H, 4.76; CH 3 OD, 1 H, 3.31, 4.78).", [["CDCl 3", "CHEMICAL", 28, 34], ["D 2 O", "CHEMICAL", 37, 42], ["CH 3 OD", "CHEMICAL", 47, 54], ["13 C", "CHEMICAL", 59, 63], ["CDCl 3", "CHEMICAL", 84, 90], ["H", "CHEMICAL", 165, 166], ["D 2 O", "CHEMICAL", 186, 191], ["H", "CHEMICAL", 195, 196], ["CH 3 OD", "CHEMICAL", 204, 211], ["D 2 O", "SIMPLE_CHEMICAL", 37, 42], ["CDCl", "TEST", 28, 32], ["D", "TEST", 37, 38], ["C spectra", "TEST", 62, 71], ["CDCl", "TEST", 84, 88], ["CDCl", "TEST", 154, 158], ["C", "TEST", 176, 177], ["D", "TEST", 186, 187], ["CH", "TEST", 204, 206], ["OD", "TEST", 209, 211]]], ["13 C Spectra recorded in D 2 O were indirectly referenced.", [["D 2 O", "CHEMICAL", 25, 30], ["D 2 O", "SIMPLE_CHEMICAL", 25, 30], ["Spectra recorded in D 2 O", "TEST", 5, 30]]], ["(7) Ph 2 SO (83 mg, 0.411 mmol), di-t-butyl-3-methyl pyridine (90.4 mg, 0.441 mmol) and crushed activated molecular sieves 4 \u00c5 (500 mg) were added to a cooled solution (\u00c070\u00b0C) of disaccharide 5, (120 mg, 0.147 mmol) in CH 2 Cl 2 (6 mL) prior to the addition of trifluoromethanesulfonic anhydride (58 mg, 36 lL, 0.205 mmol).", [["Ph 2 SO", "CHEMICAL", 4, 11], ["di-t-butyl-3-methyl pyridine", "CHEMICAL", 33, 61], ["disaccharide 5", "CHEMICAL", 179, 193], ["CH 2 Cl", "CHEMICAL", 219, 226], ["trifluoromethanesulfonic anhydride", "CHEMICAL", 261, 295], ["di-t-butyl-3-methyl pyridine", "CHEMICAL", 33, 61], ["disaccharide", "CHEMICAL", 179, 191], ["CH 2 Cl 2", "CHEMICAL", 219, 228], ["trifluoromethanesulfonic anhydride", "CHEMICAL", 261, 295], ["Ph 2 SO", "SIMPLE_CHEMICAL", 4, 11], ["di-t-butyl-3-methyl pyridine", "SIMPLE_CHEMICAL", 33, 61], ["trifluoromethanesulfonic anhydride", "SIMPLE_CHEMICAL", 261, 295], ["Ph", "TEST", 4, 6], ["di-t-butyl", "TREATMENT", 33, 43], ["methyl pyridine", "TREATMENT", 46, 61], ["crushed activated molecular sieves", "TREATMENT", 88, 122], ["a cooled solution (\u00c070\u00b0C) of disaccharide", "TREATMENT", 150, 191], ["trifluoromethanesulfonic anhydride", "TREATMENT", 261, 295]]], ["After stirring the mixture at \u00c070\u00b0C for 5 min, a solution of 6 (85.5 mg, 0.29 mmol) in CH 2 Cl 2 (0.5 mL) was added dropwise by syringe.", [["CH 2 Cl", "CHEMICAL", 87, 94], ["CH 2 Cl 2", "CHEMICAL", 87, 96]]], ["The resulting reaction mixture was stirred at \u00c060\u00b0C for 1 h and then allowed to warmed to room temperature over a period of 3 h.", [["The resulting reaction mixture", "PROBLEM", 0, 30]]], ["TLC analysis (hexanes-acetone 70:30, v:v) indicated completion of the reaction, which was quenched by the addition of solid NaHCO 3 .", [["hexanes-acetone 70:30", "CHEMICAL", 14, 35], ["hexanes", "CHEMICAL", 14, 21], ["acetone", "CHEMICAL", 22, 29], ["NaHCO 3", "CHEMICAL", 124, 131], ["hexanes-acetone", "SIMPLE_CHEMICAL", 14, 29], ["TLC analysis", "TEST", 0, 12], ["hexanes", "TEST", 14, 21], ["acetone", "TREATMENT", 22, 29], ["the reaction", "PROBLEM", 66, 78], ["solid NaHCO", "TREATMENT", 118, 129]]], ["After addition of CH 2 Cl 2 , the mixture was filtered, washed with H 2 O, aqueous NaHCO 3 and brine, dried (MgSO 4 ), filtered and concentration in vacuo.", [["CH 2 Cl", "CHEMICAL", 18, 25], ["H 2 O", "CHEMICAL", 68, 73], ["NaHCO 3", "CHEMICAL", 83, 90], ["MgSO 4", "CHEMICAL", 109, 115], ["CH 2 Cl 2", "CHEMICAL", 18, 27], ["H 2 O", "CHEMICAL", 68, 73], ["NaHCO 3", "CHEMICAL", 83, 90], ["H 2 O", "SIMPLE_CHEMICAL", 68, 73], ["aqueous NaHCO 3", "SIMPLE_CHEMICAL", 75, 90], ["CH 2 Cl", "TREATMENT", 18, 25], ["aqueous NaHCO", "TREATMENT", 75, 88], ["MgSO", "TREATMENT", 109, 113], ["concentration in vacuo", "TREATMENT", 132, 154], ["vacuo", "OBSERVATION", 149, 154]]], ["The residue was purified by silica gel column chromatography (hexanes-EtOAc 65:35, v:v) to provide 7 (122 mg, 83%);N-(Benzyloxycarbonyl) [4,6-di-O-acetyl-2-azido-2deoxy-3-O-(3,4,6-tri-O-acetyl-2-O-(2,5-difluorobenzoyl)b-D D-galactopyranosyl)-(1?3)-a-D D-galactopyranosyl]-L Lserine t-butyl ester (8)A solution of disaccharide 7 (143 mg, 0.142 mmol) in a mixture of CH 3 CO 2 H (4 mL) and H 2 O (1 mL) was kept at 80\u00b0C for 1 h after which TLC analysis (hexanes-EtOAc 1:1, v:v) indicated completion of the reaction.", [["silica gel", "CHEMICAL", 28, 38], ["hexanes-EtOAc 65:35", "CHEMICAL", 62, 81], ["N-(Benzyloxycarbonyl) [4,6-di-O-acetyl-2-azido-2deoxy-3-O-(3,4,6-tri-O-acetyl-2-O-(2,5-difluorobenzoyl)b-D D-galactopyranosyl)-(1?3)-a-D D-galactopyranosyl]-L Lserine t-butyl ester", "CHEMICAL", 115, 295], ["CH 3 CO 2 H", "CHEMICAL", 365, 376], ["H 2 O", "CHEMICAL", 388, 393], ["hexanes-EtOAc", "CHEMICAL", 452, 465], ["silica gel", "CHEMICAL", 28, 38], ["hexanes-EtOAc", "CHEMICAL", 62, 75], ["N-(Benzyloxycarbonyl) [4,6-di-O-acetyl-2-azido-2deoxy-3-O-(3,4,6-tri-O-acetyl-2-O-(2,5-difluorobenzoyl)b-D D-galactopyranosyl)-(1?3)-a-D D-galactopyranosyl]-L Lserine t-butyl ester", "CHEMICAL", 115, 295], ["disaccharide", "CHEMICAL", 313, 325], ["CH 3 CO 2 H", "CHEMICAL", 365, 376], ["H 2 O", "CHEMICAL", 388, 393], ["hexanes-EtOAc", "CHEMICAL", 452, 465], ["silica", "SIMPLE_CHEMICAL", 28, 34], ["hexanes", "SIMPLE_CHEMICAL", 62, 69], ["N-(Benzyloxycarbonyl) [4,6-di-O-acetyl-2-azido-2deoxy-3-O-(3,4,6-tri-O-acetyl-2-O-(2,5-difluorobenzoyl)b-D D-galactopyranosyl)-(1?3)-a-D D-galactopyranosyl]-L Lserine t-butyl ester (8)A", "SIMPLE_CHEMICAL", 115, 300], ["disaccharide 7", "SIMPLE_CHEMICAL", 313, 327], ["CO 2 H", "SIMPLE_CHEMICAL", 370, 376], ["H 2 O", "SIMPLE_CHEMICAL", 388, 393], ["hexanes", "SIMPLE_CHEMICAL", 452, 459], ["The residue", "PROBLEM", 0, 11], ["silica gel column chromatography", "TREATMENT", 28, 60], ["acetyl-2-azido", "TREATMENT", 147, 161], ["2deoxy", "TREATMENT", 162, 168], ["O-acetyl-2-O", "TREATMENT", 184, 196], ["D D-galactopyranosyl)", "TREATMENT", 220, 241], ["galactopyranosyl", "TREATMENT", 254, 270], ["L Lserine t-butyl ester", "TREATMENT", 272, 295], ["A solution of disaccharide", "TREATMENT", 299, 325], ["TLC analysis", "TEST", 438, 450], ["hexanes", "TEST", 452, 459], ["EtOAc", "TREATMENT", 460, 465], ["the reaction", "PROBLEM", 500, 512]]], ["The mixture was co-evaporated with toluene and the residue dried in vacuo.", [["toluene", "CHEMICAL", 35, 42], ["toluene", "CHEMICAL", 35, 42], ["toluene", "SIMPLE_CHEMICAL", 35, 42], ["toluene", "TREATMENT", 35, 42], ["the residue", "PROBLEM", 47, 58], ["vacuo", "OBSERVATION", 68, 73]]], ["The recovered material was acetylated with pyridine (2 mL) and Ac 2 O (0.2 mL) in the presence of a catalytic amount of dimethylaminopyridine (DMAP) for 12 h.", [["pyridine", "CHEMICAL", 43, 51], ["Ac 2 O", "CHEMICAL", 63, 69], ["dimethylaminopyridine", "CHEMICAL", 120, 141], ["DMAP", "CHEMICAL", 143, 147], ["pyridine", "CHEMICAL", 43, 51], ["Ac 2 O", "CHEMICAL", 63, 69], ["dimethylaminopyridine", "CHEMICAL", 120, 141], ["DMAP", "CHEMICAL", 143, 147], ["pyridine", "SIMPLE_CHEMICAL", 43, 51], ["Ac 2 O", "SIMPLE_CHEMICAL", 63, 69], ["dimethylaminopyridine", "SIMPLE_CHEMICAL", 120, 141], ["DMAP", "SIMPLE_CHEMICAL", 143, 147], ["pyridine", "TREATMENT", 43, 51], ["a catalytic amount of dimethylaminopyridine (DMAP", "TREATMENT", 98, 147]]], ["After the addition of CH 3 OH, the mixture was co-evaporated with toluene, the residue dissolved in CH 2 Cl 2 and washed with aqueous NaH-CO 3N-(Benzyloxycarbonyl) [-2-acetamido-4,6-di-Oacetyl-2-deoxy-3-O-(3,4,6-tri-O-acetyl-2-O-(2,5-difluorobenzoyl)-b-D D-galactopyranosyl)-(1?3)-a-D D-galactopyranosyl]-L L-serine t-butyl ester (9)Freshly distilled thioacetic acid (0.6 mL) was added by syringe to a solution of disaccharide 8 (128 mg, 0.128 mmol) in pyridine.", [["CH 3 OH", "CHEMICAL", 22, 29], ["toluene", "CHEMICAL", 66, 73], ["CH 2 Cl", "CHEMICAL", 100, 107], ["NaH-CO 3N-(Benzyloxycarbonyl) [-2-acetamido-4,6-di-Oacetyl-2-deoxy-3-O-(3,4,6-tri-O-acetyl-2-O-(2,5-difluorobenzoyl)-b-D D-galactopyranosyl)-(1?3)-a-D D-galactopyranosyl]-L L-serine t-butyl ester", "CHEMICAL", 134, 329], ["thioacetic acid", "CHEMICAL", 351, 366], ["disaccharide 8", "CHEMICAL", 414, 428], ["pyridine", "CHEMICAL", 453, 461], ["CH 3 OH", "CHEMICAL", 22, 29], ["toluene", "CHEMICAL", 66, 73], ["CH 2 Cl 2", "CHEMICAL", 100, 109], ["NaH-CO 3N-(Benzyloxycarbonyl) [-2-acetamido-4,6-di-Oacetyl-2-deoxy-3-O-(3,4,6-tri-O-acetyl-2-O-(2,5-difluorobenzoyl)-b-D D-galactopyranosyl)-(1?3)-a-D D-galactopyranosyl]-L L-serine t-butyl ester", "CHEMICAL", 134, 329], ["thioacetic acid", "CHEMICAL", 351, 366], ["disaccharide", "CHEMICAL", 414, 426], ["pyridine", "CHEMICAL", 453, 461], ["CH 3 OH", "SIMPLE_CHEMICAL", 22, 29], ["toluene", "SIMPLE_CHEMICAL", 66, 73], ["NaH-CO 3N-(Benzyloxycarbonyl) [-2-acetamido-4,6-di-Oacetyl-2-deoxy-3-O-(3,4,6-tri-O-acetyl-2-O-(2,5-difluorobenzoyl)-b-D D-galactopyranosyl)-(1?3)-a-D D-galactopyranosyl]-L L-serine t-butyl ester", "SIMPLE_CHEMICAL", 134, 329], ["thioacetic acid", "SIMPLE_CHEMICAL", 351, 366], ["pyridine", "SIMPLE_CHEMICAL", 453, 461], ["toluene", "TREATMENT", 66, 73], ["aqueous NaH-CO", "TEST", 126, 140], ["acetamido", "TREATMENT", 168, 177], ["Oacetyl-2-deoxy", "TEST", 185, 200], ["O-acetyl-2-O", "TEST", 216, 228], ["D-galactopyranosyl", "TREATMENT", 255, 273], ["galactopyranosyl", "TREATMENT", 287, 303], ["L L-serine t-butyl ester", "TREATMENT", 305, 329], ["Freshly distilled thioacetic acid", "TREATMENT", 333, 366], ["a solution of disaccharide", "TREATMENT", 400, 426]]], ["The resulting reaction mixture was stirred under an atmosphere of argon for 18 h after which TLC (hexanes-EtOAc 1:1, v:v) indicated completion of the reaction.", [["hexanes-EtOAc", "CHEMICAL", 98, 111], ["hexanes", "CHEMICAL", 98, 105], ["EtOAc", "CHEMICAL", 106, 111], ["hexanes", "SIMPLE_CHEMICAL", 98, 105], ["v:v", "SIMPLE_CHEMICAL", 117, 120], ["The resulting reaction mixture", "PROBLEM", 0, 30], ["argon", "TREATMENT", 66, 71], ["TLC (hexanes", "TREATMENT", 93, 105], ["EtOAc", "TREATMENT", 106, 111], ["the reaction", "PROBLEM", 146, 158], ["TLC", "ANATOMY", 93, 96]]], ["The mixture was diluted with CH 2 Cl 2 , successively washed with H 2 O, aqueous NaH-CO 3 4H, H6a, H6b, H6 0 a, H6 0 b) CTP (126 mg, 0.239 mmol) was added to a solution of Neu5,9Ac 2 3 (50 mg, 0.142 mmol) in a Tris-HCl buffer (0.1 M, 9 mL, pH 7.5) containing DET (4.75 mM) and MnCl 2 (13.80 mM).", [["CH 2 Cl", "CHEMICAL", 29, 36], ["H 2 O", "CHEMICAL", 66, 71], ["NaH-CO 3 4H, H6a, H6b", "CHEMICAL", 81, 102], ["CTP", "CHEMICAL", 120, 123], ["Neu5,9Ac 2 3", "CHEMICAL", 172, 184], ["Tris-HCl", "CHEMICAL", 210, 218], ["DET", "CHEMICAL", 259, 262], ["MnCl 2", "CHEMICAL", 277, 283], ["CH 2 Cl 2", "CHEMICAL", 29, 38], ["H 2 O", "CHEMICAL", 66, 71], ["NaH-CO 3 4H", "CHEMICAL", 81, 92], ["H6a", "CHEMICAL", 94, 97], ["H6b", "CHEMICAL", 99, 102], ["H6 0 a", "CHEMICAL", 104, 110], ["CTP", "CHEMICAL", 120, 123], ["Tris-HCl", "CHEMICAL", 210, 218], ["DET", "CHEMICAL", 259, 262], ["MnCl 2", "CHEMICAL", 277, 283], ["H 2 O", "SIMPLE_CHEMICAL", 66, 71], ["aqueous NaH-CO 3 4H", "SIMPLE_CHEMICAL", 73, 92], ["H6a", "SIMPLE_CHEMICAL", 94, 97], ["H6b", "SIMPLE_CHEMICAL", 99, 102], ["CTP", "SIMPLE_CHEMICAL", 120, 123], ["Neu5", "SIMPLE_CHEMICAL", 172, 176], ["Tris-HCl", "SIMPLE_CHEMICAL", 210, 218], ["DET", "SIMPLE_CHEMICAL", 259, 262], ["MnCl 2", "SIMPLE_CHEMICAL", 277, 283], ["The mixture", "TREATMENT", 0, 11], ["aqueous NaH-CO", "TEST", 73, 87], ["H6a", "TEST", 94, 97], ["H6b", "TEST", 99, 102], ["CTP", "TEST", 120, 123], ["a solution of Neu5,9Ac", "TREATMENT", 158, 180], ["a Tris-HCl buffer", "TREATMENT", 208, 225], ["pH", "TEST", 240, 242]]], ["Addition of CTP resulted in a change of pH from 7.5 to 6.5, which was re-adjusted to pH 7.5 using aqueous NaOH (0.3 M).", [["CTP", "CHEMICAL", 12, 15], ["aqueous NaOH", "CHEMICAL", 98, 110], ["CTP", "CHEMICAL", 12, 15], ["NaOH", "CHEMICAL", 106, 110], ["CTP", "SIMPLE_CHEMICAL", 12, 15], ["CTP", "TEST", 12, 15], ["pH", "TEST", 40, 42], ["pH", "TEST", 85, 87], ["aqueous NaOH", "TREATMENT", 98, 110]]], ["The recombinant CMP-sialic acid synthetase from N. meningitis (9.2 U, 27.0 lL) and the inorganic pyrophosphatase from T. thermophilus (4.6 U, 60.0 lL) were added, and the reaction mixture was incubated at 37\u00b0C for 1 h with occasional shaking.", [["CMP-sialic acid", "CHEMICAL", 16, 31], ["N. meningitis", "DISEASE", 48, 61], ["inorganic", "CHEMICAL", 87, 96], ["sialic acid", "CHEMICAL", 20, 31], ["CMP-sialic acid synthetase", "GENE_OR_GENE_PRODUCT", 16, 42], ["N. meningitis", "ORGANISM", 48, 61], ["T. thermophilus", "ORGANISM", 118, 133], ["recombinant CMP-sialic acid synthetase", "PROTEIN", 4, 42], ["inorganic pyrophosphatase", "PROTEIN", 87, 112], ["T. thermophilus", "SPECIES", 118, 133], ["T. thermophilus", "SPECIES", 118, 133], ["The recombinant CMP", "TEST", 0, 19], ["sialic acid synthetase", "TEST", 20, 42], ["N. meningitis", "PROBLEM", 48, 61], ["U", "TEST", 67, 68], ["the inorganic pyrophosphatase", "TEST", 83, 112], ["T. thermophilus", "TEST", 118, 133], ["the reaction mixture", "PROBLEM", 167, 187], ["occasional shaking", "PROBLEM", 223, 241], ["meningitis", "OBSERVATION", 51, 61]]], ["Another portion of CMP-sialic acid synthetase and inorganic pyrophosphatase (1.5 U, 19.5 lL) was added after 2.5 h.", [["CMP-sialic acid", "CHEMICAL", 19, 34], ["inorganic pyrophosphatase", "CHEMICAL", 50, 75], ["CMP-sialic acid", "CHEMICAL", 19, 34], ["CMP-sialic acid", "SIMPLE_CHEMICAL", 19, 34], ["inorganic pyrophosphatase", "SIMPLE_CHEMICAL", 50, 75], ["CMP-sialic acid synthetase", "PROTEIN", 19, 45], ["inorganic pyrophosphatase", "PROTEIN", 50, 75], ["CMP", "TEST", 19, 22], ["sialic acid synthetase", "TEST", 23, 45], ["inorganic pyrophosphatase", "TEST", 50, 75], ["sialic", "ANATOMY_MODIFIER", 23, 29], ["acid synthetase", "OBSERVATION", 30, 45]]], ["The formation of a white precipitate (presumably manganese-ammonium phos-phate) was observed after 1.5 h.", [["manganese-ammonium", "CHEMICAL", 49, 67], ["manganese-ammonium phos-phate", "CHEMICAL", 49, 78], ["manganese-ammonium phos-phate", "SIMPLE_CHEMICAL", 49, 78], ["a white precipitate", "PROBLEM", 17, 36], ["manganese-ammonium phos-phate", "TREATMENT", 49, 78]]], ["The progress of the reaction was monitored by TLC (EtOH-1 M NH 4 HCO 3 , 4:1, v:v), which after 5 h indicated completion of the reaction.", [["EtOH", "CHEMICAL", 51, 55], ["EtOH", "CHEMICAL", 51, 55], ["NH 4 HCO 3", "CHEMICAL", 60, 70], ["EtOH", "SIMPLE_CHEMICAL", 51, 55], ["the reaction", "PROBLEM", 16, 28], ["TLC", "TEST", 46, 49], ["the reaction", "PROBLEM", 124, 136]]], ["Ethanol (80 mL) was added and the mixture was kept on ice for 2 h prior to centrifugation.", [["Ethanol", "CHEMICAL", 0, 7], ["Ethanol", "CHEMICAL", 0, 7], ["Ethanol", "SIMPLE_CHEMICAL", 0, 7], ["Ethanol", "TREATMENT", 0, 7], ["ice", "TREATMENT", 54, 57], ["centrifugation", "TREATMENT", 75, 89]]], ["The supernatant was decanted and the pellet (mostly inorganic salts) was re-suspended in EtOH (30 mL), cooled on ice for 1 h and centrifuged.", [["supernatant", "ANATOMY", 4, 15], ["inorganic salts", "CHEMICAL", 52, 67], ["EtOH", "CHEMICAL", 89, 93], ["EtOH", "CHEMICAL", 89, 93], ["EtOH", "SIMPLE_CHEMICAL", 89, 93]]], ["The combined ethanol extracts were concentrated in vacuo providing crude material (230 mg).", [["extracts", "ANATOMY", 21, 29], ["ethanol", "CHEMICAL", 13, 20], ["ethanol", "CHEMICAL", 13, 20], ["ethanol extracts", "ORGANISM_SUBSTANCE", 13, 29], ["The combined ethanol extracts", "TREATMENT", 0, 29]]], ["Ethanol (1.8 mL) was slowly added to the material dissolved in H 2 O (0.2 mL) and precipitation occurred immediately.", [["Ethanol", "CHEMICAL", 0, 7], ["H 2 O", "CHEMICAL", 63, 68], ["Ethanol", "CHEMICAL", 0, 7], ["H 2 O", "CHEMICAL", 63, 68], ["Ethanol", "SIMPLE_CHEMICAL", 0, 7], ["H 2 O", "SIMPLE_CHEMICAL", 63, 68], ["Ethanol", "TREATMENT", 0, 7]]], ["The mixture was kept on ice for 2 h, and the supernatant was removed after centrifugation.", [["supernatant", "ANATOMY", 45, 56], ["ice", "TREATMENT", 24, 27], ["centrifugation", "TREATMENT", 75, 89]]], ["After drying, NMR (D 2 O) of the first pellet (114 mg) indicated the presence of the expected product, some Tris, ethanol and a small amount of Neu5,9Ac 2 .", [["ethanol", "CHEMICAL", 114, 121], ["Tris", "CHEMICAL", 108, 112], ["ethanol", "CHEMICAL", 114, 121], ["Neu5,9Ac 2", "CHEMICAL", 144, 154], ["Tris", "SIMPLE_CHEMICAL", 108, 112], ["ethanol", "SIMPLE_CHEMICAL", 114, 121], ["a small amount of Neu5,9Ac 2", "TREATMENT", 126, 154], ["small", "OBSERVATION_MODIFIER", 128, 133], ["amount", "OBSERVATION_MODIFIER", 134, 140]]], ["The recovered material was again dissolved in H 2 O (0.2 mL) and re-precipitated by the addition of ethanol (1.80 mL) as described above providing 75 mg of material, which was loaded on a column of extra-fine Biogel P-2 (75 \u00c2 1.5 cm) and eluted with 0.1 M NH 4 HCO 3 at 4\u00b0C. The appropriate fractions were detected by UV and TLC (as above), collected, concentrated in vacuo (bath temperature <25\u00b0C) and lyophilized from H 2 O (three times to completely remove NH 4 HCO 3 ) to afford 3 (60 mg, 61%, ammonium salt).", [["H 2 O", "CHEMICAL", 46, 51], ["ethanol", "CHEMICAL", 100, 107], ["Biogel P-2", "CHEMICAL", 209, 219], ["H 2 O", "CHEMICAL", 420, 425], ["NH 4 HCO 3", "CHEMICAL", 460, 470], ["ammonium salt", "CHEMICAL", 498, 511], ["H 2 O", "CHEMICAL", 46, 51], ["ethanol", "CHEMICAL", 100, 107], ["NH 4 HCO 3", "CHEMICAL", 256, 266], ["H 2 O", "CHEMICAL", 420, 425], ["NH 4 HCO 3", "CHEMICAL", 460, 470], ["ammonium", "CHEMICAL", 498, 506], ["H 2 O", "SIMPLE_CHEMICAL", 46, 51], ["ethanol", "SIMPLE_CHEMICAL", 100, 107], ["ammonium salt", "SIMPLE_CHEMICAL", 498, 511], ["ethanol", "TREATMENT", 100, 107], ["a column of extra-fine Biogel P", "TREATMENT", 186, 217], ["TLC", "TEST", 325, 328], ["vacuo (bath temperature", "TREATMENT", 368, 391], ["fractions", "OBSERVATION_MODIFIER", 291, 300], ["TLC", "ANATOMY", 325, 328]]], ["Recombinant rat a-(2?3)-sialyltransferase from S. frugiperda [EC 2.4.99.4] (10 mU, 7 lL) and calf intestine alkaline phosphatase (15 U, 15 lL) were added to a mixture of disaccharide 10 (4.6 mg, 7.1 lmol) in cacodylate buffer (50 mM, pH 6.2; 600 lL) containing 0.1% Triton X-100, 0.1% BSA and CMP-Neu5,9Ac 2 4 (6.7 mg, 9.5 lmol) in an Eppendorf tube, and five similar reactions were run in parallel.", [["intestine", "ANATOMY", 98, 107], ["Triton X-100", "CHEMICAL", 266, 278], ["BSA", "CHEMICAL", 285, 288], ["CMP-Neu5", "CHEMICAL", 293, 301], ["9Ac 2 4", "CHEMICAL", 302, 309], ["disaccharide", "CHEMICAL", 170, 182], ["cacodylate", "CHEMICAL", 208, 218], ["rat", "ORGANISM", 12, 15], ["a-(2?3)-sialyltransferase", "GENE_OR_GENE_PRODUCT", 16, 41], ["S. frugiperda", "ORGANISM", 47, 60], ["EC", "CELL", 62, 64], ["intestine", "ORGAN", 98, 107], ["cacodylate", "SIMPLE_CHEMICAL", 208, 218], ["Triton X-100", "SIMPLE_CHEMICAL", 266, 278], ["BSA", "SIMPLE_CHEMICAL", 285, 288], ["CMP-Neu5", "SIMPLE_CHEMICAL", 293, 301], ["sialyltransferase", "PROTEIN", 24, 41], ["alkaline phosphatase", "PROTEIN", 108, 128], ["rat", "SPECIES", 12, 15], ["S. frugiperda", "SPECIES", 47, 60], ["calf", "SPECIES", 93, 97], ["S. frugiperda", "SPECIES", 47, 60], ["calf", "SPECIES", 93, 97], ["EC", "TEST", 62, 64], ["calf intestine alkaline phosphatase", "TEST", 93, 128], ["a mixture of disaccharide", "TREATMENT", 157, 182], ["pH", "TEST", 234, 236], ["CMP", "TEST", 293, 296], ["Neu5", "TREATMENT", 297, 301], ["an Eppendorf tube", "TREATMENT", 332, 349], ["calf intestine", "ANATOMY", 93, 107], ["tube", "OBSERVATION", 345, 349]]], ["The tubes were incubated at 37\u00b0C, and progress of the reactions were monitored by TLC (CHCl 3 -CH 3 OH-H 2 O-AcOH 60:40:10:0.5, v:v:v:v).", [["tubes", "ANATOMY", 4, 9], ["CHCl 3 -CH 3 OH-H", "CHEMICAL", 87, 104], ["CHCl 3 -CH 3 OH-H", "CHEMICAL", 87, 104], ["O-AcOH", "CHEMICAL", 107, 113], ["tubes", "ORGANISM_SUBSTANCE", 4, 9], ["OH-H 2 O-AcOH", "SIMPLE_CHEMICAL", 100, 113], ["The tubes", "TREATMENT", 0, 9], ["TLC", "TEST", 82, 85], ["CHCl", "TEST", 87, 91], ["tubes", "OBSERVATION", 4, 9]]], ["After 2 h, an additional amount of a(2?3)-sial-yltransferase (10 mU), calf intestine alkaline phosphatase and CMP-Neu5,9Ac 2 (7.0 mg) was added to each of the five tubes.", [["calf intestine", "ANATOMY", 70, 84], ["CMP-Neu5,9Ac 2", "CHEMICAL", 110, 124], ["(2?3)-sial-yltransferase", "SIMPLE_CHEMICAL", 36, 60], ["calf", "ORGANISM", 70, 74], ["intestine", "ORGAN", 75, 84], ["CMP-Neu5", "SIMPLE_CHEMICAL", 110, 118], ["9Ac 2", "SIMPLE_CHEMICAL", 119, 124], ["yltransferase", "PROTEIN", 47, 60], ["alkaline phosphatase", "PROTEIN", 85, 105], ["calf", "SPECIES", 70, 74], ["a(2?3)-sial-yltransferase", "TREATMENT", 35, 60], ["calf intestine alkaline phosphatase", "TEST", 70, 105], ["CMP", "TEST", 110, 113], ["Neu5", "TREATMENT", 114, 118], ["9Ac", "TREATMENT", 119, 122], ["the five tubes", "TREATMENT", 155, 169], ["calf intestine", "ANATOMY", 70, 84], ["alkaline phosphatase", "ANATOMY", 85, 105], ["tubes", "OBSERVATION", 164, 169]]], ["After 5.5 h, TLC indicated the disappearance of disaccharide 10.", [["disaccharide", "CHEMICAL", 48, 60], ["TLC", "TEST", 13, 16], ["disaccharide", "TEST", 48, 60]]], ["Each reaction was quenched by the addition of CH 3 OH (10 lL), combined and freeze dried to provide a crude material (200 mg), which was applied on a Biogel fine P-2 column (75 \u00c2 1.5 cm, using H 2 O as eluent at 8 mL/h) at 4\u00b0C. The product was detected by TLC, and appropriate fractions were combined and freeze dried to provide 11 (37 mg).", [["CH 3 OH", "CHEMICAL", 46, 53], ["H 2 O", "CHEMICAL", 193, 198], ["CH 3 OH", "CHEMICAL", 46, 53], ["H 2 O", "CHEMICAL", 193, 198], ["Each reaction", "PROBLEM", 0, 13], ["a crude material", "TREATMENT", 100, 116], ["a Biogel fine P-2 column", "TREATMENT", 148, 172], ["TLC", "TEST", 256, 259]]], ["This material was passed through a short column of BioRad AG 50W-X8 (100-200 mesh, Na + ) resin at 4\u00b0C, and the appropriate fractions freeze dried.", [["AG 50W-X8", "CHEMICAL", 58, 67], ["Na", "CHEMICAL", 83, 85], ["50W-X8", "CHEMICAL", 61, 67], ["Na + )", "CHEMICAL", 83, 89], ["Na + ) resin", "SIMPLE_CHEMICAL", 83, 95], ["a short column of BioRad AG", "TREATMENT", 33, 60], ["Na", "TEST", 83, 85], ["fractions freeze", "OBSERVATION", 124, 140]]], ["The recovered material was purified by C-18 silica gel (5 g) column chromatography using a gradient of CH 3 CN in H 2 O (95:5?90:10, v:v, at 4\u00b0C), which removed the 9-O-deacetylated trisaccharide (1.0 mg) from the product 11 (22.5 mg, 69%); \u00bda", [["C-18 silica", "CHEMICAL", 39, 50], ["H 2 O", "CHEMICAL", 114, 119], ["9-O-deacetylated trisaccharide", "CHEMICAL", 165, 195], ["silica gel", "CHEMICAL", 44, 54], ["CH 3 CN", "CHEMICAL", 103, 110], ["H 2 O", "CHEMICAL", 114, 119], ["9-O-deacetylated trisaccharide", "CHEMICAL", 165, 195], ["C-18 silica", "SIMPLE_CHEMICAL", 39, 50], ["H 2 O", "SIMPLE_CHEMICAL", 114, 119], ["9-O-deacetylated trisaccharide", "SIMPLE_CHEMICAL", 165, 195], ["C-18 silica gel", "TREATMENT", 39, 54], ["column chromatography", "TEST", 61, 82], ["a gradient", "TEST", 89, 99], ["deacetylated trisaccharide", "TREATMENT", 169, 195]]]], "a6260fdfd903e7c8949e423f9fca742acc893e58": [["IntroductionSARS-CoV-2 is the causative agent of current pandemic of novel coronavirus disease which has infected millions of people and is responsible for more than 200,000 deaths worldwide in a span of just 4 months.", [["coronavirus disease", "DISEASE", 75, 94], ["deaths", "DISEASE", 174, 180], ["CoV-2", "ORGANISM", 17, 22], ["coronavirus", "ORGANISM", 75, 86], ["people", "ORGANISM", 126, 132], ["people", "SPECIES", 126, 132], ["IntroductionSARS", "TEST", 0, 16], ["novel coronavirus disease", "PROBLEM", 69, 94], ["coronavirus disease", "OBSERVATION", 75, 94]]], ["The virus has a positive sense, singlestranded RNA genome, which is around 30 kb in length.", [["singlestranded RNA genome", "RNA", 32, 57], ["The virus", "PROBLEM", 0, 9], ["singlestranded RNA genome", "PROBLEM", 32, 57], ["virus", "OBSERVATION", 4, 9], ["positive", "OBSERVATION_MODIFIER", 16, 24], ["RNA genome", "OBSERVATION", 47, 57], ["30 kb", "OBSERVATION_MODIFIER", 75, 80], ["length", "OBSERVATION_MODIFIER", 84, 90]]], ["The genome codes for four structural and multiple non-structural proteins (Astuti and Ysrafil 2020) .", [["non-structural proteins", "PROTEIN", 50, 73], ["Ysrafil 2020", "PROTEIN", 86, 98], ["multiple non-structural proteins", "PROBLEM", 41, 73], ["multiple", "OBSERVATION_MODIFIER", 41, 49], ["non-structural proteins", "OBSERVATION", 50, 73]]], ["While the structural proteins form capsid and envelope of the virus, non-structural proteins are involved in various steps of viral life cycle such as replication, translation, packaging and release (Lai and Cavanagh 1997) .", [["structural proteins", "PROTEIN", 10, 29], ["non-structural proteins", "PROTEIN", 69, 92], ["the structural proteins form capsid", "PROBLEM", 6, 41], ["the virus", "PROBLEM", 58, 67], ["non-structural proteins", "PROBLEM", 69, 92], ["viral life cycle", "TREATMENT", 126, 142], ["packaging", "TREATMENT", 177, 186]]], ["Although at a slower rate, mutations are emerging in the SARS-CoV-2 genome which might modulate viral transmission, replication efficiency and virulence in different regions of the world (Jia et al. 2020; Pachetti et al. 2020) .IntroductionThe genome sequence data has revealed that SARS-CoV-2 is a member of the genus Betacoronavirus and belongs to the subgenus Sarbecovirus that includes SARS-CoV while MERS-CoV belongs to a separate subgenus, Merbecovirus (Lu et al. 2020; Wu et al. 2020; Zhu et al. 2020) .", [["SARS", "DISEASE", 57, 61], ["SARS-CoV-2", "ORGANISM", 57, 67], ["SARS-CoV-2", "ORGANISM", 283, 293], ["Betacoronavirus", "GENE_OR_GENE_PRODUCT", 319, 334], ["SARS-CoV", "ORGANISM", 390, 398], ["MERS-CoV", "ORGANISM", 405, 413], ["SARS-CoV-2 genome", "DNA", 57, 74], ["SARS-CoV", "SPECIES", 57, 65], ["SARS-CoV-2", "SPECIES", 283, 293], ["SARS-CoV", "SPECIES", 390, 398], ["MERS-CoV", "SPECIES", 405, 413], ["mutations", "PROBLEM", 27, 36], ["the SARS", "PROBLEM", 53, 61], ["replication efficiency", "PROBLEM", 116, 138], ["The genome sequence data", "TEST", 240, 264], ["SARS", "PROBLEM", 283, 287], ["the genus Betacoronavirus", "PROBLEM", 309, 334], ["the subgenus Sarbecovirus", "PROBLEM", 350, 375], ["SARS", "PROBLEM", 390, 394], ["viral transmission", "OBSERVATION", 96, 114], ["replication efficiency", "OBSERVATION", 116, 138]]], ["SARS-CoV-2 is approximately 79% similar to SARS CoV at the nucleotide sequence level.", [["SARS", "DISEASE", 0, 4], ["SARS", "DISEASE", 43, 47], ["nucleotide", "CHEMICAL", 59, 69], ["SARS-CoV-2", "ORGANISM", 0, 10], ["SARS CoV", "ORGANISM", 43, 51], ["SARS-CoV", "SPECIES", 0, 8], ["SARS CoV", "SPECIES", 43, 51], ["SARS-CoV", "TEST", 0, 8], ["SARS CoV", "TEST", 43, 51], ["the nucleotide sequence level", "TEST", 55, 84]]], ["Epidemiological data suggests that SARS-CoV-2 had spread widely from the city of Wuhan in China (Chinazzi et al. 2020 ) after its zoonotic transmission originating from bats via the Malayan pangolins .", [["SARS", "DISEASE", 35, 39], ["SARS-CoV-2", "ORGANISM", 35, 45], ["pangolins", "GENE_OR_GENE_PRODUCT", 190, 199], ["SARS-CoV", "SPECIES", 35, 43], ["Malayan pangolins", "SPECIES", 182, 199], ["Epidemiological data", "TEST", 0, 20], ["SARS", "PROBLEM", 35, 39], ["CoV", "TEST", 40, 43], ["the Malayan pangolins", "TREATMENT", 178, 199]]], ["Global sequence and epidemiological data reveals that since its emergence, SARS-CoV-2 has spread rapidly to all parts of the globe, facilitated by its ability to use the human ACE2 receptor for cellular entry (Hoffmann et al. 2020) .", [["cellular", "ANATOMY", 194, 202], ["SARS", "DISEASE", 75, 79], ["SARS-CoV-2", "ORGANISM", 75, 85], ["human", "ORGANISM", 170, 175], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 176, 189], ["cellular", "CELL", 194, 202], ["human ACE2 receptor", "PROTEIN", 170, 189], ["human", "SPECIES", 170, 175], ["SARS-CoV", "SPECIES", 75, 83], ["human", "SPECIES", 170, 175], ["Global sequence", "TEST", 0, 15], ["epidemiological data", "TEST", 20, 40], ["SARS", "TEST", 75, 79], ["the human ACE2 receptor", "TREATMENT", 166, 189], ["all", "ANATOMY_MODIFIER", 108, 111], ["parts", "ANATOMY_MODIFIER", 112, 117], ["globe", "ANATOMY", 125, 130]]], ["The accumulating mutations in the SARS-CoV-2 genome have resulted in the evolution of 11 clades out of which the ancestral clade O originated in Wuhan.IntroductionSince the first report of sequence of SARS-CoV-2 from India, there have been multiple sequence submissions in Global Initiative on Sharing All Influenza Data (GISAID, https://www.gisaid.org/).", [["SARS", "DISEASE", 201, 205], ["Influenza", "DISEASE", 306, 315], ["SARS-CoV-2", "ORGANISM", 34, 44], ["SARS-CoV-2", "ORGANISM", 201, 211], ["SARS-CoV-2 genome", "DNA", 34, 51], ["SARS-CoV", "SPECIES", 34, 42], ["SARS-CoV", "SPECIES", 201, 209], ["The accumulating mutations", "PROBLEM", 0, 26], ["the SARS", "TEST", 30, 38], ["SARS", "PROBLEM", 201, 205], ["accumulating", "OBSERVATION_MODIFIER", 4, 16], ["mutations", "OBSERVATION", 17, 26], ["multiple", "OBSERVATION_MODIFIER", 240, 248]]], ["Extensive sequencing of the viral genome from different regions in India is required urgently.", [["viral genome", "DNA", 28, 40], ["the viral genome", "PROBLEM", 24, 40], ["viral genome", "OBSERVATION", 28, 40], ["different", "OBSERVATION_MODIFIER", 46, 55], ["regions", "OBSERVATION_MODIFIER", 56, 63]]], ["This will provide information on the prevalence of various viral clades and any regional differences therein, which might lead to improved understanding of the transmission patterns, tracking of the outbreak and formulation of effective containment measures.", [["various viral clades", "PROBLEM", 51, 71], ["effective containment measures", "TREATMENT", 227, 257]]], ["The mutation data might provide important clues for development of efficient vaccines, antiviral drugs and diagnostic assays.", [["The mutation data", "TEST", 0, 17], ["efficient vaccines", "TREATMENT", 67, 85], ["antiviral drugs", "TREATMENT", 87, 102], ["diagnostic assays", "TEST", 107, 124]]], ["We have initiated a study on sequencing of SARS-CoV-2 genome from swab samples obtained from infected individuals from different regions of West Bengal in Eastern India and report here the first nine sequences and the results of analysis of the sequence data with respect to other sequences reported from the country until date.", [["swab samples", "ANATOMY", 66, 78], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 43, 53], ["swab samples", "CANCER", 66, 78], ["SARS-CoV-2 genome", "DNA", 43, 60], ["SARS-CoV", "SPECIES", 43, 51], ["a study", "TEST", 18, 25], ["SARS", "PROBLEM", 43, 47], ["CoV", "TEST", 48, 51], ["swab samples", "TEST", 66, 78], ["the sequence data", "TEST", 241, 258], ["other sequences", "TEST", 275, 290]]], ["We have detected unique mutations in the RNA-dependent RNA polymerase (RdRp), Spike (S) and Nucleocapsid (N) coding viral genes.", [["RNA-dependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 41, 69], ["Spike (S)", "GENE_OR_GENE_PRODUCT", 78, 87], ["Nucleocapsid (N)", "GENE_OR_GENE_PRODUCT", 92, 108], ["RNA-dependent RNA polymerase (RdRp), Spike (S) and Nucleocapsid (N) coding viral genes", "DNA", 41, 127], ["unique mutations", "PROBLEM", 17, 33], ["the RNA", "TEST", 37, 44], ["dependent RNA polymerase", "PROBLEM", 45, 69], ["Spike (S) and Nucleocapsid (N) coding viral genes", "PROBLEM", 78, 127], ["mutations", "OBSERVATION", 24, 33], ["viral genes", "OBSERVATION", 116, 127]]], ["It appears that the mutation in nucleocapsid gene might lead to alterations in local structure of the N protein.", [["nucleocapsid gene", "DNA", 32, 49], ["N protein", "PROTEIN", 102, 111], ["the mutation in nucleocapsid gene", "PROBLEM", 16, 49]]], ["Also the putative sites of miRNA binding could be affected, which might have major consequences.", [["miRNA binding", "PROBLEM", 27, 40], ["miRNA binding", "OBSERVATION", 27, 40]]], ["The possible implications of the mutations have been discussed, which will provide important insights for functional validation to understand the molecular basis of differential disease severity.Clinical sample collectionThe Regional Virus Research & Diagnostic Laboratory (VRDL) in Indian Council of Medical research-National Institute of Cholera and Enteric Diseases (ICMR-NICED) is a Government-designated laboratory for providing laboratory diagnosis for SARS-CoV-2 (COVID19) in Eastern India.", [["Cholera", "DISEASE", 340, 347], ["Enteric Diseases", "DISEASE", 352, 368], ["SARS", "DISEASE", 459, 463], ["SARS-CoV-2", "ORGANISM", 459, 469], ["COVID19", "ORGANISM", 471, 478], ["SARS-CoV", "SPECIES", 459, 467], ["the mutations", "PROBLEM", 29, 42], ["differential disease severity", "PROBLEM", 165, 194], ["Clinical sample collection", "PROBLEM", 195, 221], ["Cholera", "PROBLEM", 340, 347], ["SARS", "PROBLEM", 459, 463], ["CoV", "TEST", 464, 467], ["possible", "UNCERTAINTY", 4, 12], ["differential", "OBSERVATION_MODIFIER", 165, 177], ["disease", "OBSERVATION", 178, 185], ["Enteric", "ANATOMY", 352, 359]]], ["Nasopharyngeal and oropharyngeal swabs in Viral transport media (VTM) (Himedia labs, India) collected from suspect cases with acute respiratory symptoms/travel history to affected countries or contacts of the COVID-19 confirmed cases were referred to the laboratory for diagnosis.", [["Nasopharyngeal", "ANATOMY", 0, 14], ["oropharyngeal swabs", "ANATOMY", 19, 38], ["respiratory", "ANATOMY", 132, 143], ["Nasopharyngeal", "CANCER", 0, 14], ["Nasopharyngeal and oropharyngeal swabs", "TEST", 0, 38], ["Viral transport media", "TREATMENT", 42, 63], ["Himedia labs", "TEST", 71, 83], ["acute respiratory symptoms", "PROBLEM", 126, 152], ["the COVID", "TEST", 205, 214], ["oropharyngeal", "ANATOMY", 19, 32], ["swabs", "OBSERVATION", 33, 38], ["acute", "OBSERVATION_MODIFIER", 126, 131]]], ["The test reports were provided to the health authorities for initiating treatment and quarantine measures.", [["treatment", "TREATMENT", 72, 81], ["quarantine measures", "TREATMENT", 86, 105]]], ["Residual deidentified positive samples for SARS-Cov-2 were used for RNA isolation and sequencing in accordance with ethics guidelines of Govt. of India.Viral RNA extraction and diagnostic test of SARS-CoV-2 (COVID-19) virusExtraction of viral RNA from the clinical sample (200 ll) was performed using the QIAamp viral RNA mini kit as per manufacturer's protocol (Qiagen, Germany).", [["samples", "ANATOMY", 31, 38], ["sample", "ANATOMY", 265, 271], ["SARS", "DISEASE", 196, 200], ["SARS-CoV-2", "ORGANISM", 196, 206], ["COVID-19", "ORGANISM", 208, 216], ["SARS-Cov-2", "DNA", 43, 53], ["SARS-CoV-2 (COVID-19", "DNA", 196, 216], ["viral RNA", "RNA", 237, 246], ["SARS-CoV", "SPECIES", 196, 204], ["Residual deidentified positive samples", "PROBLEM", 0, 38], ["SARS", "PROBLEM", 43, 47], ["Cov", "TEST", 48, 51], ["RNA isolation", "TREATMENT", 68, 81], ["Viral RNA extraction", "TREATMENT", 152, 172], ["diagnostic test", "TEST", 177, 192], ["SARS", "TEST", 196, 200], ["CoV", "TEST", 201, 204], ["COVID", "TEST", 208, 213], ["viral RNA", "PROBLEM", 237, 246], ["the QIAamp viral RNA mini kit", "TREATMENT", 301, 330], ["positive", "OBSERVATION_MODIFIER", 22, 30], ["viral RNA", "OBSERVATION", 237, 246]]], ["The extracted RNA was tested for SARS-CoV-2 (COVID-19) by Real Time Reverse Transcription PCR (qRT-PCR) (ABI 7500, Applied Biosystems, USA) using the protocol provided by NIV-Pune, India (https://www.icmr.gov.in/pdf/covid/labs/1_SOP_for_First_ Line_Screening_Assay_for_2019_nCoV.pdf; https://www. icmr.gov.in/pdf/covid/labs/2_SOP_for_Confirmatory_ Assay_for_2019_nCoV.pdf).Viral RNA extraction and diagnostic test of SARS-CoV-2 (COVID-19) virusBriefly, first line screening was done for Envelope E gene and RNase P (Internal control).", [["SARS-CoV-2", "ORGANISM", 417, 427], ["COVID-19", "CELL", 429, 437], ["Envelope E", "GENE_OR_GENE_PRODUCT", 487, 497], ["RNase P", "GENE_OR_GENE_PRODUCT", 507, 514], ["Assay_for_2019_nCoV.pdf", "PROTEIN", 348, 371], ["Envelope E gene", "DNA", 487, 502], ["RNase P", "DNA", 507, 514], ["SARS-CoV", "SPECIES", 33, 41], ["SARS-CoV-2 (COVID-19", "SPECIES", 417, 437], ["The extracted RNA", "TEST", 0, 17], ["SARS", "TEST", 33, 37], ["CoV", "TEST", 38, 41], ["COVID", "TEST", 45, 50], ["Transcription PCR", "TEST", 76, 93], ["qRT", "TEST", 95, 98], ["PCR", "TEST", 99, 102], ["ABI", "TEST", 105, 108], ["the protocol", "TREATMENT", 146, 158], ["Viral RNA extraction", "TREATMENT", 373, 393], ["diagnostic test", "TEST", 398, 413], ["SARS", "TEST", 417, 421], ["CoV", "TEST", 422, 425], ["COVID", "TEST", 429, 434], ["first line screening", "TEST", 453, 473], ["Envelope E gene", "TREATMENT", 487, 502], ["RNase P (Internal control", "TREATMENT", 507, 532]]], ["Clinical samples positive for E gene (Ct B 35.0) were subjected to confirmatory test with primers specific for RdRp and HKU ORF (HKU-orf1-nsp14).", [["samples", "ANATOMY", 9, 16], ["E", "GENE_OR_GENE_PRODUCT", 30, 31], ["RdRp", "GENE_OR_GENE_PRODUCT", 111, 115], ["HKU ORF", "GENE_OR_GENE_PRODUCT", 120, 127], ["HKU-orf1-nsp14", "GENE_OR_GENE_PRODUCT", 129, 143], ["E gene", "DNA", 30, 36], ["RdRp and HKU ORF", "DNA", 111, 127], ["HKU", "DNA", 129, 132], ["orf1", "DNA", 133, 137], ["nsp14", "DNA", 138, 143], ["Clinical samples", "TEST", 0, 16], ["Ct B", "TEST", 38, 42], ["confirmatory test", "TEST", 67, 84], ["RdRp", "PROBLEM", 111, 115], ["HKU ORF", "TEST", 120, 127], ["HKU", "TEST", 129, 132]]], ["Positive Control and No Template Control were run for all genes.", [["Template Control", "TREATMENT", 24, 40]]], ["A specimen was considered confirmed positive for SARS-CoV-2 if reaction growth curves crossed the threshold line within 35 cycles (Ct cut off B 35.0) for E gene, and both RdRp, ORF or either RdRp or ORF.Viral genome sequencingRNA isolated from nasopharyngeal and oropharyngeal swabs were depleted of ribosomal RNA using Ribo-Zero rRNA removal Kit (Illumina, USA).", [["specimen", "ANATOMY", 2, 10], ["nasopharyngeal", "ANATOMY", 244, 258], ["oropharyngeal swabs", "ANATOMY", 263, 282], ["ribosomal", "ANATOMY", 300, 309], ["SARS", "DISEASE", 49, 53], ["specimen", "CANCER", 2, 10], ["E", "GENE_OR_GENE_PRODUCT", 154, 155], ["nasopharyngeal", "CANCER", 244, 258], ["oropharyngeal swabs", "ORGAN", 263, 282], ["ribosomal", "CELLULAR_COMPONENT", 300, 309], ["E gene", "DNA", 154, 160], ["RdRp", "DNA", 171, 175], ["ORF", "DNA", 177, 180], ["RdRp", "DNA", 191, 195], ["ORF", "DNA", 199, 202], ["ribosomal RNA", "RNA", 300, 313], ["SARS-CoV", "SPECIES", 49, 57], ["A specimen", "TEST", 0, 10], ["SARS", "PROBLEM", 49, 53], ["CoV", "TEST", 54, 57], ["reaction growth curves", "PROBLEM", 63, 85], ["the threshold line", "TREATMENT", 94, 112], ["Ct cut", "TEST", 131, 137], ["both RdRp", "PROBLEM", 166, 175], ["ORF", "PROBLEM", 177, 180], ["RdRp", "PROBLEM", 191, 195], ["ORF", "PROBLEM", 199, 202], ["Viral genome sequencingRNA", "PROBLEM", 203, 229], ["nasopharyngeal and oropharyngeal swabs", "PROBLEM", 244, 282], ["ribosomal RNA", "TREATMENT", 300, 313], ["Ribo", "TEST", 320, 324], ["Zero rRNA removal", "TREATMENT", 325, 342], ["nasopharyngeal", "ANATOMY", 244, 258], ["oropharyngeal swabs", "ANATOMY", 263, 282], ["ribosomal RNA", "OBSERVATION", 300, 313]]], ["The residual RNA was then converted to double stranded cDNA and sequencing libraries prepared using TruSeq Stranded Total RNA Library Preparation Kit (Illumina Inc, USA) according to the manufacturer's instructions.", [["double stranded cDNA", "DNA", 39, 59], ["The residual RNA", "PROBLEM", 0, 16], ["double stranded cDNA", "TREATMENT", 39, 59], ["sequencing libraries", "TREATMENT", 64, 84], ["TruSeq Stranded Total RNA Library Preparation Kit (Illumina Inc, USA", "TREATMENT", 100, 168], ["residual RNA", "OBSERVATION", 4, 16]]], ["The sequencing libraries were checked using high sensitivity D1000 ScreenTape in 2200 TapeStation system (Agilent Technologies, USA) and quantified by Real Time PCR using Library Quantitation Kit (Kapa Biosystems, USA).", [["The sequencing libraries", "TEST", 0, 24]]], ["The libraries were sequenced using MiSeq Reagent Kit v3 in MiSeq system (Illumina Inc, USA) to generate 2x100 bp paired end sequencing reads.", [["MiSeq Reagent Kit", "TREATMENT", 35, 52]]], ["For viral genome amplification in samples which did not generate sufficient viral reads, the RNA samples were converted to double stranded cDNA and amplified using QIAseq SARS-CoV-2 Primer Panel (Qiagen GmbH, Germany) according to the manufacturer's instructions.", [["samples", "ANATOMY", 34, 41], ["samples", "ANATOMY", 97, 104], ["samples", "CANCER", 34, 41], ["double stranded cDNA", "DNA", 123, 143], ["viral genome amplification", "PROBLEM", 4, 30], ["the RNA samples", "TEST", 89, 104], ["double stranded cDNA", "TREATMENT", 123, 143], ["QIAseq SARS", "TEST", 164, 175], ["CoV", "TEST", 176, 179]]], ["The multiplexed amplicon pools were then converted to sequencing libraries by enzymatic fragmentation, end repair and ligation to adapters.", [["The multiplexed amplicon pools", "TREATMENT", 0, 30], ["sequencing libraries", "TREATMENT", 54, 74], ["enzymatic fragmentation", "PROBLEM", 78, 101], ["end repair", "TREATMENT", 103, 113], ["ligation", "TREATMENT", 118, 126], ["enzymatic fragmentation", "OBSERVATION", 78, 101]]], ["The sequencing libraries were checked and quantified as above and sequenced using Miseq reagent Kit v2 Nano in Miseq system (Illumina Inc, USA) to generate 2x150 bp paired end sequencing reads.Analysis of sequence dataThe sequencing reads obtained in shotgun RNA-Seq experiment were mapped to reference viral sequence, variants detected and consensus sequence for each sample built using Dragen RNA pathogen detection software (version 9) in BaseSpace (Illumina Inc, USA).", [["sample", "ANATOMY", 369, 375], ["reference viral sequence", "DNA", 293, 317], ["consensus sequence", "DNA", 341, 359], ["The sequencing libraries", "TEST", 0, 24], ["Miseq reagent Kit v2 Nano in Miseq system", "TREATMENT", 82, 123], ["Analysis of sequence data", "TEST", 193, 218], ["The sequencing reads", "TEST", 218, 238], ["viral sequence", "TEST", 303, 317], ["each sample", "TEST", 364, 375]]], ["For amplified whole genome sequencing, the viral sequences were assembled using CLC Genomics Workbench v20.0.3 (Qiagen GmbH, Germany).", [["viral sequences", "DNA", 43, 58], ["the viral sequences", "TEST", 39, 58]]], ["In both cases, the Severe acute respiratory syndrome coronavirus 2 isolate Wuhan-Hu-1 as reference genome (Accession NC_045512.2) was used as the reference sequence.", [["acute respiratory syndrome coronavirus", "DISEASE", 26, 64], ["Hu-1", "GENE_OR_GENE_PRODUCT", 81, 85], ["Wuhan-Hu-1 as reference genome", "DNA", 75, 105], ["Accession NC_045512.2", "DNA", 107, 128], ["Severe acute respiratory syndrome coronavirus", "SPECIES", 19, 64], ["Wuhan-Hu-1", "SPECIES", 75, 85], ["the Severe acute respiratory syndrome coronavirus", "PROBLEM", 15, 64], ["Severe", "OBSERVATION_MODIFIER", 19, 25], ["acute", "OBSERVATION_MODIFIER", 26, 31], ["respiratory syndrome", "OBSERVATION", 32, 52]]], ["Clustal Omega was used to display the mutations in the context of the sequence alignments.", [["Omega", "DNA", 8, 13], ["Clustal Omega", "TREATMENT", 0, 13], ["the mutations", "PROBLEM", 34, 47]]], ["BioEdit software (v7.2) was used to extract the CDS from consensus sequence and to check codon usage.", [["CDS", "DNA", 48, 51], ["consensus sequence", "DNA", 57, 75], ["BioEdit software", "TEST", 0, 16], ["consensus sequence", "TEST", 57, 75]]], ["Nucleotide to amino acid conversion was done in Emboss Transeq online tool (F Madeira et al. 2019).Phylogenetic analysisTo generate the clustering patterns of the viral sequences from West Bengal, a subset of representative virus sequence data (n = 310) were downloaded from GISAID global database (supplementary table 1).", [["Nucleotide", "CHEMICAL", 0, 10], ["amino acid", "CHEMICAL", 14, 24], ["Nucleotide", "CHEMICAL", 0, 10], ["amino acid", "CHEMICAL", 14, 24], ["amino acid", "AMINO_ACID", 14, 24], ["viral sequences", "DNA", 163, 178], ["GISAID global database", "DNA", 275, 297], ["Nucleotide to amino acid conversion", "TREATMENT", 0, 35], ["Phylogenetic analysisTo", "TEST", 99, 122], ["the viral sequences", "TEST", 159, 178], ["representative virus sequence data", "TEST", 209, 243]]], ["Only high coverage data (where the entries have less than 1% N's and less than 0.05% amino acid mutations), complete genome (entries with base pair greater than 29,000) and excluding low coverage entries (entries having more than 5% N's) were used in the analysis.", [["amino acid", "CHEMICAL", 85, 95], ["amino acid", "CHEMICAL", 85, 95], ["amino acid", "AMINO_ACID", 85, 95], ["amino acid mutations", "TEST", 85, 105], ["base pair", "TEST", 138, 147], ["5% N's", "TREATMENT", 230, 236], ["the analysis", "TEST", 251, 263], ["high", "OBSERVATION_MODIFIER", 5, 9], ["coverage", "OBSERVATION_MODIFIER", 10, 18]]], ["All of the sequences were aligned using MAFFT (Multiple alignment using fast Fourier transform).", [["MAFFT", "TEST", 40, 45]]], ["We used the Nextstrain pipeline to process the sequence data.", [["the Nextstrain pipeline", "TREATMENT", 8, 31], ["the sequence data", "TEST", 43, 60]]], ["Nextstrain with the augur pipeline was used to build phylogenetic tree based on the IQTREE method, which is a fast and effective stochastic algorithm to infer phylogenetic trees by maximum likelihood.", [["Nextstrain", "TREATMENT", 0, 10], ["the augur pipeline", "TREATMENT", 16, 34], ["the IQTREE method", "TEST", 80, 97], ["a fast and effective stochastic algorithm", "PROBLEM", 108, 149]]], ["The tree building process involves the use of these subtypes 'Wuhan-Hu-1/2019', 'Wuhan/WH01/2019' to generate the root of the tree.", [["root", "ANATOMY", 114, 118], ["Wuhan/WH01/2019", "SPECIES", 81, 96], ["root", "ANATOMY_MODIFIER", 114, 118], ["tree", "ANATOMY_MODIFIER", 126, 130]]], ["The tree is refined using RAxML (Randomized Axelerated Maximum Likelihood).", [["RAxML", "TREATMENT", 26, 31], ["tree", "ANATOMY_MODIFIER", 4, 8]]], ["A web-based visualization program, auspice was then used to present and interact with phylogenetic and phylogeographic data.Structural and function impact of mutationsWe investigated the potential miRNA binding site in the region coding for N protein, found to be mutated in our samples.", [["samples", "ANATOMY", 279, 286], ["miRNA binding site", "DNA", 197, 215], ["N protein", "PROTEIN", 241, 250], ["phylogenetic and phylogeographic data", "TEST", 86, 123], ["mutations", "PROBLEM", 158, 167], ["the potential miRNA binding site", "PROBLEM", 183, 215], ["miRNA binding", "OBSERVATION", 197, 210]]], ["STarMir (http://sfold.wadsworth.org/cgibin/starmirtest2.pl) software was used for this purpose.", [["STarMir", "DNA", 0, 7]]], ["The whole human mature miRNA library was obtained from miRbase database.", [["human", "ORGANISM", 10, 15], ["miRbase", "GENE_OR_GENE_PRODUCT", 55, 62], ["human mature miRNA library", "DNA", 10, 36], ["human", "SPECIES", 10, 15], ["human", "SPECIES", 10, 15]]], ["The sequence in query was taken 50 nt upstream and 50 nt downstream from the site of mutation.", [["50 nt upstream", "DNA", 32, 46], ["50 nt downstream", "DNA", 51, 67], ["mutation", "PROBLEM", 85, 93], ["mutation", "OBSERVATION", 85, 93]]], ["The miRNAs which bind to the mutation site through seed sequence were shortlisted.", [["mutation site", "DNA", 29, 42], ["seed sequence", "DNA", 51, 64]]], ["The change in bases can prevent certain miRNA binding and support the binding of others.", [["The change in bases", "PROBLEM", 0, 19], ["certain miRNA binding", "PROBLEM", 32, 53], ["bases", "ANATOMY_MODIFIER", 14, 19], ["miRNA binding", "OBSERVATION", 40, 53]]], ["Therefore, miRNA binding was checked for both, original and mutated site.", [["mutated site", "DNA", 60, 72], ["miRNA binding", "PROBLEM", 11, 24]]], ["We checked the levels of miRNAs in the cancer conditions around the upper respiratory tract in the dBDEMC2 database (https://www.picb.ac.cn/ dbDEMC/).", [["cancer", "ANATOMY", 39, 45], ["upper respiratory tract", "ANATOMY", 68, 91], ["cancer", "DISEASE", 39, 45], ["cancer", "CANCER", 39, 45], ["upper respiratory", "ORGANISM_SUBDIVISION", 68, 85], ["tract", "ORGANISM_SUBDIVISION", 86, 91], ["miRNAs in the cancer conditions", "PROBLEM", 25, 56], ["cancer", "OBSERVATION", 39, 45], ["upper", "ANATOMY_MODIFIER", 68, 73], ["respiratory tract", "ANATOMY", 74, 91]]], ["The TissueAtlas database (https://ccbweb.cs.uni-saarland.de/tissueatlas/) was used to analyse the presence and correlation of miRNAs in body fluids.Clinical status and contact/travel historyAll patients were diagnosed positive for SARS-CoV-2 RNA by Real Time PCR as described above.", [["body fluids", "ANATOMY", 136, 147], ["body", "ORGANISM_SUBDIVISION", 136, 140], ["fluids", "ORGANISM_SUBSTANCE", 141, 147], ["patients", "ORGANISM", 194, 202], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 231, 241], ["TissueAtlas database", "DNA", 4, 24], ["SARS-CoV-2 RNA", "RNA", 231, 245], ["patients", "SPECIES", 194, 202], ["SARS-CoV", "SPECIES", 231, 239], ["The TissueAtlas database", "TEST", 0, 24], ["miRNAs in body fluids", "TREATMENT", 126, 147], ["SARS", "PROBLEM", 231, 235], ["CoV", "TEST", 236, 239], ["Real Time PCR", "TEST", 249, 262]]], ["Five of the patients suffered from fever, while seven patients exhibited some symptoms of infection like sore throat, cough with sputum, running nose or breathlessness.", [["sputum", "ANATOMY", 129, 135], ["fever", "DISEASE", 35, 40], ["infection", "DISEASE", 90, 99], ["sore throat", "DISEASE", 105, 116], ["cough", "DISEASE", 118, 123], ["breathlessness", "DISEASE", 153, 167], ["patients", "ORGANISM", 12, 20], ["patients", "ORGANISM", 54, 62], ["nose", "ORGANISM_SUBDIVISION", 145, 149], ["patients", "SPECIES", 12, 20], ["patients", "SPECIES", 54, 62], ["fever", "PROBLEM", 35, 40], ["some symptoms of infection", "PROBLEM", 73, 99], ["sore throat", "PROBLEM", 105, 116], ["cough", "PROBLEM", 118, 123], ["sputum", "PROBLEM", 129, 135], ["running nose", "PROBLEM", 137, 149], ["breathlessness", "PROBLEM", 153, 167], ["fever", "OBSERVATION", 35, 40], ["infection", "OBSERVATION", 90, 99], ["cough", "OBSERVATION", 118, 123]]], ["One patient suffered from Acute Respiratory Distress Syndrome (ARDS).", [["Acute Respiratory Distress Syndrome", "DISEASE", 26, 61], ["ARDS", "DISEASE", 63, 67], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["Acute Respiratory Distress Syndrome", "PROBLEM", 26, 61], ["ARDS", "PROBLEM", 63, 67], ["Acute", "OBSERVATION_MODIFIER", 26, 31], ["Respiratory Distress", "OBSERVATION", 32, 52], ["Syndrome", "OBSERVATION", 53, 61], ["ARDS", "OBSERVATION", 63, 67]]], ["Two patients did not exhibit any symptom (table 1) .", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12]]], ["Five individuals had contact with COVID-19 patients in particular; both S2 and S3 had contact with the same patient (table 1).", [["individuals", "ORGANISM", 5, 16], ["patients", "ORGANISM", 43, 51], ["patient", "ORGANISM", 108, 115], ["patients", "SPECIES", 43, 51], ["patient", "SPECIES", 108, 115]]], ["One individual had history of international travel while another had history of domestic travel.SequencingThe shotgun RNA-Seq data resulted in high coverage (greater than 100X median depth of coverage) of complete genome sequences of the SARS-CoV-2 in five samples (S2, S3, S5, S6 and S11) in which greater than 96% of the viral genome was covered at greater than 5X and greater than 99% of the viral genome was covered at greater than 1X.", [["samples", "ANATOMY", 257, 264], ["SARS-CoV-2", "ORGANISM", 238, 248], ["S6", "GENE_OR_GENE_PRODUCT", 278, 280], ["S11", "GENE_OR_GENE_PRODUCT", 285, 288], ["SARS-CoV-2", "DNA", 238, 248], ["S2, S3, S5, S6 and S11", "DNA", 266, 288], ["viral genome", "DNA", 323, 335], ["viral genome", "DNA", 395, 407], ["SARS-CoV", "SPECIES", 238, 246], ["The shotgun RNA", "TEST", 106, 121], ["Seq data", "TEST", 122, 130], ["high coverage", "PROBLEM", 143, 156], ["100X median depth of coverage", "TREATMENT", 171, 200], ["the SARS", "TEST", 234, 242], ["CoV", "TEST", 243, 246], ["S2", "TEST", 266, 268], ["S3", "TEST", 270, 272], ["the viral genome", "TEST", 319, 335], ["the viral genome", "PROBLEM", 391, 407], ["high", "OBSERVATION_MODIFIER", 143, 147], ["coverage", "OBSERVATION_MODIFIER", 148, 156], ["S3", "ANATOMY_MODIFIER", 270, 272], ["S5", "ANATOMY", 274, 276], ["greater", "OBSERVATION_MODIFIER", 299, 306], ["viral genome", "OBSERVATION", 323, 335], ["viral genome", "OBSERVATION", 395, 407]]], ["A negative correlation was found between viral load (represented by the Threshold Cycle or Ct value of the RNA samples in the Real Time PCR based diagnostic assay) and the number of reads mapped to the viral genome in the RNA-Seq library.", [["RNA samples", "RNA", 107, 118], ["viral genome", "DNA", 202, 214], ["RNA-Seq library", "DNA", 222, 237], ["viral load", "PROBLEM", 41, 51], ["Ct value", "TEST", 91, 99], ["the RNA samples", "TEST", 103, 118], ["diagnostic assay", "TEST", 146, 162], ["negative", "OBSERVATION", 2, 10], ["viral genome", "OBSERVATION", 202, 214]]], ["Even with 9 samples, the Pearson Correlation Coefficient was found to be -0.63 (P value = 0.036) (table 1).", [["P value", "TEST", 80, 87]]], ["In particular, it was observed that samples with Ct values greater than 25 mostly resulted in generation of low counts of viral sequence reads leading to less than 15X median depth of coverage of the viral genome.", [["samples", "ANATOMY", 36, 43], ["viral genome", "DNA", 200, 212], ["Ct values", "TEST", 49, 58], ["low counts of viral sequence reads", "PROBLEM", 108, 142], ["the viral genome", "PROBLEM", 196, 212], ["low counts", "OBSERVATION_MODIFIER", 108, 118], ["viral genome", "OBSERVATION", 200, 212]]], ["In the remaining four samples (S1, S8, S10 and S12), the median depth of coverage was less than 15X and hence the viral genome sequencing was achieved after amplification of the viral genome by a multiplex PCR approach.", [["samples", "ANATOMY", 22, 29], ["S10", "PROTEIN", 39, 42], ["S12", "PROTEIN", 47, 50], ["viral genome", "DNA", 178, 190], ["the viral genome sequencing", "TREATMENT", 110, 137], ["the viral genome", "TREATMENT", 174, 190], ["a multiplex PCR approach", "TREATMENT", 194, 218], ["median", "OBSERVATION_MODIFIER", 57, 63], ["viral genome", "OBSERVATION", 114, 126], ["viral genome", "OBSERVATION", 178, 190]]], ["All the nine sequences have been submitted in the Global Initiative on Sharing All Influenza Data (GISAID) database.Phylogenetic analysisPhylogenetic tree analysis of the sequences, along with other complete viral genome sequences submitted from India in GISAID, revealed that seven of these sequences belonged to the A2a clade while only one sequence belonged to clade B4 (figure 1 and table 1).", [["viral genome sequences", "DNA", 208, 230], ["A2a clade", "DNA", 318, 327], ["All the nine sequences", "TEST", 0, 22], ["Phylogenetic analysis", "TEST", 116, 137], ["Phylogenetic tree analysis", "TEST", 137, 163], ["the sequences", "TEST", 167, 180], ["other complete viral genome sequences", "PROBLEM", 193, 230], ["these sequences", "TEST", 286, 301], ["tree", "OBSERVATION_MODIFIER", 150, 154]]], ["We were unable to classify one of the nine sequences, S1, into any clade due to low sequence coverage.", [["low sequence coverage", "TREATMENT", 80, 101]]], ["To understand transmission histories of these nine SARS-CoV-2 isolates from West Bengal, we aligned these sequences with more than 6000 global sequences, including thirty sequences submitted in GISAID from India (at the time of our analysis) to identify specific mutations that occur at the highest level of the tip in a branch leading to the specific subtype.", [["SARS-CoV-2", "ORGANISM", 51, 61], ["SARS-CoV", "SPECIES", 51, 59], ["these nine SARS", "TEST", 40, 55], ["these sequences", "TEST", 100, 115], ["thirty sequences", "TEST", 164, 180], ["our analysis", "TEST", 228, 240], ["specific mutations", "PROBLEM", 254, 272], ["tip", "OBSERVATION_MODIFIER", 312, 315], ["branch", "ANATOMY_MODIFIER", 321, 327]]], ["The predicted origin of the transmitted subtype in each case was identified with 98-100% confidence from the branch in which our samples were located in the phylogenetic tree (table 1) .Mutation analysisThe list of mutations detected in the sequences from nine samples are provided (table 2) .", [["samples", "ANATOMY", 129, 136], ["samples", "ANATOMY", 261, 268], ["samples", "CANCER", 129, 136], ["our samples", "TEST", 125, 136], ["Mutation analysis", "TEST", 186, 203], ["mutations", "PROBLEM", 215, 224], ["origin", "ANATOMY_MODIFIER", 14, 20], ["subtype", "OBSERVATION_MODIFIER", 40, 47], ["branch", "ANATOMY_MODIFIER", 109, 115], ["phylogenetic", "ANATOMY_MODIFIER", 157, 169], ["tree", "ANATOMY_MODIFIER", 170, 174]]], ["Seven sequences harboured the important signature mutations of A2a clade.", [["A2a", "GENE_OR_GENE_PRODUCT", 63, 66], ["A2a clade", "DNA", 63, 72], ["Seven sequences", "TEST", 0, 15], ["A2a clade", "TREATMENT", 63, 72]]], ["These consisted of the 14408 C/T mutation resulting in a change of P323L in the RdRp and the 23403 A/G mutation resulting in a change of D614G in the Spike glycoprotein of the virus.", [["P323L", "GENE_OR_GENE_PRODUCT", 67, 72], ["G", "GENE_OR_GENE_PRODUCT", 101, 102], ["Spike glycoprotein", "GENE_OR_GENE_PRODUCT", 150, 168], ["P323L", "PROTEIN", 67, 72], ["D614G", "PROTEIN", 137, 142], ["Spike glycoprotein", "PROTEIN", 150, 168], ["T mutation", "PROBLEM", 31, 41], ["a change of P323L in the RdRp", "PROBLEM", 55, 84], ["A/G mutation", "TREATMENT", 99, 111], ["a change of D614G", "TREATMENT", 125, 142], ["the virus", "PROBLEM", 172, 181]]], ["In addition to these, 24933 G/T mutation in the gene coding for Spike glycoprotein (G1124V) and triple base mutations of 2881-2883 GGG/AAC in the gene coding for nucleocapsid resulting in two consecutive amino acid changes R203K and G204R were detected in S2, S3 and S2, S3, S5 respectively.", [["amino acid", "CHEMICAL", 204, 214], ["amino acid", "CHEMICAL", 204, 214], ["G/T", "GENE_OR_GENE_PRODUCT", 28, 31], ["Spike glycoprotein", "GENE_OR_GENE_PRODUCT", 64, 82], ["G1124V", "GENE_OR_GENE_PRODUCT", 84, 90], ["amino acid", "AMINO_ACID", 204, 214], ["G204R", "GENE_OR_GENE_PRODUCT", 233, 238], ["S5", "GENE_OR_GENE_PRODUCT", 275, 277], ["Spike glycoprotein", "PROTEIN", 64, 82], ["G1124V", "PROTEIN", 84, 90], ["S2", "PROTEIN", 256, 258], ["S3", "PROTEIN", 260, 262], ["S2", "PROTEIN", 267, 269], ["S3", "PROTEIN", 271, 273], ["S5", "PROTEIN", 275, 277], ["G/T mutation", "TREATMENT", 28, 40], ["Spike glycoprotein", "PROBLEM", 64, 82], ["triple base mutations", "TREATMENT", 96, 117], ["GGG/AAC", "TREATMENT", 131, 138], ["nucleocapsid", "PROBLEM", 162, 174], ["two consecutive amino acid changes", "PROBLEM", 188, 222], ["G204R", "TEST", 233, 238], ["amino acid", "OBSERVATION", 204, 214], ["S2", "ANATOMY_MODIFIER", 256, 258], ["S3", "ANATOMY_MODIFIER", 260, 262], ["S2", "ANATOMY_MODIFIER", 267, 269], ["S3", "ANATOMY_MODIFIER", 271, 273]]], ["While the 24933 G/T S gene mutation was unique to these samples and could not be found in any other sequence from India or the rest of the World, the nucleocapsid mutations could be detected in only three other sequences from India (figure 2).", [["samples", "ANATOMY", 56, 63], ["G/T S", "GENE_OR_GENE_PRODUCT", 16, 21], ["samples", "CANCER", 56, 63], ["nucleocapsid", "GENE_OR_GENE_PRODUCT", 150, 162], ["24933 G/T S gene", "DNA", 10, 26], ["these samples", "TEST", 50, 63], ["the nucleocapsid mutations", "PROBLEM", 146, 172]]], ["Out of these, two sequences were obtained from individuals with contact history of a COVID-19 patient who had travelled from Italy.", [["patient", "ORGANISM", 94, 101], ["patient", "SPECIES", 94, 101]]], ["Interestingly, two out of three sequences harbouring these mutations obtained by us belonged to Kolkata and with contact history with one COVID-19 patient who had travelled from London (UK).", [["patient", "ORGANISM", 147, 154], ["patient", "SPECIES", 147, 154]]], ["The third sequence was obtained from a COVID-19 patient from Darjeeling, India who had history of travel from Chennai, India.", [["patient", "ORGANISM", 48, 55], ["patient", "SPECIES", 48, 55], ["The third sequence", "TEST", 0, 18]]], ["These mutations have been found in 16% of SARS-CoV-2 sequences reported World-wide from countries like UK, Netherlands, Iceland, Belgium, Portugal, USA, Australia, Brazil, etc.Mutation analysisRdRp (NSP12) gene of the SARS-CoV-2 codes for the RNA-dependent RNA polymerase and is vital for the replication machinery of the virus.", [["SARS", "DISEASE", 42, 46], ["analysisRdRp", "GENE_OR_GENE_PRODUCT", 185, 197], ["NSP12", "GENE_OR_GENE_PRODUCT", 199, 204], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 218, 228], ["SARS-CoV-2 sequences", "DNA", 42, 62], ["analysisRdRp (NSP12) gene", "DNA", 185, 210], ["SARS-CoV-2", "DNA", 218, 228], ["RNA-dependent RNA polymerase", "PROTEIN", 243, 271], ["SARS-CoV", "SPECIES", 42, 50], ["SARS-CoV", "SPECIES", 218, 226], ["These mutations", "PROBLEM", 0, 15], ["SARS", "PROBLEM", 42, 46], ["CoV-2 sequences", "TEST", 47, 62], ["Mutation analysisRdRp", "TEST", 176, 197], ["the SARS", "TEST", 214, 222], ["the RNA-dependent RNA polymerase", "PROBLEM", 239, 271], ["the virus", "PROBLEM", 318, 327]]], ["We detected a total of six mutations in this gene in the nine samples, out of which four were nonsynonymous, including the A2a clade specific 14408 C/T (RdRp: P323L) mutation.", [["samples", "ANATOMY", 62, 69], ["14408 C/T", "GENE_OR_GENE_PRODUCT", 142, 151], ["six mutations", "PROBLEM", 23, 36], ["mutation", "PROBLEM", 166, 174]]], ["Two individuals, S11 and S12, harboured viral genome sequences that shared a unique 13730 C/T (A88V) mutation which was not found in any other sequence reported from India or rest of the World.", [["S12", "GENE_OR_GENE_PRODUCT", 25, 28], ["13730 C/T", "GENE_OR_GENE_PRODUCT", 84, 93], ["viral genome sequences", "DNA", 40, 62], ["harboured viral genome sequences", "PROBLEM", 30, 62], ["mutation", "PROBLEM", 101, 109], ["viral genome", "OBSERVATION", 40, 52]]], ["One individual S10, whose viral sequence belonged to B4 clade, harboured 3 mutations in RdRp, which appear to be clade specific, out of which 2 were nonsynonymous.Impact of mutations in nucleocapsid gene on miRNA bindingTo study the functional relevance of the mutations, we investigated the alteration in miRNA binding in the nucleocapsid coding region, predicted to be caused by the 28881-3 GGG/AAC mutations.", [["S10", "GENE_OR_GENE_PRODUCT", 15, 18], ["RdRp", "GENE_OR_GENE_PRODUCT", 88, 92], ["28881-3", "GENE_OR_GENE_PRODUCT", 385, 392], ["AAC", "GENE_OR_GENE_PRODUCT", 397, 400], ["S10", "DNA", 15, 18], ["nucleocapsid gene", "DNA", 186, 203], ["nucleocapsid coding region", "DNA", 327, 353], ["whose viral sequence", "TEST", 20, 40], ["harboured 3 mutations in RdRp", "PROBLEM", 63, 92], ["mutations in nucleocapsid gene on miRNA binding", "PROBLEM", 173, 220], ["the mutations", "PROBLEM", 257, 270], ["the alteration in miRNA binding", "PROBLEM", 288, 319], ["GGG/AAC mutations", "TREATMENT", 393, 410], ["S10", "ANATOMY", 15, 18], ["mutations", "OBSERVATION", 173, 182], ["nucleocapsid gene", "OBSERVATION", 186, 203], ["miRNA binding", "OBSERVATION", 306, 319]]], ["We found seven miRNAs which bind to the original sequence and three which bind the mutated sequence exclusively (table 3 and figure 3 ).", [["mutated sequence", "DNA", 83, 99], ["seven miRNAs", "OBSERVATION", 9, 21]]], ["The number of bases in the sequence (GGG/AAC) which bind the seed sequence of miRNA were also identified.", [["seed sequence", "DNA", 61, 74], ["GGG/AAC", "TREATMENT", 37, 44], ["bases", "ANATOMY_MODIFIER", 14, 19], ["miRNA", "ANATOMY", 78, 83]]], ["The strength of miRNA prediction is reflected by the DG value mentioned in the figure 3.", [["DG", "SIMPLE_CHEMICAL", 53, 55], ["miRNA prediction", "TEST", 16, 32], ["the DG value", "TEST", 49, 61]]], ["Mutant Base S1 S2 S3 S5 S6 S8 S10 S11 S12 Lesser the value, stronger is the binding.", [["Mutant Base S1 S2 S3 S5 S6 S8 S10 S11 S12", "PROTEIN", 0, 41], ["Base", "ANATOMY_MODIFIER", 7, 11], ["S1", "ANATOMY_MODIFIER", 12, 14], ["S2 S3", "ANATOMY", 15, 20], ["S11", "OBSERVATION_MODIFIER", 34, 37], ["S12", "OBSERVATION_MODIFIER", 38, 41], ["Lesser", "OBSERVATION_MODIFIER", 42, 48], ["stronger", "OBSERVATION_MODIFIER", 60, 68]]], ["The values are comparable to some of the experimentally validated miRNA bindings like miR122 binding to HCV RNA has DG value of -18.3 kcal/mol for S1 binding site and -22.6 kcal/mol for S2 binding site (data not shown).Impact of mutations in nucleocapsid gene on miRNA bindingThe values of DG obtained for the miRNAs binding to N protein coding region are comparable to these values, suggesting their relevance in the in vivo conditions.", [["miR122", "GENE_OR_GENE_PRODUCT", 86, 92], ["HCV", "ORGANISM", 104, 107], ["DG", "SIMPLE_CHEMICAL", 116, 118], ["DG", "SIMPLE_CHEMICAL", 290, 292], ["miR122", "PROTEIN", 86, 92], ["HCV RNA", "RNA", 104, 111], ["S1 binding site", "DNA", 147, 162], ["S2 binding site", "DNA", 186, 201], ["nucleocapsid gene", "DNA", 242, 259], ["N protein coding region", "DNA", 328, 351], ["HCV", "SPECIES", 104, 107], ["The values", "TEST", 0, 10], ["the experimentally validated miRNA bindings", "PROBLEM", 37, 80], ["miR122 binding", "PROBLEM", 86, 100], ["HCV RNA", "TEST", 104, 111], ["DG value", "TEST", 116, 124], ["S1 binding site", "PROBLEM", 147, 162], ["S2 binding site", "PROBLEM", 186, 201], ["mutations in nucleocapsid gene on miRNA binding", "PROBLEM", 229, 276], ["The values of DG", "TEST", 276, 292], ["the miRNAs binding", "PROBLEM", 306, 324], ["mutations", "OBSERVATION", 229, 238], ["nucleocapsid gene", "OBSERVATION", 242, 259]]], ["We checked the levels of these miRNAs in cancer conditions around the upper respiratory tract in the Only two samples from West Bengal (S11 and S12) harbour this mutation.", [["cancer", "ANATOMY", 41, 47], ["upper respiratory tract", "ANATOMY", 70, 93], ["samples", "ANATOMY", 110, 117], ["cancer", "DISEASE", 41, 47], ["cancer", "CANCER", 41, 47], ["upper respiratory", "ORGANISM_SUBDIVISION", 70, 87], ["tract", "ORGANISM_SUBDIVISION", 88, 93], ["these miRNAs in cancer conditions", "PROBLEM", 25, 58], ["this mutation", "PROBLEM", 157, 170], ["miRNAs", "ANATOMY", 31, 37], ["cancer", "OBSERVATION", 41, 47], ["upper", "ANATOMY_MODIFIER", 70, 75], ["respiratory tract", "ANATOMY", 76, 93]]], ["(D) 14323 C/T, 14326 C/A and 14331 T/C mutations in the RdRp gene in Clustal Omega.", [["14331 T/C", "GENE_OR_GENE_PRODUCT", 29, 38], ["RdRp gene", "DNA", 56, 65], ["T/C mutations", "TREATMENT", 35, 48]]], ["Only one sample from West Bengal (S10) harbour these mutations. dBDEMC2 database.", [["dBDEMC2", "PROTEIN", 64, 71]]], ["We found that miR-24-1-5p and miR-299-5p were downregulated in most of the cancers. miR-24-2-5p was found to be upregulated in Esophageal Cancer (ESCA), Head and neck cancer (HNSC), Lung cancer (LUCA) and downregulated in Nasopharyngeal cancer (NSCA) (supplementary figure 1).", [["cancers", "ANATOMY", 75, 82], ["Esophageal Cancer", "ANATOMY", 127, 144], ["ESCA", "ANATOMY", 146, 150], ["Head and neck cancer", "ANATOMY", 153, 173], ["HNSC", "ANATOMY", 175, 179], ["Lung cancer", "ANATOMY", 182, 193], ["LUCA", "ANATOMY", 195, 199], ["Nasopharyngeal cancer", "ANATOMY", 222, 243], ["NSCA", "ANATOMY", 245, 249], ["cancers", "DISEASE", 75, 82], ["Esophageal Cancer", "DISEASE", 127, 144], ["ESCA", "DISEASE", 146, 150], ["Head and neck cancer", "DISEASE", 153, 173], ["HNSC", "DISEASE", 175, 179], ["Lung cancer", "DISEASE", 182, 193], ["Nasopharyngeal cancer", "DISEASE", 222, 243], ["NSCA", "DISEASE", 245, 249], ["miR-24-1-5p", "GENE_OR_GENE_PRODUCT", 14, 25], ["miR-299-5p", "GENE_OR_GENE_PRODUCT", 30, 40], ["cancers", "CANCER", 75, 82], ["miR-24-2-5p", "GENE_OR_GENE_PRODUCT", 84, 95], ["Esophageal Cancer", "CANCER", 127, 144], ["ESCA", "CANCER", 146, 150], ["Head and neck cancer", "CANCER", 153, 173], ["HNSC", "CANCER", 175, 179], ["Lung cancer", "CANCER", 182, 193], ["LUCA", "CANCER", 195, 199], ["Nasopharyngeal cancer", "CANCER", 222, 243], ["NSCA", "CANCER", 245, 249], ["miR-24-1-5p and miR-299-5p", "DNA", 14, 40], ["miR-24-2-5p", "DNA", 84, 95], ["miR", "TEST", 14, 17], ["miR", "TEST", 30, 33], ["the cancers", "PROBLEM", 71, 82], ["Esophageal Cancer", "PROBLEM", 127, 144], ["Head and neck cancer (HNSC)", "PROBLEM", 153, 180], ["Lung cancer (LUCA)", "PROBLEM", 182, 200], ["downregulated in Nasopharyngeal cancer (NSCA)", "PROBLEM", 205, 250], ["cancers", "OBSERVATION", 75, 82], ["Esophageal", "ANATOMY", 127, 137], ["Cancer", "OBSERVATION", 138, 144], ["Head", "ANATOMY", 153, 157], ["neck", "ANATOMY", 162, 166], ["cancer", "OBSERVATION", 167, 173], ["Lung", "ANATOMY", 182, 186], ["cancer", "OBSERVATION", 187, 193], ["downregulated", "OBSERVATION_MODIFIER", 205, 218], ["Nasopharyngeal", "ANATOMY", 222, 236], ["cancer", "OBSERVATION", 237, 243]]], ["Assuming that the binding of miRNAs would inhibit the viral replication/stability, higher abundance of that miRNA would be protective against infection and lower abundance would increase the susceptibility towards infection.", [["infection", "DISEASE", 142, 151], ["infection", "DISEASE", 214, 223], ["the binding of miRNAs", "PROBLEM", 14, 35], ["the viral replication/stability", "PROBLEM", 50, 81], ["infection", "PROBLEM", 142, 151], ["lower abundance", "PROBLEM", 156, 171], ["the susceptibility towards infection", "PROBLEM", 187, 223], ["stability", "OBSERVATION_MODIFIER", 72, 81], ["infection", "OBSERVATION", 142, 151], ["infection", "OBSERVATION", 214, 223]]], ["To comprehend the results, we have found that if a patient suffering from ESCA, HNSC, LUCA is infected with the original virus containing GGG sequence, the upregulated miR-24-2-5p would be protective against the infection.", [["HNSC", "ANATOMY", 80, 84], ["ESCA", "DISEASE", 74, 78], ["HNSC", "DISEASE", 80, 84], ["LUCA", "DISEASE", 86, 90], ["miR-24-2-5p", "CHEMICAL", 168, 179], ["infection", "DISEASE", 212, 221], ["patient", "ORGANISM", 51, 58], ["ESCA", "CANCER", 74, 78], ["HNSC", "CANCER", 80, 84], ["LUCA", "CANCER", 86, 90], ["miR-24-2", "GENE_OR_GENE_PRODUCT", 168, 176], ["GGG sequence", "DNA", 138, 150], ["miR-24-2-5p", "DNA", 168, 179], ["patient", "SPECIES", 51, 58], ["ESCA", "PROBLEM", 74, 78], ["HNSC", "PROBLEM", 80, 84], ["GGG sequence", "TEST", 138, 150], ["the infection", "PROBLEM", 208, 221], ["infected", "OBSERVATION", 94, 102], ["infection", "OBSERVATION", 212, 221]]], ["But, if the same patient is infected with the mutated virus containing AAC sequence, miR-24-2-5p will not be functional anymore and miR-299-5p which targets the mutated site is also downregulated.", [["patient", "ORGANISM", 17, 24], ["miR-24-2", "GENE_OR_GENE_PRODUCT", 85, 93], ["miR-299-5p", "GENE_OR_GENE_PRODUCT", 132, 142], ["AAC sequence", "DNA", 71, 83], ["miR-24-2-5p", "DNA", 85, 96], ["miR-299-5p", "DNA", 132, 142], ["mutated site", "DNA", 161, 173], ["patient", "SPECIES", 17, 24], ["AAC sequence", "TEST", 71, 83], ["the mutated site", "PROBLEM", 157, 173], ["infected", "OBSERVATION", 28, 36]]], ["This could make the patients suffering from described cancers, highly susceptible to infection with the mutant virus.Impact of mutations in nucleocapsid gene on miRNA bindingWe also checked if these miRNAs are associated with other disease conditions and found that miR-299-5p is down regulated in Type 2 Diabetes Mellitus (T2DM) and hence could serve as one of factors for increased susceptibility of T2DM patients for the mutated viral subtype and increase the risk of comorbidity (Huang et al. 2018) .", [["cancers", "ANATOMY", 54, 61], ["cancers", "DISEASE", 54, 61], ["infection", "DISEASE", 85, 94], ["Type 2 Diabetes Mellitus", "DISEASE", 298, 322], ["T2DM", "DISEASE", 324, 328], ["T2DM", "DISEASE", 402, 406], ["patients", "ORGANISM", 20, 28], ["cancers", "CANCER", 54, 61], ["mutant virus", "ORGANISM", 104, 116], ["miR-299-5p", "GENE_OR_GENE_PRODUCT", 266, 276], ["patients", "ORGANISM", 407, 415], ["nucleocapsid gene", "DNA", 140, 157], ["miR-299-5p", "DNA", 266, 276], ["patients", "SPECIES", 20, 28], ["patients", "SPECIES", 407, 415], ["described cancers", "PROBLEM", 44, 61], ["infection", "PROBLEM", 85, 94], ["the mutant virus", "PROBLEM", 100, 116], ["mutations in nucleocapsid gene on miRNA binding", "PROBLEM", 127, 174], ["these miRNAs", "PROBLEM", 193, 205], ["other disease conditions", "PROBLEM", 226, 250], ["miR", "TEST", 266, 269], ["Type 2 Diabetes Mellitus (T2DM)", "PROBLEM", 298, 329], ["increased susceptibility of T2DM", "PROBLEM", 374, 406], ["the mutated viral subtype", "PROBLEM", 420, 445], ["comorbidity", "PROBLEM", 471, 482], ["cancers", "OBSERVATION", 54, 61], ["infection", "OBSERVATION", 85, 94], ["mutations", "OBSERVATION", 127, 136], ["nucleocapsid gene", "OBSERVATION", 140, 157]]], ["Another miR-3162-3p, targeting original subtype, is reported to be higher in Asthma patients (Fang et al. 2016) .", [["Asthma", "DISEASE", 77, 83], ["miR-3162-3p", "GENE_OR_GENE_PRODUCT", 8, 19], ["patients", "ORGANISM", 84, 92], ["miR-3162-3p", "DNA", 8, 19], ["patients", "SPECIES", 84, 92], ["original subtype", "OBSERVATION_MODIFIER", 31, 47], ["higher", "OBSERVATION_MODIFIER", 67, 73], ["Asthma", "OBSERVATION", 77, 83]]], ["This could be one of the factors limiting the original viral propagation, but the loss of its targeting site in mutated viral subtype could increase the host susceptibility towards viral infection.Impact of mutations in nucleocapsid gene on miRNA bindingWe further checked if there are some other conditions that could alter the availability of these miRNAs at the site of infection.", [["viral infection", "DISEASE", 181, 196], ["infection", "DISEASE", 373, 382], ["nucleocapsid gene", "DNA", 220, 237], ["the original viral propagation", "PROBLEM", 42, 72], ["the loss of its targeting site", "PROBLEM", 78, 108], ["mutated viral subtype", "PROBLEM", 112, 133], ["viral infection", "PROBLEM", 181, 196], ["mutations in nucleocapsid gene on miRNA binding", "PROBLEM", 207, 254], ["some other conditions", "PROBLEM", 286, 307], ["these miRNAs", "PROBLEM", 345, 357], ["infection", "PROBLEM", 373, 382], ["viral propagation", "OBSERVATION", 55, 72], ["loss", "OBSERVATION_MODIFIER", 82, 86], ["viral subtype", "OBSERVATION", 120, 133], ["host susceptibility", "OBSERVATION", 153, 172], ["viral", "OBSERVATION_MODIFIER", 181, 186], ["infection", "OBSERVATION", 187, 196], ["mutations", "OBSERVATION", 207, 216], ["nucleocapsid gene", "OBSERVATION", 220, 237], ["infection", "OBSERVATION", 373, 382]]], ["Therefore, we used the Tis-sueAtlas database to analyse the presence and correlation of these miRNAs in body fluids.", [["body fluids", "ANATOMY", 104, 115], ["body", "ORGANISM_SUBDIVISION", 104, 108], ["the Tis-sueAtlas database", "TREATMENT", 19, 44], ["these miRNAs in body fluids", "TREATMENT", 88, 115]]], ["We found that there is differential expression of certain miRNAs in the saliva of patients suffering from pancreatic cancer. miR-642b-5p, miR-3162-3p and miR-299-5p were found to be upregulated in the saliva of pancreatic cancer patients which could provide similar protective/susceptible effect as mentioned of miRNAs before (supplementary figure 2) . miRNAs have been known to affect viral replication and stability by binding to protein coding regions of the genome of H1N1, EV71, CVB3 and many more viruses (Bruscella et al. 2017; Trobaugh and Klimstra 2017) .", [["saliva", "ANATOMY", 72, 78], ["pancreatic cancer", "ANATOMY", 106, 123], ["saliva", "ANATOMY", 201, 207], ["pancreatic cancer", "ANATOMY", 211, 228], ["pancreatic cancer", "DISEASE", 106, 123], ["pancreatic cancer", "DISEASE", 211, 228], ["EV71", "DISEASE", 478, 482], ["saliva", "ORGANISM_SUBSTANCE", 72, 78], ["patients", "ORGANISM", 82, 90], ["pancreatic cancer", "CANCER", 106, 123], ["miR-642b-5p", "GENE_OR_GENE_PRODUCT", 125, 136], ["miR-3162-3p", "GENE_OR_GENE_PRODUCT", 138, 149], ["miR-299-5p", "GENE_OR_GENE_PRODUCT", 154, 164], ["saliva", "ORGANISM_SUBSTANCE", 201, 207], ["pancreatic cancer", "CANCER", 211, 228], ["patients", "ORGANISM", 229, 237], ["EV71", "ORGANISM", 478, 482], ["CVB3", "ORGANISM", 484, 488], ["miR-642b-5p, miR-3162-3p", "DNA", 125, 149], ["miR-299-5p", "DNA", 154, 164], ["protein coding regions", "DNA", 432, 454], ["patients", "SPECIES", 82, 90], ["patients", "SPECIES", 229, 237], ["EV71", "SPECIES", 478, 482], ["CVB3", "SPECIES", 484, 488], ["pancreatic cancer", "PROBLEM", 106, 123], ["pancreatic cancer", "PROBLEM", 211, 228], ["viral replication", "PROBLEM", 386, 403], ["H1N1", "PROBLEM", 472, 476], ["EV71", "PROBLEM", 478, 482], ["CVB3", "PROBLEM", 484, 488], ["differential", "OBSERVATION_MODIFIER", 23, 35], ["expression", "OBSERVATION_MODIFIER", 36, 46], ["certain miRNAs", "OBSERVATION", 50, 64], ["pancreatic", "ANATOMY", 106, 116], ["cancer", "OBSERVATION", 117, 123], ["upregulated", "OBSERVATION", 182, 193], ["pancreatic", "ANATOMY", 211, 221], ["cancer", "OBSERVATION", 222, 228], ["genome", "ANATOMY", 462, 468]]], ["In most of the cases, binding of miRNAs leads to translational repression of the targeted protein and hence directly affects viral RNA replication.", [["targeted protein", "PROTEIN", 81, 97], ["the targeted protein", "TREATMENT", 77, 97], ["viral RNA replication", "TREATMENT", 125, 146]]], ["Targeting by miRNAs could decrease the levels of N protein, which is involved in various steps of viral life cycle including replication, translation and coating of viral RNA to form the nucleocapsid.", [["nucleocapsid", "CELLULAR_COMPONENT", 187, 199], ["N protein", "PROTEIN", 49, 58], ["viral RNA", "RNA", 165, 174], ["viral life cycle", "TREATMENT", 98, 114], ["replication", "TREATMENT", 125, 136], ["viral RNA", "PROBLEM", 165, 174], ["the nucleocapsid", "PROBLEM", 183, 199], ["viral RNA", "OBSERVATION", 165, 174]]], ["Hence, altered levels of the shortlisted miRNA could regulate various viral processes and severity of SARS-CoV-2 infection.", [["SARS-CoV-2 infection", "DISEASE", 102, 122], ["SARS-CoV-2", "ORGANISM", 102, 112], ["SARS-CoV-2", "SPECIES", 102, 112], ["altered levels", "PROBLEM", 7, 21], ["the shortlisted miRNA", "PROBLEM", 25, 46], ["various viral processes", "PROBLEM", 62, 85], ["SARS", "PROBLEM", 102, 106], ["CoV", "PROBLEM", 107, 110], ["2 infection", "PROBLEM", 111, 122], ["SARS", "OBSERVATION", 102, 106], ["infection", "OBSERVATION", 113, 122]]], ["The effect of miRNAs would be opposite if they assist in viral replication/stability, but that needs to be experimentally confirmed and still holds the importance of miRNAs targeting the original and mutated sites.Structural impact of mutations in nucleocapsidWe analysed the 28881-3 GGG/AAC mutations in the nucleocapsid gene which results in contiguous amino acid changes of R203K and G204R for their potential role in alteration of structure of the encoded protein.Structural impact of mutations in nucleocapsidThe sites of these mutations at position are located in the SR-rich region which is known to be intrinsically disordered (Chang et al. 2014 ).", [["amino acid", "CHEMICAL", 355, 365], ["amino acid", "CHEMICAL", 355, 365], ["AAC", "GENE_OR_GENE_PRODUCT", 288, 291], ["amino acid", "AMINO_ACID", 355, 365], ["R203K", "GENE_OR_GENE_PRODUCT", 377, 382], ["G204R", "GENE_OR_GENE_PRODUCT", 387, 392], ["nucleocapsid", "GENE_OR_GENE_PRODUCT", 502, 514], ["mutated sites", "DNA", 200, 213], ["28881-3 GGG/AAC mutations", "DNA", 276, 301], ["nucleocapsid gene", "DNA", 309, 326], ["R203K", "PROTEIN", 377, 382], ["G204R", "PROTEIN", 387, 392], ["encoded protein", "PROTEIN", 452, 467], ["nucleocapsid", "PROTEIN", 502, 514], ["SR-rich region", "DNA", 574, 588], ["viral replication/stability", "PROBLEM", 57, 84], ["mutations in nucleocapsidWe", "PROBLEM", 235, 262], ["3 GGG/AAC mutations", "TREATMENT", 282, 301], ["contiguous amino acid changes", "PROBLEM", 344, 373], ["G204R", "TREATMENT", 387, 392], ["mutations in nucleocapsid", "PROBLEM", 489, 514], ["these mutations", "PROBLEM", 527, 542], ["mutations", "OBSERVATION", 235, 244], ["mutations", "OBSERVATION", 489, 498], ["mutations", "OBSERVATION", 533, 542], ["position", "OBSERVATION_MODIFIER", 546, 554], ["SR", "ANATOMY", 574, 576], ["rich", "ANATOMY_MODIFIER", 577, 581], ["region", "ANATOMY_MODIFIER", 582, 588], ["known to be", "UNCERTAINTY", 598, 609]]], ["In addition, this region is known to encompass a few phosphorylation hsa-miR-3162-3p 3 hsa-miR-4699-3p 2 hsa-miR-6826-3p 3 hsa-miR-299-5p 3 hsa-miR-5195-5p 3 hsa-miR-12132 1 hsa-miR-24-1-5p 2 hsa-miR-3679-3p 3 hsa-miR-642b-5p 3 hsa-miR-24-2-5p 2 sites (Surjit et al. 2005) , notably the GSK3 phosphorylation site at Ser202 and a CDK phosphorylation site at Ser206 which are in close proximity to these mutations.", [["hsa-miR-24-2-5p 2", "GENE_OR_GENE_PRODUCT", 228, 245], ["GSK3", "GENE_OR_GENE_PRODUCT", 287, 291], ["Ser202", "AMINO_ACID", 316, 322], ["CDK", "GENE_OR_GENE_PRODUCT", 329, 332], ["Ser206", "AMINO_ACID", 357, 363], ["phosphorylation hsa-miR-3162-3p 3 hsa-miR-4699-3p 2 hsa-miR-6826-3p 3 hsa-miR-299-5p 3 hsa-miR-5195-5p 3 hsa-miR-12132 1 hsa-miR-24-1-5p 2 hsa-miR-3679-3p 3 hsa-miR-642b-5p 3 hsa-miR-24-2-5p 2 sites", "DNA", 53, 251], ["GSK3 phosphorylation site", "DNA", 287, 312], ["CDK phosphorylation site", "DNA", 329, 353], ["hsa-miR-6826-3p", "TEST", 105, 120], ["hsa-miR-299-5p", "TEST", 123, 137], ["hsa-miR-5195-5p", "TEST", 140, 155], ["hsa-miR-24-1-5p", "TEST", 174, 189], ["hsa-miR-3679-3p", "TEST", 192, 207], ["hsa-miR", "TEST", 210, 217], ["hsa-miR", "TEST", 228, 235], ["the GSK3 phosphorylation site", "PROBLEM", 283, 312], ["a CDK phosphorylation site", "PROBLEM", 327, 353], ["mutations", "OBSERVATION", 402, 411]]], ["The sequence motifs and are entirely consistent with GSK3 and CDK phosphorylation motifs, respectively.", [["GSK3", "GENE_OR_GENE_PRODUCT", 53, 57], ["CDK", "GENE_OR_GENE_PRODUCT", 62, 65], ["GSK3", "PROTEIN", 53, 57], ["CDK", "PROTEIN", 62, 65], ["The sequence motifs", "TEST", 0, 19], ["GSK3", "PROBLEM", 53, 57], ["CDK phosphorylation motifs", "PROBLEM", 62, 88], ["entirely consistent with", "UNCERTAINTY", 28, 52], ["CDK phosphorylation motifs", "OBSERVATION", 62, 88]]], ["When Ser202 is phosphorylated which incorporates a large negative group tethered to the sidechain of Ser, as seen in many other substrates of kinases, it is likely that charge neutralization takes place involving positively charged sidechains in the sequential and spatial vicinity.", [["Ser202", "CHEMICAL", 5, 11], ["Ser", "CHEMICAL", 101, 104], ["Ser202", "GENE_OR_GENE_PRODUCT", 5, 11], ["Ser", "AMINO_ACID", 101, 104], ["Ser202", "PROTEIN", 5, 11], ["kinases", "PROTEIN", 142, 149], ["charge neutralization", "PROBLEM", 169, 190], ["large", "OBSERVATION_MODIFIER", 51, 56], ["is likely", "UNCERTAINTY", 154, 163], ["neutralization", "OBSERVATION", 176, 190]]], ["Arg203 is a part of GSK3 phosphorylation motif and its sidechain could potentially contribute to charge neutralization at P-Ser202.", [["Arg203", "GENE_OR_GENE_PRODUCT", 0, 6], ["GSK3", "GENE_OR_GENE_PRODUCT", 20, 24], ["Arg203", "PROTEIN", 0, 6], ["GSK3 phosphorylation motif", "PROTEIN", 20, 46], ["P-Ser202", "DNA", 122, 130], ["GSK3 phosphorylation motif", "TREATMENT", 20, 46]]], ["Given the sequential, and therefore spatial proximity of Arg203 to P-Ser206 the sidechain of Arg203 could potentially be involved in interaction also with phosphate group at position 206.", [["Arg203", "CHEMICAL", 93, 99], ["phosphate", "CHEMICAL", 155, 164], ["Arg203", "CHEMICAL", 57, 63], ["P-Ser206", "CHEMICAL", 67, 75], ["Arg203", "CHEMICAL", 93, 99], ["phosphate", "CHEMICAL", 155, 164], ["Arg203", "GENE_OR_GENE_PRODUCT", 57, 63], ["Arg203", "AMINO_ACID", 93, 99], ["phosphate", "SIMPLE_CHEMICAL", 155, 164], ["P", "DNA", 67, 68], ["P", "TEST", 67, 68], ["Arg203", "TREATMENT", 93, 99], ["phosphate group at position", "TREATMENT", 155, 182]]], ["This interaction would contribute to reduction of conformational entropy.", [["conformational entropy", "PROBLEM", 50, 72], ["conformational entropy", "OBSERVATION", 50, 72]]], ["Similarly, Arg209, a part of CDK phosphorylation motif, would contribute to charge neutralization at P-Ser206.", [["Arg209", "GENE_OR_GENE_PRODUCT", 11, 17], ["CDK", "GENE_OR_GENE_PRODUCT", 29, 32], ["Arg209", "PROTEIN", 11, 17], ["CDK phosphorylation motif", "PROTEIN", 29, 54], ["P-Ser206", "DNA", 101, 109], ["CDK phosphorylation motif", "TREATMENT", 29, 54]]], ["Arg203 and Gly204 are mutated to Lys and Arg respectively (figure 4).Possible implications of D614G mutation (in S D domain) on protein structural stabilitySpike protein (S) of coronaviruses is a class I viral fusion protein which is synthesized as a single chain precursor that trimerizes upon folding.", [["Lys", "CHEMICAL", 33, 36], ["Arg", "CHEMICAL", 41, 44], ["Arg203", "GENE_OR_GENE_PRODUCT", 0, 6], ["Gly204", "GENE_OR_GENE_PRODUCT", 11, 17], ["Lys", "AMINO_ACID", 33, 36], ["Arg", "AMINO_ACID", 41, 44], ["D614G", "GENE_OR_GENE_PRODUCT", 94, 99], ["Spike protein", "GENE_OR_GENE_PRODUCT", 156, 169], ["D614G", "PROTEIN", 94, 99], ["S D domain", "PROTEIN", 113, 123], ["Spike protein", "PROTEIN", 156, 169], ["S", "PROTEIN", 171, 172], ["class I viral fusion protein", "PROTEIN", 196, 224], ["Arg203", "TREATMENT", 0, 6], ["Gly204", "TREATMENT", 11, 17], ["D614G mutation", "PROBLEM", 94, 108], ["coronaviruses", "PROBLEM", 177, 190], ["a class I viral fusion protein", "PROBLEM", 194, 224], ["a single chain precursor", "PROBLEM", 249, 273]]], ["It is composed of two subunits: S 1 (in the amino terminal) containing the receptor binding domain (RBD) and S 2 (in the carboxy terminal) that drives membrane fusion ( In all the three structure, D614 lies in a loop at the interface between any two out of the three protomers.", [["membrane", "ANATOMY", 151, 159], ["amino", "CHEMICAL", 44, 49], ["carboxy", "CHEMICAL", 121, 128], ["S 1", "GENE_OR_GENE_PRODUCT", 32, 35], ["S 2", "GENE_OR_GENE_PRODUCT", 109, 112], ["membrane", "CELLULAR_COMPONENT", 151, 159], ["S 1", "PROTEIN", 32, 35], ["amino terminal", "PROTEIN", 44, 58], ["receptor binding domain", "PROTEIN", 75, 98], ["RBD", "PROTEIN", 100, 103], ["S 2", "PROTEIN", 109, 112], ["carboxy terminal", "PROTEIN", 121, 137], ["D614", "PROTEIN", 197, 201], ["the amino terminal)", "TREATMENT", 40, 59], ["membrane fusion", "TREATMENT", 151, 166], ["membrane fusion", "OBSERVATION", 151, 166]]], ["The co-ordinates for the D614 side-chain in chain A and C of 6VYB are available only up to C b -atom and the orientation of these atoms are similar to that observed in the respective atoms of D614 in 6VXX.", [["D614", "CHEMICAL", 25, 29], ["D614", "CHEMICAL", 192, 196], ["D614", "CHEMICAL", 25, 29], ["6VYB", "CHEMICAL", 61, 65], ["C", "CHEMICAL", 91, 92], ["D614", "CHEMICAL", 192, 196], ["6VXX", "CHEMICAL", 200, 204], ["6VYB", "SIMPLE_CHEMICAL", 61, 65], ["D614", "SIMPLE_CHEMICAL", 192, 196], ["6VXX", "SIMPLE_CHEMICAL", 200, 204], ["D614 side-chain", "PROTEIN", 25, 40], ["C", "PROTEIN", 56, 57], ["6VYB", "PROTEIN", 61, 65], ["C b", "PROTEIN", 91, 94], ["6VXX", "PROTEIN", 200, 204], ["the D614 side-chain", "TREATMENT", 21, 40], ["6VYB", "TREATMENT", 61, 65], ["D614 in 6VXX", "TREATMENT", 192, 204]]], ["The co-ordinates of all the side-chain atoms of D614 in chain B of 6VYB are available and they are similar to that observed in chain B of 6VXX.", [["D614", "CHEMICAL", 48, 52], ["D614", "CHEMICAL", 48, 52], ["6VYB", "CHEMICAL", 67, 71], ["6VXX", "CHEMICAL", 138, 142], ["D614", "SIMPLE_CHEMICAL", 48, 52], ["6VYB", "SIMPLE_CHEMICAL", 67, 71], ["6VXX", "GENE_OR_GENE_PRODUCT", 138, 142], ["D614", "PROTEIN", 48, 52], ["chain B", "PROTEIN", 56, 63], ["6VYB", "PROTEIN", 67, 71], ["chain B", "PROTEIN", 127, 134], ["6VXX", "PROTEIN", 138, 142]]], ["The side-chain of D614 in all the protomers of 6VXX and chain B of 6VYB point outward from the core of the protein toward the solvent.", [["D614", "CHEMICAL", 18, 22], ["D614", "SIMPLE_CHEMICAL", 18, 22], ["6VXX", "SIMPLE_CHEMICAL", 47, 51], ["D614", "PROTEIN", 18, 22], ["6VXX", "PROTEIN", 47, 51], ["chain B", "PROTEIN", 56, 63], ["6VYB", "PROTEIN", 67, 71], ["D614", "TREATMENT", 18, 22], ["6VXX", "TREATMENT", 47, 51]]], ["The side-chain orientation of D614 in all the three chains of 6VSB is different from the former two structures.", [["D614", "CHEMICAL", 30, 34], ["D614", "CHEMICAL", 30, 34], ["D614", "SIMPLE_CHEMICAL", 30, 34], ["6VSB", "SIMPLE_CHEMICAL", 62, 66], ["D614", "PROTEIN", 30, 34], ["6VSB", "PROTEIN", 62, 66], ["The side-chain orientation of D614", "TREATMENT", 0, 34], ["chain", "OBSERVATION_MODIFIER", 9, 14], ["different", "OBSERVATION_MODIFIER", 70, 79]]], ["This differential orientation of D614 side-chain in 6VSB facilitates formation of hydrogen bond between D614 (present in S 1 subunit) and T859 (present in S 2 subunit) from the neighbouring chain in two out of the three interfaces found in 6VSB ( figure 6 ).", [["D614", "CHEMICAL", 33, 37], ["6VSB", "CHEMICAL", 52, 56], ["D614", "CHEMICAL", 33, 37], ["6VSB", "CHEMICAL", 52, 56], ["hydrogen", "CHEMICAL", 82, 90], ["D614", "CHEMICAL", 104, 108], ["6VSB", "SIMPLE_CHEMICAL", 52, 56], ["D614", "SIMPLE_CHEMICAL", 104, 108], ["S 1 subunit", "GENE_OR_GENE_PRODUCT", 121, 132], ["T859", "AMINO_ACID", 138, 142], ["S 2 subunit", "GENE_OR_GENE_PRODUCT", 155, 166], ["D614 side-chain", "PROTEIN", 33, 48], ["6VSB", "PROTEIN", 52, 56], ["D614", "PROTEIN", 104, 108], ["S 1 subunit", "PROTEIN", 121, 132], ["T859", "PROTEIN", 138, 142], ["S 2 subunit", "PROTEIN", 155, 166], ["neighbouring chain", "PROTEIN", 177, 195], ["6VSB", "PROTEIN", 240, 244], ["D614 side-chain", "TREATMENT", 33, 48]]], ["Taken together, these facts suggest that D614 is highly flexible and support the wobbly nature of the inter-protomeric hydrogen bond observed between D614 and T859.", [["D614", "CHEMICAL", 41, 45], ["hydrogen", "CHEMICAL", 119, 127], ["D614", "CHEMICAL", 150, 154], ["T859", "CHEMICAL", 159, 163], ["D614", "SIMPLE_CHEMICAL", 41, 45]]], ["Contribution of this transient hydrogen bond toward stability of the pre-fusion state cannot be negated.", [["hydrogen", "CHEMICAL", 31, 39], ["this transient hydrogen bond", "PROBLEM", 16, 44], ["the pre-fusion state", "PROBLEM", 65, 85], ["transient", "OBSERVATION_MODIFIER", 21, 30], ["hydrogen bond", "OBSERVATION", 31, 44], ["stability", "OBSERVATION_MODIFIER", 52, 61]]], ["Interestingly, S protein of mouse coronavirus (MHV-A59) which has a similar structural topology as that of the SARS-CoV-2 S protein but shares a low overall sequence identity (*32%), has a conservative substitution at the position equivalent to D614 of the latter.", [["mouse coronavirus", "ORGANISM", 28, 45], ["MHV-A59", "ORGANISM", 47, 54], ["SARS-CoV-2 S", "GENE_OR_GENE_PRODUCT", 111, 123], ["S protein", "PROTEIN", 15, 24], ["SARS-CoV-2 S protein", "PROTEIN", 111, 131], ["D614", "PROTEIN", 245, 249], ["mouse", "SPECIES", 28, 33], ["coronavirus", "SPECIES", 34, 45], ["mouse coronavirus (MHV-A59", "SPECIES", 28, 54], ["mouse coronavirus", "PROBLEM", 28, 45], ["the SARS", "TEST", 107, 115], ["CoV", "TEST", 116, 119], ["a conservative substitution", "TREATMENT", 187, 214], ["mouse coronavirus", "OBSERVATION", 28, 45]]], ["The Asn (N655) of mouse coronavirus (MHV-A59) is replaced with Asp (D614) in SARS-CoV-2 ( figure 5 and figure 7) .", [["Asn", "CHEMICAL", 4, 7], ["Asn", "CHEMICAL", 4, 7], ["Asp", "CHEMICAL", 63, 66], ["Asn", "AMINO_ACID", 4, 7], ["mouse coronavirus", "ORGANISM", 18, 35], ["MHV-A59", "ORGANISM", 37, 44], ["mouse", "SPECIES", 18, 23], ["coronavirus", "SPECIES", 24, 35], ["mouse coronavirus (MHV-A59", "SPECIES", 18, 44], ["The Asn", "TEST", 0, 7], ["mouse coronavirus", "TREATMENT", 18, 35], ["Asp", "TEST", 63, 66], ["SARS", "TEST", 77, 81], ["CoV", "TEST", 82, 85]]], ["In earlier literature, N655 has been suggested to offer inter-protomeric interactions that contribute toward maintenance of the S 2 fusion machinery in its metastable state (AC Walls et al. 2016) .", [["N655", "CHEMICAL", 23, 27], ["S 2", "GENE_OR_GENE_PRODUCT", 128, 131], ["N655", "PROTEIN", 23, 27], ["the S 2 fusion machinery", "TREATMENT", 124, 148]]], ["Given the conservation of Asp at this position in closely related coronaviruses (Bat coronaviruses: BtCoV-RaTG13 and BtCoV-HKU3; SARS-CoV) and its conservative substitution in mouse coronavirus (MHV-A59), it is likely that D614 is important for structural stability of S protein.Possible implications of D614G mutation (in S D domain) on protein structural stabilityAs Gly lacks a side-chain, the transient hydrogen bond as observed in the wild-type S protein would be lost in the variant with D614G mutation.", [["Asp", "CHEMICAL", 26, 29], ["D614", "CHEMICAL", 223, 227], ["Gly", "CHEMICAL", 369, 372], ["Asp", "CHEMICAL", 26, 29], ["As", "CHEMICAL", 366, 368], ["Gly", "CHEMICAL", 369, 372], ["hydrogen", "CHEMICAL", 407, 415], ["Asp", "AMINO_ACID", 26, 29], ["coronaviruses", "ORGANISM", 66, 79], ["Bat coronaviruses", "ORGANISM", 81, 98], ["BtCoV-RaTG13", "GENE_OR_GENE_PRODUCT", 100, 112], ["BtCoV-HKU3; SARS-CoV", "GENE_OR_GENE_PRODUCT", 117, 137], ["mouse coronavirus", "ORGANISM", 176, 193], ["MHV-A59", "ORGANISM", 195, 202], ["D614", "SIMPLE_CHEMICAL", 223, 227], ["S protein", "GENE_OR_GENE_PRODUCT", 269, 278], ["D614G", "GENE_OR_GENE_PRODUCT", 304, 309], ["Gly", "AMINO_ACID", 369, 372], ["D614G", "GENE_OR_GENE_PRODUCT", 494, 499], ["BtCoV", "PROTEIN", 100, 105], ["RaTG13", "PROTEIN", 106, 112], ["BtCoV", "PROTEIN", 117, 122], ["HKU3", "PROTEIN", 123, 127], ["S protein", "PROTEIN", 269, 278], ["D614G", "PROTEIN", 304, 309], ["S D domain", "PROTEIN", 323, 333], ["wild-type S protein", "PROTEIN", 440, 459], ["D614G", "PROTEIN", 494, 499], ["mouse", "SPECIES", 176, 181], ["coronavirus", "SPECIES", 182, 193], ["Bat coronaviruses", "SPECIES", 81, 98], ["SARS-CoV", "SPECIES", 129, 137], ["mouse coronavirus (MHV-A59", "SPECIES", 176, 202], ["Asp", "PROBLEM", 26, 29], ["coronaviruses", "PROBLEM", 66, 79], ["Bat coronaviruses", "TEST", 81, 98], ["BtCoV", "TEST", 100, 105], ["RaTG13", "TEST", 106, 112], ["BtCoV", "TEST", 117, 122], ["SARS", "PROBLEM", 129, 133], ["its conservative substitution", "TREATMENT", 143, 172], ["mouse coronavirus", "PROBLEM", 176, 193], ["D614G mutation", "PROBLEM", 304, 318], ["the transient hydrogen bond", "PROBLEM", 393, 420], ["type S protein", "PROBLEM", 445, 459], ["D614G mutation", "TREATMENT", 494, 508], ["conservative substitution", "OBSERVATION", 147, 172], ["stability", "OBSERVATION", 357, 366], ["side-chain", "OBSERVATION_MODIFIER", 381, 391], ["transient", "OBSERVATION_MODIFIER", 397, 406], ["hydrogen bond", "OBSERVATION", 407, 420]]], ["This can potentially compromise on the structural stability of pre-fusion state of S protein possibly interfering with conformational transitions.", [["S protein", "PROTEIN", 83, 92], ["S protein", "PROBLEM", 83, 92], ["conformational transitions", "PROBLEM", 119, 145], ["stability", "OBSERVATION_MODIFIER", 50, 59]]], ["Moreover, replacement of Asp with Gly at this position would come with higher conformational freedom at the backbone (C Ramakrishnan and GN Ramachandran 1965) of the polypeptide resulting in enhancement of local conformational entropy.Possible implications of G1124V mutation (in S 2 subunit) on protein structural stabilityThe Gly at this position is solvent exposed and is present at the tip of the C-terminal end of a b-strand.", [["Asp", "CHEMICAL", 25, 28], ["Gly", "CHEMICAL", 34, 37], ["Gly", "CHEMICAL", 328, 331], ["Asp", "CHEMICAL", 25, 28], ["Gly", "CHEMICAL", 34, 37], ["Gly", "CHEMICAL", 328, 331], ["C", "CHEMICAL", 401, 402], ["Asp", "AMINO_ACID", 25, 28], ["Gly", "AMINO_ACID", 34, 37], ["G1124V", "GENE_OR_GENE_PRODUCT", 260, 266], ["S 2 subunit", "GENE_OR_GENE_PRODUCT", 280, 291], ["Gly", "AMINO_ACID", 328, 331], ["G1124V", "PROTEIN", 260, 266], ["S 2 subunit", "PROTEIN", 280, 291], ["C-terminal end", "PROTEIN", 401, 415], ["replacement of Asp with Gly", "TREATMENT", 10, 37], ["the polypeptide", "TREATMENT", 162, 177], ["local conformational entropy", "PROBLEM", 206, 234], ["G1124V mutation", "PROBLEM", 260, 275], ["replacement", "OBSERVATION", 10, 21], ["enhancement", "OBSERVATION_MODIFIER", 191, 202], ["local conformational entropy", "OBSERVATION", 206, 234], ["stability", "OBSERVATION", 315, 324], ["solvent exposed", "OBSERVATION", 352, 367], ["tip", "OBSERVATION_MODIFIER", 390, 393], ["terminal end", "ANATOMY_MODIFIER", 403, 415]]], ["This position is proximal to the region where the S protein attaches itself to the viral membrane (figure 5).", [["membrane", "ANATOMY", 89, 97], ["membrane", "CELLULAR_COMPONENT", 89, 97], ["S protein", "PROTEIN", 50, 59], ["proximal", "OBSERVATION_MODIFIER", 17, 25], ["region", "ANATOMY_MODIFIER", 33, 39], ["viral membrane", "OBSERVATION", 83, 97]]], ["It is to be noted that the Gly at this position is conserved among the closely related coronaviruses (Bat coronavirus RaTG13 and HKU3, SARS-CoV) hinting toward its possible role in maintenance of structure and function of the S protein (figure 7).", [["Gly", "CHEMICAL", 27, 30], ["Gly", "CHEMICAL", 27, 30], ["Gly", "AMINO_ACID", 27, 30], ["coronaviruses", "ORGANISM", 87, 100], ["Bat coronavirus", "ORGANISM", 102, 117], ["RaTG13", "ORGANISM", 118, 124], ["HKU3", "GENE_OR_GENE_PRODUCT", 129, 133], ["SARS-CoV", "ORGANISM", 135, 143], ["S protein", "GENE_OR_GENE_PRODUCT", 226, 235], ["S protein", "PROTEIN", 226, 235], ["figure 7", "PROTEIN", 237, 245], ["Bat coronavirus", "SPECIES", 102, 117], ["Bat coronavirus", "SPECIES", 102, 117], ["SARS-CoV", "SPECIES", 135, 143], ["the closely related coronaviruses", "PROBLEM", 67, 100], ["Bat coronavirus RaTG13", "TEST", 102, 124], ["HKU3", "TEST", 129, 133], ["SARS", "PROBLEM", 135, 139], ["the S protein", "TEST", 222, 235]]], ["In general, as explained above, Gly backbone has higher conformational freedom than any other amino acid residues (Ramakrishnan and Ramachandran 1965) .", [["Gly", "CHEMICAL", 32, 35], ["amino acid", "CHEMICAL", 94, 104], ["Gly", "CHEMICAL", 32, 35], ["amino acid", "CHEMICAL", 94, 104], ["amino acid", "AMINO_ACID", 94, 104], ["higher conformational freedom", "PROBLEM", 49, 78], ["any other amino acid residues", "PROBLEM", 84, 113]]], ["Conformation of D614 in three structures (6VXX, 6VYB, 6VSB). (a), (b), (c) Overlay of D614 (6VXX: yellow carbon; 6VYB: white carbon; 6VSB: dark pink carbon) from chain A, B and C of the three structures, respectively.", [["D614", "CHEMICAL", 86, 90], ["D614", "CHEMICAL", 86, 90], ["carbon", "CHEMICAL", 105, 111], ["6VYB", "CHEMICAL", 113, 117], ["carbon", "CHEMICAL", 125, 131], ["6VSB", "CHEMICAL", 133, 137], ["carbon", "CHEMICAL", 149, 155], ["D614", "SIMPLE_CHEMICAL", 16, 20], ["D614", "PROTEIN", 16, 20], ["6VSB", "PROTEIN", 54, 58], ["B", "PROTEIN", 171, 172], ["yellow carbon", "TEST", 98, 111], ["white carbon", "TEST", 119, 131], ["three structures", "ANATOMY", 186, 202]]], ["To maintain visual clarity, only the backbone of respective chain of 6VXX is shown in cartoon representation. (d), (e), (f) Orientation of D614 (green carbon) from chain A (purple cartoon) and T859 (dark blue carbon) from chain B (teal cartoon) in 6VXX, 6VYB and 6VSB, respectively.", [["green carbon", "CHEMICAL", 145, 157], ["carbon", "CHEMICAL", 151, 157], ["carbon", "CHEMICAL", 209, 215], ["6VXX", "GENE_OR_GENE_PRODUCT", 69, 73], ["green carbon", "SIMPLE_CHEMICAL", 145, 157], ["6VXX", "PROTEIN", 69, 73], ["chain B", "PROTEIN", 222, 229], ["6VSB", "PROTEIN", 263, 267], ["dark blue carbon", "TREATMENT", 199, 215], ["chain B (teal cartoon", "TREATMENT", 222, 243], ["visual clarity", "OBSERVATION", 12, 26]]], ["Hydrogen bond is depicted as black dashed line. (g), (h), (i) Orientation of D614 (green carbon) from chain C (orange cartoon) and T859 (dark blue carbon) from chain A (purple cartoon) in 6VXX, 6VYB and 6VSB, respectively.", [["Hydrogen", "CHEMICAL", 0, 8], ["green carbon", "CHEMICAL", 83, 95], ["Hydrogen", "CHEMICAL", 0, 8], ["D614", "CHEMICAL", 77, 81], ["carbon", "CHEMICAL", 89, 95], ["T859", "CHEMICAL", 131, 135], ["carbon", "CHEMICAL", 147, 153], ["6VSB", "CHEMICAL", 203, 207], ["green carbon", "SIMPLE_CHEMICAL", 83, 95], ["T859", "SIMPLE_CHEMICAL", 131, 135], ["black", "OBSERVATION_MODIFIER", 29, 34], ["dashed line", "OBSERVATION", 35, 46]]], ["Hydrogen bond is depicted as black dashed line.", [["Hydrogen", "CHEMICAL", 0, 8], ["Hydrogen", "CHEMICAL", 0, 8], ["Hydrogen", "SIMPLE_CHEMICAL", 0, 8], ["black dashed line", "CELL_LINE", 29, 46], ["black", "OBSERVATION_MODIFIER", 29, 34], ["dashed line", "OBSERVATION", 35, 46]]], ["The side-chain co-ordinates for D614 in chain A and C of 6VYB are unavailable.", [["D614", "SIMPLE_CHEMICAL", 32, 36], ["C", "SIMPLE_CHEMICAL", 52, 53], ["6VYB", "SIMPLE_CHEMICAL", 57, 61], ["D614", "PROTEIN", 32, 36], ["6VYB", "PROTEIN", 57, 61]]], ["Protein rendering has been done using PyMOL (Schr\u00f6dinger, LLC). substitution of Gly with Val would impart rigidity to the local region.", [["Gly", "CHEMICAL", 80, 83], ["Val", "CHEMICAL", 89, 92], ["rigidity", "DISEASE", 106, 114], ["Gly", "CHEMICAL", 80, 83], ["Val", "CHEMICAL", 89, 92], ["PyMOL", "SIMPLE_CHEMICAL", 38, 43], ["Gly", "AMINO_ACID", 80, 83], ["Val", "AMINO_ACID", 89, 92], ["Protein rendering", "TEST", 0, 17], ["PyMOL (Schr\u00f6dinger, LLC", "TREATMENT", 38, 61], ["substitution of Gly", "TREATMENT", 64, 83], ["LLC", "ANATOMY", 58, 61], ["rigidity", "OBSERVATION", 106, 114], ["local", "ANATOMY_MODIFIER", 122, 127], ["region", "ANATOMY_MODIFIER", 128, 134]]], ["The possible implication of such rigidity on the association of S protein with viral membrane could be understood from a structure of S protein in association with the viral membrane.", [["membrane", "ANATOMY", 85, 93], ["membrane", "ANATOMY", 174, 182], ["rigidity", "DISEASE", 33, 41], ["S protein", "GENE_OR_GENE_PRODUCT", 64, 73], ["S protein", "GENE_OR_GENE_PRODUCT", 134, 143], ["membrane", "CELLULAR_COMPONENT", 174, 182], ["S protein", "PROTEIN", 64, 73], ["S protein", "PROTEIN", 134, 143], ["such rigidity", "PROBLEM", 28, 41], ["S protein", "PROBLEM", 64, 73], ["viral membrane", "PROBLEM", 79, 93], ["S protein", "PROBLEM", 134, 143], ["the viral membrane", "PROBLEM", 164, 182], ["possible implication of", "UNCERTAINTY", 4, 27], ["rigidity", "OBSERVATION", 33, 41], ["viral membrane", "OBSERVATION", 79, 93], ["viral membrane", "OBSERVATION", 168, 182]]], ["However, such a structure is currently unavailable.DiscussionSubstantial uncertainties surround the trajectory of the recent epidemic of COVID-19 in India.", [["COVID-19", "CHEMICAL", 137, 145], ["COVID", "TEST", 137, 142]]], ["It is extremely important to track the outbreak by analysing the phylogenetic relationships between different SARS-CoV-2 genomes prevalent in India and compare them with genomes reported from rest of the world.", [["SARS-CoV-2", "ORGANISM", 110, 120], ["SARS-CoV-2 genomes", "DNA", 110, 128], ["SARS-CoV", "SPECIES", 110, 118]]], ["The errorprone replication process of all RNA viruses in general, results in introduction of mutations in their genomes which behave as a molecular clock that can provide insights into the emergence and evolution of the virus.", [["The errorprone replication process", "TREATMENT", 0, 34], ["all RNA viruses", "PROBLEM", 38, 53], ["mutations in their genomes", "PROBLEM", 93, 119], ["the virus", "PROBLEM", 216, 225], ["all", "OBSERVATION_MODIFIER", 38, 41], ["RNA viruses", "OBSERVATION", 42, 53], ["virus", "OBSERVATION", 220, 225]]], ["The data till date suggests that SARS-CoV-2 emerged not long before the first cases of pneumonia in Wuhan occurred .DiscussionIn this study, direct massively parallel sequencing of the viral genome was undertaken on nasopharyngeal and oropharyngeal swab samples collected from infected individuals from different districts of West Bengal.", [["nasopharyngeal", "ANATOMY", 216, 230], ["oropharyngeal swab samples", "ANATOMY", 235, 261], ["SARS", "DISEASE", 33, 37], ["pneumonia", "DISEASE", 87, 96], ["SARS-CoV-2", "ORGANISM", 33, 43], ["nasopharyngeal", "CANCER", 216, 230], ["oropharyngeal swab samples", "CANCER", 235, 261], ["viral genome", "DNA", 185, 197], ["SARS-CoV", "SPECIES", 33, 41], ["The data", "TEST", 0, 8], ["SARS", "PROBLEM", 33, 37], ["pneumonia", "PROBLEM", 87, 96], ["this study", "TEST", 129, 139], ["the viral genome", "PROBLEM", 181, 197], ["nasopharyngeal and oropharyngeal swab samples", "TEST", 216, 261], ["infected individuals", "PROBLEM", 277, 297], ["pneumonia", "OBSERVATION", 87, 96], ["viral genome", "OBSERVATION", 185, 197], ["nasopharyngeal", "ANATOMY", 216, 230], ["oropharyngeal swab", "ANATOMY", 235, 253]]], ["Recent analysis of SARS-CoV-2 sequences from all over the globe has revealed that the outbreaks have been initially triggered in most countries by the original strain from Wuhan, clade O, which thereafter have diversified into multiple clades (Yadav et al. 2020; Biswas and Majumder 2020) .", [["SARS-CoV-2", "ORGANISM", 19, 29], ["SARS-CoV-2 sequences", "DNA", 19, 39], ["SARS-CoV", "SPECIES", 19, 27], ["Recent analysis", "TEST", 0, 15], ["SARS", "PROBLEM", 19, 23], ["CoV-2 sequences", "TEST", 24, 39], ["globe", "ANATOMY", 58, 63]]], ["Temporal sweeps leading to replacement of the ancestral O and other clades by A2a, have been detected.", [["A2a", "GENE_OR_GENE_PRODUCT", 78, 81], ["A2a", "PROTEIN", 78, 81], ["Temporal sweeps", "PROBLEM", 0, 15], ["replacement", "TREATMENT", 27, 38], ["sweeps", "OBSERVATION", 9, 15], ["replacement", "OBSERVATION", 27, 38]]], ["Until our report, initial sequences from samples obtained from individuals with travel history to China, reported genetic similarity to the clade O, which was obtained at the beginning of the outbreak in Wuhan, China.", [["samples", "ANATOMY", 41, 48], ["initial sequences from samples", "TEST", 18, 48]]], ["Rest of the sequences reported from India mostly belonged to either clade A3 (18%) or A2a (44%) (supplementary table 3), with evidence of the temporal sweep where the A2a is emerging as the predominant clade (Biswas and Majumder 2020) .", [["A2a", "DNA", 167, 170], ["the sequences", "TEST", 8, 21], ["A2a", "TEST", 86, 89], ["the temporal sweep", "PROBLEM", 138, 156], ["temporal", "ANATOMY_MODIFIER", 142, 150], ["sweep", "OBSERVATION", 151, 156]]], ["The A2a clade is characterized by the signature nonsynonymous mutations leading to amino acid changes of P323L in the RdRp which is involved in replication of the viral genome and the change of D614G in the Spike glycoprotein which is essential for the entry of the virus in the host cell by binding to the ACE2 receptor.", [["cell", "ANATOMY", 284, 288], ["amino acid", "CHEMICAL", 83, 93], ["amino acid", "CHEMICAL", 83, 93], ["A2a", "GENE_OR_GENE_PRODUCT", 4, 7], ["amino acid", "AMINO_ACID", 83, 93], ["P323L", "GENE_OR_GENE_PRODUCT", 105, 110], ["RdRp", "GENE_OR_GENE_PRODUCT", 118, 122], ["D614G", "GENE_OR_GENE_PRODUCT", 194, 199], ["Spike glycoprotein", "GENE_OR_GENE_PRODUCT", 207, 225], ["host cell", "CELL", 279, 288], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 307, 320], ["P323L", "PROTEIN", 105, 110], ["RdRp", "PROTEIN", 118, 122], ["viral genome", "DNA", 163, 175], ["D614G", "PROTEIN", 194, 199], ["Spike glycoprotein", "PROTEIN", 207, 225], ["ACE2 receptor", "PROTEIN", 307, 320], ["the signature nonsynonymous mutations", "PROBLEM", 34, 71], ["amino acid changes of P323L in the RdRp", "PROBLEM", 83, 122], ["the viral genome", "PROBLEM", 159, 175], ["D614G", "TREATMENT", 194, 199], ["the Spike glycoprotein", "TREATMENT", 203, 225], ["the virus", "PROBLEM", 262, 271], ["A2a clade", "OBSERVATION", 4, 13], ["nonsynonymous mutations", "OBSERVATION", 48, 71], ["viral genome", "OBSERVATION", 163, 175], ["virus", "OBSERVATION", 266, 271], ["host cell", "OBSERVATION", 279, 288]]], ["Notably, the D614G mutation is close to the Furin recognition site for cleavage of the Spike protein, which plays an important role in virus entry.", [["D614G", "GENE_OR_GENE_PRODUCT", 13, 18], ["Spike", "GENE_OR_GENE_PRODUCT", 87, 92], ["Furin recognition site", "DNA", 44, 66], ["Spike protein", "PROTEIN", 87, 100], ["the D614G mutation", "PROBLEM", 9, 27], ["the Spike protein", "PROBLEM", 83, 100]]], ["Whether both these mutations have resulted in the evolution of a more transmissible viral subtype i.e. the A2a clade, is yet to be verified by in vitro and in silico analyses.", [["these mutations", "PROBLEM", 13, 28]]], ["Interestingly, we also found that one of viral sequences in our study belonged to the B4 clade, which originated in China (Gonzalez-Reiche et al. 2020).", [["viral sequences", "DNA", 41, 56], ["viral sequences", "TEST", 41, 56], ["our study", "TEST", 60, 69]]], ["B4 clade sequences have not been reported from India earlier and are only less than 1% of sequences reported worldwide.", [["B4 clade sequences", "TEST", 0, 18]]], ["Probably, the individual S10 was transmitted this subtype by contact with others who had travel history to China although this information was not available in the patient clinical history.DiscussionEmergence of viral subclones in an outbreak can affect the transmission patterns and disease severity, which are immensely important for public health (Harvala et al. 2017; Jones et al. 2019) .", [["subclones", "ANATOMY", 218, 227], ["patient", "ORGANISM", 164, 171], ["subclones", "CELL", 218, 227], ["patient", "SPECIES", 164, 171], ["viral subclones", "PROBLEM", 212, 227], ["disease severity", "PROBLEM", 284, 300], ["viral subclones", "OBSERVATION", 212, 227]]], ["Given the large size of the infected population in India, with the possibility of regional differences in the population and host-related factors, this can have the potential to affect the course of the outbreak.", [["the infected population", "PROBLEM", 24, 47], ["regional differences", "PROBLEM", 82, 102], ["large", "OBSERVATION_MODIFIER", 10, 15], ["size", "OBSERVATION_MODIFIER", 16, 20], ["infected", "OBSERVATION_MODIFIER", 28, 36], ["population", "OBSERVATION_MODIFIER", 37, 47], ["regional", "OBSERVATION_MODIFIER", 82, 90], ["differences", "OBSERVATION_MODIFIER", 91, 102]]], ["Population surveillance is essential for early detection of emergence of such subclones.", [["subclones", "ANATOMY", 78, 87], ["subclones", "CELL", 78, 87], ["Population surveillance", "TEST", 0, 23], ["such subclones", "PROBLEM", 73, 87]]], ["We analysed the mutations detected in each sequence that we generated and found preliminary evidence of this.", [["the mutations", "PROBLEM", 12, 25]]], ["We found that three individuals of this study, viz.", [["this study", "TEST", 35, 45]]], ["S2, S3 and S5, shared rare set of three contiguous mutations in their genome which resulted in the consecutive alterations of R203K and G204R.", [["S2", "GENE_OR_GENE_PRODUCT", 0, 2], ["S3", "GENE_OR_GENE_PRODUCT", 4, 6], ["S5", "GENE_OR_GENE_PRODUCT", 11, 13], ["R203K", "GENE_OR_GENE_PRODUCT", 126, 131], ["G204R", "GENE_OR_GENE_PRODUCT", 136, 141], ["S2", "PROTEIN", 0, 2], ["S3", "PROTEIN", 4, 6], ["S5", "PROTEIN", 11, 13], ["R203K", "PROTEIN", 126, 131], ["G204R", "PROTEIN", 136, 141], ["three contiguous mutations", "PROBLEM", 34, 60], ["the consecutive alterations of R203K", "PROBLEM", 95, 131], ["S3", "ANATOMY", 4, 6], ["S5", "ANATOMY", 11, 13]]], ["Interestingly, while two out the three sequences harbouring these mutations were from individuals who shared contact history with a COVID-19 patient with history of travel from Italy, two out of the three samples from West Bengal shared contact history with the same COVID-19 patient with history of travel from UK.", [["patient", "ORGANISM", 141, 148], ["patient", "ORGANISM", 276, 283], ["patient", "SPECIES", 141, 148], ["patient", "SPECIES", 276, 283]]], ["S5, was found to have history of travel from Chennai, India, but the possibility of the patient having contact in transit with an individual with international travel history cannot be excluded.", [["S5", "GENE_OR_GENE_PRODUCT", 0, 2], ["patient", "ORGANISM", 88, 95], ["patient", "SPECIES", 88, 95], ["cannot be excluded", "UNCERTAINTY", 175, 193]]], ["Additionally, origin of the viral subtypes infecting S5 and S6 has also been predicted by phylogenetic analysis to be Europe (UK).", [["S5", "GENE_OR_GENE_PRODUCT", 53, 55], ["S6", "GENE_OR_GENE_PRODUCT", 60, 62], ["S5", "PROTEIN", 53, 55], ["S6", "PROTEIN", 60, 62], ["the viral subtypes infecting S5 and S6", "PROBLEM", 24, 62], ["phylogenetic analysis", "TEST", 90, 111], ["origin", "OBSERVATION_MODIFIER", 14, 20], ["viral subtypes", "OBSERVATION", 28, 42], ["infecting S5", "OBSERVATION", 43, 55]]], ["S6 had been infected in Delhi, India where he had contact with an infected individual who travelled from Europe.", [["S6", "PROTEIN", 0, 2], ["infected", "OBSERVATION", 12, 20], ["infected", "OBSERVATION", 66, 74]]], ["One of the individuals S10, harboured a viral subtype which is predicted to have been transmitted in China.", [["a viral subtype", "PROBLEM", 38, 53], ["viral subtype", "OBSERVATION", 40, 53]]], ["S2 and S3, who shared an identical sequence of the virus, also harboured one unique mutation resulting in the amino acid alteration of G1124V in the Spike protein.", [["amino acid", "CHEMICAL", 110, 120], ["amino acid", "CHEMICAL", 110, 120], ["S2", "GENE_OR_GENE_PRODUCT", 0, 2], ["S3", "GENE_OR_GENE_PRODUCT", 7, 9], ["amino acid", "AMINO_ACID", 110, 120], ["G1124V", "AMINO_ACID", 135, 141], ["Spike", "GENE_OR_GENE_PRODUCT", 149, 154], ["S2", "PROTEIN", 0, 2], ["S3", "PROTEIN", 7, 9], ["G1124V", "PROTEIN", 135, 141], ["Spike protein", "PROTEIN", 149, 162], ["the virus", "PROBLEM", 47, 56], ["the amino acid alteration of G1124V", "PROBLEM", 106, 141], ["S3", "ANATOMY", 7, 9]]], ["This correlates with the fact that these two individuals had also been known to have contact with the same COVID-19 patient.", [["patient", "ORGANISM", 116, 123], ["patient", "SPECIES", 116, 123]]], ["Viral RNA sequences obtained from two samples S11 and S12 shared all mutations except a V32L mutation at ORF8 harboured by S11 and not by S12.", [["samples", "ANATOMY", 38, 45], ["S12", "GENE_OR_GENE_PRODUCT", 54, 57], ["S12", "PROTEIN", 54, 57], ["ORF8", "DNA", 105, 109], ["S11", "PROTEIN", 123, 126], ["S12", "PROTEIN", 138, 141], ["Viral RNA sequences", "TEST", 0, 19], ["a V32L mutation", "TREATMENT", 86, 101]]], ["Interestingly, both these individuals belonged to the same district of East Medinipur, had history of contact with COVID-19 patients and did not exhibit any clinical symptom.", [["patients", "ORGANISM", 124, 132], ["patients", "SPECIES", 124, 132], ["any clinical symptom", "PROBLEM", 153, 173]]], ["Thus our findings indicate that the viral subtypes transmitted in the eastern region of India, in particular West Bengal, have mostly originated from Europe and also China.", [["the viral subtypes", "PROBLEM", 32, 50], ["viral subtypes", "OBSERVATION", 36, 50], ["eastern", "ANATOMY_MODIFIER", 70, 77], ["region", "ANATOMY_MODIFIER", 78, 84]]], ["Sequencing of large number of samples are being presently undertaken to confirm and elaborate these initial findings.DiscussionRdRp is essential for replication of viral RNA genome and hence this gene is expected to be conserved.", [["samples", "ANATOMY", 30, 37], ["samples", "CANCER", 30, 37], ["DiscussionRdRp", "GENE_OR_GENE_PRODUCT", 117, 131], ["DiscussionRdRp", "PROTEIN", 117, 131], ["viral RNA genome", "DNA", 164, 180], ["viral RNA genome", "TREATMENT", 164, 180], ["large", "OBSERVATION_MODIFIER", 14, 19], ["essential for", "UNCERTAINTY", 135, 148], ["viral RNA genome", "OBSERVATION", 164, 180]]], ["Interestingly, we detected multiple mutations in this gene, the majority of which were non synonymous and hence result in alteration of protein sequence.", [["multiple mutations", "PROBLEM", 27, 45], ["alteration of protein sequence", "PROBLEM", 122, 152], ["multiple", "OBSERVATION_MODIFIER", 27, 35], ["mutations", "OBSERVATION", 36, 45]]], ["In particular, the P323L was present in all A2a sequences in our samples.", [["samples", "ANATOMY", 65, 72], ["P323L", "GENE_OR_GENE_PRODUCT", 19, 24], ["P323L", "DNA", 19, 24], ["A2a sequences", "DNA", 44, 57], ["our samples", "TEST", 61, 72]]], ["This mutation is located adjacent to a hydrophobic cleft in RdRp which is a promising target for potential drugs (Pachetti et al. 2020) .", [["RdRp", "PROTEIN", 60, 64], ["This mutation", "PROBLEM", 0, 13], ["a hydrophobic cleft in RdRp", "PROBLEM", 37, 64], ["hydrophobic", "OBSERVATION_MODIFIER", 39, 50], ["cleft", "OBSERVATION", 51, 56], ["RdRp", "OBSERVATION", 60, 64]]], ["Sequences from two samples, S11 and S12, shared a unique RdRp mutation at A88V which has not been detected until date in rest of the sequences submitted from India or Worldwide.", [["samples", "ANATOMY", 19, 26], ["S11", "GENE_OR_GENE_PRODUCT", 28, 31], ["S12", "GENE_OR_GENE_PRODUCT", 36, 39], ["Sequences", "TEST", 0, 9], ["two samples", "TEST", 15, 26], ["a unique RdRp mutation", "PROBLEM", 48, 70], ["the sequences", "TEST", 129, 142], ["RdRp mutation", "OBSERVATION", 57, 70]]], ["As observed earlier, these two samples harbour viral subtypes whose genomes are strikingly similar.", [["viral subtypes", "OBSERVATION_MODIFIER", 47, 61], ["strikingly", "OBSERVATION_MODIFIER", 80, 90], ["similar", "OBSERVATION_MODIFIER", 91, 98]]], ["Sequence obtained from one of the samples S10, which belonged to the clade B4, did not possess the P323L mutation.", [["samples", "ANATOMY", 34, 41], ["P323L", "GENE_OR_GENE_PRODUCT", 99, 104], ["P323L", "PROTEIN", 99, 104]]], ["Instead, it harboured three different mutations resulting in two non-synonymous changes of H286Y, P287T and a synonymous mutation which were not found in any other sequences reported from India until date and are specific for the B4 clade.", [["two non-synonymous changes of H286Y", "PROBLEM", 61, 96], ["a synonymous mutation", "PROBLEM", 108, 129], ["two", "OBSERVATION_MODIFIER", 61, 64], ["non-synonymous", "OBSERVATION", 65, 79]]], ["It remains to be seen whether these amino acid alterations result in substantial changes in structure or function of RdRp, resulting in emergence of drug resistant subtypes or enhancement in mutation rate in the viral genome.DiscussionWe investigated the potential of the mutations detected in the nucleocapsid region to effect alterations in the viral and host processes.", [["amino acid", "CHEMICAL", 36, 46], ["amino acid", "CHEMICAL", 36, 46], ["amino acid", "AMINO_ACID", 36, 46], ["RdRp", "GENE_OR_GENE_PRODUCT", 117, 121], ["RdRp", "PROTEIN", 117, 121], ["viral genome", "DNA", 212, 224], ["nucleocapsid region", "DNA", 298, 317], ["these amino acid alterations", "PROBLEM", 30, 58], ["substantial changes in structure or function of RdRp", "PROBLEM", 69, 121], ["drug resistant subtypes", "PROBLEM", 149, 172], ["enhancement in mutation rate", "PROBLEM", 176, 204], ["the mutations", "PROBLEM", 268, 281], ["alterations in the viral and host processes", "PROBLEM", 328, 371], ["substantial", "OBSERVATION_MODIFIER", 69, 80], ["changes", "OBSERVATION", 81, 88], ["RdRp", "OBSERVATION_MODIFIER", 117, 121], ["enhancement", "OBSERVATION_MODIFIER", 176, 187], ["viral genome", "OBSERVATION", 212, 224], ["viral", "OBSERVATION", 347, 352], ["host processes", "OBSERVATION", 357, 371]]], ["We found that this mutation results in considerable alterations in the predicted binding of miRNAs, which might play a role in the establishment and progress of infection in the patient.", [["infection", "DISEASE", 161, 170], ["patient", "ORGANISM", 178, 185], ["patient", "SPECIES", 178, 185], ["this mutation", "PROBLEM", 14, 27], ["considerable alterations", "PROBLEM", 39, 63], ["infection", "PROBLEM", 161, 170], ["considerable", "OBSERVATION_MODIFIER", 39, 51], ["alterations", "OBSERVATION", 52, 63], ["infection", "OBSERVATION", 161, 170]]], ["We also found that some of the miRNAs which are predicted to bind to the mutated subtype might be downregulated in multiple cancer types.", [["cancer", "ANATOMY", 124, 130], ["cancer", "DISEASE", 124, 130], ["cancer", "CANCER", 124, 130], ["the miRNAs", "PROBLEM", 27, 37], ["multiple cancer types", "PROBLEM", 115, 136], ["miRNAs", "OBSERVATION", 31, 37], ["multiple", "OBSERVATION_MODIFIER", 115, 123], ["cancer", "OBSERVATION", 124, 130]]], ["This raises the possibility that cancer patients might have higher susceptibility to the mutated sub-clone due to the reduced ability to contain the virus in vivo, compared to infection by the original virus of the same clade.", [["cancer", "ANATOMY", 33, 39], ["cancer", "DISEASE", 33, 39], ["infection", "DISEASE", 176, 185], ["cancer", "CANCER", 33, 39], ["patients", "ORGANISM", 40, 48], ["patients", "SPECIES", 40, 48], ["cancer", "PROBLEM", 33, 39], ["higher susceptibility", "PROBLEM", 60, 81], ["the mutated sub-clone", "PROBLEM", 85, 106], ["the reduced ability", "PROBLEM", 114, 133], ["the virus", "PROBLEM", 145, 154], ["infection", "PROBLEM", 176, 185], ["raises the possibility", "UNCERTAINTY", 5, 27], ["cancer", "OBSERVATION", 33, 39], ["virus", "OBSERVATION", 149, 154], ["infection", "OBSERVATION", 176, 185]]], ["The leads obtained from this study need to be pursued to develop miRNA based novel therapeutic approaches.DiscussionWe also analysed the predicted structural alterations in the viral nucleocapsid protein, which might be caused by consecutive alterations of R203K and G204R.", [["R203K", "GENE_OR_GENE_PRODUCT", 257, 262], ["G204R", "GENE_OR_GENE_PRODUCT", 267, 272], ["viral nucleocapsid protein", "PROTEIN", 177, 203], ["R203K", "PROTEIN", 257, 262], ["G204R", "PROTEIN", 267, 272], ["this study", "TEST", 24, 34], ["the predicted structural alterations", "PROBLEM", 133, 169], ["the viral nucleocapsid protein", "PROBLEM", 173, 203], ["consecutive alterations of R203K", "PROBLEM", 230, 262], ["viral nucleocapsid protein", "OBSERVATION", 177, 203]]], ["As a result of these mutations, we have two strong positively charged residues in close sequential positions as opposed to only one positively charged residue in the other genotype.", [["these mutations", "PROBLEM", 15, 30]]], ["Given the structural vicinity of P-Ser202 and P-Ser206 and the long sidechains of Lys and Arg with high positive charge and significant side-chain conformational freedom in this genotype, both these residues potentially could contribute to charge neutralization of the phosphorylated serine residues.", [["Lys", "CHEMICAL", 82, 85], ["Arg", "CHEMICAL", 90, 93], ["P-Ser202", "CHEMICAL", 33, 41], ["P-Ser206", "CHEMICAL", 46, 54], ["Lys", "CHEMICAL", 82, 85], ["Arg", "CHEMICAL", 90, 93], ["serine", "CHEMICAL", 284, 290], ["Lys", "AMINO_ACID", 82, 85], ["Arg", "AMINO_ACID", 90, 93], ["serine", "AMINO_ACID", 284, 290], ["P", "DNA", 33, 34], ["P", "DNA", 46, 47], ["P", "TEST", 46, 47], ["the long sidechains of Lys", "TREATMENT", 59, 85], ["Arg", "TEST", 90, 93], ["high positive charge", "PROBLEM", 99, 119], ["significant side-chain conformational freedom in this genotype", "PROBLEM", 124, 186], ["the phosphorylated serine residues", "TREATMENT", 265, 299]]], ["This contributes to further reduction of conformational entropy compared to the other genotype.", [["conformational entropy", "PROBLEM", 41, 63], ["reduction", "OBSERVATION_MODIFIER", 28, 37], ["conformational entropy", "OBSERVATION", 41, 63]]], ["While Lys203 is likely to offer electrostatic interactions to P-Ser202, Arg204 (with a greater number of positively charged centres as compared to Lys) could potentially simultaneously interact with the phosphate groups at both P-Ser202 and P-Ser206.", [["Lys203", "CHEMICAL", 6, 12], ["Arg204", "CHEMICAL", 72, 78], ["phosphate", "CHEMICAL", 203, 212], ["Lys203", "CHEMICAL", 6, 12], ["P-Ser202", "CHEMICAL", 62, 70], ["Arg204", "CHEMICAL", 72, 78], ["Lys", "CHEMICAL", 147, 150], ["phosphate", "CHEMICAL", 203, 212], ["Lys203", "SIMPLE_CHEMICAL", 6, 12], ["Arg204", "AMINO_ACID", 72, 78], ["phosphate", "SIMPLE_CHEMICAL", 203, 212], ["P", "DNA", 62, 63], ["P-Ser202 and P-Ser206", "DNA", 228, 249], ["the phosphate groups", "TREATMENT", 199, 219]]], ["Together, these two positively charged residues (Lys203 and Arg204) have the potential to offer additional interactions to the phosphorylated serine residues at 202 and 206 positions as opposed to only one of them (Arg203) in the other genotype.", [["Lys203 and Arg204", "CHEMICAL", 49, 66], ["Arg203", "CHEMICAL", 215, 221], ["Lys203", "CHEMICAL", 49, 55], ["Arg", "CHEMICAL", 60, 63], ["serine", "CHEMICAL", 142, 148], ["Arg", "CHEMICAL", 215, 218], ["Arg204", "AMINO_ACID", 60, 66], ["serine", "AMINO_ACID", 142, 148], ["the phosphorylated serine residues", "TREATMENT", 123, 157], ["positively", "OBSERVATION_MODIFIER", 20, 30], ["charged residues", "OBSERVATION", 31, 47]]], ["Consequently, one can expect a significant difference in conformational entropy as well as in the inter-residue interaction structural network between the two genotypes especially when Ser202 and Ser206 are phosphorylated.", [["Ser202", "CHEMICAL", 185, 191], ["Ser206", "CHEMICAL", 196, 202], ["Ser202", "GENE_OR_GENE_PRODUCT", 185, 191], ["Ser206", "GENE_OR_GENE_PRODUCT", 196, 202], ["Ser202", "PROTEIN", 185, 191], ["Ser206", "PROTEIN", 196, 202], ["a significant difference in conformational entropy", "PROBLEM", 29, 79], ["significant", "OBSERVATION_MODIFIER", 31, 42], ["difference", "OBSERVATION_MODIFIER", 43, 53], ["conformational entropy", "OBSERVATION", 57, 79]]], ["Further, Gly at position 204 in one of the genotypes would confer significantly higher conformational freedom at the backbone (Ramakrishnan and Ramachandran 1965) of the polypeptide chain compared to Arg in the equivalent position in the other genotype.", [["Gly", "CHEMICAL", 9, 12], ["Arg", "CHEMICAL", 200, 203], ["Gly", "CHEMICAL", 9, 12], ["Arg", "CHEMICAL", 200, 203], ["Gly", "AMINO_ACID", 9, 12], ["Arg", "AMINO_ACID", 200, 203], ["polypeptide chain", "PROTEIN", 170, 187], ["the polypeptide chain", "TREATMENT", 166, 187], ["position", "OBSERVATION_MODIFIER", 222, 230]]], ["This mutation adds another dimension to the likely structural differences in this local region of the two genotypes.", [["This mutation", "PROBLEM", 0, 13]]], ["Subsequently, phosphorylation-mediated functional events might be different in the two genotypes (Surjit and Lal 2008; Surjit et al. 2006 ).", [["phosphorylation", "TREATMENT", 14, 29]]], ["However, given two positively charged residues in one genotype compared to only one in the other genotype, the charge neutralization structural interaction networks involving P-Ser202 and P-Ser206 has to be certainly different going by the highly established literature on kinase substrates (Kitchen et al. 2008; Krupa et al. 2004) .DiscussionInterestingly, the mutations D614G (in S D domain) is supposed to confer flexibility in the S D domain and the mutation G1124V might impart partial rigidity in the conformation of S 2 domain.", [["rigidity", "DISEASE", 491, 499], ["P-Ser202", "CHEMICAL", 175, 183], ["P-Ser206", "CHEMICAL", 188, 196], ["P-Ser202 and P-Ser206", "DNA", 175, 196], ["S D domain", "PROTEIN", 382, 392], ["S D domain", "PROTEIN", 435, 445], ["S 2 domain", "PROTEIN", 523, 533], ["two positively charged residues in one genotype", "PROBLEM", 15, 62], ["the mutation", "PROBLEM", 450, 462], ["partial rigidity", "PROBLEM", 483, 499], ["partial rigidity", "OBSERVATION", 483, 499]]], ["Obvious question is whether such structural alterations in local region would have any consequence in receptor binding affinity of Spike protein.", [["Spike", "GENE_OR_GENE_PRODUCT", 131, 136], ["Spike protein", "PROTEIN", 131, 144], ["such structural alterations in local region", "PROBLEM", 28, 71], ["Spike protein", "PROBLEM", 131, 144]]], ["Since the mutation resides in RBD domain-S1 subunit of Spike protein, residue 614 is not directly involved in the interaction with ACE2.", [["Spike", "GENE_OR_GENE_PRODUCT", 55, 60], ["residue 614", "AMINO_ACID", 70, 81], ["ACE2", "GENE_OR_GENE_PRODUCT", 131, 135], ["RBD domain-S1 subunit", "PROTEIN", 30, 51], ["Spike protein", "PROTEIN", 55, 68], ["ACE2", "PROTEIN", 131, 135], ["the mutation", "PROBLEM", 6, 18], ["Spike protein", "PROBLEM", 55, 68]]], ["But the mutation might have some effect on the positioning of the residues involved in interaction.", [["the mutation", "PROBLEM", 4, 16]]], ["Now to address the concerns whether these mutations are expected to affect the sensitivity of the existing diagnostic kit, we have again explored the implications of the structural changes.", [["these mutations", "PROBLEM", 36, 51], ["the structural changes", "PROBLEM", 166, 188]]], ["Most likely, the presence of mutation should not affect the Rapid detection kits because these kits detect the presence of specific IgG/IgM antibody against viral N protein or viral S protein.", [["IgG", "GENE_OR_GENE_PRODUCT", 132, 135], ["IgM antibody against viral N protein", "GENE_OR_GENE_PRODUCT", 136, 172], ["viral S protein", "GENE_OR_GENE_PRODUCT", 176, 191], ["IgG", "PROTEIN", 132, 135], ["IgM antibody", "PROTEIN", 136, 148], ["viral N protein", "PROTEIN", 157, 172], ["viral S protein", "PROTEIN", 176, 191], ["mutation", "PROBLEM", 29, 37], ["the Rapid detection kits", "TEST", 56, 80], ["these kits", "TEST", 89, 99], ["specific IgG", "TEST", 123, 135], ["IgM antibody", "TEST", 136, 148], ["viral N protein", "TEST", 157, 172], ["viral S protein", "TEST", 176, 191]]], ["The whole protein is coated for the test and therefore polyclonal antibodies would provide the result here.", [["polyclonal antibodies", "PROTEIN", 55, 76], ["the test", "TEST", 32, 40], ["polyclonal antibodies", "TEST", 55, 76]]], ["We have further checked if the mutation sites fall in immunodominant epitopes.", [["immunodominant epitopes", "PROTEIN", 54, 77], ["the mutation sites", "PROBLEM", 27, 45], ["immunodominant epitopes", "PROBLEM", 54, 77], ["immunodominant epitopes", "OBSERVATION", 54, 77]]], ["This data is available for SARS proteins and the sites where we have found mutation have been shown to be conserved in SARS and SARS-CoV-2.DiscussionWhile the mutation site of N protein does not elicit much antibody response, region 603-634 of the S protein of SARS has been shown to be a major immunodominant epitope in S protein (He et al. 2004) .", [["SARS", "DISEASE", 119, 123], ["SARS", "DISEASE", 128, 132], ["SARS", "DISEASE", 261, 265], ["SARS-CoV-2", "ORGANISM", 128, 138], ["S protein", "GENE_OR_GENE_PRODUCT", 321, 330], ["SARS proteins", "PROTEIN", 27, 40], ["N protein", "PROTEIN", 176, 185], ["S protein", "PROTEIN", 248, 257], ["S protein", "PROTEIN", 321, 330], ["SARS-CoV", "SPECIES", 128, 136], ["This data", "TEST", 0, 9], ["SARS proteins", "PROBLEM", 27, 40], ["mutation", "PROBLEM", 75, 83], ["CoV", "TEST", 133, 136], ["N protein", "TEST", 176, 185], ["the S protein", "TEST", 244, 257], ["SARS", "PROBLEM", 261, 265]]], ["Change in this epitope by mutation could alter the sensitivity of the IgG/IgM tests conducted.DiscussionAlso, there are certain diagnostic kits being designed to check the presence of viral antigen in the clinical sample.", [["IgG", "GENE_OR_GENE_PRODUCT", 70, 73], ["IgG", "PROTEIN", 70, 73], ["IgM", "PROTEIN", 74, 77], ["viral antigen", "PROTEIN", 184, 197], ["the IgG/IgM tests", "TEST", 66, 83], ["viral antigen", "PROBLEM", 184, 197]]], ["The abundance of antibodies targeting the mutation sites needs to be checked in those kits, to be more effective across the viral strains harbouring different mutations.DiscussionWe also detected interesting relationships between Ct value of diagnostic assay as a surrogate of viral copy number and viral sequence reads obtained.", [["antibodies", "PROTEIN", 17, 27], ["antibodies", "TREATMENT", 17, 27], ["the mutation sites", "PROBLEM", 38, 56], ["the viral strains harbouring different mutations", "PROBLEM", 120, 168], ["Ct value", "TEST", 230, 238], ["diagnostic assay", "TEST", 242, 258], ["viral copy number", "TEST", 277, 294], ["viral sequence reads", "TEST", 299, 319]]], ["We recommend that for future sequencing studies, the shotgun RNA-Seq approach should be used for high viral copy number represented by low Ct values while for rest, a viral genome amplification method should be used.", [["future sequencing studies", "TEST", 22, 47], ["the shotgun RNA", "TREATMENT", 49, 64], ["Seq approach", "TREATMENT", 65, 77], ["high viral copy number", "PROBLEM", 97, 119], ["rest", "TREATMENT", 159, 163], ["a viral genome amplification method", "TREATMENT", 165, 200]]], ["Although the sample size of our preliminary report is small, follow up studies are underway to confirm these observations for understanding the impact of the same in the ongoing outbreak of COVID-19 in India.", [["COVID-19", "CHEMICAL", 190, 198], ["follow up studies", "TEST", 61, 78], ["COVID", "TEST", 190, 195], ["size", "OBSERVATION_MODIFIER", 20, 24], ["small", "OBSERVATION_MODIFIER", 54, 59]]], ["We have not commented on the relationship of the viral sequence alterations with disease severity due to the limited sample size of this analysis.", [["the viral sequence alterations", "PROBLEM", 45, 75], ["disease severity", "PROBLEM", 81, 97], ["this analysis", "TEST", 132, 145], ["viral", "OBSERVATION", 49, 54]]], ["We hope to provide valuable information on this aspect based on the expanded number of samples being sequenced at present.", [["samples", "ANATOMY", 87, 94], ["samples", "CANCER", 87, 94]]], ["Our findings provide leads which might benefit outbreak tracking and development of therapeutic and prophylactic strategies to contain the infection.DiscussionFinally, we conclude that the initial sequences generated by us from first nine samples in West Bengal in Eastern India indicate a selective sweep of the A2a clade of SARS-Cov-2.", [["infection", "DISEASE", 139, 148], ["SARS", "DISEASE", 326, 330], ["SARS-Cov-2", "GENE_OR_GENE_PRODUCT", 326, 336], ["therapeutic and prophylactic strategies", "TREATMENT", 84, 123], ["the infection", "PROBLEM", 135, 148], ["SARS", "TEST", 326, 330], ["Cov", "TEST", 331, 334], ["infection", "OBSERVATION", 139, 148]]], ["However, the viral population is not homogenous and other clades like B4 also exist.", [["B4", "GENE_OR_GENE_PRODUCT", 70, 72], ["the viral population", "PROBLEM", 9, 29], ["viral", "OBSERVATION_MODIFIER", 13, 18], ["population", "OBSERVATION", 19, 29], ["not", "UNCERTAINTY", 33, 36], ["homogenous", "OBSERVATION_MODIFIER", 37, 47]]], ["We have also detected emergence of mutations in the important regions of the viral genome including Spike, RdRP and nucleocapsid coding genes.", [["Spike", "GENE_OR_GENE_PRODUCT", 100, 105], ["RdRP", "GENE_OR_GENE_PRODUCT", 107, 111], ["viral genome", "DNA", 77, 89], ["Spike", "DNA", 100, 105], ["RdRP", "DNA", 107, 111], ["nucleocapsid coding genes", "DNA", 116, 141], ["mutations", "PROBLEM", 35, 44], ["the viral genome", "PROBLEM", 73, 89], ["Spike", "PROBLEM", 100, 105], ["RdRP", "PROBLEM", 107, 111], ["nucleocapsid coding genes", "PROBLEM", 116, 141], ["viral genome", "OBSERVATION", 77, 89], ["nucleocapsid coding genes", "OBSERVATION", 116, 141]]], ["Some of these mutations are predicted to have impact on viral and host factors, which might affect transmission and disease severity.", [["these mutations", "PROBLEM", 8, 23], ["viral and host factors", "PROBLEM", 56, 78], ["disease severity", "PROBLEM", 116, 132], ["mutations", "OBSERVATION", 14, 23]]], ["This preliminary evidence of emergence of multiple subclones of SARS-CoV-2, which might have altered phenotypes, can have important consequences on the ongoing outbreak in India.Discussionduring the ongoing COVID-19 pandemic.", [["subclones", "ANATOMY", 51, 60], ["SARS", "DISEASE", 64, 68], ["subclones", "CELL", 51, 60], ["SARS-CoV-2", "ORGANISM", 64, 74], ["SARS-CoV", "SPECIES", 64, 72], ["multiple subclones of SARS", "PROBLEM", 42, 68], ["altered phenotypes", "PROBLEM", 93, 111], ["the ongoing COVID", "TEST", 195, 212], ["pandemic", "PROBLEM", 216, 224], ["multiple", "OBSERVATION_MODIFIER", 42, 50], ["subclones", "OBSERVATION", 51, 60]]], ["We also acknowledge the assistance provided by Dr. Sillarine Kurkalang (NIBMG), Mr. Sumitava Roy (NIBMG) in reviewing the sequence data, Ms. Soumi Sarkar (NIBMG) for assistance in statistical analysis, and Mr. Anand Bhushan and Ms. Meghna Chowdhury for providing assistance in laboratory support and logistics.", [["the sequence data", "TEST", 118, 135]]], ["SD and NS would like to acknowledge support from J C Bose fellowship.", [["SD", "DISEASE", 0, 2], ["NS", "TREATMENT", 7, 9]]], ["HR and SC would like to acknowledge support from CSIR-SPM fellowship and DST-INSPIRE fellowship, respectively.", [["SC", "ANATOMY", 7, 9]]], ["TG would like to acknowledge DBT-RA fellowship.", [["TG", "DISEASE", 0, 2], ["DBT", "CHEMICAL", 29, 32], ["TG", "SIMPLE_CHEMICAL", 0, 2], ["RA", "ANATOMY", 33, 35]]]], "PMC7354771": [["All authors provided critical revision of the manuscript for important intellectual content.Declaration of competing interestE.", [["critical revision", "TREATMENT", 21, 38], ["revision", "OBSERVATION", 30, 38]]], ["Morton, S. J. Barnes, and E. E. Michalak have no potential conflicts of interest to disclose.", [["no potential", "UNCERTAINTY", 46, 58]]]], "PMC1884151": [["BackgroundThe incubation period is defined as the time from exposure to onset of disease [1], and when limited to infectious diseases, corresponds to the time from infection with a microorganism to symptom development.", [["infectious diseases", "DISEASE", 114, 133], ["infection", "DISEASE", 164, 173], ["disease", "PROBLEM", 81, 88], ["infectious diseases", "PROBLEM", 114, 133], ["infection", "PROBLEM", 164, 173], ["a microorganism to symptom development", "PROBLEM", 179, 217], ["infectious", "OBSERVATION", 114, 124], ["infection", "OBSERVATION", 164, 173]]], ["According to a rigorous descriptive review [2], historical descriptions of the incubation period can be traced back to the mid-16th century when Girolamo Fracastoro (Fracastorius) (1478\u20131553), an Italian physician, documented for the first time the incubation period of rabies in 1546 [3].", [["rabies", "DISEASE", 270, 276]]], ["The incubation period of infectious diseases ranges from the order of a few hours, which is common for toxic food poisoning, to a few decades as seen in the case of tuberculosis, AIDS and variant Creutzfeldt-Jakob disease (vCJD).", [["infectious diseases", "DISEASE", 25, 44], ["food poisoning", "DISEASE", 109, 123], ["tuberculosis", "DISEASE", 165, 177], ["AIDS", "DISEASE", 179, 183], ["Creutzfeldt-Jakob disease", "DISEASE", 196, 221], ["vCJD", "DISEASE", 223, 227], ["Creutzfeldt-Jakob disease", "SPECIES", 196, 221], ["infectious diseases", "PROBLEM", 25, 44], ["toxic food poisoning", "PROBLEM", 103, 123], ["tuberculosis", "PROBLEM", 165, 177], ["AIDS", "PROBLEM", 179, 183], ["Jakob disease", "PROBLEM", 208, 221], ["infectious", "OBSERVATION", 25, 35], ["tuberculosis", "OBSERVATION", 165, 177]]], ["Since symptom onset reflects pathogen growth and invasion, excretion of toxins and initiation of host-defense mechanisms, the length of the incubation period varies largely according to the replication rate of the pathogen, the mechanism of disease development, the route of infection and other underlying factors.BackgroundDuring the incubation period of acute infectious diseases, which is subsequently followed by a symptomatic period, it should be noted that the infected host can be infectious.", [["infection", "DISEASE", 275, 284], ["acute infectious diseases", "DISEASE", 356, 381], ["symptom", "PROBLEM", 6, 13], ["pathogen growth", "PROBLEM", 29, 44], ["invasion", "PROBLEM", 49, 57], ["toxins", "PROBLEM", 72, 78], ["host-defense mechanisms", "TREATMENT", 97, 120], ["the pathogen", "PROBLEM", 210, 222], ["disease development", "PROBLEM", 241, 260], ["infection", "PROBLEM", 275, 284], ["other underlying factors", "PROBLEM", 289, 313], ["acute infectious diseases", "PROBLEM", 356, 381], ["the infected host", "PROBLEM", 463, 480], ["infectious", "PROBLEM", 488, 498], ["pathogen", "OBSERVATION_MODIFIER", 29, 37], ["growth", "OBSERVATION_MODIFIER", 38, 44], ["invasion", "OBSERVATION_MODIFIER", 49, 57], ["host-defense", "OBSERVATION_MODIFIER", 97, 109], ["disease", "OBSERVATION", 241, 248], ["infection", "OBSERVATION", 275, 284], ["incubation", "OBSERVATION_MODIFIER", 335, 345], ["period", "OBSERVATION_MODIFIER", 346, 352], ["acute", "OBSERVATION_MODIFIER", 356, 361], ["infectious", "OBSERVATION", 362, 372], ["infected", "OBSERVATION", 467, 475], ["infectious", "OBSERVATION", 488, 498]]], ["Whereas the incubation and symptomatic periods are distinguished by symptom onset, other epidemiologic terms are distinguished by acquisition of infectiousness.", [["symptomatic periods", "PROBLEM", 27, 46], ["infectiousness", "PROBLEM", 145, 159], ["symptomatic", "OBSERVATION_MODIFIER", 27, 38]]], ["That is, the time from infection to acquisition of infectiousness is referred to as the latent period, which is subsequently followed by the infectious period [4].", [["infection", "DISEASE", 23, 32], ["infection", "PROBLEM", 23, 32], ["infectiousness", "PROBLEM", 51, 65], ["infection", "OBSERVATION", 23, 32]]], ["The incubation period of infectious diseases offers various insights into clinical and public health practices, as well as being important for epidemiologic and ecological studies.BackgroundTo enhance our understanding of the incubation period distributions of infectious diseases, it is useful to revisit previous efforts and reassess explicit models.", [["infectious diseases", "DISEASE", 25, 44], ["infectious diseases", "DISEASE", 261, 280], ["infectious diseases", "PROBLEM", 25, 44], ["epidemiologic and ecological studies", "TEST", 143, 179], ["infectious diseases", "PROBLEM", 261, 280], ["infectious", "OBSERVATION", 25, 35], ["infectious", "OBSERVATION", 261, 271]]], ["This paper discusses relatively unknown historical efforts, paying particular attention to diseases with an acute course of illness.", [["illness", "DISEASE", 124, 131], ["illness", "PROBLEM", 124, 131], ["acute", "OBSERVATION_MODIFIER", 108, 113]]], ["Table 1 summarizes a number of common examples, presenting historical as well as recent major uses [1,5-27]; however, it is worth noting that this list does not cover all utilities in full.The usefulness of understanding the incubation period ::: AnalysisIn clinical practice, the incubation period is useful not only for making rough guesses as to the causes and sources of infection of individual cases [5], but also for developing treatment strategies to extend the incubation period (e.g., antiretroviral therapy for HIV infection [1]) and for performing early projection of disease prognosis when the incubation period is clearly associated with clinical severity due to dose-response mechanisms (e.g., diseases caused by exotoxin) [6,7].", [["infection", "DISEASE", 375, 384], ["HIV infection", "DISEASE", 521, 534], ["exotoxin", "GENE_OR_GENE_PRODUCT", 727, 735], ["HIV", "SPECIES", 521, 524], ["infection of individual cases", "PROBLEM", 375, 404], ["treatment strategies", "TREATMENT", 434, 454], ["antiretroviral therapy", "TREATMENT", 494, 516], ["HIV infection", "PROBLEM", 521, 534], ["disease prognosis", "PROBLEM", 579, 596], ["clinical severity", "PROBLEM", 651, 668], ["diseases", "PROBLEM", 708, 716], ["exotoxin", "PROBLEM", 727, 735]]], ["Moreover, during an outbreak of a newly emerged directly transmitted disease, the incubation period distribution permits determination of the length of quarantine required for a potentially exposed individual (i.e., by restricting movement of an exposed individual for a duration sufficiently longer than the incubation period) [10].", [["directly transmitted disease", "DISEASE", 48, 76], ["a newly emerged directly transmitted disease", "PROBLEM", 32, 76], ["disease", "OBSERVATION", 69, 76]]], ["Further, if the time lag between acquiring infectiousness and symptom onset appears long (i.e., if the incubation period is relatively long compared to the latent period), it implies that isolation measures (e.g, restriction of movement until the infectious individual loses infectiousness) are likely to be ineffective, complicating disease control [1,11].The usefulness of understanding the incubation period ::: AnalysisUnderstanding the incubation period distribution also enables statistical estimation of the time of exposure during a point source outbreak [12] as well as a hypothesis-testing to determine whether the outbreak has ended [13]; the former is discussed below.", [["infectiousness", "PROBLEM", 43, 57], ["symptom", "PROBLEM", 62, 69], ["isolation measures", "TREATMENT", 188, 206], ["the infectious individual loses infectiousness", "PROBLEM", 243, 289], ["complicating disease control", "PROBLEM", 321, 349], ["a hypothesis-testing", "TEST", 579, 599], ["isolation", "OBSERVATION", 188, 197], ["likely to be", "UNCERTAINTY", 295, 307], ["ineffective", "OBSERVATION_MODIFIER", 308, 319]]], ["The distribution is also useful in statistical approaches of epidemic curve reconstruction and short-term predictions of slowly progressing diseases; the backcalculation method uses the incubation period to estimate HIV prevalence and project the future incidence of AIDS [14,15].", [["AIDS", "DISEASE", 267, 271], ["HIV", "SPECIES", 216, 219], ["epidemic curve reconstruction", "TREATMENT", 61, 90], ["slowly progressing diseases", "PROBLEM", 121, 148], ["the backcalculation method", "TREATMENT", 150, 176], ["slowly", "OBSERVATION_MODIFIER", 121, 127], ["progressing", "OBSERVATION_MODIFIER", 128, 139], ["diseases", "OBSERVATION", 140, 148]]], ["During the last decade, this method has also been extended to prion diseases such as Bovine Spongiform Encephalopathy (BSE) [16,17], vCJD [18-22] and Kuru [23].", [["prion diseases", "DISEASE", 62, 76], ["Bovine Spongiform Encephalopathy", "DISEASE", 85, 117], ["BSE", "DISEASE", 119, 122], ["vCJD", "DISEASE", 133, 137], ["Bovine", "SPECIES", 85, 91], ["Bovine Spongiform Encephalopathy (BSE)", "SPECIES", 85, 123], ["this method", "TREATMENT", 24, 35], ["prion diseases", "PROBLEM", 62, 76], ["Bovine Spongiform Encephalopathy", "PROBLEM", 85, 117], ["vCJD", "TEST", 133, 137], ["Spongiform", "OBSERVATION_MODIFIER", 92, 102]]], ["This approach has also recently diverged to quantification of the transmission potential of diseases with an acute course of illness [24] and infectiousness relative to disease-age [25].", [["illness", "DISEASE", 125, 132], ["diseases", "PROBLEM", 92, 100], ["illness", "PROBLEM", 125, 132], ["infectiousness", "PROBLEM", 142, 156], ["diseases", "OBSERVATION", 92, 100], ["acute", "OBSERVATION_MODIFIER", 109, 114], ["course", "OBSERVATION_MODIFIER", 115, 121]]], ["Moreover, in cases such as the short and long incubation periods of Plasmodium vivax malaria in temperate zones, the incubation period also enhances ecological understanding of adaptation strategies; in temperate zones, clearly separate bimodal peaks with approximate lengths of 2 and 50 weeks are observed [26,27], helping malaria transmissions continue over the winter season when transmission is usually greatly reduced due to seasonal entomologic characteristics.The earliest model developed using incomplete data ::: AnalysisWhereas the incubation period is conveniently extracted from specific data indicating the time of exposure, i.e., experimental inoculation data and case travel histories [2], most infection events are not directly observable for diseases transmitted by non-sexual direct contact.", [["Plasmodium vivax malaria", "DISEASE", 68, 92], ["malaria", "DISEASE", 324, 331], ["infection", "DISEASE", 710, 719], ["Plasmodium vivax malaria", "ORGANISM", 68, 92], ["Plasmodium vivax", "SPECIES", 68, 84], ["Plasmodium vivax", "SPECIES", 68, 84], ["Plasmodium vivax malaria in temperate zones", "PROBLEM", 68, 111], ["adaptation strategies", "TREATMENT", 177, 198], ["seasonal entomologic characteristics", "PROBLEM", 430, 466], ["most infection events", "PROBLEM", 705, 726], ["diseases", "PROBLEM", 759, 767], ["Plasmodium vivax", "OBSERVATION", 68, 84], ["bimodal peaks", "OBSERVATION", 237, 250], ["infection", "OBSERVATION", 710, 719]]], ["The majority of epidemiologic data informs us that exposure (i.e., infection) occurred in a defined period, data of which is referred to as interval censored [29].", [["infection", "DISEASE", 67, 76], ["epidemiologic data", "TEST", 16, 34], ["infection", "PROBLEM", 67, 76], ["infection", "OBSERVATION", 67, 76]]], ["This is a common concern for acute infectious diseases transmitted by droplets and droplet nuclei and, most noteworthily, was discussed in detail during the outbreak of severe acute respiratory syndrome (SARS) [30,31].", [["droplet nuclei", "ANATOMY", 83, 97], ["acute respiratory syndrome", "DISEASE", 176, 202], ["SARS", "DISEASE", 204, 208], ["severe acute respiratory syndrome (SARS)", "SPECIES", 169, 209], ["acute infectious diseases", "PROBLEM", 29, 54], ["severe acute respiratory syndrome", "PROBLEM", 169, 202], ["common concern for", "UNCERTAINTY", 10, 28], ["acute", "OBSERVATION_MODIFIER", 29, 34], ["infectious", "OBSERVATION", 35, 45], ["droplet nuclei", "OBSERVATION", 83, 97], ["severe", "OBSERVATION_MODIFIER", 169, 175], ["acute", "OBSERVATION_MODIFIER", 176, 181], ["respiratory syndrome", "OBSERVATION", 182, 202]]], ["Previous studies on the population dynamics of influenza tend to make assumptions with regard to the incubation period distribution without employing observed data [32,33], perhaps mainly due to difficulties in identifying the time of exposure.", [["influenza", "DISEASE", 47, 56], ["Previous studies", "TEST", 0, 16], ["influenza", "PROBLEM", 47, 56]]], ["The incubation period distribution of influenza remained almost unknown until a recent study reanalyzed the data of influenza transmission on an aircraft with a short duration of flight [34,35].", [["influenza", "DISEASE", 38, 47], ["influenza", "DISEASE", 116, 125], ["influenza", "PROBLEM", 38, 47], ["a recent study", "TEST", 78, 92], ["influenza transmission", "PROBLEM", 116, 138], ["influenza", "OBSERVATION", 38, 47]]], ["Assuming Weibull distribution, this study estimated the mean (and standard deviation (SD)) incubation period as 1.48 (0.47) days [35].", [["this study", "TEST", 31, 41], ["Weibull distribution", "OBSERVATION", 9, 29]]], ["Not only was the sample size of the estimate limited (i.e., 37 secondary cases), but since no other estimates are currently available, the present paper revisits a historical study on this topic.The earliest model developed using incomplete data ::: AnalysisThe earliest study concerned with estimating the incubation period of influenza was published by Anderson Gray McKendrick (1876\u20131943) and J. Morison in the Indian Journal of Medical Sciences in 1919 [36].", [["influenza", "DISEASE", 328, 337], ["a historical study", "TEST", 162, 180], ["Analysis", "TEST", 250, 258], ["The earliest study", "TEST", 258, 276], ["influenza", "PROBLEM", 328, 337], ["size", "OBSERVATION_MODIFIER", 24, 28]]], ["Dr. McKendrick, a physician and epidemiologist, applied various mathematical methods to the field of medicine and is a known pioneer in the biomathematics of infectious disease epidemiology [37-39].", [["infectious disease", "DISEASE", 158, 176], ["infectious", "OBSERVATION", 158, 168]]], ["Whereas Dr. McKendrick, in collaboration with William Ogilvy Kermack (1898\u20131970) [40,41], is relatively well known as the first to suggest the deterministic epidemic model given by differential equations, his analysis of the incubation period of Spanish flu preceded this, and remains relatively unknown even among specialists (see Online Additional File 1 for the original).", [["his analysis", "TEST", 205, 217]]], ["Except for this work, no other historical study on influenza has explicitly accounted for the unknown time of exposure or identified the time of exposure in a specific setting (as in the above mentioned study documenting transmission on an aircraft [34,35]).The earliest model developed using incomplete data ::: AnalysisIn Dr. McKendrick's study, an attempt was made to infer the incubation period of pandemic influenza using the daily incidence of cases on ships departing, with incubating individuals, from several ports in Australia.", [["influenza", "DISEASE", 51, 60], ["influenza", "DISEASE", 411, 420], ["other historical study", "TEST", 25, 47], ["influenza", "PROBLEM", 51, 60], ["pandemic influenza", "PROBLEM", 402, 420]]], ["No influenza case developed symptoms on or after the 5th day of voyage and the observed cases were thought to have been exposed to influenza before departure.", [["influenza", "DISEASE", 131, 140], ["influenza", "PROBLEM", 3, 12], ["symptoms", "PROBLEM", 28, 36], ["influenza", "PROBLEM", 131, 140], ["influenza", "OBSERVATION", 3, 12]]], ["Since the data for each voyage mainly included only a few initial cases that developed influenza on board, it is assumed that potential secondary transmission on board was negligible, and potential asymptomatic transmission was also ignored (detailed information on the observed and excluded secondary transmissions are documented in the original [43] and Dr. McKendrick also addressed the issue of secondary transmission by limiting the number of cases per ship).", [["influenza", "DISEASE", 87, 96], ["influenza", "PROBLEM", 87, 96], ["secondary transmissions", "PROBLEM", 292, 315], ["influenza", "OBSERVATION", 87, 96]]], ["Further technical details are given in the Additional File 2.The earliest model developed using incomplete data ::: AnalysisUsing the data in Figure 1 (with a total of N cases), the number of cases, G(t), t days after departure was modeled as:The earliest model developed using incomplete data ::: AnalysisG(t)N=\u222b\u2212\u221e0f(t\u2212\u03c4)d\u03c4=1\u2212F(t).MathType@MTEF@+=feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY=wiFfYdH8Gipec8Eeeu0xXdbba9frFj0=OqFfea0dXdd9vqai=hGuQ8kuc9pgc9s8qqaq=dirpe0xb9q8qiLsFr0=vr0=vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaafaqabeGabaaabaWaaSaaaeaacqWGhbWrcqGGOaakcqWG0baDcqGGPaqkaeaacqWGobGtaaGaeyypa0Zaa8qmaeaacqWGMbGzcqGGOaakcqWG0baDcqGHsisliiGacqWFepaDcqGGPaqkcqWGKbazcqWFepaDaSqaaiabgkHiTiabg6HiLcqaaiabicdaWaqdcqGHRiI8aaGcbaGaeyypa0JaeGymaeJaeyOeI0IaemOrayKaeiikaGIaemiDaqNaeiykaKIaeiOla4caaaaa@4AEE@The earliest model developed using incomplete data ::: Analysiswhere f(t) and F(t) are the probability density and cumulative distribution functions of an incubation period of length t (see Additional File 2).", [["AnalysisG", "TEST", 298, 307], ["d\u03c4", "TEST", 322, 324], ["the probability density", "PROBLEM", 937, 960], ["density", "OBSERVATION", 953, 960], ["cumulative distribution", "OBSERVATION", 965, 988]]], ["From this, Dr. McKendrick suggested that the mean incubation period was 32.71 hours, which is consistent with recent estimate [35].", [["consistent with", "UNCERTAINTY", 94, 109]]], ["However, this value was likely slightly underestimated, because the model implicitly assumed the possible time of exposure as being from time 0 to infinite before departure; it has been extensively discussed that data assuming long possible periods of exposure is likely to be uninformative.", [["this value", "TEST", 9, 19], ["slightly underestimated", "OBSERVATION_MODIFIER", 31, 54], ["likely to be", "UNCERTAINTY", 264, 276]]], ["Moreover, in a recent work on SARS concerned with analysis of data with short periods of exposure [44], the equal probability of exposure for each possible date was likely to have overestimated the variance of the incubation period distribution [31].", [["SARS", "DISEASE", 30, 34]]], ["Thus, to obtain a precise estimate of the incubation period, appropriate censoring methods with well-defined short periods of exposure are needed in addition to a large sample size [30,45].", [["a large sample size", "TEST", 161, 180], ["large", "OBSERVATION_MODIFIER", 163, 168], ["size", "OBSERVATION_MODIFIER", 176, 180]]], ["However, despite these technical concerns, it is remarkable that Dr. McKendrick was able to estimate the incubation period of pandemic influenza considering the unknown time of exposure in the given data.Classic right-skewed distribution ::: AnalysisAfter Dr. McKendrick's initial work and his use of implicit assumptions to determine the incubation period distribution, John R. Miner (1892-unknown), a biologist and epidemiologist at Johns Hopkins University, is believed to have documented the first explicit model of the incubation period distribution [46].", [["influenza", "DISEASE", 135, 144], ["pandemic influenza", "PROBLEM", 126, 144], ["implicit assumptions", "TREATMENT", 301, 321], ["right", "ANATOMY_MODIFIER", 212, 217], ["skewed", "OBSERVATION", 218, 224]]], ["Dr. Miner collected epidemic records of several outbreaks of typhoid fever, claiming that the length of the incubation period clearly differs by source of infection (i.e., comparing water- and food-borne outbreaks, he found that the food-borne outbreaks had a much shorter incubation period, most likely reflecting dose-response phenomena).", [["typhoid fever", "DISEASE", 61, 74], ["infection", "DISEASE", 155, 164], ["typhoid fever", "PROBLEM", 61, 74], ["infection", "PROBLEM", 155, 164], ["several", "OBSERVATION_MODIFIER", 40, 47], ["outbreaks", "OBSERVATION_MODIFIER", 48, 57], ["typhoid", "OBSERVATION_MODIFIER", 61, 68], ["infection", "OBSERVATION", 155, 164], ["most likely", "UNCERTAINTY", 292, 303]]], ["During his analysis, Dr. Miner paid close attention to variance in the incubation period, describing a distribution that always skewed to the right.", [["his analysis", "TEST", 7, 19], ["right", "ANATOMY_MODIFIER", 142, 147]]], ["In calculating \"moments\" of the incubation period in a water-borne outbreak at the Old Salem Chautauqua, 1916, he used the following equation to explain the epidemic curve:Classic right-skewed distribution ::: Analysisy=12.396(1+x5.955)0.8573(1\u2212x40.040)5.7641MathType@MTEF@+=feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY=wiFfYdH8Gipec8Eeeu0xXdbba9frFj0=OqFfea0dXdd9vqai=hGuQ8kuc9pgc9s8qqaq=dirpe0xb9q8qiLsFr0=vr0=vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacqWG5bqEcqGH9aqpcqaIXaqmcqaIYaGmcqGGUaGlcqaIZaWmcqaI5aqocqaI2aGndaqadaqaaiabigdaXiabgUcaRmaalaaabaGaemiEaGhabaGaeGynauJaeiOla4IaeGyoaKJaeGynauJaeGynaudaaaGaayjkaiaawMcaamaaCaaaleqabaGaeGimaaJaeiOla4IaeGioaGJaeGynauJaeG4naCJaeG4mamdaaOWaaeWaaeaacqaIXaqmcqGHsisldaWcaaqaaiabdIha4bqaaiabisda0iabicdaWiabc6caUiabicdaWiabisda0iabicdaWaaaaiaawIcacaGLPaaadaahaaWcbeqaaiabiwda1iabc6caUiabiEda3iabiAda2iabisda0iabigdaXaaaaaa@54EE@Classic right-skewed distribution ::: Analysiswhere y and x are the expected number of cases and time after exposure, respectively (Figure 2).", [["Analysisy", "TEST", 210, 219], ["right", "ANATOMY_MODIFIER", 180, 185]]], ["The general form of eqn.", [["eqn", "PROTEIN", 20, 23]]], ["(2) is referred to as Pearson's type I distribution, which is given by [47]:Classic right-skewed distribution ::: Analysisy=y0(1+xa1)m1(1\u2212xa2)m2MathType@MTEF@+=feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY=wiFfYdH8Gipec8Eeeu0xXdbba9frFj0=OqFfea0dXdd9vqai=hGuQ8kuc9pgc9s8qqaq=dirpe0xb9q8qiLsFr0=vr0=vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacqWG5bqEcqGH9aqpcqWG5bqEdaWgaaWcbaGaeGimaadabeaakmaabmaabaGaeGymaeJaey4kaSYaaSaaaeaacqWG4baEaeaacqWGHbqydaWgaaWcbaGaeGymaedabeaaaaaakiaawIcacaGLPaaadaahaaWcbeqaaiabd2gaTnaaBaaameaacqaIXaqmaeqaaaaakmaabmaabaGaeGymaeJaeyOeI0YaaSaaaeaacqWG4baEaeaacqWGHbqydaWgaaWcbaGaeGOmaidabeaaaaaakiaawIcacaGLPaaadaahaaWcbeqaaiabd2gaTnaaBaaameaacqaIYaGmaeqaaaaaaaa@45E9@Classic right-skewed distribution ::: Analysiswhere m1/a1 = m2/a2.", [["a2", "DNA", 796, 798], ["Analysiswhere", "TEST", 771, 784], ["right", "ANATOMY_MODIFIER", 84, 89], ["right", "ANATOMY_MODIFIER", 741, 746], ["a2", "ANATOMY", 796, 798]]], ["Among Pearson's curves, type I distribution is the most standard and relatively flexible, and can realize right-skewed distribution [47].", [["Pearson's curves", "TEST", 6, 22], ["right", "ANATOMY_MODIFIER", 106, 111]]], ["Although no other works concerned with models of the incubation period have been identified, Major Greenwood (1880\u20131949) applied Pearson's type III distribution to the distribution of the serial interval (i.e., the time from symptom onset in a primary case to symptom onset in a secondary case [48]) of measles within a number of households [49].Lognormal distribution proposed by Philip Sartwell ::: AnalysisThe epidemiologist Philip E. Sartwell (1908\u20131999), who previously acted as chairman of the Department of Epidemiology, Johns Hopkins School of Hygiene and Public Health, contributed most to the foundation of incubation period distribution modeling [50].", [["measles", "DISEASE", 303, 310], ["measles", "PROBLEM", 303, 310], ["Analysis", "TEST", 401, 409]]], ["Dr. Sartwell initially found that the incubation period of acute infectious diseases tends to follow lognormal distribution [12], and applied the distribution to various diseases [51,52].", [["infectious diseases", "DISEASE", 65, 84], ["acute infectious diseases", "PROBLEM", 59, 84], ["various diseases", "PROBLEM", 162, 178], ["acute", "OBSERVATION_MODIFIER", 59, 64], ["infectious", "OBSERVATION", 65, 75], ["various", "OBSERVATION_MODIFIER", 162, 169], ["diseases", "OBSERVATION", 170, 178]]], ["Observing that the distributions often skewed to the right, Dr. Sartwell suggested the use of two parameters (i.e., an estimated \"median\", which is also the geometric mean due to the characteristics of lognormal distribution, and a \"dispersion factor\" as a measure of variability) rather than the sample mean and standard deviation.", [["a \"dispersion factor", "PROBLEM", 230, 250], ["the sample mean", "TEST", 293, 308], ["right", "ANATOMY_MODIFIER", 53, 58], ["lognormal distribution", "OBSERVATION", 202, 224]]], ["Lognormal distribution has a probability density function (pdf) of:Lognormal distribution proposed by Philip Sartwell ::: Analysisf(x;\u03bc,\u03c32)=1x\u03c32\u03c0exp\u2061(\u2212(ln\u2061(x)\u2212\u03bc)22\u03c32)MathType@MTEF@+=feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY=wiFfYdH8Gipec8Eeeu0xXdbba9frFj0=OqFfea0dXdd9vqai=hGuQ8kuc9pgc9s8qqaq=dirpe0xb9q8qiLsFr0=vr0=vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacqWGMbGzcqGGOaakcqWG4baEcqGG7aWoiiGacqWF8oqBcqGGSaalcqWFdpWCdaahaaWcbeqaaiabikdaYaaakiabcMcaPiabg2da9maalaaabaGaeGymaedabaGaemiEaGNae83Wdm3aaOaaaeaacqaIYaGmcqWFapaCaSqabaaaaOGagiyzauMaeiiEaGNaeiiCaa3aaeWaaeaadaWcaaqaaiabgkHiTiabcIcaOiGbcYgaSjabc6gaUjabcIcaOiabdIha4jabcMcaPiabgkHiTiab=X7aTjabcMcaPmaaCaaaleqabaGaeGOmaidaaaGcbaGaeGOmaiJae83Wdm3aaWbaaSqabeaacqaIYaGmaaaaaaGccaGLOaGaayzkaaaaaa@55B7@Lognormal distribution proposed by Philip Sartwell ::: Analysisfor x > 0, where \u03bc and \u03c3 are the mean and standard deviation of the variable's logarithm [53].", [["Analysisf(", "TEST", 122, 132], ["the variable's logarithm", "TEST", 925, 949], ["probability density", "OBSERVATION_MODIFIER", 29, 48]]], ["The coefficient of variation (CV), a dimensionless number, is a measure of dispersion of the distribution given by:Lognormal distribution proposed by Philip Sartwell ::: AnalysisCV=exp\u2061(\u03c32)\u22121.MathType@MTEF@+=feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY=wiFfYdH8Gipec8Eeeu0xXdbba9frFj0=OqFfea0dXdd9vqai=hGuQ8kuc9pgc9s8qqaq=dirpe0xb9q8qiLsFr0=vr0=vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacqWGdbWqcqWGwbGvcqGH9aqpdaGcaaqaaiGbcwgaLjabcIha4jabcchaWjabcIcaOGGaciab=n8aZnaaCaaaleqabaGaeGOmaidaaOGaeiykaKIaeyOeI0IaeGymaedaleqaaOGaeiOla4caaa@3BB5@Lognormal distribution proposed by Philip Sartwell ::: AnalysisFigure 3 shows the frequency distributions of the incubation periods of measles and poliomyelitis based on careful observations of the times of exposure and onset [54,55] (the maximum likelihood method was used to obtain Fig. 3 and will be discussed later).", [["measles", "DISEASE", 715, 722], ["poliomyelitis", "DISEASE", 727, 740], ["AnalysisFigure", "TEST", 635, 649], ["measles", "PROBLEM", 715, 722], ["poliomyelitis", "PROBLEM", 727, 740], ["variation", "OBSERVATION_MODIFIER", 19, 28]]], ["Both incubation periods were reasonably generalized using lognormal distributions, yielding maximum likelihood estimates of \u03bc and CV of 2.47 log(days) and 28.0% and 2.37 log(days) and 47.4%, respectively.", [["CV", "TEST", 130, 132]]], ["3B and 3D).Lognormal distribution proposed by Philip Sartwell ::: AnalysisEven at present, it is frequently assumed that the incubation period of acute infectious diseases follows lognormal distribution [25,56,57].", [["infectious diseases", "DISEASE", 152, 171], ["acute infectious diseases", "PROBLEM", 146, 171], ["acute", "OBSERVATION_MODIFIER", 146, 151], ["infectious", "OBSERVATION", 152, 162]]], ["Using the lognormal assumption for incubation period, Dr. Sartwell further developed a method to estimate the time of exposure during a point source outbreak [52].", [["a method", "TREATMENT", 85, 93]]], ["The earliest Japanese work appeared immediately after Dr. Sartwell's first publication and was conducted by Takeshi Hirayama (1923\u20131995), an epidemiologist who, later in life, worked mainly on the epidemiology of various cancers [59,60].", [["cancers", "ANATOMY", 221, 228], ["cancers", "DISEASE", 221, 228], ["cancers", "CANCER", 221, 228], ["various cancers", "PROBLEM", 213, 228], ["cancers", "OBSERVATION", 221, 228]]], ["The theoretical basis of Dr. Hirayama's method is illustrated in Figure 4, the logic of which is explained in the following.Lognormal models proposed by Japanese epidemiologists ::: AnalysisSince all cases in a point source outbreak share the same time of exposure, the epidemic curve, which is drawn according to the time of onset (i.e., incidence), is equivalent to the incubation period distribution (Figure 4).", [["Analysis", "TEST", 182, 190], ["the epidemic curve", "TEST", 266, 284]]], ["Suppose that the median point of the case frequency was observed x days after exposure and, further, that there are \u03b1 percentile points on both sides of the observed distribution (upper and lower percentiles \u03b1) with the distances from the median to both percentiles points being a and b days, respectively, the following relationship is given (because the logarithm follows normal distribution):Lognormal models proposed by Japanese epidemiologists ::: Analysisln(x) - ln(x - a) = ln(x + b) - ln(x).Lognormal models proposed by Japanese epidemiologists ::: AnalysisThis is rearranged as:Lognormal models proposed by Japanese epidemiologists ::: Analysisxx\u2212a=x+bxMathType@MTEF@+=feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY=wiFfYdH8Gipec8Eeeu0xXdbba9frFj0=OqFfea0dXdd9vqai=hGuQ8kuc9pgc9s8qqaq=dirpe0xb9q8qiLsFr0=vr0=vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaadaWcaaqaaiabdIha4bqaaiabdIha4jabgkHiTiabdggaHbaacqGH9aqpdaWcaaqaaiabdIha4jabgUcaRiabdkgaIbqaaiabdIha4baaaaa@381D@Lognormal models proposed by Japanese epidemiologists ::: AnalysisConsequently, the time of exposure can be inferred using the distance from the time of exposure to the median, x, by taking the distances to any equal percentiles on both sides:Lognormal models proposed by Japanese epidemiologists ::: Analysisx^=abb\u2212aMathType@MTEF@+=feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY=wiFfYdH8Gipec8Eeeu0xXdbba9frFj0=OqFfea0dXdd9vqai=hGuQ8kuc9pgc9s8qqaq=dirpe0xb9q8qiLsFr0=vr0=vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWG4baEgaqcaiabg2da9maalaaabaGaemyyaeMaemOyaigabaGaemOyaiMaeyOeI0Iaemyyaegaaaaa@3568@Lognormal models proposed by Japanese epidemiologists ::: AnalysisThis estimator is theoretically the same as that suggested by Dr. Sartwell in his later work [52].", [["upper", "ORGANISM_SUBDIVISION", 180, 185], ["ln(x + b)", "SIMPLE_CHEMICAL", 481, 490], ["Analysisln", "TEST", 453, 463], ["Analysis", "TEST", 557, 565], ["Analysis", "TEST", 1069, 1077], ["Analysis", "TEST", 1708, 1716], ["upper", "ANATOMY_MODIFIER", 180, 185], ["lower", "ANATOMY_MODIFIER", 190, 195], ["ln", "ANATOMY", 493, 495]]], ["The likelihood function is given by the pdf:More modern studies employing lognormal distribution ::: AnalysisL(\u03b3,\u03bc,\u03c32)=\u220fi=1nf(xi;\u03b3,\u03bc,\u03c32)MathType@MTEF@+=feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY=wiFfYdH8Gipec8Eeeu0xXdbba9frFj0=OqFfea0dXdd9vqai=hGuQ8kuc9pgc9s8qqaq=dirpe0xb9q8qiLsFr0=vr0=vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacqWGmbatcqGGOaakiiGacqWFZoWzcqGGSaalcqWF8oqBcqGGSaalcqWFdpWCdaahaaWcbeqaaiabikdaYaaakiabcMcaPiabg2da9maarahabaGaemOzayMaeiikaGIaemiEaG3aaSbaaSqaaiabdMgaPbqabaGccqGG7aWocqWFZoWzcqGGSaalcqWF8oqBcqGGSaalcqWFdpWCdaahaaWcbeqaaiabikdaYaaakiabcMcaPaWcbaGaemyAaKMaeyypa0JaeGymaedabaGaemOBa4ganiabg+Givdaaaa@4E7B@More modern studies employing lognormal distribution ::: Analysiswhere n is the total number of cases observed in an outbreak.", [["AnalysisL", "TEST", 101, 110], ["\u03b3", "TEST", 111, 112], ["\u03bc", "TEST", 113, 114]]], ["Although maximum likelihood estimates of \u03b3, \u03bc and \u03c3 are obtained by minimizing the negative logarithm of eqn.(13), it is often the case that the iteration does not converge [82], and thus, Dr. Tango proposed his estimators [77,81].", [["\u03b3, \u03bc and \u03c3", "PROTEIN", 41, 51]]], ["Assuming that \u03b3 is known, maximum likelihood estimators of \u03bc and \u03c3 are given by:More modern studies employing lognormal distribution ::: Analysis\u03bc^(\u03b3)=1n\u22111nln\u2061(xi\u2212\u03b3),MathType@MTEF@+=feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY=wiFfYdH8Gipec8Eeeu0xXdbba9frFj0=OqFfea0dXdd9vqai=hGuQ8kuc9pgc9s8qqaq=dirpe0xb9q8qiLsFr0=vr0=vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaaiiGacuWF8oqBgaqcaiabcIcaOiab=n7aNjabcMcaPiabg2da9maalaaabaGaeGymaedabaGaemOBa4gaamaaqahabaGagiiBaWMaeiOBa4MaeiikaGIaemiEaG3aaSbaaSqaaiabdMgaPbqabaGccqGHsislcqWFZoWzcqGGPaqkaSqaaiabigdaXaqaaiabd6gaUbqdcqGHris5aOGaeiilaWcaaa@44CA@More modern studies employing lognormal distribution ::: Analysis\u03c3(\u03b3)}2.MathType@MTEF@+=feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY=wiFfYdH8Gipec8Eeeu0xXdbba9frFj0=OqFfea0dXdd9vqai=hGuQ8kuc9pgc9s8qqaq=dirpe0xb9q8qiLsFr0=vr0=vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaaiiGacuWFdpWCgaqcamaaCaaaleqabaGaeGOmaidaaOGaeiikaGIae83SdCMaeiykaKIaeyypa0ZaaSaaaeaacqaIXaqmaeaacqWGUbGBaaWaaabCaeaadaGadaqaaiGbcYgaSjabc6gaUjabcIcaOiabdIha4naaBaaaleaacqWGPbqAaeqaaOGaeyOeI0Iae83SdCMaeiykaKIaeyOeI0Iaf8hVd0MbaKaacqGGOaakcqWFZoWzcqGGPaqkaiaawUhacaGL9baadaahaaWcbeqaaiabikdaYaaaaeaacqaIXaqmaeaacqWGUbGBa0GaeyyeIuoakiabc6caUaaa@4F4B@More modern studies employing lognormal distribution ::: AnalysisUsing these, the maximum log likelihood is given as a function of \u03b3 :More modern studies employing lognormal distribution ::: Analysisln\u2061L\u2217\u2217(\u03b3)\u2261ln\u2061sup\u2061\u03bc,\u03c32L(\u03b3,\u03bc,\u03c32)=\u2212n(\u03bc(\u03b3))\u2212n2(1+log\u2061(2\u03c0))MathType@MTEF@+=feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY=wiFfYdH8Gipec8Eeeu0xXdbba9frFj0=OqFfea0dXdd9vqai=hGuQ8kuc9pgc9s8qqaq=dirpe0xb9q8qiLsFr0=vr0=vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacyGGSbaBcqGGUbGBcqWGmbatdaahaaWcbeqaaiabgEHiQiabgEHiQaaakiabcIcaOGGaciab=n7aNjabcMcaPiabggMi6kGbcYgaSjabc6gaUnaaxababaGagi4CamNaeiyDauNaeiiCaahaleaacqWF8oqBcqGGSaalcqWFdpWCdaahaaadbeqaaiabikdaYaaaaSqabaGccqWGmbatcqGGOaakcqWFZoWzcqGGSaalcqWF8oqBcqGGSaalcqWFdpWCdaahaaWcbeqaaiabikdaYaaakiabcMcaPiabg2da9iabgkHiTiabd6gaUjabcIcaOiqb=X7aTzaajaGaeiikaGIae83SdCMaeiykaKIaey4kaSIagiiBaWMaeiOBa4Maf83WdmNbaKaacqGGOaakcqWFZoWzcqGGPaqkcqGGPaqkcqGHsisldaWcaaqaaiabd6gaUbqaaiabikdaYaaacqGGOaakcqaIXaqmcqGHRaWkcyGGSbaBcqGGVbWBcqGGNbWzcqGGOaakcqaIYaGmcqWFapaCcqGGPaqkcqGGPaqkaaa@71A6@More modern studies employing lognormal distribution ::: Analysiswhich is the profile likelihood of \u03b3 ; the estimate of \u03b3 maximizes eqn.(16).", [["\u03b3,\u03bc,\u03c32)=\u2212n(\u03bc(\u03b3))\u2212n2(1+log\u2061(2\u03c0))", "CHEMICAL", 1506, 1537], ["\u03b3", "DNA", 14, 15], ["\u03c3", "CELL_LINE", 65, 66], ["\u03b3", "PROTEIN", 1506, 1507], ["\u03b3", "PROTEIN", 2462, 2463], ["Analysisln\u2061", "TEST", 1475, 1486], ["L\u2217\u2217(", "TEST", 1486, 1490], ["\u2261ln\u2061sup\u2061\u03bc", "TEST", 1492, 1501], ["(\u03bc(\u03b3))\u2212n2(1+log\u2061", "TEST", 1516, 1532]]], ["A Bayesian method was also proposed by Dr. Hill, in addition to the maximum likelihood method [80].The validity of a lognormal assumption ::: AnalysisDespite rigorous studies, it should be noted that we have limited explicit explanations for the biological validity of assuming lognormal distribution for the incubation period.", [["A Bayesian method", "TREATMENT", 0, 17], ["rigorous studies", "TEST", 158, 174]]], ["The fundamental biological reason to assume lognormal distribution is related to an inoculation study of ectromelia virus (mouse pox) [83], which suggested exponential growth of pathogens within the host during the initial phase.", [["ectromelia virus", "ORGANISM", 105, 121], ["mouse pox", "ORGANISM", 123, 132], ["ectromelia virus", "SPECIES", 105, 121], ["mouse", "SPECIES", 123, 128], ["pox", "SPECIES", 129, 132], ["ectromelia virus", "SPECIES", 105, 121], ["mouse", "SPECIES", 123, 128], ["an inoculation study", "TEST", 81, 101], ["ectromelia virus", "PROBLEM", 105, 121], ["exponential growth of pathogens", "PROBLEM", 156, 187], ["ectromelia virus", "OBSERVATION", 105, 121], ["exponential", "OBSERVATION_MODIFIER", 156, 167], ["growth", "OBSERVATION_MODIFIER", 168, 174], ["pathogens", "OBSERVATION", 178, 187]]], ["Another similar study suggested that a fixed threshold likely exists when the host response is observed [84].", [["Another similar study", "TEST", 0, 21], ["a fixed threshold", "PROBLEM", 37, 54]]], ["Based on these findings, pathogen growth in inoculation experiments was modeled using the birth-death process, supporting right skewed distribution of the incubation period and its long tail [85-87].", [["birth-death", "DISEASE", 90, 101], ["these findings", "TEST", 9, 23], ["pathogen growth in inoculation experiments", "PROBLEM", 25, 67], ["pathogen", "OBSERVATION_MODIFIER", 25, 33], ["growth", "OBSERVATION_MODIFIER", 34, 40], ["right", "ANATOMY_MODIFIER", 122, 127]]], ["Also, given similar results from further birth-death process models [76,88] and another previous model [89], what we have learnt to date can be described as follows: if the growth rate of a microorganism is implicitly assumed to follow normal distribution, and if there is a fixed threshold of pathogen load at which symptoms are revealed due to the host response, exponential growth of microorganisms should result in an incubation period sufficiently approximated by lognormal distribution.The validity of a lognormal assumption ::: AnalysisGiven the above reasonable explanations, a previous Japanese study examined 86 outbreak records for which the date of infection was known and the population exposed was homogeneous [90].", [["death", "DISEASE", 47, 52], ["infection", "DISEASE", 661, 670], ["the growth rate", "TEST", 169, 184], ["a microorganism", "PROBLEM", 188, 203], ["pathogen load", "PROBLEM", 294, 307], ["symptoms", "PROBLEM", 317, 325], ["the host response", "PROBLEM", 346, 363], ["exponential growth of microorganisms", "PROBLEM", 365, 401], ["a previous Japanese study", "TEST", 584, 609], ["infection", "PROBLEM", 661, 670], ["infection", "OBSERVATION", 661, 670]]], ["By assessing the goodness-of-fit, 61 out of the 86 examples (70.9%) were accepted as lognormal at a 5% level of significance or better, from which it was concluded that, in general, lognormal distribution represents the incubation period of acute infectious diseases [90,91].", [["infectious diseases", "DISEASE", 247, 266], ["acute infectious diseases", "PROBLEM", 241, 266], ["acute", "OBSERVATION_MODIFIER", 241, 246], ["infectious", "OBSERVATION", 247, 257]]], ["It may also be true that the lognormal distribution was preferred because of its statistical usefulness (as described in the above Japanese study).", [["the above Japanese study", "TEST", 121, 145], ["may also be", "UNCERTAINTY", 3, 14], ["lognormal distribution", "OBSERVATION", 29, 51]]], ["However, the host-defense mechanism, which is almost entirely responsible for symptom onset, was later shown to be far more complex than previously expected.", [["symptom", "PROBLEM", 78, 85], ["host-", "OBSERVATION_MODIFIER", 13, 18], ["defense mechanism", "OBSERVATION", 18, 35], ["more complex", "OBSERVATION_MODIFIER", 119, 131]]], ["For example, fever is induced by very complex reactions and by several factors including circulating cytokines such as interluekin-2 [92].", [["fever", "DISEASE", 13, 18], ["interluekin-2", "GENE_OR_GENE_PRODUCT", 119, 132], ["circulating cytokines", "PROTEIN", 89, 110], ["interluekin", "PROTEIN", 119, 130], ["fever", "PROBLEM", 13, 18], ["very complex reactions", "PROBLEM", 33, 55], ["circulating cytokines", "TREATMENT", 89, 110], ["interluekin", "TEST", 119, 130], ["fever", "OBSERVATION", 13, 18]]], ["Thus, whereas lognormal distribution may be applied to the incubation periods of many acute infectious diseases, it is necessary to bear in mind that the assumption is supported only by previous experience.A further critique of the lognormal assumption ::: AnalysisUntil recently, the validity of assuming lognormal distribution has not been explicitly compared with that of other distributions.", [["infectious diseases", "DISEASE", 92, 111], ["many acute infectious diseases", "PROBLEM", 81, 111], ["many", "OBSERVATION_MODIFIER", 81, 85], ["acute", "OBSERVATION_MODIFIER", 86, 91], ["infectious", "OBSERVATION", 92, 102], ["lognormal distribution", "OBSERVATION", 306, 328]]], ["As discussed above, Weibull distribution with a threshold (i.e., three parameter Weibull distribution) was assumed for the incubation period of influenza [35].", [["influenza", "DISEASE", 144, 153], ["influenza", "PROBLEM", 144, 153]]], ["Such study indicates that a simple lognormal assumption does not always hold in practice.", [["Such study", "TEST", 0, 10], ["a simple lognormal assumption", "PROBLEM", 26, 55]]], ["Other studies have assumed gamma distribution for the incubation periods of SARS and smallpox [24,30,93-95], and regarding the latter, lognormal distribution has also been assumed [25,96].", [["SARS", "DISEASE", 76, 80], ["smallpox", "DISEASE", 85, 93], ["Other studies", "TEST", 0, 13], ["SARS", "PROBLEM", 76, 80], ["smallpox", "PROBLEM", 85, 93], ["gamma distribution", "OBSERVATION", 27, 45]]], ["Figure 5 compares the quantile plots of lognormal and gamma distribution for the incubation period of smallpox, showing that both fit almost equally well with the observed data.", [["smallpox", "PROBLEM", 102, 110]]], ["For both distributions, the \u03c72 goodness-of-fit test revealed no significant deviation between the observed and predicted values (\u03c7212 = 11.6, p = 0.48 and \u03c7212 = 16.8, p = 0.16 for lognormal and gamma distributions, respectively).", [["the \u03c72 goodness", "TEST", 24, 39], ["fit test", "TEST", 43, 51], ["significant deviation", "PROBLEM", 64, 85], ["p", "TEST", 142, 143], ["p", "TEST", 168, 169], ["lognormal and gamma distributions", "TEST", 181, 214], ["no", "UNCERTAINTY", 61, 63], ["significant", "OBSERVATION_MODIFIER", 64, 75], ["deviation", "OBSERVATION", 76, 85], ["gamma distributions", "OBSERVATION", 195, 214]]], ["However, two-parameter Weibull distribution did not represent well the probability density functions of the incubation period (p < 0.001).", [["probability density", "OBSERVATION", 71, 90]]], ["These discussions imply that comparisons using different distributions are needed; it is important to at least compare the goodness-of-fit of different and arbitrarily chosen distributions for acute infectious diseases.A further critique of the lognormal assumption ::: AnalysisThe validity of lognormal assumption is particularly lacking for slowly progressing diseases.", [["infectious diseases", "DISEASE", 199, 218], ["the goodness", "TEST", 119, 131], ["acute infectious diseases", "PROBLEM", 193, 218], ["Analysis", "TEST", 270, 278], ["slowly progressing diseases", "PROBLEM", 343, 370], ["acute", "OBSERVATION_MODIFIER", 193, 198], ["infectious", "OBSERVATION", 199, 209]]], ["One important reason for this is that the mechanisms of disease development for AIDS and prion diseases, for example, are far more complicated than those of acute infectious diseases.", [["AIDS", "DISEASE", 80, 84], ["prion diseases", "DISEASE", 89, 103], ["infectious diseases", "DISEASE", 163, 182], ["disease development", "PROBLEM", 56, 75], ["AIDS", "PROBLEM", 80, 84], ["prion diseases", "PROBLEM", 89, 103], ["acute infectious diseases", "PROBLEM", 157, 182], ["disease", "OBSERVATION", 56, 63], ["acute", "OBSERVATION_MODIFIER", 157, 162], ["infectious", "OBSERVATION", 163, 173]]], ["In the case of AIDS, where Weibull distribution is frequently assumed for the incubation period [15], symptom onset is induced by immunodeficiency resulting from HIV infection followed by various opportunistic infections.", [["AIDS", "DISEASE", 15, 19], ["immunodeficiency", "DISEASE", 130, 146], ["HIV infection", "DISEASE", 162, 175], ["opportunistic infections", "DISEASE", 196, 220], ["HIV", "ORGANISM", 162, 165], ["HIV", "SPECIES", 162, 165], ["AIDS", "PROBLEM", 15, 19], ["symptom onset", "PROBLEM", 102, 115], ["immunodeficiency", "PROBLEM", 130, 146], ["HIV infection", "PROBLEM", 162, 175], ["various opportunistic infections", "PROBLEM", 188, 220], ["HIV infection", "OBSERVATION", 162, 175], ["opportunistic", "OBSERVATION_MODIFIER", 196, 209], ["infections", "OBSERVATION", 210, 220]]], ["For BSE and vCJD, various distributions have been assumed for the backcalculation, permitting some uncertainty analyses [19,20,22,97].", [["vCJD", "DISEASE", 12, 16], ["BSE", "PROBLEM", 4, 7], ["vCJD", "PROBLEM", 12, 16], ["the backcalculation", "PROBLEM", 62, 81], ["vCJD", "OBSERVATION", 12, 16]]], ["Although the disease mechanisms of vCJD are yet to be clarified, considering within-host dynamics it is evident that the incubation period cannot be explained by the above simple explanation [98,99].", [["vCJD", "DISEASE", 35, 39], ["the disease mechanisms of vCJD", "PROBLEM", 9, 39], ["disease", "OBSERVATION", 13, 20]]], ["That is, for these diseases, the above mentioned explanation for the lognormal assumption is not justified, and thus, the choice of distribution for the incubation period needs to be carefully assessed using sensitivity and uncertainty analyses.", [["these diseases", "PROBLEM", 13, 27], ["sensitivity", "TEST", 208, 219], ["uncertainty analyses", "TEST", 224, 244]]], ["Indeed, various right skewed distributions are often used in sensitivity analysis, revealing whether or not the final results depend on the arbitrarily chosen standard distribution for the incubation period [19,20,97].A further critique of the lognormal assumption ::: AnalysisTwo conclusions can be drawn from the above discussions.", [["sensitivity analysis", "TEST", 61, 81], ["Analysis", "TEST", 269, 277], ["right", "ANATOMY_MODIFIER", 16, 21]]], ["Thus, as far as we continue to rely on observed frequencies and arbitrarily chosen specific distributions, it is essential that comparisons using different distributions are made; any assumptions should be explicitly evaluated by means of significance tests and visual assessments.", [["significance tests", "TEST", 239, 257], ["visual assessments", "TEST", 262, 280]]], ["For example, within-host dynamics would help clarify disease onset mechanisms in the most explicit way [102].", [["disease onset mechanisms", "PROBLEM", 53, 77]]], ["Moreover, if information associated with within-host dynamics is not available, an accumulation of distributions obtained using different datasets would be of interest, as would examination of various characteristic factors (e.g., dose-response mechanisms [6,7,9], and variable susceptibility due to age, race and genetic factors (for example, see [45,94])).ConclusionThe present study revisited previous works concerned with models of the incubation period of acute infectious diseases.", [["infectious diseases", "DISEASE", 467, 486], ["examination", "TEST", 178, 189], ["response mechanisms", "TEST", 236, 255], ["variable susceptibility", "PROBLEM", 269, 292], ["The present study", "TEST", 368, 385], ["acute infectious diseases", "PROBLEM", 461, 486], ["acute", "OBSERVATION_MODIFIER", 461, 466], ["infectious", "OBSERVATION", 467, 477]]], ["In particular, the following were highlighted: (i) the earliest modeling effort conducted using incomplete data of a pandemic influenza, (ii) the explicit distribution of the incubation period, (iii) the application of a lognormal assumption to estimations of the time of exposure during a point source outbreak, and (iv) the validity of assuming lognormal distribution for the incubation period.", [["influenza", "DISEASE", 126, 135], ["a pandemic influenza", "PROBLEM", 115, 135]]], ["Although it was not highlighted in the present paper, Norman T. J. Bailey also formed a framework using a chain binomial model, which is useful for household transmission data [103,104].", [["a chain binomial model", "TREATMENT", 104, 126]]], ["This method estimates the incubation period as the sum of the mean latent period, which follows normal distribution, and a further fixed infectious period; however, the estimated period does not precisely imply the incubation period, but rather is closer to what is presently referred to as the serial interval [48,105].", [["infectious", "OBSERVATION", 137, 147]]], ["That is, the incubation period that can be extracted from household transmission data remains to be clarified.ConclusionThe lessons that can be learnt from the presented discussion are as follows: (I) although it is historically remarkable that the incubation period of pandemic influenza was assessed based on an explicit understanding of an unknown time of exposure, the assumed periods of exposure were too long and equal probability of exposure was assumed for each possible date.", [["influenza", "DISEASE", 279, 288], ["pandemic influenza", "PROBLEM", 270, 288]]], ["Well-defined short periods of exposure are needed to decipher the incubation period distribution using appropriate statistical methods.", [["-defined", "OBSERVATION_MODIFIER", 4, 12], ["short", "OBSERVATION_MODIFIER", 13, 18]]], ["Taking this point into account will be critically important in estimating the incubation period of newly emerging diseases in the future.", [["newly emerging diseases", "PROBLEM", 99, 122]]], ["(II) The epidemiologic usefulness of the lognormal assumption was highlighted with respect to the basic characteristics of lognormal distribution, but this assumption is likely to remain unwarrantable until details of disease mechanisms are fully clarified; thus, this assumption may be merely an approximation of the right-skewed distribution.", [["the lognormal assumption", "TEST", 37, 61], ["disease mechanisms", "PROBLEM", 218, 236], ["lognormal distribution", "OBSERVATION", 123, 145], ["approximation", "OBSERVATION", 297, 310], ["right", "ANATOMY_MODIFIER", 318, 323], ["skewed", "OBSERVATION_MODIFIER", 324, 330], ["distribution", "OBSERVATION_MODIFIER", 331, 343]]], ["For example, considering the mechanisms of disease development, the lognormal assumption does not hold for HIV/AIDS and prion diseases.", [["HIV/AIDS", "DISEASE", 107, 115], ["prion diseases", "DISEASE", 120, 134], ["HIV", "SPECIES", 107, 110], ["disease development", "PROBLEM", 43, 62], ["HIV", "PROBLEM", 107, 110], ["AIDS", "PROBLEM", 111, 115], ["prion diseases", "PROBLEM", 120, 134], ["disease", "OBSERVATION", 43, 50]]], ["Various datasets on the same disease would also help assess the uncertainty.", [["the same disease", "PROBLEM", 20, 36]]], ["Ideally, assumptions in the future should be supported by a detailed understanding of the underlying disease mechanisms provided by observations of within-host dynamics.", [["the underlying disease mechanisms", "PROBLEM", 86, 119]]], ["Since the incubation period of infectious diseases is directly relevant to prevention and control, and because such knowledge can enhance our theoretical understanding of the spread of disease, further clarifications of the above points are deemed necessary.AbbreviationsAIDS \u2013 Acquired Immunodeficiency SyndromeAbbreviationsCV \u2013 Coefficient of variationAbbreviationsHIV \u2013 Human Immunodeficiency VirusAbbreviationspdf \u2013 Probability density functionAbbreviationsSARS \u2013 Severe Acute Respiratory SyndromeAbbreviationsvCJD \u2013 variant Creutzfeldt-Jakob diseaseCompeting interestsThe author(s) declare that they have no competing interests.Authors' contributionsHN carried out paper reviews, proposed the study, performed mathematical analyses and drafted the manuscript.", [["infectious diseases", "DISEASE", 31, 50], ["Acquired Immunodeficiency SyndromeAbbreviationsCV", "DISEASE", 278, 327], ["Human", "ORGANISM", 373, 378], ["Human", "SPECIES", 373, 378], ["infectious diseases", "PROBLEM", 31, 50], ["disease", "PROBLEM", 185, 192], ["the above points", "TREATMENT", 220, 236], ["AbbreviationsAIDS", "TEST", 258, 275], ["Acquired Immunodeficiency SyndromeAbbreviationsCV", "PROBLEM", 278, 327], ["variationAbbreviationsHIV", "TEST", 345, 370], ["Human Immunodeficiency VirusAbbreviationspdf", "PROBLEM", 373, 417], ["Probability density function", "PROBLEM", 420, 448], ["AbbreviationsSARS", "TEST", 448, 465], ["Severe Acute Respiratory SyndromeAbbreviationsvCJD", "PROBLEM", 468, 518], ["Creutzfeldt", "PROBLEM", 529, 540], ["Jakob diseaseCompeting interests", "PROBLEM", 541, 573], ["the study", "TEST", 694, 703], ["mathematical analyses", "TEST", 715, 736], ["infectious", "OBSERVATION", 31, 41], ["Severe", "OBSERVATION_MODIFIER", 468, 474], ["Acute", "OBSERVATION_MODIFIER", 475, 480], ["Respiratory SyndromeAbbreviationsvCJD", "OBSERVATION", 481, 518]]]], "71a69ee751988f710ff8942cc05b2daf61af6b5e": [["BackgroundPublic health emergencies have increased in recent years and have shown a trend of causing considerable damage [1] .", [["considerable damage", "PROBLEM", 101, 120], ["increased", "OBSERVATION_MODIFIER", 41, 50]]], ["According to the emergency events database (EM-DAT), the most widely used and influential disaster database in the world, the average number of deaths per major public health event was more than 10,000 [2] .", [["deaths", "DISEASE", 144, 150]]], ["Population growth, urban development, migration, and other issues brought about by globalization have sped up the incidence of public health events, such as epidemics [3, 4] .", [["Population growth", "PROBLEM", 0, 17], ["growth", "OBSERVATION_MODIFIER", 11, 17], ["migration", "OBSERVATION_MODIFIER", 38, 47]]], ["Public health events also propelled the process of emergency management, giving top priority to changes in emergency operations.", [["emergency management", "TREATMENT", 51, 71], ["emergency operations", "TREATMENT", 107, 127]]], ["The outbreak of coronavirus disease 2019 in China spread rapidly throughout the world in a short time, which illustrated the need to build a resilient health emergency system that can withstand epidemics [5] .BackgroundPublic health emergency management (PHEM) is a relatively new field that draws on specific sets of knowledge, techniques, and organizing principles found in emergency management [6] .", [["coronavirus disease", "DISEASE", 16, 35], ["coronavirus", "SPECIES", 16, 27], ["coronavirus disease", "PROBLEM", 16, 35], ["coronavirus disease", "OBSERVATION", 16, 35]]], ["Specifically, it includes public health emergency planning, organization, leadership, coordination, control, evaluation, prevention, preparation, and response [7] .", [["evaluation", "TEST", 109, 119]]], ["For COVID-19, China's PHEM system quickly took the following measures: emergency mobilization measures within the government, lockdown of cities and communities, nationwide medical mobilization, provision of financial support, preferential policies for the medical community and pharmaceutical industry, and the categorical comprehensive publicity to spread prevention and treatment knowledge [8] .", [["COVID", "TEST", 4, 9], ["China's PHEM system", "TREATMENT", 14, 33], ["emergency mobilization measures", "TREATMENT", 71, 102], ["medical mobilization", "TREATMENT", 173, 193], ["financial support", "TREATMENT", 208, 225]]], ["These measures effectively reduced the spread of the disease.", [["the disease", "PROBLEM", 49, 60], ["reduced", "OBSERVATION_MODIFIER", 27, 34], ["spread", "OBSERVATION_MODIFIER", 39, 45], ["disease", "OBSERVATION", 53, 60]]], ["Given the weaknesses and deficiencies exposed by the COVID-19 outbreak, people have recognized the need to improve the national PHEM system [10, 11] .BackgroundA growing body of research has studied PHEM from different perspectives, mainly those of institutions, funds, technologies, and laws.", [["people", "ORGANISM", 72, 78], ["people", "SPECIES", 72, 78], ["the weaknesses", "PROBLEM", 6, 20], ["deficiencies", "PROBLEM", 25, 37], ["growing", "OBSERVATION_MODIFIER", 162, 169]]], ["The public health emergency was a severe challenge to health institutions such as hospitals, the Centers for Disease Control and Prevention (CDC), and governments [7, 12] .", [["Disease Control", "TREATMENT", 109, 124]]], ["The solutions to these challenges were characterized by sustainability, redundancy, and flexibility [13] .", [["The solutions", "TREATMENT", 0, 13]]], ["Monetary and technology resources can merge the roles and responsibilities of public health preparedness and emergency management [14] .", [["emergency management", "TREATMENT", 109, 129]]], ["Severe deficiencies in legal preparedness can undermine effective responses to public health emergencies [15, 16] .", [["Severe deficiencies", "PROBLEM", 0, 19], ["deficiencies", "OBSERVATION", 7, 19]]], ["Additionally, many countries took corresponding measures to strengthen the emergency management of public health.", [["the emergency management", "TREATMENT", 71, 95]]], ["In March 2018, the Ministry of Emergency Management of the People's Republic of China was established, which was an integral part of the State Council.", [["People", "SPECIES", 59, 65]]], ["Thus, we can see that PHEM is still a timely topic for scholars and governments [18, 19] .BackgroundHowever, there are still some problems that need to be solved.", [["still some problems", "PROBLEM", 119, 138]]], ["To the best of our knowledge, there is little evidence about the differences that occurred between international and Chinese PHEM.", [["little evidence about", "UNCERTAINTY", 39, 60]]], ["It is necessary to sort out the characteristics of the development of PHEM and explore the hotspots of PHEM research.", [["PHEM", "CANCER", 70, 74], ["PHEM", "PROBLEM", 70, 74]]], ["Study conclusions are helpful to draw people's attention to public health emergencies, provide a reference for scholars to understand the current situation and trends of PHEM, and for government departments to formulate guidance strategies.Data sourcesData were divided into two categories: international and Chinese data.", [["people", "ORGANISM", 38, 44], ["people", "SPECIES", 38, 44]]], ["According to the relevant authoritative research [20] , the database of bibliometric methods should contain complete documents.", [["bibliometric methods", "TREATMENT", 72, 92]]], ["A considerable amount of literature has shown that the Web of Science (WoS) is the largest comprehensive academic information resource, covering peer-reviewed journals with high impact factors [21] [22] [23] [24] .", [["[21] [22] [23", "SIMPLE_CHEMICAL", 193, 206], ["high impact factors", "PROBLEM", 173, 192], ["considerable", "OBSERVATION_MODIFIER", 2, 14], ["amount", "OBSERVATION_MODIFIER", 15, 21], ["largest", "OBSERVATION_MODIFIER", 83, 90]]], ["Accordingly, the international data used for our study were collected from the WoS Core Collection, including Science Citation Index Expanded (SCI-E), Science Citation Index Expanded (SSCI), and Arts & Humanities Citation Index (A&HCI) databases.", [["the international data", "TEST", 13, 35], ["our study", "TEST", 45, 54], ["Science Citation Index", "TEST", 110, 132], ["SSCI", "TEST", 184, 188]]], ["Chinese data were downloaded from the China National Knowledge Infrastructure (CNKI), which had the largest Chinese journal full-text database, including the vast majority of Chinese journals relating to public health management.", [["Chinese data", "TEST", 0, 12], ["public health management", "TREATMENT", 204, 228]]], ["More importantly, it has become one of the critical basic data sources for bibliometric research in China [25] .Data retrievalData obtained by inappropriate literature information retrieval strategies could not accurately reflect the content of the research [26] .", [["Data retrievalData", "TEST", 112, 130], ["retrieval strategies", "TREATMENT", 180, 200]]], ["Emergency management is a common term in China that focuses on the occurrence, development, and evolution of emergencies and finding effective ways of responding to them [27] .", [["Emergency management", "TREATMENT", 0, 20]]], ["After consulting the experts from the Chinese CDC who once worked for the World Health Organization (WHO), we learned that the management was refined by preparedness, operation, response, and recovery for an international public health emergency.", [["the management", "TREATMENT", 123, 137]]], ["A total of 2759 articles from 1991 to 2018 were retained from WoS, while 999 articles from 2003 to 2018 were retained from CNKI.Data retrievalAfter discussing the results with the team members, we further selected the articles based on inclusion and exclusion criteria to ensure that all of the data were closely aligned to the study targets.", [["CNKI", "DNA", 123, 127], ["Data retrieval", "TEST", 128, 142], ["exclusion criteria", "TEST", 250, 268], ["the data", "TEST", 291, 299], ["the study targets", "TEST", 324, 341], ["total", "OBSERVATION_MODIFIER", 2, 7]]], ["The inclusion criteria were as follows: (1) occurrence, development, and evolution of PHEM; (2) prevention, preparedness, response, operation, and recovery of the PHEM system; (3) planning, organization, leadership, coordination, and control of public health emergencies; and (4) practice and method of PHEM.", [["PHEM", "DISEASE", 86, 90], ["The inclusion criteria", "TEST", 0, 22], ["operation", "TREATMENT", 132, 141]]], ["The exclusion criteria were as follows: (1) health care, medical record management, or disease treatment; (2) guidelines on the action, proceedings paper or book chapter, interviews, summaries of conferences, and patent abstracts.", [["medical record management", "TREATMENT", 57, 82], ["disease treatment", "TREATMENT", 87, 104], ["patent", "OBSERVATION", 213, 219]]], ["Finally, 2247 international articles and 959 Chinese articles were accepted for the analysis after data filtering and removing duplications.", [["the analysis", "TEST", 80, 92], ["duplications", "TREATMENT", 127, 139]]], ["The international articles were downloaded in \"plain text\" format with a full record and cited references for classification and statistical analysis.", [["statistical analysis", "TEST", 129, 149]]], ["Accordingly, we obtained the data for this study.", [["this study", "TEST", 38, 48]]], ["Figure 1 shows the specific search steps.Data analysis toolsWe used CiteSpace 5.5.", [["Data analysis", "TEST", 41, 54], ["CiteSpace", "TREATMENT", 68, 77]]], ["R2 and Microsoft Excel 2016 for the data analysis.", [["R2", "DNA", 0, 2], ["the data analysis", "TEST", 32, 49]]], ["CiteSpace was a free Java-based application found by Chaomei Chen to analyze the potential knowledge contained in the scientific literature.", [["CiteSpace", "TREATMENT", 0, 9]]], ["It has been widely adopted for scientometric analysis in various scientific fields [29] , and has achieved excellent results [30, 31] .", [["scientometric analysis", "TEST", 31, 53]]], ["The parameters of CiteSpace for this study were set as follows: time slicing (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) (2016) (2017) (2018) , respectively), years per slice (1), term source (all selection), node type (author, institution, keyword, for Chinese and international data; country for international data), selection criteria (top 50), and visualization (cluster viewstatic, show merged network).", [["CiteSpace", "TREATMENT", 18, 27], ["this study", "TEST", 32, 42], ["selection criteria", "TEST", 366, 384], ["visualization", "TEST", 399, 412], ["node", "ANATOMY", 256, 260]]], ["Microsoft Excel 2016 was used for temporal distribution and polynomial prediction of the number of articles.", [["temporal distribution", "PROBLEM", 34, 55], ["polynomial prediction", "OBSERVATION", 60, 81]]], ["It should be noted that the results of the CNKI database made by CiteSpace were presented in Chinese.", [["the CNKI database", "TEST", 39, 56]]], ["To make it easier to read, we translated the Chinese results into English.Data analysis strategiesThis study involved using bibliometric and mapping knowledge domain analysis methods.", [["Data analysis", "TEST", 74, 87], ["This study", "TEST", 98, 108], ["bibliometric and mapping knowledge domain analysis methods", "TEST", 124, 182]]], ["Bibliometric methods provided an approach to identify the development trends or future research orientations by combining different tools and methods to analyze the articles [32, 33] .", [["an approach", "TREATMENT", 30, 41]]], ["We were mainly engaged in cooperation network analysis (including the network analysis of the authors, institutions, and countries) and co-word network analysis (including keyword co-occurrence network and burst detection analysis) in the mapping knowledge domain analysis.", [["cooperation network analysis", "TEST", 26, 54], ["co-word network analysis", "TEST", 136, 160], ["burst detection analysis", "TEST", 206, 230], ["the mapping knowledge domain analysis", "TEST", 235, 272]]], ["First, we performed a statistical analysis of the temporal distribution of relevant articles.", [["a statistical analysis", "TEST", 20, 42], ["temporal", "ANATOMY_MODIFIER", 50, 58], ["relevant articles", "OBSERVATION", 75, 92]]], ["Then, we made a polynomial prediction of the number of articles, fitted the trend line of international and Chinese study, and predicted it for the next 3 years.", [["Chinese study", "TEST", 108, 121]]], ["Betweenness centrality is an index to measure the importance of nodes in the network.", [["nodes", "OBSERVATION", 64, 69]]], ["The purple circle represents documents with betweenness centrality not less than 0.1, which means that the authors, institutions, or countries occupied an essential position in this field [20, 36] .", [["betweenness centrality", "TEST", 44, 66], ["purple circle", "OBSERVATION", 4, 17], ["essential", "OBSERVATION_MODIFIER", 155, 164], ["position", "OBSERVATION_MODIFIER", 165, 173]]], ["Co-word analysis was a content analysis technique that was effective for mapping co-occurrence relationships and the strength of the relationship between a pair of items existing in the same text, revealing the inner construction of a research field [24] .", [["word analysis", "TEST", 3, 16], ["a content analysis technique", "TEST", 21, 49]]], ["In addition, keyword burst detection analysis can clearly grasp articles that receive particular attention from related scientific communities in a certain period.", [["keyword burst detection analysis", "TEST", 13, 45]]], ["Therefore, the frontiers founded by burst detection analysis can provide researchers with up- to-date information [39, 40] .", [["burst detection analysis", "TEST", 36, 60]]], ["The analysis of the highly cited articles in the field can reflect the development of the discipline in a period, examine timely topics, and supplement the above results to provide a reference for topic selection by scientific researchers [41] .ResultsTemporal distribution analysis countries, yet a large number of Chinese scholars participated in this study at the beginning.ResultsAfter the descriptive analysis of the data, we conducted a polynomial prediction analysis of the number of articles and predicted it for the next 3 years.", [["The analysis", "TEST", 0, 12], ["this study", "TEST", 349, 359], ["a polynomial prediction analysis", "TEST", 441, 473], ["large", "OBSERVATION_MODIFIER", 300, 305], ["number", "OBSERVATION_MODIFIER", 306, 312]]], ["The trend of chronological distribution of articles related to PHEM in international data can be expressed as follows: y = 0.2790x 2 + 0.7688x\u22127.7708 (R 2 = 0.9577), while Chinese data was y = \u22120.0345x 3 + 1.5079x 2 \u221214.142x + 27.273 (R 2 = 0.9251).", [["PHEM", "DNA", 63, 67], ["Chinese data", "TEST", 172, 184]]], ["R 2 > 0.9, indicating a good degree of fit.", [["good degree", "OBSERVATION_MODIFIER", 24, 35], ["fit", "OBSERVATION", 39, 42]]], ["The chronological distribution of international articles showed a trend of increasing year by year.", [["increasing", "OBSERVATION_MODIFIER", 75, 85]]], ["At the same time, the trend line of Chinese articles, such as a wave line, and the number of articles will continue to decrease over the next 3 years.", [["a wave line", "TREATMENT", 62, 73], ["Chinese articles", "OBSERVATION", 36, 52], ["wave line", "OBSERVATION", 64, 73]]], ["In Fig. 4 , the top-ranked item for Chinese scholars by citation count was Qunhong Wu with a citation count of 22.", [["a citation count", "TEST", 91, 107]]], ["She was followed by Yanhua Hao (17), Feng Han (11), Ning (10), Yadong Wang (10), Zheng Kang (8), Ying Liu (6), Jincheng Ma (6), Mingli Jiao (5), and Libo Liang (5) .", [["She", "ORGANISM", 0, 3], ["Zheng Kang", "TREATMENT", 81, 91], ["Jincheng Ma", "TREATMENT", 111, 122], ["Mingli Jiao", "TREATMENT", 128, 139], ["Libo Liang", "TREATMENT", 149, 159]]], ["The top-ranked items by centrality were Yanhua Hao and Ning, with a centrality of 0.02.", [["top", "OBSERVATION_MODIFIER", 4, 7]]], ["Their nodes' centrality is also less than 0.1.", [["nodes", "ANATOMY", 6, 11], ["nodes", "MULTI-TISSUE_STRUCTURE", 6, 11], ["Their nodes' centrality", "TEST", 0, 23], ["nodes", "OBSERVATION", 6, 11]]], ["In terms of the quantity and quality of articles, Qunhong Wu and Yanhua Hao were the leaders of PHEM in China.", [["quantity", "OBSERVATION_MODIFIER", 16, 24]]], ["The top-ranked item by international citation count was the Centers for Disease Control and Prevention (Ctr Dis Control & Prevent.), with citation counts of 255, which means that the institution publishes the largest number of articles in this field.", [["international citation count", "TEST", 23, 51], ["Disease Control", "TREATMENT", 72, 87], ["Prevention (Ctr Dis Control", "TREATMENT", 92, 119], ["citation counts", "TEST", 138, 153], ["top", "OBSERVATION_MODIFIER", 4, 7], ["largest", "OBSERVATION_MODIFIER", 209, 216], ["number", "OBSERVATION_MODIFIER", 217, 223]]], ["The second one was Johns Hopkins University (Johns Hopkins Univ.), with citation counts of 92, which means that Johns Hopkins University had the largest number of articles published among the universities in this field.", [["citation counts", "TEST", 72, 87], ["largest", "OBSERVATION_MODIFIER", 145, 152]]], ["The above analysis showed that the CDC and universities were the leading institutions to study international PHEM.", [["The above analysis", "TEST", 0, 18]]], ["The centrality ranked item was CDC (0.50).", [["CDC", "TEST", 31, 34]]], ["The centrality of all these nodes was no less than 0.1 with the purple circle, which meant that they were the institutions with higher publication quality and the leading institutions in this field.", [["nodes", "MULTI-TISSUE_STRUCTURE", 28, 33], ["centrality", "OBSERVATION_MODIFIER", 4, 14], ["all", "OBSERVATION_MODIFIER", 18, 21], ["nodes", "OBSERVATION", 28, 33], ["no", "UNCERTAINTY", 38, 40], ["less", "OBSERVATION_MODIFIER", 41, 45]]], ["The top-ranked item by citation count in the Chinese database was the School of Health Management, Harbin Medical University, with a citation count of 20, followed by Shanghai Publishing and Printing College (9) Table S3 , Table S4 , and Figure S2 ).", [["citation count", "TEST", 23, 37], ["a citation count", "TEST", 131, 147], ["top", "OBSERVATION_MODIFIER", 4, 7]]], ["Among these countries, the USA was the most productive, far ahead of the rest in this field, and its centrality was the largest.", [["productive", "OBSERVATION_MODIFIER", 44, 54], ["largest", "OBSERVATION_MODIFIER", 120, 127]]], ["This showed that in the field of PHEM, the USA carries out the most studies, and their studies were more advanced.", [["the most studies", "TEST", 59, 75], ["their studies", "TEST", 81, 94]]], ["It is worth noting that although the number of articles from Switzerland (44) and Sweden (34) was much lower than that of the USA, the articles' centrality of these two countries was more than 0.10, which showed that the quality of the articles was still high.Co-word network analysis Keywords co-occurrence network analysisGenerally, keywords represent the research hotspots, which represent topics of wide concern for researchers in this field.", [["network analysis", "TEST", 308, 324]]], ["Figure 7 shows that the top 10 keywords ranked by citation count for the international database were public health (297), preparedness (215), emergency preparedness ( preparedness and monitoring for public health events, while Chinese research mainly focuses on analysis and disposition (Additional file 1: Table S5, Table S6 , and Figure S3 ).", [["S6", "PROTEIN", 323, 325], ["citation count", "TEST", 50, 64], ["public health events", "PROBLEM", 199, 219]]], ["To further explain the above research hotspots, the top 8 cited articles are shown in Tables 2 and 3 article Elevated blood lead levels in children associated with the flint drinking water crisis: a spatial analysis of risk and public health response was the most cited (372) international article [43] followed by The 2006 California Heat Wave: Impacts on Hospitalizations and Emergency department visits [44] .", [["blood", "ANATOMY", 118, 123], ["blood", "ORGANISM_SUBSTANCE", 118, 123], ["children", "ORGANISM", 139, 147], ["children", "SPECIES", 139, 147], ["Elevated blood lead levels", "PROBLEM", 109, 135]]], ["This was basically consistent with the analysis results of the above research keywords.", [["the analysis", "TEST", 35, 47]]], ["This was followed by Kaibin Zhong's article Review and prospect: construction of emergency management system in China [52] .", [["emergency management system", "TREATMENT", 81, 108]]], ["The next three articles, Legislative situation and characteristics of China's emergencyDiscussionInternational research on PHEM occurred earlier than the Chinese research, and it has been growing over time.", [["growing", "OBSERVATION_MODIFIER", 188, 195]]], ["In 1991, the first article on PHEM was written by Richard L. Siegel and was titled Code 9: a systematic approach for responding to medical emergencies occurring in and around a hospital [56] .", [["PHEM", "CANCER", 30, 34]]], ["It mentioned the need for an organized system to respond to such emergencies involving patients, visitors, local community residents, and hospital employees, both inside the hospital and on the grounds surrounding the building.", [["patients", "ORGANISM", 87, 95], ["patients", "SPECIES", 87, 95]]], ["Since then, academia has begun to pay attention to emergency management of public health incidents.", [["emergency management", "TREATMENT", 51, 71]]], ["The number of international articles is increasing gradually, reaching the maximum in 2017, and it is expected to continue to grow in the next 3 years.", [["number", "OBSERVATION_MODIFIER", 4, 10], ["international articles", "OBSERVATION", 14, 36], ["increasing", "OBSERVATION_MODIFIER", 40, 50], ["gradually", "OBSERVATION_MODIFIER", 51, 60]]], ["The development of PHEM in China shows a fluctuating pattern.", [["PHEM", "CHEMICAL", 19, 23], ["PHEM", "OBSERVATION", 19, 23], ["fluctuating pattern", "OBSERVATION", 41, 60]]], ["It is likely related to the number of significant events that occur in each year [57] .", [["significant events", "PROBLEM", 38, 56], ["likely related to", "UNCERTAINTY", 6, 23]]], ["The severe acute respiratory syndrome (SARS) epidemic in 2003 resulted in significant increases in both the amount of research and articles on emergency management [7] .", [["acute respiratory syndrome", "DISEASE", 11, 37], ["SARS", "DISEASE", 39, 43], ["The severe acute respiratory syndrome", "PROBLEM", 0, 37], ["SARS", "PROBLEM", 39, 43], ["significant increases", "PROBLEM", 74, 95], ["emergency management", "TREATMENT", 143, 163], ["severe", "OBSERVATION_MODIFIER", 4, 10], ["acute", "OBSERVATION_MODIFIER", 11, 16], ["respiratory syndrome", "OBSERVATION", 17, 37], ["significant", "OBSERVATION_MODIFIER", 74, 85], ["increases", "OBSERVATION_MODIFIER", 86, 95], ["amount", "OBSERVATION_MODIFIER", 108, 114]]], ["The number of articles reached a small climax in 2008.", [["small", "OBSERVATION_MODIFIER", 33, 38], ["climax", "OBSERVATION_MODIFIER", 39, 45]]], ["Events such as the Wenchuan earthquake and the southern snow disaster occurred in that year.", [["earthquake", "DISEASE", 28, 38]]], ["The maximum was in 2013, with human infection from H7N9, the Ya'an earthquake, and death from a hepatitis B vaccine occurring that year.", [["infection", "DISEASE", 36, 45], ["Ya'an earthquake", "DISEASE", 61, 77], ["death", "DISEASE", 83, 88], ["hepatitis B", "DISEASE", 96, 107], ["human", "ORGANISM", 30, 35], ["hepatitis B", "ORGANISM", 96, 107], ["human", "SPECIES", 30, 35], ["human", "SPECIES", 30, 35], ["H7N9", "SPECIES", 51, 55], ["human infection", "PROBLEM", 30, 45], ["H7N9", "PROBLEM", 51, 55], ["a hepatitis B vaccine", "TREATMENT", 94, 115], ["maximum", "OBSERVATION_MODIFIER", 4, 11], ["infection", "OBSERVATION", 36, 45]]], ["Moreover, 10 years after the SARS outbreak, some authors compared the development of PHEM in China over the 10-year period.", [["SARS", "DISEASE", 29, 33], ["PHEM", "DISEASE", 85, 89], ["the SARS outbreak", "PROBLEM", 25, 42]]], ["This article was published during the epidemic of SARS.", [["SARS", "DISEASE", 50, 54]]], ["The author combined the development of emergency management, reform of health and epidemic prevention institutions, and discussed the capacity building of public health emergency response.", [["emergency management", "TREATMENT", 39, 59]]], ["It is helpful for the social function orientation of the disease control center and the improvement of disease prevention ability.", [["disease prevention ability", "PROBLEM", 103, 129], ["disease", "OBSERVATION", 103, 110]]], ["Although the number of Chinese articles decreased in the following years, it remained above 48.", [["number", "OBSERVATION_MODIFIER", 13, 19], ["decreased", "OBSERVATION_MODIFIER", 40, 49]]], ["In summary, the above analysis shows that PHEM is still a timely topic.", [["the above analysis", "TEST", 12, 30]]], ["The cooperation between different research institutions is believed to be highly effective in facilitating high-level and fruitful research, which can also help develop the research field into a more established area [59] .", [["believed to be", "UNCERTAINTY", 59, 73]]], ["Reasons include the following: the western region had poor fiscal capacity, a limited personnel size, and an inadequate stockpile in terms of working budget, timely reserves, and prompt delivery [60] .", [["poor fiscal capacity", "PROBLEM", 54, 74], ["fiscal capacity", "OBSERVATION", 59, 74], ["size", "OBSERVATION_MODIFIER", 96, 100], ["inadequate", "OBSERVATION_MODIFIER", 109, 119], ["stockpile", "OBSERVATION", 120, 129]]], ["As a leader in international PHEM, the CDC has begun to help other entities strengthen their capacity, recognition, and technical expertise to strengthen their PHEM capacity [61] .", [["the CDC", "TEST", 35, 42]]], ["The Chinese CDC has carried out more disease prevention and control services, but its scientific research ability is weak.", [["more disease prevention", "TREATMENT", 32, 55], ["weak", "OBSERVATION", 117, 121]]], ["The country network analysis shows obvious differences in regional and economic development levels for PHEM.", [["The country network analysis", "TEST", 0, 28], ["obvious differences in regional and economic development levels", "PROBLEM", 35, 98], ["PHEM", "PROBLEM", 103, 107]]], ["Geographically, most of these countries are concentrated in Europe, where the numbers of publications and citations are also significantly higher [60] .", [["concentrated", "OBSERVATION_MODIFIER", 44, 56], ["numbers", "OBSERVATION_MODIFIER", 78, 85], ["significantly", "OBSERVATION_MODIFIER", 125, 138], ["higher", "OBSERVATION_MODIFIER", 139, 145]]], ["Co-word analysis of PHEM international research is more complex, extensive, and multidimensional.", [["word analysis", "TEST", 3, 16], ["more complex", "OBSERVATION_MODIFIER", 51, 63]]], ["Based on these ideas, scholars mainly focused on emergency preparedness and monitoring of public health events.", [["emergency preparedness", "TREATMENT", 49, 71]]], ["From the perspective of Chinese PHEM development, it has gone through a process from theory to preparation, disposition, response, evaluation, organization, and discussion.", [["evaluation", "TEST", 131, 141]]], ["That is, the main contents of China's health emergency management include the prevention and preparation of health emergencies as well as the key links of disposition, evaluation, and management, system construction, personnel training, and so on.", [["emergency management", "TREATMENT", 45, 65], ["evaluation", "TEST", 168, 178], ["personnel training", "TREATMENT", 217, 235], ["main", "OBSERVATION_MODIFIER", 13, 17], ["contents", "OBSERVATION_MODIFIER", 18, 26]]], ["The development of the whole discipline is therefore systematic and clear.", [["clear", "OBSERVATION", 68, 73]]], ["The keywords with the strongest citation burst for international research on PHEM started with terrorism and bioterrorism [63] , followed by disaster planning and emergency preparedness.", [["PHEM", "CHEMICAL", 77, 81]]], ["In recent years, epidemics and infectious diseases have become the new research frontier.", [["infectious diseases", "DISEASE", 31, 50], ["epidemics", "PROBLEM", 17, 26], ["infectious diseases", "PROBLEM", 31, 50], ["infectious", "OBSERVATION_MODIFIER", 31, 41]]], ["From the perspective of the whole development context, international research on PHEM has been related to current affairs hotspots, such as terrorism, which may have originated from the 911 incident, and epidemics, which may be related to the epidemic of infectious diseases caused by viruses and bacteria such as the Ebola virus.", [["PHEM", "CHEMICAL", 81, 85], ["infectious diseases", "DISEASE", 255, 274], ["Ebola virus", "DISEASE", 318, 329], ["PHEM", "CANCER", 81, 85], ["Ebola virus", "ORGANISM", 318, 329], ["Ebola virus", "SPECIES", 318, 329], ["Ebola virus", "SPECIES", 318, 329], ["epidemics", "PROBLEM", 204, 213], ["infectious diseases", "PROBLEM", 255, 274], ["viruses", "PROBLEM", 285, 292], ["bacteria", "PROBLEM", 297, 305], ["the Ebola virus", "PROBLEM", 314, 329], ["infectious", "OBSERVATION", 255, 265], ["viruses", "OBSERVATION", 285, 292]]], ["The study of PHEM in China is a process from theory formation to practice discussion, involving many links of management.", [["PHEM", "CHEMICAL", 13, 17], ["The study", "TEST", 0, 9], ["management", "TREATMENT", 110, 120]]], ["Some new methods have gradually been applied to Chinese PHEM in recent years.DiscussionThe top-ranked articles by citation for the international knowledge domain of PHEM appeared in 2005, 2007, 2009, 2014, 2015, and 2016 .", [["Some new methods", "PROBLEM", 0, 16], ["new", "OBSERVATION_MODIFIER", 5, 8], ["methods", "OBSERVATION", 9, 16]]], ["In 2005, Lawrence M. Wein [45] developed a mathematical model of a cow-toconsumer supply chain to reduce bioterrorism events.", [["a cow-toconsumer supply chain", "TREATMENT", 65, 94], ["bioterrorism events", "PROBLEM", 105, 124]]], ["Once again, it shows that international emergency management research is based on terrorism and bioterrorism.", [["international emergency management", "TREATMENT", 26, 60], ["bioterrorism", "PROBLEM", 96, 108]]], ["The above three articles are all about the factors involved in health emergency management.", [["health emergency management", "TREATMENT", 63, 90]]], ["From the above analysis, it can be seen that terrorism, emergency response and health incident management, and the disposition of public health events are the hotspots of international attention.", [["the above analysis", "TEST", 5, 23], ["health incident management", "TREATMENT", 79, 105]]], ["Legislative situation and characteristics of China's emergency law [53] , Legal construction of public emergency response in China: legal construction task proposed by SARS crisis management practice [54] , and The realistic subject of administrative rule of law in public emergency management [55] were published in 2003.", [["SARS", "DISEASE", 168, 172]]], ["All three articles discussed the problems existing in the construction of the administrative legal system under the background of SARS.", [["SARS", "DISEASE", 130, 134], ["the problems", "PROBLEM", 29, 41], ["SARS", "PROBLEM", 130, 134]]], ["After that, three articles were published in 2004, mainly studying the mechanism and structure of PHEM in China.", [["PHEM", "CHEMICAL", 98, 102]]], ["This research proposed the need to establish the emergency response mechanism for PHEM and establish emergency structure construction as soon as possible.", [["PHEM", "PROBLEM", 82, 86], ["emergency structure construction", "TREATMENT", 101, 133]]], ["He elaborated on the core contents of Chinese PHEM construction, including emergency plans, emergency structures, emergency mechanisms, and legal systems.", [["Chinese PHEM construction", "TREATMENT", 38, 63]]], ["In 2011, The status quo of emergency management system for sudden public health events in America and Japan and its enlightenment [64] was published, showing that China has been learning the theory and experience of PHEM from some advanced countries.", [["emergency management system", "TREATMENT", 27, 54], ["sudden public health events", "PROBLEM", 59, 86]]], ["From the above analysis, it can be seen that the legal system, mechanism, and structure, system, and learning from abroad are the theoretical guidance for Chinese PHEM in the past 30 years.DiscussionAdmittedly, there are some limitations to this study.", [["the above analysis", "TEST", 5, 23], ["this study", "TEST", 241, 251]]], ["First, the conclusions drawn from this study were based on only two large literature retrieval libraries.", [["this study", "TEST", 34, 44], ["two large literature retrieval libraries", "TREATMENT", 64, 104], ["large", "OBSERVATION_MODIFIER", 68, 73]]], ["Other databases, such as Embase and Springer Link, were not studied.", [["Other databases", "TEST", 0, 15]]], ["Second, CiteSpace has some shortcomings in processing the results of the Chinese database; it cannot translate the result from Chinese into English directly.", [["CiteSpace", "TREATMENT", 8, 17]]], ["Fourth, we conducted a comparison between Chinese and international databases similar to that performed in many other studies.", [["many other studies", "TEST", 107, 125]]], ["It should be acknowledged that the two databases had different acceptance ratios, and this difference in data sources might lead to bias in the study results.", [["the study", "TEST", 140, 149]]], ["Although only a small part of the total, this may have created some deficiencies.", [["some deficiencies", "PROBLEM", 63, 80], ["small", "OBSERVATION_MODIFIER", 16, 21], ["some", "OBSERVATION_MODIFIER", 63, 67], ["deficiencies", "OBSERVATION", 68, 80]]], ["This limitation may constitute an object of future studies, namely, those analyzing the differences between English papers focusing on China vs. Chinese papers.ConclusionsIn summary, we selected two large retrieval library documents to define the PHEM domain and detected the research status and the trends related to it from 1991 to 2018.", [["PHEM domain", "DNA", 247, 258], ["future studies", "TEST", 44, 58]]], ["In the next 3 years, the number of international PHEM articles will continue to increase, while the number of Chinese articles will decline.", [["international PHEM articles", "TREATMENT", 35, 62]]], ["There are differences in regional and economic distribution between international and Chinese cooperation networks.", [["differences", "OBSERVATION_MODIFIER", 10, 21], ["regional", "OBSERVATION_MODIFIER", 25, 33], ["economic", "OBSERVATION_MODIFIER", 38, 46], ["distribution", "OBSERVATION_MODIFIER", 47, 59]]], ["The international research on PHEM begins with terrorism and bioterrorism, followed by disaster planning and emergency preparedness, and emerging infectious diseases.", [["infectious diseases", "DISEASE", 146, 165], ["terrorism", "PROBLEM", 47, 56], ["bioterrorism", "PROBLEM", 61, 73], ["infectious", "OBSERVATION", 146, 156]]], ["China uses SARS as the research background and the legal system construction as the research starting point, which is followed by the mechanism and structure, system, and training abroad.", [["SARS", "DISEASE", 11, 15]]]], "PMC7125761": [["IntroductionDengue virus or as commonly called DENV is a single stranded RNA virus that infects approximately 390 million people each year (Achee et al., 2015), putting more than two-fifth of the world's population under the threat of this efficacious virus.", [["Dengue virus", "DISEASE", 12, 24], ["Dengue virus", "ORGANISM", 12, 24], ["DENV", "ORGANISM", 47, 51], ["people", "ORGANISM", 122, 128], ["Dengue virus", "SPECIES", 12, 24], ["people", "SPECIES", 122, 128], ["Dengue virus", "SPECIES", 12, 24], ["DENV", "SPECIES", 47, 51], ["IntroductionDengue virus", "PROBLEM", 0, 24], ["DENV", "PROBLEM", 47, 51], ["a single stranded RNA virus", "PROBLEM", 55, 82], ["this efficacious virus", "PROBLEM", 235, 257]]], ["The dengue fever has, thus become one of the most widespread disease (Sukhralia et al., 2018).", [["dengue fever", "DISEASE", 4, 16], ["The dengue fever", "PROBLEM", 0, 16], ["dengue", "OBSERVATION_MODIFIER", 4, 10], ["fever", "OBSERVATION", 11, 16], ["widespread", "OBSERVATION_MODIFIER", 50, 60], ["disease", "OBSERVATION", 61, 68]]], ["The virus belongs to the family Flaviviridae and genus Flavivirus (Westaway et al., 1985; Back and Lundkvist, 2013).", [["virus", "OBSERVATION", 4, 9], ["genus Flavivirus", "ANATOMY", 49, 65]]], ["DENV is an arbovirus, having two known mosquito vectors Aedes aegypti (Gratz, 1999) and Aedes albopictus (Lambrechts et al., 2010).", [["DENV", "ORGANISM", 0, 4], ["Aedes aegypti", "ORGANISM", 56, 69], ["Aedes albopictus", "ORGANISM", 88, 104], ["Aedes aegypti", "SPECIES", 56, 69], ["Aedes albopictus", "SPECIES", 88, 104], ["DENV", "SPECIES", 0, 4], ["Aedes aegypti", "SPECIES", 56, 69], ["Aedes albopictus", "SPECIES", 88, 104], ["DENV", "PROBLEM", 0, 4], ["an arbovirus", "PROBLEM", 8, 20], ["arbovirus", "OBSERVATION", 11, 20]]], ["The positive stranded RNA genome of dengue virus is of 10.7 Kb size and composed of three structural proteins (Envelope, Capsid, Membrane) and seven non-structural proteins (NS1, NS2A, NS2B,NS3, NS4A, NS4B, NS5) (Imrie et al., 2010; Guzman et al., 2010; Sukhralia et al., 2018).", [["dengue", "DISEASE", 36, 42], ["dengue virus", "ORGANISM", 36, 48], ["Envelope", "GENE_OR_GENE_PRODUCT", 111, 119], ["Capsid", "GENE_OR_GENE_PRODUCT", 121, 127], ["Membrane", "CELLULAR_COMPONENT", 129, 137], ["NS1", "GENE_OR_GENE_PRODUCT", 174, 177], ["NS2A", "GENE_OR_GENE_PRODUCT", 179, 183], ["NS2B", "GENE_OR_GENE_PRODUCT", 185, 189], ["NS3", "GENE_OR_GENE_PRODUCT", 190, 193], ["NS4A", "GENE_OR_GENE_PRODUCT", 195, 199], ["NS4B", "GENE_OR_GENE_PRODUCT", 201, 205], ["positive stranded RNA genome", "DNA", 4, 32], ["structural proteins", "PROTEIN", 90, 109], ["Envelope", "PROTEIN", 111, 119], ["Capsid", "PROTEIN", 121, 127], ["Membrane", "PROTEIN", 129, 137], ["non-structural proteins", "PROTEIN", 149, 172], ["NS1", "PROTEIN", 174, 177], ["NS2A", "PROTEIN", 179, 183], ["NS2B", "PROTEIN", 185, 189], ["NS3", "PROTEIN", 190, 193], ["NS4A", "PROTEIN", 195, 199], ["NS4B", "PROTEIN", 201, 205], ["NS5", "PROTEIN", 207, 210], ["dengue virus", "SPECIES", 36, 48], ["The positive stranded RNA genome of dengue virus", "PROBLEM", 0, 48], ["Kb size", "TEST", 60, 67], ["three structural proteins", "PROBLEM", 84, 109], ["seven non-structural proteins", "TEST", 143, 172], ["NS1", "TEST", 174, 177], ["NS2A", "TEST", 179, 183], ["NS2B", "TEST", 185, 189], ["NS3", "TEST", 190, 193], ["NS4A", "TREATMENT", 195, 199], ["NS4B", "TEST", 201, 205], ["positive", "OBSERVATION_MODIFIER", 4, 12], ["stranded", "OBSERVATION_MODIFIER", 13, 21], ["RNA genome", "OBSERVATION", 22, 32], ["dengue virus", "OBSERVATION", 36, 48], ["10.7 Kb size", "OBSERVATION_MODIFIER", 55, 67], ["structural proteins", "OBSERVATION", 90, 109], ["NS4A", "ANATOMY", 195, 199]]], ["There are atleast four serotypes and they show 65% similarity in the genome structure (Azhar et al., 2015; Ramanathan et al., 2016).IntroductionThe dengue infection is caused by one of the four serotypes of DENV that are spread by Aedes mosquito (Kalayanarooj, 2011).", [["dengue infection", "DISEASE", 148, 164], ["DENV", "DISEASE", 207, 211], ["DENV", "ORGANISM", 207, 211], ["Aedes mosquito", "ORGANISM", 231, 245], ["dengue", "SPECIES", 148, 154], ["DENV", "SPECIES", 207, 211], ["Aedes mosquito", "SPECIES", 231, 245], ["The dengue infection", "PROBLEM", 144, 164], ["DENV", "PROBLEM", 207, 211], ["genome structure", "OBSERVATION", 69, 85], ["dengue", "OBSERVATION_MODIFIER", 148, 154], ["infection", "OBSERVATION", 155, 164], ["serotypes", "OBSERVATION_MODIFIER", 194, 203], ["DENV", "OBSERVATION", 207, 211]]], ["During primary infection, the body develops immune responses in the form of antibodies against the particular serotype attacked (Schmid et al., 2016).", [["body", "ANATOMY", 30, 34], ["primary infection", "DISEASE", 7, 24], ["body", "ORGANISM_SUBDIVISION", 30, 34], ["antibodies", "PROTEIN", 76, 86], ["primary infection", "PROBLEM", 7, 24], ["antibodies", "TREATMENT", 76, 86], ["primary", "OBSERVATION_MODIFIER", 7, 14], ["infection", "OBSERVATION", 15, 24], ["immune responses", "OBSERVATION", 44, 60]]], ["But the main complexity of DENV arises during the secondary infection with another serotype, leading to serious version of dengue infection like Dengue Haemorrhagic fever (DHF) and Dengue Shock Syndrome (DSS) (Dar and Ghosh, 2015; Matheus et al., 2005; Schmid et al., 2016).", [["infection", "DISEASE", 60, 69], ["dengue infection", "DISEASE", 123, 139], ["Dengue Haemorrhagic fever", "DISEASE", 145, 170], ["DHF", "DISEASE", 172, 175], ["Dengue Shock Syndrome", "DISEASE", 181, 202], ["DSS", "DISEASE", 204, 207], ["DENV", "ORGANISM", 27, 31], ["Dengue Haemorrhagic fever", "ORGANISM", 145, 170], ["Dengue Haemorrhagic fever", "SPECIES", 145, 170], ["DENV", "SPECIES", 27, 31], ["dengue", "SPECIES", 123, 129], ["Dengue Haemorrhagic fever (DHF)", "SPECIES", 145, 176], ["DENV", "PROBLEM", 27, 31], ["the secondary infection", "PROBLEM", 46, 69], ["another serotype", "PROBLEM", 75, 91], ["dengue infection", "PROBLEM", 123, 139], ["Dengue Haemorrhagic fever", "PROBLEM", 145, 170], ["DHF", "PROBLEM", 172, 175], ["Dengue Shock Syndrome", "PROBLEM", 181, 202], ["main", "OBSERVATION_MODIFIER", 8, 12], ["complexity", "OBSERVATION_MODIFIER", 13, 23], ["DENV", "OBSERVATION", 27, 31], ["secondary", "OBSERVATION_MODIFIER", 50, 59], ["infection", "OBSERVATION", 60, 69], ["infection", "OBSERVATION", 130, 139], ["Haemorrhagic", "OBSERVATION_MODIFIER", 152, 164], ["Shock Syndrome", "OBSERVATION", 188, 202]]], ["This is caused due to the antibodies produced during primary attack which complicate the secondary DENV infection by a phenomenon known as Antibody Dependent Enhancement (ADE) (Durbin and Whitehead, 2011; Flipse et al., 2016).", [["DENV infection", "DISEASE", 99, 113], ["antibodies", "PROTEIN", 26, 36], ["DENV", "SPECIES", 99, 103], ["the antibodies", "PROBLEM", 22, 36], ["primary attack", "PROBLEM", 53, 67], ["the secondary DENV infection", "PROBLEM", 85, 113], ["a phenomenon", "PROBLEM", 117, 129], ["Antibody Dependent Enhancement", "PROBLEM", 139, 169], ["secondary", "OBSERVATION_MODIFIER", 89, 98], ["DENV", "OBSERVATION_MODIFIER", 99, 103], ["infection", "OBSERVATION", 104, 113]]], ["During ADE, there is a cross reaction between the antibodies of the primary infection and virus of secondary infection such that there is an increased infection in macrophages and monocytes (Whitehorn and Simmons, 2011; Durbin et al., 2010).", [["macrophages", "ANATOMY", 164, 175], ["monocytes", "ANATOMY", 180, 189], ["primary infection", "DISEASE", 68, 85], ["infection", "DISEASE", 109, 118], ["infection", "DISEASE", 151, 160], ["macrophages", "CELL", 164, 175], ["monocytes", "CELL", 180, 189], ["antibodies", "PROTEIN", 50, 60], ["macrophages", "CELL_TYPE", 164, 175], ["monocytes", "CELL_TYPE", 180, 189], ["a cross reaction", "PROBLEM", 21, 37], ["the primary infection", "PROBLEM", 64, 85], ["virus", "PROBLEM", 90, 95], ["secondary infection", "PROBLEM", 99, 118], ["an increased infection in macrophages", "PROBLEM", 138, 175], ["monocytes", "TEST", 180, 189], ["primary", "OBSERVATION_MODIFIER", 68, 75], ["infection", "OBSERVATION", 76, 85], ["secondary", "OBSERVATION_MODIFIER", 99, 108], ["infection", "OBSERVATION", 109, 118], ["increased", "OBSERVATION_MODIFIER", 141, 150], ["infection", "OBSERVATION", 151, 160], ["macrophages", "OBSERVATION_MODIFIER", 164, 175], ["monocytes", "OBSERVATION_MODIFIER", 180, 189]]], ["These challenges bring the importance of an archetypal dengue vaccine which can provide life time immunity against all the serotypes (Thomas, 2011; Russell and Halstead, 2016).IntroductionCurrently, the vaccine candidates that are under various stages of clinical trial are the live attenuated viruses (Thomas et al., 2012), chimeric vaccine (Guy et al., 2015), recombinant vaccine with adjuvants (Hertz et al., 2017), reverse vaccinology (Baliga et al., 2018), purified and inactivated virions (Fernandez et al., 2015), subunit proteins and plasmid DNA (Thisyakorn and Thisyakorn, 2014).", [["dengue", "DISEASE", 55, 61], ["DNA", "CELLULAR_COMPONENT", 550, 553], ["subunit proteins", "PROTEIN", 521, 537], ["plasmid DNA", "DNA", 542, 553], ["an archetypal dengue vaccine", "TREATMENT", 41, 69], ["IntroductionCurrently", "TREATMENT", 176, 197], ["the vaccine candidates", "TREATMENT", 199, 221], ["clinical trial", "TREATMENT", 255, 269], ["subunit proteins", "TREATMENT", 521, 537], ["plasmid DNA", "PROBLEM", 542, 553]]], ["Among these, live attenuated DENGVAXIA or CYD-TDV, a tetravalent chimeric dengue vaccine (Scott, 2016), developed by Sanofi Pasteur in December 2015, is the first licensed vaccine in some Asian and Latin American countries (Pitisuttithum and Bouckenooghe, 2016; Flaschw et al., 2016).", [["DENGVAXIA", "CHEMICAL", 29, 38], ["CYD-TDV", "CHEMICAL", 42, 49], ["dengue", "DISEASE", 74, 80], ["DENGVAXIA", "SIMPLE_CHEMICAL", 29, 38], ["CYD-TDV", "SIMPLE_CHEMICAL", 42, 49], ["a tetravalent chimeric dengue vaccine", "TREATMENT", 51, 88]]], ["These clinical manifestations caused by the vaccine are ascribed to inefficiency of the vaccine in producing competent T- cells that protect against DENV disease (Kim et al., 2010).", [["T- cells", "ANATOMY", 119, 127], ["DENV disease", "DISEASE", 149, 161], ["T- cells", "CELL", 119, 127], ["DENV", "ORGANISM", 149, 153], ["competent T- cells", "CELL_TYPE", 109, 127], ["DENV", "SPECIES", 149, 153], ["These clinical manifestations", "PROBLEM", 0, 29], ["the vaccine", "TREATMENT", 40, 51], ["the vaccine", "TREATMENT", 84, 95], ["DENV disease", "PROBLEM", 149, 161]]], ["Moreover, the vaccine does not encode any non- structural proteins which are required by the virus to evade immune response of the host (Halstead, 2017; Morrison et al., 2012).", [["structural proteins", "PROTEIN", 47, 66], ["any non- structural proteins", "PROBLEM", 38, 66]]], ["All these studies imply that a vaccine that is tetravalent and simultaneously prevents antibody- dependent enhancement (ADE) needs to be designed urgently.", [["All these studies", "TEST", 0, 17], ["a vaccine", "TREATMENT", 29, 38], ["tetravalent", "TREATMENT", 47, 58], ["antibody- dependent enhancement", "PROBLEM", 87, 118], ["dependent enhancement", "OBSERVATION_MODIFIER", 97, 118]]], ["These concerns led to the need for a relatively new technique of vaccine development i.e. Epitope or synthetic peptide based vaccines.", [["a relatively new technique of vaccine development", "TREATMENT", 35, 84], ["Epitope or synthetic peptide based vaccines", "TREATMENT", 90, 133]]], ["As DENV has both structural and non-structural proteins for its viral activity (Oliveira et al., 2014), conserved epitopes may prove to be useful in designing synthetic peptide based vaccine.", [["DENV", "ORGANISM", 3, 7], ["non-structural proteins", "PROTEIN", 32, 55], ["DENV", "SPECIES", 3, 7], ["DENV", "PROBLEM", 3, 7], ["synthetic peptide based vaccine", "TREATMENT", 159, 190], ["non-structural proteins", "OBSERVATION", 32, 55]]], ["This can be easily initiated in today's time, as there is no dearth of information about genome sequences in the databases (Hasan et al., 2013; Sharmin and Islam, 2014).IntroductionOur study provides answers to all above mentioned concerns as we could successfully find conserved epitopes in structural as well as non- structural proteins.", [["genome sequences", "DNA", 89, 105], ["epitopes", "PROTEIN", 280, 288], ["structural proteins", "PROTEIN", 319, 338], ["IntroductionOur study", "TEST", 169, 190]]], ["These conserved epitopes can be used for further analysis and exploited to develop the vaccine against the deadly dengue virus as well as in rapid diagnostics.Retrieval of sequences and alignment ::: Materials and methodsA sum total of 23,622 partial sequences of structural and non-structural proteins of dengue virus were retrieved from NCBI (www.ncbi.nih.gov) (Table 1).", [["dengue", "DISEASE", 114, 120], ["dengue", "DISEASE", 306, 312], ["dengue virus", "ORGANISM", 306, 318], ["non-structural proteins", "PROTEIN", 279, 302], ["dengue virus", "SPECIES", 306, 318], ["dengue virus", "SPECIES", 114, 126], ["dengue virus", "SPECIES", 306, 318], ["further analysis", "TEST", 41, 57], ["the vaccine", "TREATMENT", 83, 94], ["the deadly dengue virus", "PROBLEM", 103, 126], ["rapid diagnostics", "TEST", 141, 158], ["dengue virus", "PROBLEM", 306, 318]]], ["After retrieving, the sequences were aligned using multiple sequence alignment program CLUSTAL_X (Thompson et al., 1997).", [["the sequences", "TEST", 18, 31]]], ["These aligned sequence files were then used for further analysis.Search for conserved sequences ::: Materials and methodsSequences were used for detecting the species-specific signature sequences or motifs.", [["species-specific signature sequences", "DNA", 159, 195], ["These aligned sequence files", "TEST", 0, 28], ["further analysis", "TEST", 48, 64], ["methodsSequences", "TEST", 114, 130], ["the species", "TEST", 155, 166]]], ["Motifs were obtained for each serotype of DENV individually using an online tool multiple em for motif elicitation or MEME Suite (Bailey et al., 2009).", [["DENV", "ORGANISM", 42, 46], ["DENV", "SPECIES", 42, 46], ["DENV", "PROBLEM", 42, 46]]], ["Motifs common for all serotypes were also obtained using the same method.", [["all serotypes", "PROBLEM", 18, 31]]], ["In order to get a maximum number of motifs, the default setting was adjusted from 3 motifs to 10 motifs.Linear B-cell epitope prediction ::: Materials and methodsThe motifs were then analyzed for the presence of B cell epitopes.", [["B-cell", "ANATOMY", 111, 117], ["B cell", "ANATOMY", 212, 218], ["B-cell", "CELL", 111, 117], ["B cell", "CELL", 212, 218], ["B cell epitopes", "PROTEIN", 212, 227], ["B cell epitopes", "PROBLEM", 212, 227], ["B-cell epitope", "OBSERVATION", 111, 125], ["B cell epitopes", "OBSERVATION", 212, 227]]], ["The linear B cell epitopes were found using BCPRED and BEPIPRED tools of immune epitope database with default settings.", [["B cell", "ANATOMY", 11, 17], ["B cell", "CELL", 11, 17], ["The linear B cell epitopes", "PROBLEM", 0, 26], ["immune epitope database", "PROBLEM", 73, 96], ["default settings", "TREATMENT", 102, 118], ["linear", "OBSERVATION_MODIFIER", 4, 10], ["cell epitopes", "OBSERVATION", 13, 26]]], ["Bepipred used Hidden Markov model for the prediction of B cell epitopes (Larsen et al., 2006; Potocnakova et al., 2016).IEDB analysis ::: Materials and methodsThe immunogenicity of each epitope was checked using Kolaskar and Tangaonkar antigenicity method (Kolaskar and Tongaonkar, 1990) with a default threshold value 0.9.", [["B cell", "ANATOMY", 56, 62], ["B cell", "CELL", 56, 62], ["B cell epitopes", "PROTEIN", 56, 71], ["each epitope", "TEST", 181, 193], ["Kolaskar", "TREATMENT", 212, 220], ["Tangaonkar antigenicity method", "TREATMENT", 225, 255], ["a default threshold value", "TEST", 293, 318]]], ["Hydrophilicity of the antigenic epitopes, required to check the accessibility were found using Parker Hydrophilicity method (Parker et al., 1986) at a threshold value of 3.448 (Sharmin and Islam, 2014).", [["antigenic epitopes", "PROTEIN", 22, 40], ["the antigenic epitopes", "PROBLEM", 18, 40], ["a threshold value", "TEST", 149, 166], ["antigenic epitopes", "OBSERVATION", 22, 40]]], ["Epitopes were checked for their surface accessibility using Emini surface accessibility method (Emini et al., 1985) with a threshold value of 1.00.", [["surface", "ANATOMY", 32, 39], ["surface", "ANATOMY", 66, 73], ["Epitopes", "TEST", 0, 8], ["a threshold value", "TEST", 121, 138]]], ["Flexibility and Beta turns were checked using Karplus and Schulz Flexibility (Karplus and Schulz, 1985) and Chou and Fasman Beta-turn methods (Chou and Fasman, 1978) respectively, with a threshold of 1.00 for both (Sharmin and Islam, 2014).", [["Beta turns", "TEST", 16, 26], ["Karplus", "TREATMENT", 46, 53]]], ["Conservancy of epitopes was checked using Epitope Conservancy Analysis tool (Bui et al., 2007).3-D structure prediction ::: Materials and methodsModels of the 3D structures of DENV proteins were downloaded from RCSB PDB server (https://www.rcsb.org/) for mapping the epitopes.", [["DENV", "ORGANISM", 176, 180], ["epitopes", "PROTEIN", 15, 23], ["DENV proteins", "PROTEIN", 176, 189], ["epitopes", "PROTEIN", 267, 275], ["DENV", "SPECIES", 176, 180], ["DENV proteins", "PROBLEM", 176, 189], ["mapping the epitopes", "TEST", 255, 275], ["DENV", "OBSERVATION", 176, 180]]], ["For DENV proteins where no 3D strcture was available, I-TASSER server was used to predict the 3-D structures (Zhang, 2008; Roy et al., 2010).", [["DENV proteins", "PROTEIN", 4, 17], ["I-TASSER server", "DNA", 54, 69], ["DENV", "SPECIES", 4, 8], ["DENV proteins", "PROBLEM", 4, 17], ["3D strcture", "TEST", 27, 38], ["I-TASSER server", "TEST", 54, 69]]], ["The predicted models were saved in pdb format files, which were later used to generate Ramachandran plot using PDBsum \u2013PROCHECK software (Laskowski et al., 2001).", [["pdb", "ANATOMY", 35, 38]]], ["This was done to verify the models generated by I-TASSER.Conserved epitope in RNA-dependent RNA polymerase (RdRp) of DENV ::: ResultsAmong all the proteins of dengue virus, RNA-dependent RNA polymerase (RdRp) is encoded by non-structural gene NS5 and consists of 20 important enzymatic activities needed for viral propagation.", [["dengue", "DISEASE", 159, 165], ["RNA-dependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 78, 106], ["dengue virus", "ORGANISM", 159, 171], ["RNA-dependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 173, 201], ["RdRp", "GENE_OR_GENE_PRODUCT", 203, 207], ["RNA-dependent RNA polymerase", "PROTEIN", 78, 106], ["RdRp", "PROTEIN", 108, 112], ["RNA-dependent RNA polymerase", "PROTEIN", 173, 201], ["RdRp", "PROTEIN", 203, 207], ["non-structural gene NS5", "DNA", 223, 246], ["DENV", "SPECIES", 117, 121], ["dengue virus", "SPECIES", 159, 171], ["Conserved epitope in RNA", "PROBLEM", 57, 81], ["dependent RNA polymerase", "PROBLEM", 82, 106], ["DENV", "PROBLEM", 117, 121], ["dengue virus", "PROBLEM", 159, 171], ["RNA", "TEST", 173, 176], ["non-structural gene NS5", "TREATMENT", 223, 246], ["viral propagation", "PROBLEM", 308, 325], ["dengue virus", "OBSERVATION", 159, 171]]], ["Studies have been conducted on RdRp for designing drug against dengue virus as it is known to be the largest and highly conserved protein (Noble et al., 2010; Noble et al., 2013; El Sahili and Lescar, 2017; Lim et al., 2015).", [["dengue virus", "DISEASE", 63, 75], ["dengue virus", "ORGANISM", 63, 75], ["dengue virus", "SPECIES", 63, 75], ["Studies", "TEST", 0, 7], ["RdRp", "TREATMENT", 31, 35], ["dengue virus", "PROBLEM", 63, 75]]], ["Conserved motif \u2018YQNKVVRVQRPAKNGTVMDVISSRDQRGSGQVGTYGLNTFTNMEAQLIRQ\u2019 was found in NS5 (Fig. 1), which when inspected for presence of potential epitope resulted in \u2018QRGSGQV\u2019 (Table 2).", [["YQNKVVRVQRPAKNGTVMDVISSRDQRGSGQVGTYGLNTFTNMEAQLIRQ", "DNA", 17, 67], ["NS5", "PROTEIN", 82, 85], ["potential epitope", "PROBLEM", 133, 150]]], ["Linear B-cell epitope prediction, Antigenicity prediction, Surface accessibility prediction, Hydrophilicity prediction and flexibility prediction of this region (Fig. 2A\u2013E) showed \u2018QRGSGQV\u2019 as the most desirable epitope.", [["B-cell", "ANATOMY", 7, 13], ["B-cell", "CELL", 7, 13], ["QRGSGQV", "PROTEIN", 181, 188], ["Linear B-cell epitope prediction", "PROBLEM", 0, 32], ["Antigenicity prediction", "PROBLEM", 34, 57], ["Hydrophilicity prediction", "TEST", 93, 118], ["B-cell", "OBSERVATION", 7, 13], ["epitope prediction", "OBSERVATION", 14, 32], ["Surface", "OBSERVATION_MODIFIER", 59, 66]]], ["The epitope was further checked for conservancy using IEDB Conservancy analysis and was found to be 100% conserved in all serotypes of DENV (Table 3), thus making it one of the most efficient epitope for vaccine development based on in silico analysis.", [["DENV", "SPECIES", 135, 139], ["IEDB Conservancy analysis", "TEST", 54, 79], ["DENV", "PROBLEM", 135, 139], ["vaccine development", "TREATMENT", 204, 223], ["silico analysis", "TEST", 236, 251], ["DENV", "OBSERVATION", 135, 139]]], ["PDB protein structure of dengue virus NS5 protein (4V0Q) (Zhao et al., 2015) was used to map this epitope and the epitope was found to be located in beta turn region of the RNA-directed RNA polymerase of DENV structure (Fig. 3), thus making it accessible for interaction.Highly conserved epitope \u2018RCPTQGE\u2019 on structural protein - Envelope ::: ResultsAs stated above, there are three structural and 7 non-structural proteins in DENV polyprotein.", [["dengue", "DISEASE", 25, 31], ["dengue virus", "ORGANISM", 25, 37], ["NS5", "ORGANISM", 38, 41], ["DENV", "ORGANISM", 427, 431], ["dengue virus NS5 protein", "PROTEIN", 25, 49], ["4V0Q", "PROTEIN", 51, 55], ["beta turn region", "PROTEIN", 149, 165], ["RNA-directed RNA polymerase", "PROTEIN", 173, 200], ["RCPTQGE", "PROTEIN", 297, 304], ["structural protein", "PROTEIN", 309, 327], ["non-structural proteins", "PROTEIN", 400, 423], ["DENV polyprotein", "PROTEIN", 427, 443], ["dengue virus NS5", "SPECIES", 25, 41], ["dengue virus", "SPECIES", 25, 37], ["DENV", "SPECIES", 427, 431], ["dengue virus NS5 protein", "PROBLEM", 25, 49], ["the epitope", "TREATMENT", 110, 121], ["three structural and 7 non-structural proteins in DENV polyprotein", "PROBLEM", 377, 443], ["DENV", "OBSERVATION", 204, 208], ["DENV polyprotein", "OBSERVATION", 427, 443]]], ["Envelope protein is highly variable and is notably displayed on the surface of DENV (Modis et al., 2005), thus making it the crucial candidate for vaccine development (Keasey et al., 2018).", [["surface", "ANATOMY", 68, 75], ["surface", "CELLULAR_COMPONENT", 68, 75], ["Envelope protein", "PROTEIN", 0, 16], ["DENV", "SPECIES", 79, 83], ["Envelope protein", "TEST", 0, 16], ["DENV", "PROBLEM", 79, 83], ["protein", "OBSERVATION", 9, 16], ["highly variable", "OBSERVATION_MODIFIER", 20, 35]]], ["In our study, we could find two epitopes in Envelope protein (Table 2), but among them, epitope \u2018RCPTQGE\u2019 was found not only antigenic and surface accessible, but was also 100% conserved in all serotypes of DENV (Table 3, Supplementary Figs.", [["surface", "ANATOMY", 139, 146], ["Envelope protein (Table 2", "GENE_OR_GENE_PRODUCT", 44, 69], ["RCPTQGE", "GENE_OR_GENE_PRODUCT", 97, 104], ["epitopes", "PROTEIN", 32, 40], ["Envelope protein", "PROTEIN", 44, 60], ["Table 2", "PROTEIN", 62, 69], ["epitope", "PROTEIN", 88, 95], ["RCPTQGE", "PROTEIN", 97, 104], ["DENV", "SPECIES", 207, 211], ["our study", "TEST", 3, 12], ["DENV", "PROBLEM", 207, 211], ["surface", "OBSERVATION_MODIFIER", 139, 146], ["DENV", "OBSERVATION", 207, 211]]], ["S1\u2013S3).", [["S1", "PROTEIN", 0, 2], ["S3", "ANATOMY", 3, 5]]], ["On mapping this epitope on 3D structure of Envelope protein CryoEM structure of Dengue virus envelope protein heterotetramer (pdb id 3J2P), it was found to be present in beta turn region and therefore, is accessible for interaction, making it yet another highly suitable candidate for vaccine target.", [["Dengue virus", "ORGANISM", 80, 92], ["envelope protein heterotetramer (pdb id 3J2P", "GENE_OR_GENE_PRODUCT", 93, 137], ["beta", "GENE_OR_GENE_PRODUCT", 170, 174], ["Envelope protein CryoEM structure", "PROTEIN", 43, 76], ["Dengue virus envelope protein heterotetramer", "PROTEIN", 80, 124], ["pdb id 3J2P", "PROTEIN", 126, 137], ["beta turn region", "PROTEIN", 170, 186], ["Dengue virus", "SPECIES", 80, 92], ["Dengue virus", "SPECIES", 80, 92], ["this epitope", "PROBLEM", 11, 23], ["Envelope protein CryoEM structure", "TREATMENT", 43, 76], ["Dengue virus envelope protein heterotetramer", "TREATMENT", 80, 124], ["vaccine target", "TREATMENT", 285, 299], ["Envelope protein CryoEM", "OBSERVATION", 43, 66], ["Dengue virus", "OBSERVATION", 80, 92]]], ["As the structural proteins are highly variable, therefore it was difficult to find any conserved epitope for capsid and PrM proteins.Other highly conserved epitopes of DENV serotypes ::: ResultsTo our surprise, four more predicted epitopes (other than the conserved epitopes of NS5 and envelope proteins) were found to be 100% conserved i.e., NS3 (SAAQRRGR, PGTSGSPI); NS4A (QRTPQDNQL); NS4B (LQAKATREAQKRA) and in all DENV serotypes (Table 3).Other highly conserved epitopes of DENV serotypes ::: ResultsThe three dimensional visualization of predicted epitopes of NS4A and NS4B protein was performed using I-TASSER server (Supplementary Figs.", [["PrM", "GENE_OR_GENE_PRODUCT", 120, 123], ["DENV", "ORGANISM", 168, 172], ["NS5", "GENE_OR_GENE_PRODUCT", 278, 281], ["NS3", "GENE_OR_GENE_PRODUCT", 343, 346], ["SAAQRRGR", "GENE_OR_GENE_PRODUCT", 348, 356], ["PGTSGSPI", "GENE_OR_GENE_PRODUCT", 358, 366], ["DENV", "ORGANISM", 479, 483], ["NS4A", "GENE_OR_GENE_PRODUCT", 566, 570], ["structural proteins", "PROTEIN", 7, 26], ["capsid and PrM proteins", "PROTEIN", 109, 132], ["epitopes", "PROTEIN", 231, 239], ["conserved epitopes", "PROTEIN", 256, 274], ["NS5", "PROTEIN", 278, 281], ["envelope proteins", "PROTEIN", 286, 303], ["NS3", "PROTEIN", 343, 346], ["SAAQRRGR", "PROTEIN", 348, 356], ["PGTSGSPI", "PROTEIN", 358, 366], ["NS4A", "PROTEIN", 369, 373], ["QRTPQDNQL", "PROTEIN", 375, 384], ["NS4B", "PROTEIN", 387, 391], ["LQAKATREAQKRA", "PROTEIN", 393, 406], ["NS4A", "PROTEIN", 566, 570], ["NS4B protein", "PROTEIN", 575, 587], ["DENV", "SPECIES", 419, 423], ["the structural proteins", "TEST", 3, 26], ["capsid and PrM proteins", "PROBLEM", 109, 132], ["NS5 and envelope proteins", "TREATMENT", 278, 303], ["NS3 (SAAQRRGR, PGTSGSPI)", "TREATMENT", 343, 367], ["NS4A (QRTPQDNQL)", "TREATMENT", 369, 385], ["NS4B (LQAKATREAQKRA)", "TREATMENT", 387, 407], ["all DENV serotypes", "PROBLEM", 415, 433], ["NS4A", "TREATMENT", 566, 570], ["NS4B protein", "TEST", 575, 587], ["DENV serotypes", "OBSERVATION", 168, 182], ["DENV serotypes", "OBSERVATION", 479, 493]]], ["S12, S15) as the pdb structure was not available for these proteins.", [["S12", "GENE_OR_GENE_PRODUCT", 0, 3], ["S15", "GENE_OR_GENE_PRODUCT", 5, 8], ["S12", "PROTEIN", 0, 3], ["S15", "PROTEIN", 5, 8], ["pdb structure", "PROTEIN", 17, 30], ["the pdb structure", "TEST", 13, 30], ["these proteins", "PROBLEM", 53, 67]]], ["The predicted structure of protein sequences was validated by plotting Ramachandran graph using PROCheck software (data not shown).", [["protein sequences", "TEST", 27, 44], ["PROCheck software", "TEST", 96, 113]]], ["Remaining epitopes were found to be serotype-specific (Table 3) and hence 3D structure prediction and validation was not performed for these epitopes.Serotype-specific conserved epitopes of DENV ::: ResultsFor developing a successful vaccine candidate, epitope common in all the serotypes is a perquisite.", [["epitopes", "PROTEIN", 10, 18], ["epitopes", "PROTEIN", 141, 149], ["Serotype-specific conserved epitopes", "PROTEIN", 150, 186], ["DENV", "SPECIES", 190, 194], ["3D structure prediction", "TEST", 74, 97], ["validation", "TEST", 102, 112], ["these epitopes", "PROBLEM", 135, 149], ["a successful vaccine candidate", "TREATMENT", 221, 251], ["epitope", "TREATMENT", 253, 260], ["DENV", "OBSERVATION", 190, 194], ["serotypes", "OBSERVATION", 279, 288]]], ["But for developing serotype-specific drugs and in diagnostics of serotype specific strains, serotype-specific conserved epitopes may prove to be useful.", [["serotype-specific drugs", "TREATMENT", 19, 42], ["serotype specific strains", "PROBLEM", 65, 90], ["serotype", "PROBLEM", 92, 100]]], ["Hence, epitopes like \u2018TPQAPTS\u2019 of Envelope protein (specific for DENV-1 serotype); Capsid protein epitopes \u2018EHRREKRS\u2019 for DENV-2 and \u2018ERRREKRS\u2019 for DENV-4; NS1 epitope \u2018GYH/F/ATQT/IA\u2019 and \u2018PN/D/ETP/S/AECPN/SA/E/T\u2019; NS5 epitope \u2018WHYDQDHPYKT\u2019 in DENV-2 and \u2018SHWV/FPTSRTT\u2019 epitope may be exploited for developing diagnostic kits for early detection.", [["DENV-1 serotype", "ORGANISM", 65, 80], ["Capsid", "GENE_OR_GENE_PRODUCT", 83, 89], ["DENV-2", "GENE_OR_GENE_PRODUCT", 122, 128], ["DENV-4", "ORGANISM", 148, 154], ["NS1", "ORGANISM", 156, 159], ["NS5", "ORGANISM", 215, 218], ["DENV-2", "ORGANISM", 244, 250], ["SHWV", "GENE_OR_GENE_PRODUCT", 256, 260], ["epitopes", "PROTEIN", 7, 15], ["TPQAPTS", "PROTEIN", 22, 29], ["Envelope protein", "PROTEIN", 34, 50], ["Capsid protein epitopes", "PROTEIN", 83, 106], ["EHRREKRS", "PROTEIN", 108, 116], ["ERRREKRS", "PROTEIN", 134, 142], ["NS1 epitope", "PROTEIN", 156, 167], ["GYH", "PROTEIN", 169, 172], ["F", "PROTEIN", 173, 174], ["ATQT", "PROTEIN", 175, 179], ["IA", "PROTEIN", 180, 182], ["D", "PROTEIN", 192, 193], ["ETP", "PROTEIN", 194, 197], ["S", "PROTEIN", 198, 199], ["AECPN", "PROTEIN", 200, 205], ["SA", "PROTEIN", 206, 208], ["E", "PROTEIN", 209, 210], ["T\u2019", "PROTEIN", 211, 213], ["NS5 epitope", "PROTEIN", 215, 226], ["WHYDQDHPYKT", "PROTEIN", 228, 239], ["SHWV", "PROTEIN", 256, 260], ["FPTSRTT", "PROTEIN", 261, 268], ["DENV-1", "SPECIES", 65, 71], ["epitopes", "TREATMENT", 7, 15], ["Envelope protein", "TEST", 34, 50], ["DENV", "PROBLEM", 65, 69], ["Capsid protein epitopes", "TEST", 83, 106], ["EHRREKRS", "TEST", 108, 116], ["DENV", "TEST", 122, 126], ["ERRREKRS", "TEST", 134, 142], ["DENV", "PROBLEM", 148, 152], ["NS1 epitope", "TEST", 156, 167], ["GYH", "TEST", 169, 172], ["AECPN", "TREATMENT", 200, 205], ["T\u2019", "TREATMENT", 211, 213], ["NS5 epitope", "TREATMENT", 215, 226], ["DENV", "TEST", 244, 248], ["early detection", "TEST", 330, 345]]], ["Among the above reported serotype specific epitopes, both the epitopes of NS1 are potential candidates for distinguishing one serotype from other.DiscussionDengue is one of the most rapidly spreading mosquito-borne viral disease (WHO Dengue factsheet, 2016) and has emerged as one of the biggest threats to public health (Gubler, 2012; Thisyakorn and Thisyakorn, 2014; Artpradit et al., 2013).", [["DiscussionDengue", "DISEASE", 146, 162], ["mosquito-borne viral disease", "DISEASE", 200, 228], ["Dengue factsheet", "DISEASE", 234, 250], ["NS1", "GENE_OR_GENE_PRODUCT", 74, 77], ["serotype specific epitopes", "PROTEIN", 25, 51], ["epitopes", "PROTEIN", 62, 70], ["NS1", "PROTEIN", 74, 77], ["serotype specific epitopes", "PROBLEM", 25, 51], ["viral disease", "OBSERVATION", 215, 228]]], ["There are four serotypes of DENV which show 65% similarity at genomic level and share same epidemics.", [["DENV", "ORGANISM", 28, 32], ["DENV", "SPECIES", 28, 32], ["DENV", "PROBLEM", 28, 32], ["65% similarity at genomic level", "PROBLEM", 44, 75], ["same epidemics", "PROBLEM", 86, 100], ["four", "OBSERVATION_MODIFIER", 10, 14], ["serotypes", "OBSERVATION_MODIFIER", 15, 24], ["DENV", "OBSERVATION", 28, 32], ["same", "OBSERVATION_MODIFIER", 86, 90], ["epidemics", "OBSERVATION", 91, 100]]], ["Yet the difference in their interactions with antibodies is enough to make the development of a common vaccine, a mammoth task (Lalla et al., 2014).", [["antibodies", "PROTEIN", 46, 56], ["a common vaccine", "TREATMENT", 94, 110], ["difference", "OBSERVATION_MODIFIER", 8, 18]]], ["The urgent need of dengue vaccine development is presented by the alarming rise in the dengue endemics (Deen, 2016; Wichmann et al., 2017).", [["dengue", "DISEASE", 19, 25], ["dengue", "DISEASE", 87, 93], ["dengue", "SPECIES", 19, 25], ["dengue vaccine development", "TREATMENT", 19, 45]]], ["Although various vaccines are undergoing clinical trials worldwide but presently, there is no specific dengue therapeutics or vaccine available which provides overall protection against this viral infection.", [["dengue", "DISEASE", 103, 109], ["viral infection", "DISEASE", 191, 206], ["dengue", "SPECIES", 103, 109], ["various vaccines", "TREATMENT", 9, 25], ["vaccine", "TREATMENT", 126, 133], ["this viral infection", "PROBLEM", 186, 206], ["no", "UNCERTAINTY", 91, 93], ["infection", "OBSERVATION", 197, 206]]], ["Recently, the only licensed DENV vaccine Dengvaxia, has been reported as a failure as it lacks DENV non-structural protein antigens, and is found to be incompetent to raise antibodies against NS1 (Halstead, 2017).DiscussionIn the present study, Comparative Genomics and immunoinformatics was used as a tool to explore the potential candidates of dengue virus to find novel drug and vaccine targets.", [["Dengvaxia", "CHEMICAL", 41, 50], ["dengue", "DISEASE", 346, 352], ["DENV", "ORGANISM", 28, 32], ["NS1", "GENE_OR_GENE_PRODUCT", 192, 195], ["dengue virus", "ORGANISM", 346, 358], ["DENV non-structural protein antigens", "PROTEIN", 95, 131], ["antibodies", "PROTEIN", 173, 183], ["NS1", "PROTEIN", 192, 195], ["DENV", "SPECIES", 95, 99], ["dengue virus", "SPECIES", 346, 358], ["DENV vaccine Dengvaxia", "TREATMENT", 28, 50], ["a failure", "PROBLEM", 73, 82], ["DENV non-structural protein antigens", "PROBLEM", 95, 131], ["NS1", "PROBLEM", 192, 195], ["the present study", "TEST", 226, 243], ["immunoinformatics", "TREATMENT", 270, 287], ["dengue virus", "PROBLEM", 346, 358], ["novel drug", "TREATMENT", 367, 377], ["vaccine targets", "TREATMENT", 382, 397], ["DENV", "OBSERVATION", 28, 32], ["incompetent", "OBSERVATION", 152, 163]]], ["The advantage of development of an epitope based vaccine over other vaccines is its ability to induce specific immune response without undesirable effects.", [["an epitope based vaccine", "TREATMENT", 32, 56], ["other vaccines", "TREATMENT", 62, 76]]], ["Also, both time and expenditure needed to screen a large number of epitopes can be saved using such computational approaches (Davidson and Doranz, 2014).", [["epitopes", "PROTEIN", 67, 75], ["large", "OBSERVATION_MODIFIER", 51, 56]]], ["Similar studies have been conducted on Human Coronavirus (Sharmin and Islam, 2014), Saint Louis encephalitis virus (Hasan et al., 2013), Rotaviruses (Morozova et al., 2018), H1N1 influenza A virus strains (Baratelli et al., 2017) and Zika virus (Dos Santos Franco et al., 2017), however, the analysis has been conducted for only some selective proteins.", [["Saint Louis encephalitis", "DISEASE", 84, 108], ["influenza A virus", "DISEASE", 179, 196], ["Human", "ORGANISM", 39, 44], ["Saint Louis encephalitis virus", "ORGANISM", 84, 114], ["H1N1 influenza A virus", "ORGANISM", 174, 196], ["Zika virus", "ORGANISM", 234, 244], ["selective proteins", "PROTEIN", 334, 352], ["Human", "SPECIES", 39, 44], ["Saint Louis encephalitis virus", "SPECIES", 84, 114], ["H1N1 influenza A virus", "SPECIES", 174, 196], ["Human Coronavirus", "SPECIES", 39, 56], ["Saint Louis encephalitis virus", "SPECIES", 84, 114], ["H1N1 influenza A virus", "SPECIES", 174, 196], ["Zika virus", "SPECIES", 234, 244], ["Similar studies", "TEST", 0, 15], ["Saint Louis encephalitis virus", "PROBLEM", 84, 114], ["Rotaviruses", "PROBLEM", 137, 148], ["H1N1 influenza A virus strains", "PROBLEM", 174, 204], ["Zika virus", "PROBLEM", 234, 244], ["the analysis", "TEST", 288, 300], ["some selective proteins", "PROBLEM", 329, 352]]], ["Therefore our study is the first one to deal with all the proteins of any viral genome for designing an efficient vaccine.DiscussionTo achieve our objective, conserved epitopes have been obtained from both structural and non-structural proteins.", [["viral genome", "DNA", 74, 86], ["structural and non-structural proteins", "PROTEIN", 206, 244], ["our study", "TEST", 10, 19], ["any viral genome", "PROBLEM", 70, 86], ["an efficient vaccine", "TREATMENT", 101, 121], ["viral genome", "OBSERVATION", 74, 86], ["non-structural proteins", "OBSERVATION", 221, 244]]], ["We could successfully found six highly conserved epitopes, one from structural protein and other five from non-structural proteins.", [["epitopes", "PROTEIN", 49, 57], ["structural protein", "PROTEIN", 68, 86], ["non-structural proteins", "PROTEIN", 107, 130], ["epitopes", "OBSERVATION", 49, 57], ["non-structural proteins", "OBSERVATION", 107, 130]]], ["Among structural proteins, only Envelope protein showed 100% conserved epitope (RCPTQGE), indicating this as a good target for vaccine designing.", [["structural proteins", "PROTEIN", 6, 25], ["Envelope protein", "PROTEIN", 32, 48], ["RCPTQGE", "PROTEIN", 80, 87], ["Envelope protein", "TEST", 32, 48], ["vaccine designing", "TREATMENT", 127, 144]]], ["Other structural proteins like PrM and Capsid did not show any conservancy among the predicted epitopes.", [["PrM", "GENE_OR_GENE_PRODUCT", 31, 34], ["structural proteins", "PROTEIN", 6, 25], ["PrM", "PROTEIN", 31, 34], ["Capsid", "PROTEIN", 39, 45], ["epitopes", "PROTEIN", 95, 103], ["Other structural proteins like PrM", "PROBLEM", 0, 34], ["proteins", "OBSERVATION", 17, 25]]], ["This was expected as the structural proteins are known to be highly variable even within serotypes (Modis et al., 2005).", [["structural proteins", "PROTEIN", 25, 44], ["the structural proteins", "PROBLEM", 21, 44]]], ["The predicted epitopes of Envelope protein (RCPTQGE); NS3 (SAAQRRGR, PGTSGSPI); NS4A (QRTPQDNQL); NS4B (LQAKATREAQKRA) and NS5 proteins (QRGSGQV) were found out to be antigenic, hydrophillic, surface accessible, flexible and consists of beta turn.", [["surface", "ANATOMY", 192, 199], ["SAAQRRGR", "GENE_OR_GENE_PRODUCT", 59, 67], ["PGTSGSPI", "GENE_OR_GENE_PRODUCT", 69, 77], ["NS4B (LQAKATREAQKRA)", "GENE_OR_GENE_PRODUCT", 98, 118], ["NS5 proteins", "GENE_OR_GENE_PRODUCT", 123, 135], ["beta", "GENE_OR_GENE_PRODUCT", 237, 241], ["epitopes", "PROTEIN", 14, 22], ["Envelope protein", "PROTEIN", 26, 42], ["RCPTQGE", "PROTEIN", 44, 51], ["NS3", "PROTEIN", 54, 57], ["SAAQRRGR", "PROTEIN", 59, 67], ["PGTSGSPI", "PROTEIN", 69, 77], ["NS4A", "PROTEIN", 80, 84], ["QRTPQDNQL", "PROTEIN", 86, 95], ["NS4B", "PROTEIN", 98, 102], ["LQAKATREAQKRA", "PROTEIN", 104, 117], ["NS5 proteins", "PROTEIN", 123, 135], ["QRGSGQV", "PROTEIN", 137, 144], ["Envelope protein (RCPTQGE)", "TREATMENT", 26, 52], ["NS3 (SAAQRRGR, PGTSGSPI)", "TREATMENT", 54, 78], ["NS4A (QRTPQDNQL)", "TREATMENT", 80, 96], ["NS4B (LQAKATREAQKRA)", "TREATMENT", 98, 118], ["NS5 proteins", "TREATMENT", 123, 135], ["antigenic", "PROBLEM", 167, 176], ["hydrophillic", "PROBLEM", 178, 190], ["beta turn", "TREATMENT", 237, 246]]], ["Thus, these epitopes fulfill all the pre-requisite conditions of a desired epitope.", [["epitopes", "PROTEIN", 12, 20], ["a desired epitope", "PROBLEM", 65, 82]]], ["Moreover, the functions of these proteins can be used as an asset for controlling the effect of the virus on the host.", [["these proteins", "TREATMENT", 27, 41], ["the virus", "PROBLEM", 96, 105]]], ["For instance, NS1 is an important cofactor for the formation of replication complex, and has also been exploited for the development of vaccine (Mackenzie et al., 1996; Hertz et al., 2017) whereas NS4B regulates the helicase activity of NS3 and NS4A-NS4B complex is required for genome replication (Miller et al., 2006; Umareddy et al., 2006).", [["NS1", "GENE_OR_GENE_PRODUCT", 14, 17], ["NS4B", "GENE_OR_GENE_PRODUCT", 197, 201], ["NS3", "GENE_OR_GENE_PRODUCT", 237, 240], ["NS1", "PROTEIN", 14, 17], ["replication complex", "PROTEIN", 64, 83], ["NS4B", "PROTEIN", 197, 201], ["NS3", "PROTEIN", 237, 240], ["NS4A", "PROTEIN", 245, 249], ["NS4B complex", "PROTEIN", 250, 262], ["NS1", "PROBLEM", 14, 17], ["NS4B regulates", "TREATMENT", 197, 211], ["NS3", "TREATMENT", 237, 240], ["NS4A-NS4B complex", "TREATMENT", 245, 262]]], ["NS5 is the most conserved protein of DENV and its C-terminal containing RdRp (RNA dependent RNA polymerase) domain is crucial for genomic replication (Hannemann et al., 2013: Ashour et al., 2009).", [["C", "CHEMICAL", 50, 51], ["NS5", "GENE_OR_GENE_PRODUCT", 0, 3], ["NS5", "PROTEIN", 0, 3], ["C-terminal containing RdRp (RNA dependent RNA polymerase) domain", "PROTEIN", 50, 114], ["DENV", "SPECIES", 37, 41], ["NS5", "TREATMENT", 0, 3], ["DENV", "PROBLEM", 37, 41], ["its C-terminal containing RdRp (RNA dependent RNA polymerase", "TREATMENT", 46, 106], ["DENV", "OBSERVATION", 37, 41]]], ["Therefore, we can say that each of these proteins are essential for replication of the virus inside the host and therefore, they can be used as common vaccine target for all the four serotypes of Dengue virus.", [["Dengue", "DISEASE", 196, 202], ["Dengue virus", "ORGANISM", 196, 208], ["Dengue virus", "SPECIES", 196, 208], ["Dengue virus", "SPECIES", 196, 208], ["the virus", "PROBLEM", 83, 92], ["common vaccine target", "TREATMENT", 144, 165], ["Dengue virus", "PROBLEM", 196, 208]]], ["Serotype specific conserved epitopes can also be exploited for detection of Dengue at early stages.", [["Dengue", "DISEASE", 76, 82], ["Dengue", "ORGANISM", 76, 82], ["Serotype specific conserved epitopes", "PROTEIN", 0, 36], ["Serotype specific conserved epitopes", "PROBLEM", 0, 36], ["Dengue", "PROBLEM", 76, 82]]], ["During the Phase IIb and III trials, DENGVAXIA's specific response against DENV2 serotype largely became negligible.", [["DENGVAXIA", "SIMPLE_CHEMICAL", 37, 46], ["DENV2", "ORGANISM", 75, 80], ["DENGVAXIA", "PROTEIN", 37, 46], ["DENV2", "SPECIES", 75, 80], ["III trials", "TREATMENT", 25, 35], ["DENGVAXIA", "TREATMENT", 37, 46], ["DENV2 serotype", "PROBLEM", 75, 89]]], ["So, a vaccine developed using these epitopes could overcome this problem as these predicted epitopes are found to be conserved in all four serotypes of DENV.ConclusionDengue Virus (DENV) has emerged as a potential threat to human health worldwide.", [["DENV", "DISEASE", 152, 156], ["DENV", "ORGANISM", 152, 156], ["ConclusionDengue Virus", "ORGANISM", 157, 179], ["DENV", "ORGANISM", 181, 185], ["human", "ORGANISM", 224, 229], ["epitopes", "PROTEIN", 36, 44], ["epitopes", "PROTEIN", 92, 100], ["human", "SPECIES", 224, 229], ["DENV", "SPECIES", 152, 156], ["DENV", "SPECIES", 181, 185], ["human", "SPECIES", 224, 229], ["a vaccine", "TREATMENT", 4, 13], ["these epitopes", "TREATMENT", 30, 44], ["DENV", "PROBLEM", 152, 156], ["ConclusionDengue Virus (DENV", "PROBLEM", 157, 185], ["DENV", "OBSERVATION", 152, 156]]], ["The therapeutics against DENV are either not available in major parts of the world or if available in some endemic countries, are found to be inefficient.", [["DENV", "ORGANISM", 25, 29], ["DENV", "SPECIES", 25, 29], ["DENV", "PROBLEM", 25, 29]]], ["In this study we used computational approaches to find novel vaccine targets.", [["this study", "TEST", 3, 13], ["computational approaches", "TREATMENT", 22, 46], ["novel vaccine targets", "TREATMENT", 55, 76]]], ["It focuses to explore B-cell epitopes for all serotypes for each protein of dengue virus.", [["B-cell", "ANATOMY", 22, 28], ["dengue", "DISEASE", 76, 82], ["B-cell", "CELL", 22, 28], ["dengue virus", "ORGANISM", 76, 88], ["B-cell epitopes", "PROTEIN", 22, 37], ["dengue virus", "SPECIES", 76, 88], ["B-cell epitopes", "TREATMENT", 22, 37], ["all serotypes", "TREATMENT", 42, 55], ["dengue virus", "PROBLEM", 76, 88], ["dengue virus", "OBSERVATION", 76, 88]]], ["We found six highly conserved epitopes in all serotypes of DENV [Envelope protein (RCPTQGE); NS3 (SAAQRRGR, PGTSGSPI); NS4A (QRTPQDNQL); NS4B (LQAKATREAQKRA) and NS5 proteins (QRGSGQV)].", [["DENV", "ORGANISM", 59, 63], ["NS3 (SAAQRRGR, PGTSGSPI); NS4A (QRTPQDNQL); NS4B (LQAKATREAQKRA)", "GENE_OR_GENE_PRODUCT", 93, 157], ["NS5 proteins", "GENE_OR_GENE_PRODUCT", 162, 174], ["Envelope protein", "PROTEIN", 65, 81], ["RCPTQGE", "PROTEIN", 83, 90], ["NS3", "PROTEIN", 93, 96], ["SAAQRRGR", "PROTEIN", 98, 106], ["PGTSGSPI", "PROTEIN", 108, 116], ["NS4A", "PROTEIN", 119, 123], ["QRTPQDNQL", "PROTEIN", 125, 134], ["NS4B", "PROTEIN", 137, 141], ["LQAKATREAQKRA", "PROTEIN", 143, 156], ["NS5 proteins", "PROTEIN", 162, 174], ["QRGSGQV", "PROTEIN", 176, 183], ["DENV", "SPECIES", 59, 63], ["DENV", "PROBLEM", 59, 63], ["Envelope protein (RCPTQGE)", "TREATMENT", 65, 91], ["NS3 (SAAQRRGR, PGTSGSPI)", "TREATMENT", 93, 117], ["NS4A (QRTPQDNQL)", "TREATMENT", 119, 135], ["NS4B (LQAKATREAQKRA)", "TREATMENT", 137, 157], ["NS5 proteins", "TREATMENT", 162, 174]]], ["Thus, our results suggest any of these proteins can be targeted to stimulate a specific immune response against all serotypes of DENV.", [["DENV", "DISEASE", 129, 133], ["DENV", "ORGANISM", 129, 133], ["DENV", "SPECIES", 129, 133], ["these proteins", "PROBLEM", 33, 47], ["DENV", "PROBLEM", 129, 133], ["DENV", "OBSERVATION", 129, 133]]], ["These predicted epitopes would be the candidate target for the universal multi-subunit vaccine.ConclusionNevertheless, further studies are needed to confirm the utility of these epitopes.ConclusionMV and RL conceptualized the work; MV, SB, KK, NM, SS,SG curated data; formal analysis was done by MV, PSD; MV, PSD were involved in fund acquisition and project administration; MV supervised the work; MV.", [["epitopes", "PROTEIN", 178, 186], ["MV", "SPECIES", 232, 234], ["MV", "SPECIES", 296, 298], ["MV", "SPECIES", 305, 307], ["MV", "SPECIES", 375, 377], ["the universal multi-subunit vaccine", "TREATMENT", 59, 94], ["further studies", "TEST", 119, 134], ["these epitopes", "PROBLEM", 172, 186], ["ConclusionMV", "TEST", 187, 199], ["MV", "TEST", 232, 234], ["SB", "TEST", 236, 238], ["KK", "TEST", 240, 242], ["NM", "TEST", 244, 246], ["formal analysis", "TEST", 268, 283], ["PSD", "PROBLEM", 300, 303], ["PSD", "PROBLEM", 309, 312]]], ["SB, KK were involved in writing original draft; Review and editing was done by MV, PSD, RL.FundingThe funding to conduct this work was provided by Delhi University Innovative Scheme.Ethical approvalNot applicable.Conflict of interestThe authors declare that they have no conflict of interest.Authors' informationThis work is performed by the undergraduate students at Sri Venkateswara College, University of Delhi.Declaration of interestsThe authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.", [["MV", "SPECIES", 79, 81], ["Ethical approval", "TREATMENT", 182, 198], ["RL", "ANATOMY", 88, 90]]]], "f6d409a4fff5c3c4d7d84cee872e80615e2027a4": [["INTRODUCTIONto have been caused by ZIKV infection among pregnant women (Staples et al., 2016) .", [["ZIKV infection", "DISEASE", 35, 49], ["women", "ORGANISM", 65, 70], ["women", "SPECIES", 65, 70], ["ZIKV", "SPECIES", 35, 39], ["ZIKV infection", "PROBLEM", 35, 49], ["ZIKV", "OBSERVATION_MODIFIER", 35, 39], ["infection", "OBSERVATION", 40, 49]]], ["The causal relationship between ZIKV infection and microcephaly has yet to be fully established, but an increasing amount of scientific evidence strongly supports the epidemiological link of ZIKV with microcephaly (Mlakar et al., in press; Brasil et al., in press; Nishiura et al., 2016b) .", [["ZIKV infection", "DISEASE", 32, 46], ["microcephaly", "DISEASE", 51, 63], ["ZIKV", "DISEASE", 191, 195], ["microcephaly", "DISEASE", 201, 213], ["ZIKV", "GENE_OR_GENE_PRODUCT", 32, 36], ["ZIKV", "ORGANISM", 191, 195], ["ZIKV", "SPECIES", 32, 36], ["ZIKV", "SPECIES", 191, 195], ["ZIKV infection", "PROBLEM", 32, 46], ["microcephaly", "PROBLEM", 51, 63], ["ZIKV", "PROBLEM", 191, 195], ["microcephaly", "PROBLEM", 201, 213], ["ZIKV", "OBSERVATION_MODIFIER", 32, 36], ["infection", "OBSERVATION", 37, 46], ["microcephaly", "OBSERVATION", 51, 63], ["increasing", "OBSERVATION_MODIFIER", 104, 114], ["amount", "OBSERVATION_MODIFIER", 115, 121]]], ["Considering the expected impact on neurological manifestations including microcephaly and Guillain-Barr\u00e9 Syndrome (GBS), the World Health Organization issued the Public Health Emergency of International Concern (PHEIC) on 1 February 2016.INTRODUCTIONZIKV shares self-limiting clinical signs and symptoms with dengue virus (DENV) and chikungunya virus (CHIKV) (Ioos et al., 2014) .", [["neurological", "ANATOMY", 35, 47], ["microcephaly", "DISEASE", 73, 85], ["Guillain-Barr\u00e9 Syndrome", "DISEASE", 90, 113], ["GBS", "DISEASE", 115, 118], ["dengue virus (DENV) and chikungunya virus", "DISEASE", 309, 350], ["dengue virus", "ORGANISM", 309, 321], ["DENV", "ORGANISM", 323, 327], ["chikungunya virus", "ORGANISM", 333, 350], ["CHIKV", "ORGANISM", 352, 357], ["dengue virus", "SPECIES", 309, 321], ["chikungunya virus", "SPECIES", 333, 350], ["dengue virus", "SPECIES", 309, 321], ["DENV", "SPECIES", 323, 327], ["chikungunya virus", "SPECIES", 333, 350], ["CHIKV", "SPECIES", 352, 357], ["neurological manifestations", "PROBLEM", 35, 62], ["microcephaly", "PROBLEM", 73, 85], ["Guillain-Barr\u00e9 Syndrome", "PROBLEM", 90, 113], ["GBS", "PROBLEM", 115, 118], ["clinical signs", "PROBLEM", 276, 290], ["symptoms", "PROBLEM", 295, 303], ["dengue virus (DENV", "PROBLEM", 309, 327], ["chikungunya virus", "PROBLEM", 333, 350], ["Barr\u00e9 Syndrome", "OBSERVATION", 99, 113]]], ["Moreover, these viruses are also conveyed by the common mosquito vector, Aedes species.", [["Aedes species", "ORGANISM", 73, 86], ["viruses", "OBSERVATION", 16, 23]]], ["Technically, the infected cases could be observed in any part of the world in the presence of Aedes species, but the risk of transmission in Latin American and Caribbean countries has been anticipated to be high (Musso, Cao-Lormeau & Gubler, 2015; Bogoch et al., 2016) .", [["Aedes species", "ORGANISM", 94, 107], ["the infected cases", "PROBLEM", 13, 31], ["Aedes species", "PROBLEM", 94, 107], ["infected", "OBSERVATION", 17, 25]]], ["The transmission potential of ZIKV infection has been shown to be comparable to those of DENV and CHIKV (Nishiura et al., 2016a) .", [["ZIKV", "CHEMICAL", 30, 34], ["infection", "DISEASE", 35, 44], ["ZIKV", "ORGANISM", 30, 34], ["DENV", "ORGANISM", 89, 93], ["CHIKV", "ORGANISM", 98, 103], ["ZIKV", "SPECIES", 30, 34], ["DENV", "SPECIES", 89, 93], ["CHIKV", "SPECIES", 98, 103], ["ZIKV infection", "PROBLEM", 30, 44], ["DENV", "PROBLEM", 89, 93], ["ZIKV infection", "OBSERVATION", 30, 44]]], ["Considering that there are no specific treatments for these arboviruses, it is of utmost importance to intervene transmission by preventing mosquito biting (e.g., the use of repellent) or controlling Aedes species, most notably by targeting highly invasive species including Aedes aegypti and Aedes albopictus.", [["arboviruses", "DISEASE", 60, 71], ["Aedes species", "ORGANISM", 200, 213], ["Aedes aegypti", "ORGANISM", 275, 288], ["Aedes albopictus", "ORGANISM", 293, 309], ["Aedes aegypti", "SPECIES", 275, 288], ["Aedes albopictus", "SPECIES", 293, 309], ["Aedes aegypti", "SPECIES", 275, 288], ["Aedes albopictus", "SPECIES", 293, 309], ["specific treatments", "TREATMENT", 30, 49], ["these arboviruses", "PROBLEM", 54, 71], ["mosquito biting", "PROBLEM", 140, 155], ["Aedes species", "PROBLEM", 200, 213], ["highly invasive species", "PROBLEM", 241, 264], ["arboviruses", "OBSERVATION", 60, 71]]], ["The control option of Aedes spp. includes source reduction (i.e., removal of water and covering water storage containers), the use of ovitrap, chemical control, bioinsecticides and biological control (e.g., mosquitofish) (Anonymous, 2016), while recent approaches include transgenic and symbiont-based approaches and the use of plant-borne molecules (Adelman & Tu, 2016; Benelli, 2016; Benelli & Mehlhorn, 2016) .INTRODUCTIONTo plan for forthcoming potential local transmission at each country level, it is fruitful to understand the actual risk of Zika virus epidemic in a quantitative manner.", [["ovitrap", "CHEMICAL", 134, 141], ["Aedes spp", "ORGANISM", 22, 31], ["Zika virus", "ORGANISM", 549, 559], ["Zika virus", "SPECIES", 549, 559], ["Aedes spp", "PROBLEM", 22, 31], ["source reduction", "TREATMENT", 42, 58], ["removal of water and covering water storage containers", "TREATMENT", 66, 120], ["ovitrap", "TREATMENT", 134, 141], ["chemical control", "TREATMENT", 143, 159], ["bioinsecticides", "TREATMENT", 161, 176], ["transgenic and symbiont", "TREATMENT", 272, 295], ["Zika virus", "PROBLEM", 549, 559], ["reduction", "OBSERVATION_MODIFIER", 49, 58], ["Zika virus", "OBSERVATION", 549, 559]]], ["The present real-time study aimed to identify countries at high risk of importing ZIKV infection and also of local transmission as a part of risk assessment practice and for improved understanding of the predicted risk of the spread, with distinct differentiation of ZIKV importation alone from that of local transmission.Epidemiological dataArrival times of ZIKV importation, i.e., the time at which first ZIKV case was imported, in each imported country was collected from publicly available data sources (see Supplemental Information).", [["ZIKV infection", "DISEASE", 82, 96], ["ZIKV", "ORGANISM", 267, 271], ["ZIKV", "SPECIES", 82, 86], ["ZIKV", "SPECIES", 267, 271], ["ZIKV", "SPECIES", 359, 363], ["ZIKV", "SPECIES", 407, 411], ["time study", "TEST", 17, 27], ["importing ZIKV infection", "PROBLEM", 72, 96], ["risk assessment", "TEST", 141, 156], ["the spread", "PROBLEM", 222, 232], ["ZIKV importation", "TREATMENT", 267, 283], ["ZIKV importation", "TREATMENT", 359, 375], ["ZIKV infection", "OBSERVATION", 82, 96], ["ZIKV", "OBSERVATION", 267, 271]]], ["The criterion to include a country as imported was the presence of a report based on confirmatory diagnosis made either by serological testing or detection of virus RNA.", [["virus RNA", "RNA", 159, 168], ["serological testing", "TEST", 123, 142], ["virus RNA", "PROBLEM", 159, 168], ["virus RNA", "OBSERVATION", 159, 168]]], ["When ZIKV was isolated from mosquitoes or primates other than humans, it was considered that the country had already imported the virus, because the virus isolation implies that the local transmission had taken place.", [["ZIKV", "GENE_OR_GENE_PRODUCT", 5, 9], ["primates", "ORGANISM", 42, 50], ["humans", "ORGANISM", 62, 68], ["humans", "SPECIES", 62, 68], ["ZIKV", "SPECIES", 5, 9], ["humans", "SPECIES", 62, 68], ["ZIKV", "PROBLEM", 5, 9], ["the virus", "PROBLEM", 126, 135], ["the virus isolation", "TREATMENT", 145, 164]]], ["When monthly or yearly data were only available or when a seroepidemiological study identified the local transmission, the median week was used as the week of importation.", [["a seroepidemiological study", "TEST", 56, 83]]], ["The latest time at which the importation week was systematically examined was 31 January 2016.Epidemiological dataIn addition to the importation data, we collected the list of countries with local transmission of ZIKV from the European Centre for Disease Prevention and Control (2016) and Gatherer & Kohl (2016) .", [["ZIKV", "SPECIES", 213, 217], ["ZIKV", "PROBLEM", 213, 217], ["Disease Prevention", "TREATMENT", 247, 265]]], ["ECDC resource has specified countries or territories with reported confirmed autochthonous cases of ZIKV infection in the past 9 months.", [["ZIKV infection", "DISEASE", 100, 114], ["ZIKV", "SPECIES", 100, 104], ["ZIKV infection", "PROBLEM", 100, 114], ["ZIKV infection", "OBSERVATION", 100, 114]]], ["Again, the virus isolation from mosquitoes or primates other than humans was regarded as a signature of local transmission.Epidemiological dataAs additional input of prediction models, an open source airline transportation network data were extracted.", [["primates", "ORGANISM", 46, 54], ["humans", "ORGANISM", 66, 72], ["humans", "SPECIES", 66, 72], ["humans", "SPECIES", 66, 72], ["the virus isolation", "TREATMENT", 7, 26], ["prediction models", "TEST", 166, 183]]], ["Furthermore, the country-specific presence of Aedes species, especially focusing on Aedes albopictus, Aedes aegypti and Aedes africana, was explored (Kraemer et al., 2015; The Walter Reed Biosystematics Unit, USA, 2016) .", [["Aedes species", "ORGANISM", 46, 59], ["Aedes albopictus", "ORGANISM", 84, 100], ["Aedes aegypti", "ORGANISM", 102, 115], ["Aedes africana", "ORGANISM", 120, 134], ["Aedes albopictus", "SPECIES", 84, 100], ["Aedes aegypti", "SPECIES", 102, 115], ["Aedes africana", "SPECIES", 120, 134], ["Aedes albopictus", "SPECIES", 84, 100], ["Aedes aegypti", "SPECIES", 102, 115], ["Aedes africana", "SPECIES", 120, 134], ["Aedes species", "PROBLEM", 46, 59]]], ["The list of countries with at least one of the abovementioned Aedes species was prepared, because the local human-vectorhuman transmission of ZIKV infection occurs only where the vector species are present.", [["ZIKV", "CHEMICAL", 142, 146], ["infection", "DISEASE", 147, 156], ["human", "ORGANISM", 108, 113], ["ZIKV", "ORGANISM", 142, 146], ["human", "SPECIES", 108, 113], ["human", "SPECIES", 108, 113], ["ZIKV", "SPECIES", 142, 146], ["the local human-vectorhuman transmission", "TREATMENT", 98, 138], ["ZIKV infection", "PROBLEM", 142, 156], ["ZIKV infection", "OBSERVATION", 142, 156], ["vector species", "OBSERVATION", 179, 193]]], ["Similarly, we also retrieved the country-specific data regarding DENV and CHIKV epidemic (Centers for Disease Control and Prevention, 2016a; Centers for Disease Control and Prevention, 2016b) , because they share major vector species with ZIKV and their epidemics indicate that the vector species have been actively involved in local transmission.", [["DENV", "SPECIES", 65, 69], ["CHIKV", "SPECIES", 74, 79], ["ZIKV", "SPECIES", 239, 243], ["DENV", "PROBLEM", 65, 69], ["CHIKV epidemic", "PROBLEM", 74, 88], ["Disease Control", "TREATMENT", 102, 117], ["Disease Control", "TREATMENT", 153, 168], ["ZIKV", "PROBLEM", 239, 243], ["the vector species", "PROBLEM", 278, 296]]], ["Moreover, it has been explicitly discussed that international spread of Zika virus followed the geographic path of CHIKV (Musso, Cao-Lormeau & Gubler, 2015) .", [["Zika virus", "DISEASE", 72, 82], ["CHIKV", "DISEASE", 115, 120], ["Zika virus", "ORGANISM", 72, 82], ["CHIKV", "ORGANISM", 115, 120], ["Zika virus", "SPECIES", 72, 82], ["CHIKV", "SPECIES", 115, 120], ["Zika virus", "PROBLEM", 72, 82], ["CHIKV", "PROBLEM", 115, 120], ["CHIKV", "OBSERVATION", 115, 120]]], ["The presence of Aedes species, DENV and CHIKV were all dealt with as dichotomous variable.Prediction modelWe estimated the risk of importing ZIKV and that of local transmission using a survival analysis model.", [["Aedes species", "ORGANISM", 16, 29], ["DENV", "ORGANISM", 31, 35], ["CHIKV", "ORGANISM", 40, 45], ["DENV", "SPECIES", 31, 35], ["CHIKV", "SPECIES", 40, 45], ["ZIKV", "SPECIES", 141, 145], ["Aedes species", "PROBLEM", 16, 29], ["DENV", "PROBLEM", 31, 35], ["CHIKV", "PROBLEM", 40, 45], ["importing ZIKV", "PROBLEM", 131, 145], ["a survival analysis model", "TEST", 183, 208], ["Aedes species", "OBSERVATION", 16, 29]]], ["Let T be a continuous random variable with probability density function of the time from importation in Brazil to importation in country j, f j (t ), and cumulative distribution function F j (t ) = Pr(T < t ).", [["Let T", "GENE_OR_GENE_PRODUCT", 0, 5], ["a continuous random variable", "PROBLEM", 9, 37]]], ["The function F j (t ) describes the probability that ZIKV has been already imported to a country j by time t .", [["ZIKV", "SPECIES", 53, 57], ["ZIKV", "PROBLEM", 53, 57], ["ZIKV", "OBSERVATION", 53, 57]]], ["The time t = 0 corresponds to the time at which ZIKV infection was first recognized in Brazil and started to rapidly spread across countries (i.e., week 12 of 2015).", [["infection", "DISEASE", 53, 62], ["ZIKV", "SPECIES", 48, 52], ["ZIKV infection", "PROBLEM", 48, 62], ["infection", "OBSERVATION", 53, 62]]], ["The effective length of the path, dn 1 n l , is defined byPrediction modelwhere P ji denotes the conditional probability that an individual that left i moves to j.Prediction modelAssuming that the number of passengers is identical among all international flights, the transition matrix is calculated as P ji = w ji k w ki , where w ki is the number of direct flights from country i to country k per unit time derived from airline transportation network data (Contentshare, 2016) .", [["matrix", "CELLULAR_COMPONENT", 279, 285], ["P ji", "DNA", 80, 84], ["ki", "DNA", 332, 334], ["the transition matrix", "TREATMENT", 264, 285], ["effective", "OBSERVATION_MODIFIER", 4, 13], ["length", "OBSERVATION_MODIFIER", 14, 20], ["left", "ANATOMY_MODIFIER", 145, 149]]], ["Finally, the effective distance m j of a country j from the country of origin (i.e., Brazil) is calculated as the minimum of the all possible effective lengths of path that goes from the origin country to the country j.", [["effective", "OBSERVATION_MODIFIER", 142, 151], ["lengths", "OBSERVATION_MODIFIER", 152, 159]]], ["The effective distance has been known as an excellent predictor of the arrival time of SARS (severe acute respiratory syndrome) and influenza pH1N1 2009 (Brockmann & Helbing, 2013) .", [["SARS", "DISEASE", 87, 91], ["acute respiratory syndrome", "DISEASE", 100, 126], ["SARS (severe acute respiratory syndrome", "PROBLEM", 87, 126], ["influenza", "PROBLEM", 132, 141], ["H1N1", "PROBLEM", 143, 147], ["severe", "OBSERVATION_MODIFIER", 93, 99], ["acute", "OBSERVATION_MODIFIER", 100, 105], ["respiratory syndrome", "OBSERVATION", 106, 126]]], ["Considering that the effective distance is a critical indicator of the risk of importation, we assume that the hazard function is an inverse of the effective distance, i.e.,Prediction modelwhere k is a constant.", [["the hazard function", "TEST", 107, 126], ["constant", "OBSERVATION_MODIFIER", 202, 210]]], ["Using the hazard function, the abovementioned density function is modeled asPrediction modelModeling f j (t ) in this way, the mean arrival time of the ZIKV to a country j would be proportional to the effective distance from the origin of spread (i.e., Brazil in our case study).Prediction modelUsing the calculated risk of importation, we subsequently model the country specific risk of local transmission.", [["the hazard function", "TEST", 6, 25], ["density", "OBSERVATION", 46, 53], ["origin", "ANATOMY_MODIFIER", 229, 235], ["local transmission", "OBSERVATION", 388, 406]]], ["Let p j be the conditional probability of ZIKV transmission given an importation event in a country j.", [["Let p j", "GENE_OR_GENE_PRODUCT", 0, 7], ["ZIKV", "SPECIES", 42, 46]]], ["Since our time scale of examining the risk of importation is much longer than the generation time of ZIKV infection, we ignore the time-lag that is required for observing the transmission cycle, and the risk of the local transmission of ZIKV in a country j is modeled asPrediction modelIn order to estimate p j , the conditional probability of experiencing local transmission, we use datasets of the presence of Aedes species, CHIKV and DENV in each country.", [["infection", "DISEASE", 106, 115], ["ZIKV", "DISEASE", 237, 241], ["Aedes species", "ORGANISM", 412, 425], ["CHIKV", "ORGANISM", 427, 432], ["ZIKV", "SPECIES", 101, 105], ["ZIKV", "SPECIES", 237, 241], ["CHIKV", "SPECIES", 427, 432], ["DENV", "SPECIES", 437, 441], ["ZIKV infection", "PROBLEM", 101, 115], ["ZIKV", "PROBLEM", 237, 241], ["Aedes species", "PROBLEM", 412, 425], ["CHIKV", "PROBLEM", 427, 432], ["DENV", "PROBLEM", 437, 441]]], ["More specifically, we model p j by employing a logit modelPrediction modelwhere a 0 is an intercept, x ji is the dichotomous variable that describes the presence of Aedes mosquitoes (for i = 1), CHIKV (for i = 2) and DENV (for i = 3) in country j, and \u03b2 i represents the coefficient for corresponding variable i.Parameter estimation and risk assessmentWe estimate parameters k, a 0 and three \u03b2 i using a maximum likelihood method.", [["Aedes mosquitoes", "ORGANISM", 165, 181], ["CHIKV", "ORGANISM", 195, 200], ["Aedes mosquitoes", "SPECIES", 165, 181], ["CHIKV", "SPECIES", 195, 200], ["a logit model", "TREATMENT", 45, 58], ["CHIKV", "PROBLEM", 195, 200], ["DENV", "PROBLEM", 217, 221], ["Parameter estimation", "TEST", 312, 332], ["risk assessment", "TEST", 337, 352], ["a maximum likelihood method", "TREATMENT", 402, 429]]], ["Since we start the clock from week 12, 2015 originated from Brazil (Campos, Bandeira & Sardi, 2015) , countries that had imported ZIKV in advance (e.g., Africa and South Pacific) were removed before the implementation.", [["ZIKV", "CHEMICAL", 130, 134]]], ["Although five countries (Aruba, Trinidad and Tobago, Marshall Islands, Saint Vincent and the Grenadines, and American Samoa) were specified as countries with local transmission by ECDC data source (European Centre for Disease Prevention and Control , 2016) , these countries have experienced importation and confirmation in February 2016, and were thus removed from the list of countries with importation as well as local transmission.", [["the Grenadines", "TREATMENT", 89, 103], ["Disease Prevention", "TREATMENT", 218, 236]]], ["The likelihood of importation risk adhered to survival model.", [["survival model", "TREATMENT", 46, 60]]], ["That is, among countries that have already imported ZIKV by then, the arrival time t j was used for parameter estimation.", [["ZIKV", "DNA", 52, 56], ["ZIKV", "SPECIES", 52, 56], ["parameter estimation", "TEST", 100, 120]]], ["In other words, the survival time for those countries is considered to be at least as long as the duration of our study.", [["our study", "TEST", 110, 119]]], ["The likelihood function readsParameter estimation and risk assessmentwhere A represents the set of countries which experienced local transmission of ZIKV by time of observation t m (31 January 2016), B represents countries which imported ZIKV before t m but without local transmission, and C is the set of countries which has not imported by t m .", [["ZIKV", "SPECIES", 149, 153], ["Parameter estimation", "TEST", 29, 49]]], ["Once the parameter k is estimated, we are able to predict the probability of country j to experience local transmission of ZIKV by time t asParameter estimation and risk assessmentWe assessed the diagnostic performance of our models in predicting risks of importation and local transmission by employing the receiver operating characteristic (ROC) curve and measuring the area under the curve (AUC) (Greiner, Pfeiffer & Smith, 2000) .", [["ZIKV", "SPECIES", 123, 127], ["the parameter k", "TEST", 5, 20], ["ZIKV", "TREATMENT", 123, 127], ["risk assessment", "TEST", 165, 180]]], ["(5) were varied by using 1-3 variables (by examining all possible combinations of Aedes, DENV and CHIKV), and we compared AUC to identify the best predictive model.", [["DENV", "ORGANISM", 89, 93], ["CHIKV", "ORGANISM", 98, 103], ["DENV", "SPECIES", 89, 93], ["CHIKV", "SPECIES", 98, 103], ["DENV", "PROBLEM", 89, 93], ["CHIKV", "PROBLEM", 98, 103], ["AUC", "TEST", 122, 125]]], ["To avoid serious collinearity among Aedes, DENV and CHIKV, Cohen's kappa, an agreement statistic, was computed to examine correlations between two dichotomous explanatory variables.", [["DENV", "ORGANISM", 43, 47], ["CHIKV", "ORGANISM", 52, 57], ["DENV", "SPECIES", 43, 47], ["CHIKV", "SPECIES", 52, 57], ["DENV", "PROBLEM", 43, 47], ["CHIKV", "PROBLEM", 52, 57]]], ["For each model, the optimal cut-off value of estimated risk was calculated using Youden's index.", [["Youden's index", "TEST", 81, 95]]], ["One year was calculated to be exactly equal to 52 weeks in our analysis.", [["our analysis", "TEST", 59, 71]]], ["Although three confirmed cases of ZIKV infection were reported in Chile on 2 February 2016, that data was ignored in the present study because the latest time was set at fourth week of 2016.", [["ZIKV infection", "DISEASE", 34, 48], ["ZIKV", "ORGANISM", 34, 38], ["ZIKV", "SPECIES", 34, 38], ["ZIKV infection", "PROBLEM", 34, 48], ["the present study", "TEST", 117, 134], ["ZIKV infection", "OBSERVATION", 34, 48]]], ["We also did not count a case report from Easter Island, a Chilean island in the southeastern Pacific Ocean, because the island is geographically distant from other parts of Chile and has only one airport (World Health Organization, Western Pacific Region, 2016) .", [["geographically", "OBSERVATION_MODIFIER", 130, 144], ["distant", "OBSERVATION", 145, 152]]], ["In Zambia, a cross sectional study was conducted, but there was no available information to identify the date of importation or survey.", [["a cross sectional study", "TEST", 11, 34]]], ["Thus, the year of the acceptance of the article, 2015, was assumed as the year of importation (Babaniyi et al., 2015) . (continued on next page) Notes. a AUC, area under the curve.", [["a AUC", "TEST", 152, 157]]], ["The confidence intervals were calculated using Mann-Whitney method (Gengsheng & Hotilovac, 2008) . b CI, confidence interval.Countryfirst identified ZIKV case in 1947, Uganda (Dick, 1952) , but the country was not specified as the origin, because a long time has passed since the emergence and the path of global spread must not have followed a static network.", [["global spread", "PROBLEM", 306, 319]]], ["Note that 39 countries which had already imported ZIKV prior to importation event in Brazil were excluded from the analysis.", [["ZIKV", "CHEMICAL", 50, 54], ["ZIKV", "SPECIES", 50, 54], ["the analysis", "TEST", 111, 123]]], ["Figure 2 shows the global distribution of the risk of importation.", [["global", "OBSERVATION_MODIFIER", 19, 25], ["distribution", "OBSERVATION_MODIFIER", 26, 38]]], ["Among the top 30 countries predicted at high risk of ZIKV importation in the end of 2016 (Fig. 3) , 18 countries (60%) had already imported ZIKV before week 46.", [["ZIKV", "SPECIES", 53, 57], ["ZIKV", "SPECIES", 140, 144], ["ZIKV importation", "TREATMENT", 53, 69], ["ZIKV", "OBSERVATION", 53, 57]]], ["Table 2 shows the fitting results of various models to predict the risk of local transmission.", [["local transmission", "OBSERVATION", 75, 93]]], ["Comparing predictive performance by AUC among models with all possible combinations of three explanatory variables, the model with CHIKV and DENV appeared to yield the greatest value of AUC (0.90 (95% CI [0.60-1.00])).", [["CHIKV", "ORGANISM", 131, 136], ["DENV", "ORGANISM", 141, 145], ["CHIKV", "SPECIES", 131, 136], ["DENV", "SPECIES", 141, 145], ["CHIKV", "PROBLEM", 131, 136], ["DENV", "PROBLEM", 141, 145], ["AUC", "TEST", 186, 189], ["CI", "TEST", 201, 203]]], ["Figures 1B and 1D show the distribution of the estimated risk and ROC curve, respectively.", [["ROC curve", "TEST", 66, 75]]], ["Using the best model, sensitivity was as high as 96.4% (95% CI [89.6-100.0]), while the specificity was estimated at 67.7% (95% CI [60.5-74.9]).", [["sensitivity", "TEST", 22, 33], ["CI", "TEST", 60, 62], ["the specificity", "TEST", 84, 99], ["CI", "TEST", 128, 130]]], ["The second best model was the one with CHIKV only.", [["CHIKV", "ORGANISM", 39, 44], ["CHIKV", "SPECIES", 39, 44], ["CHIKV", "PROBLEM", 39, 44], ["CHIKV", "OBSERVATION", 39, 44]]], ["Compared with the absence of Chikungunya virus, the risk of local transmission in the presence of this virus was shown to be indicative of 22.9 times (95% CI [3.3-238.3]) higher.", [["Chikungunya virus", "DISEASE", 29, 46], ["Chikungunya virus", "ORGANISM", 29, 46], ["Chikungunya virus", "SPECIES", 29, 46], ["Chikungunya virus", "PROBLEM", 29, 46], ["this virus", "PROBLEM", 98, 108], ["CI", "TEST", 155, 157], ["Chikungunya virus", "OBSERVATION", 29, 46]]], ["The presence of dengue was not statistically significant, but the adjusted odds ratio was estimated to be 7.7 (95% CI [1.0-73.6]).", [["dengue", "DISEASE", 16, 22], ["dengue", "SPECIES", 16, 22], ["dengue", "PROBLEM", 16, 22], ["the adjusted odds ratio", "TEST", 62, 85], ["CI", "TEST", 115, 117], ["dengue", "OBSERVATION", 16, 22]]], ["No particular correlation that could lead to multi-collinearity (e.g., kappa > 0.60) was identified.", [["multi-collinearity", "TEST", 45, 63], ["kappa", "TEST", 71, 76]]], ["Figure 2B shows the country-specific global distribution of local transmission using the best model.", [["global", "OBSERVATION_MODIFIER", 37, 43], ["distribution", "OBSERVATION_MODIFIER", 44, 56], ["local transmission", "OBSERVATION", 60, 78]]], ["The high risk of local transmission is seen mainly among countries in The importation risk of ZIKV by week 92 is colored by intensity (0-20%, 20-40%, 40-60%, 60-80%).", [["ZIKV", "DISEASE", 94, 98], ["ZIKV", "ORGANISM", 94, 98], ["ZIKV", "SPECIES", 94, 98], ["ZIKV", "PROBLEM", 94, 98], ["high", "OBSERVATION_MODIFIER", 4, 8], ["local transmission", "OBSERVATION", 17, 35]]], ["The origin country, Brazil, is colored in grey.", [["colored", "OBSERVATION", 31, 38]]], ["Other additional countries colored in grey were excluded, because they experienced importation of ZIKV infection prior to the event in Brazil (week 12, 2015) .", [["ZIKV infection", "DISEASE", 98, 112], ["ZIKV", "SPECIES", 98, 102], ["ZIKV infection", "PROBLEM", 98, 112], ["ZIKV", "OBSERVATION", 98, 102]]], ["(B) The local transmission risk of ZIKV infection by week 92 accounting for dengue and chikungunya epidemic data.", [["ZIKV infection", "DISEASE", 35, 49], ["dengue", "DISEASE", 76, 82], ["chikungunya", "DISEASE", 87, 98], ["ZIKV", "ORGANISM", 35, 39], ["ZIKV", "SPECIES", 35, 39], ["dengue", "SPECIES", 76, 82], ["ZIKV infection", "PROBLEM", 35, 49], ["dengue", "PROBLEM", 76, 82], ["chikungunya epidemic data", "PROBLEM", 87, 112], ["ZIKV infection", "OBSERVATION", 35, 49]]], ["The local transmission risk of ZIKV is colored by intensity (0-15%, 15-30%, 30-45%, 45-60%).", [["ZIKV", "ORGANISM", 31, 35], ["ZIKV", "SPECIES", 31, 35], ["ZIKV", "PROBLEM", 31, 35], ["intensity", "TEST", 50, 59], ["ZIKV", "OBSERVATION", 31, 35]]], ["The origin country, Brazil, is colored in grey.", [["colored", "OBSERVATION", 31, 38]]], ["Other additional countries colored in grey were excluded, because they experienced importation of ZIKV infection prior to the event in Brazil (week 12, 2015) . tropical and subtropical areas.", [["ZIKV infection", "DISEASE", 98, 112], ["ZIKV", "SPECIES", 98, 102], ["ZIKV infection", "PROBLEM", 98, 112], ["tropical and subtropical areas", "PROBLEM", 160, 190], ["ZIKV", "OBSERVATION", 98, 102], ["subtropical", "OBSERVATION_MODIFIER", 173, 184]]], ["Figure 3B show the top 30 countries with high risk of local transmission by week 92, using Brazil as the origin of spread.", [["Brazil", "TREATMENT", 91, 97], ["spread", "OBSERVATION", 115, 121]]], ["Among the total, 19 countries (63.3%) were predicted to have already allowed local transmission before week 46.DISCUSSIONThe present study estimated country-specific risk of importation and local transmission of ZIKV infection using a simple statistical model.", [["ZIKV infection", "DISEASE", 212, 226], ["ZIKV", "ORGANISM", 212, 216], ["ZIKV", "SPECIES", 212, 216], ["The present study", "TEST", 121, 138], ["ZIKV infection", "PROBLEM", 212, 226], ["a simple statistical model", "TREATMENT", 233, 259], ["ZIKV infection", "OBSERVATION", 212, 226]]], ["As reported elsewhere, ZIKV infection was often internationally spread by mildly infected travellers (Tappe et al., 2014; Kutsuna et al., 2014; Korhonen et al., 2016) .", [["infection", "DISEASE", 28, 37], ["ZIKV", "SPECIES", 23, 27], ["ZIKV infection", "PROBLEM", 23, 37], ["mildly infected travellers", "PROBLEM", 74, 100], ["ZIKV infection", "OBSERVATION", 23, 37], ["mildly", "OBSERVATION_MODIFIER", 74, 80], ["infected", "OBSERVATION_MODIFIER", 81, 89]]], ["Potentially high importation risk in many temperate countries has motivated us to explore the risks of importation and local transmission fuelled by travellers.", [["high", "OBSERVATION_MODIFIER", 12, 16]]], ["Our model is not as sophisticated as mapping precise risk of transmission using seasonal population dynamics of Aedes species and temperature/climatological data (Bogoch et al., 2016; Nah et al., in press ), but the findings at country levels from our study are broadly consistent with what has been briefly described at finer scales (Bogoch et al., 2016) .", [["Aedes species", "TEST", 112, 125], ["climatological data", "TEST", 142, 161], ["our study", "TEST", 248, 257]]], ["Without using finer scale spatial data (e.g., ecological data on Geographic Information Systems), our approach has crudely and clearly distinguished the risk of local transmission from importation risk at country levels using a more tractable approach.", [["a more tractable approach", "TREATMENT", 226, 251]]], ["We have shown that the predicted risk of local transmission was frequently seen in tropical and subtropical countries with DENV or CHIKV epidemic experience, while the risk of importation was more scattered around the world.", [["DENV", "SPECIES", 123, 127], ["CHIKV", "SPECIES", 131, 136], ["DENV", "PROBLEM", 123, 127], ["scattered", "OBSERVATION_MODIFIER", 197, 206]]], ["The diagnostic performance of risk model for local transmission was well supported by AUC value of 0.90.", [["AUC value", "TEST", 86, 95]]], ["Our study contributes to the risk assessment practice at each country level using estimated risks of importation and local transmission expressed as probabilities.", [["Our study", "TEST", 0, 9], ["the risk assessment", "TEST", 25, 44]]], ["We have shown that the risk of importation may be high in several countries given continued global travel of mildly infected travellers.", [["mildly infected travellers", "PROBLEM", 109, 135], ["mildly", "OBSERVATION_MODIFIER", 109, 115], ["infected", "OBSERVATION", 116, 124]]], ["However, considering that the public health concerns over ZIKV infection stems from the presence of microcephaly, it is more important to focus on the risk of local and widespread transmission that could involve pregnant women.", [["infection", "DISEASE", 63, 72], ["microcephaly", "DISEASE", 100, 112], ["ZIKV", "ORGANISM", 58, 62], ["women", "ORGANISM", 221, 226], ["women", "SPECIES", 221, 226], ["ZIKV", "SPECIES", 58, 62], ["ZIKV infection stems", "PROBLEM", 58, 78], ["microcephaly", "PROBLEM", 100, 112], ["microcephaly", "OBSERVATION", 100, 112]]], ["Compared with the risk of importation, the risk of local transmission was particularly highlighted in countries with DENV and CHIKV epidemic experience.", [["DENV", "SPECIES", 117, 121], ["CHIKV", "SPECIES", 126, 131], ["DENV", "PROBLEM", 117, 121]]], ["Considering that the Olympic Game in Brazil 2016 will elevate the risk of ZIKV to spread over a wider spatial extent (Petersen et al., 2016) , the distinction between importation and local transmission will be even more important than it has been recognized.", [["ZIKV", "SPECIES", 74, 78], ["ZIKV", "PROBLEM", 74, 78], ["ZIKV", "OBSERVATION", 74, 78]]], ["Whereas our risk model of local transmission relied on the presence of transmission by DENV or CHIKV, the use of such a dataset should be deemed only as a proxy.", [["DENV", "ORGANISM", 87, 91], ["CHIKV", "ORGANISM", 95, 100], ["DENV", "SPECIES", 87, 91], ["CHIKV", "SPECIES", 95, 100], ["DENV", "PROBLEM", 87, 91], ["CHIKV", "PROBLEM", 95, 100], ["a dataset", "TREATMENT", 118, 127], ["DENV", "OBSERVATION", 87, 91]]], ["The sensitivity of our best model was 96.4%, and thus there is limited case in which the absence of DENV or CHIKV lead to the local transmission of ZIKV.", [["ZIKV", "DISEASE", 148, 152], ["DENV", "ORGANISM", 100, 104], ["CHIKV", "ORGANISM", 108, 113], ["ZIKV", "ORGANISM", 148, 152], ["DENV", "SPECIES", 100, 104], ["CHIKV", "SPECIES", 108, 113], ["ZIKV", "SPECIES", 148, 152], ["our best model", "TEST", 19, 33], ["DENV", "PROBLEM", 100, 104], ["CHIKV", "PROBLEM", 108, 113], ["ZIKV", "PROBLEM", 148, 152], ["DENV", "OBSERVATION", 100, 104]]], ["However, the specificity was limited to 67.7%, indicating that there would be a number of countries in which ZIKV transmission has yet to occur even in the presence of DENV and CHIKV.", [["CHIKV", "DISEASE", 177, 182], ["ZIKV", "ORGANISM", 109, 113], ["DENV", "ORGANISM", 168, 172], ["CHIKV", "ORGANISM", 177, 182], ["ZIKV", "SPECIES", 109, 113], ["DENV", "SPECIES", 168, 172], ["CHIKV", "SPECIES", 177, 182], ["the specificity", "TEST", 9, 24], ["ZIKV transmission", "PROBLEM", 109, 126], ["DENV", "PROBLEM", 168, 172], ["CHIKV", "PROBLEM", 177, 182], ["DENV", "OBSERVATION", 168, 172], ["CHIKV", "OBSERVATION", 177, 182]]], ["Moreover, to further improve the prediction, ecological data of vector behaviour at finer spatial scale must be incorporated with validation using epidemic data.DISCUSSIONA few limitations must be discussed.", [["the prediction", "TEST", 29, 43], ["epidemic data", "TEST", 147, 160]]], ["First, ascertainment bias cannot be ignored for ZIKV infection with substantial fraction of asymptomatic and mild infections.", [["infection", "DISEASE", 53, 62], ["infections", "DISEASE", 114, 124], ["ZIKV", "SPECIES", 48, 52], ["ZIKV infection", "PROBLEM", 48, 62], ["asymptomatic and mild infections", "PROBLEM", 92, 124], ["asymptomatic", "OBSERVATION_MODIFIER", 92, 104], ["mild", "OBSERVATION_MODIFIER", 109, 113], ["infections", "OBSERVATION", 114, 124]]], ["Second, the network data we used were static, and the airline transportation data represented only the number of flight routes (i.e., not the number of passengers).", [["the airline transportation data", "TEST", 50, 81]]], ["For instance, the United States, China and Australia have both high and low risk areas of transmission due to vast land with different climatological areas.DISCUSSIONFinally, we estimated the importation risk of ZIKV in a country as a risk of importing ZIKV from Brazil to the country.", [["ZIKV", "CHEMICAL", 212, 216], ["ZIKV", "SPECIES", 212, 216], ["ZIKV", "SPECIES", 253, 257], ["ZIKV", "PROBLEM", 212, 216], ["high", "OBSERVATION_MODIFIER", 63, 67], ["low risk", "OBSERVATION_MODIFIER", 72, 80], ["ZIKV", "OBSERVATION", 212, 216]]], ["Therefore, our model cannot capture the risk of importing ZIKV from other endemic area such as South Pacific.DISCUSSIONDespite a clear need to improve predictions in the future, the present study successfully devised a simple global risk prediction of importation and local transmission.", [["ZIKV", "SPECIES", 58, 62], ["the present study", "TEST", 178, 195], ["ZIKV", "OBSERVATION", 58, 62]]], ["Countries with DENV and CHIKV epidemic experience are likely to be at particular high risk, and such countries should be prepared for vector control measures such as avoiding daytime biting and the use of mosquito repellent.", [["daytime biting", "DISEASE", 175, 189], ["DENV", "SPECIES", 15, 19], ["CHIKV", "SPECIES", 24, 29], ["DENV", "PROBLEM", 15, 19], ["CHIKV", "PROBLEM", 24, 29], ["vector control measures", "TREATMENT", 134, 157], ["daytime biting", "PROBLEM", 175, 189], ["DENV", "OBSERVATION", 15, 19]]], ["To further improve model predictions, it is essential to have laboratory capacity built up in every single country at risk of local transmission.CONCLUSIONSRisks of importation and local transmission of Zika virus infection were estimated, analyzing epidemiological, ecological and mobility data.", [["Zika virus infection", "DISEASE", 203, 223], ["Zika virus", "ORGANISM", 203, 213], ["Zika virus", "SPECIES", 203, 213], ["Zika virus", "SPECIES", 203, 213], ["laboratory capacity", "PROBLEM", 62, 81], ["Zika virus infection", "PROBLEM", 203, 223], ["local transmission", "OBSERVATION", 126, 144], ["Zika virus", "OBSERVATION", 203, 213]]], ["Whereas the risk of importation was well explained by the airline transportation network data, the risk of local transmission appeared to be best captured by additionally accounting for the presence of an epidemic of dengue and chikungunya viruses.", [["dengue", "DISEASE", 217, 223], ["chikungunya viruses", "DISEASE", 228, 247], ["chikungunya viruses", "ORGANISM", 228, 247], ["dengue", "SPECIES", 217, 223], ["chikungunya viruses", "SPECIES", 228, 247], ["dengue", "PROBLEM", 217, 223], ["chikungunya viruses", "PROBLEM", 228, 247], ["epidemic", "OBSERVATION_MODIFIER", 205, 213], ["chikungunya viruses", "OBSERVATION", 228, 247]]]], "PMC7279692": [["IntroductionMyeloid sarcoma (MS), also called granulocytic sarcoma or chloroma, is an extramedullary solid tumor that arises from myeloid precursor cells [1].", [["Myeloid sarcoma", "ANATOMY", 12, 27], ["granulocytic sarcoma", "ANATOMY", 46, 66], ["chloroma", "ANATOMY", 70, 78], ["extramedullary solid tumor", "ANATOMY", 86, 112], ["myeloid precursor cells", "ANATOMY", 130, 153], ["Myeloid sarcoma", "DISEASE", 12, 27], ["MS", "DISEASE", 29, 31], ["granulocytic sarcoma", "DISEASE", 46, 66], ["chloroma", "DISEASE", 70, 78], ["tumor", "DISEASE", 107, 112], ["Myeloid sarcoma", "CANCER", 12, 27], ["MS", "CANCER", 29, 31], ["granulocytic sarcoma", "CANCER", 46, 66], ["chloroma", "CANCER", 70, 78], ["extramedullary solid tumor", "CANCER", 86, 112], ["myeloid precursor cells", "CELL", 130, 153], ["myeloid precursor cells", "CELL_TYPE", 130, 153], ["IntroductionMyeloid sarcoma (MS)", "PROBLEM", 0, 32], ["granulocytic sarcoma", "PROBLEM", 46, 66], ["chloroma", "PROBLEM", 70, 78], ["an extramedullary solid tumor", "PROBLEM", 83, 112], ["Myeloid sarcoma", "OBSERVATION", 12, 27], ["granulocytic sarcoma", "OBSERVATION", 46, 66], ["chloroma", "OBSERVATION", 70, 78], ["extramedullary", "OBSERVATION_MODIFIER", 86, 100], ["solid", "OBSERVATION_MODIFIER", 101, 106], ["tumor", "OBSERVATION", 107, 112], ["myeloid precursor cells", "OBSERVATION", 130, 153]]], ["Its pathogenesis is highly variable; it can develop as an isolated mass or in relation to other hematological malignancies such as myeloproliferative disorder, myelodysplastic syndrome (MDS), and acute myeloid leukemia (AML) [2].", [["mass", "ANATOMY", 67, 71], ["hematological malignancies", "ANATOMY", 96, 122], ["acute myeloid leukemia", "ANATOMY", 196, 218], ["AML", "ANATOMY", 220, 223], ["hematological malignancies", "DISEASE", 96, 122], ["myeloproliferative disorder", "DISEASE", 131, 158], ["myelodysplastic syndrome", "DISEASE", 160, 184], ["MDS", "DISEASE", 186, 189], ["acute myeloid leukemia", "DISEASE", 196, 218], ["AML", "DISEASE", 220, 223], ["malignancies", "CANCER", 110, 122], ["acute myeloid leukemia", "CANCER", 196, 218], ["AML", "CANCER", 220, 223], ["an isolated mass", "PROBLEM", 55, 71], ["other hematological malignancies", "PROBLEM", 90, 122], ["myeloproliferative disorder", "PROBLEM", 131, 158], ["myelodysplastic syndrome", "PROBLEM", 160, 184], ["MDS)", "PROBLEM", 186, 190], ["acute myeloid leukemia (AML)", "PROBLEM", 196, 224], ["highly", "OBSERVATION_MODIFIER", 20, 26], ["variable", "OBSERVATION_MODIFIER", 27, 35], ["isolated", "OBSERVATION_MODIFIER", 58, 66], ["mass", "OBSERVATION", 67, 71], ["hematological", "ANATOMY", 96, 109], ["malignancies", "OBSERVATION", 110, 122], ["myeloproliferative disorder", "OBSERVATION", 131, 158], ["myelodysplastic syndrome", "OBSERVATION", 160, 184], ["acute", "OBSERVATION_MODIFIER", 196, 201], ["myeloid leukemia", "OBSERVATION", 202, 218]]], ["MS can be the initial manifestation of extramedullary blood cancer, can occur concurrently with it, or can represent a relapsing disease in a patient in remission [3].", [["extramedullary blood cancer", "ANATOMY", 39, 66], ["MS", "DISEASE", 0, 2], ["extramedullary blood cancer", "DISEASE", 39, 66], ["extramedullary blood cancer", "CANCER", 39, 66], ["patient", "ORGANISM", 142, 149], ["patient", "SPECIES", 142, 149], ["extramedullary blood cancer", "PROBLEM", 39, 66], ["a relapsing disease", "PROBLEM", 117, 136], ["extramedullary blood cancer", "OBSERVATION", 39, 66], ["relapsing", "OBSERVATION_MODIFIER", 119, 128], ["disease", "OBSERVATION", 129, 136]]], ["Isolated MS, in particular, is exceedingly rare as it occurs in 2 per 1,000,000 individuals [4].", [["MS", "DISEASE", 9, 11], ["Isolated MS", "PROBLEM", 0, 11], ["MS", "OBSERVATION", 9, 11]]], ["Cases in the literature have described the lymph nodes, bones, skin, lungs, external genitalia, bowels, and brain as sites of incidence.", [["lymph nodes", "ANATOMY", 43, 54], ["bones", "ANATOMY", 56, 61], ["skin", "ANATOMY", 63, 67], ["lungs", "ANATOMY", 69, 74], ["external genitalia", "ANATOMY", 76, 94], ["bowels", "ANATOMY", 96, 102], ["brain", "ANATOMY", 108, 113], ["sites", "ANATOMY", 117, 122], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 43, 54], ["bones", "TISSUE", 56, 61], ["skin", "ORGAN", 63, 67], ["lungs", "ORGAN", 69, 74], ["external genitalia", "MULTI-TISSUE_STRUCTURE", 76, 94], ["bowels", "ORGAN", 96, 102], ["brain", "ORGAN", 108, 113], ["the lymph nodes, bones, skin, lungs, external genitalia, bowels, and brain", "PROBLEM", 39, 113], ["lymph nodes", "OBSERVATION", 43, 54], ["bones", "ANATOMY", 56, 61], ["skin", "ANATOMY", 63, 67], ["lungs", "ANATOMY", 69, 74], ["external genitalia", "ANATOMY", 76, 94], ["bowels", "ANATOMY", 96, 102], ["brain", "ANATOMY", 108, 113]]], ["We present an unusual case of isolated pancreatic MS several years post-stem cell transplant in a nonleukemic patient.Case presentationA 57-year-old female presented to the emergency department with the chief complaints of progressive generalized weakness, epigastric abdominal pain radiating to her back, and a progressively worsening yellow tint to the skin and eyes.", [["pancreatic", "ANATOMY", 39, 49], ["stem cell", "ANATOMY", 72, 81], ["epigastric abdominal", "ANATOMY", 257, 277], ["back", "ANATOMY", 300, 304], ["skin", "ANATOMY", 355, 359], ["eyes", "ANATOMY", 364, 368], ["pancreatic MS", "DISEASE", 39, 52], ["weakness", "DISEASE", 247, 255], ["epigastric abdominal pain", "DISEASE", 257, 282], ["pancreatic", "ORGAN", 39, 49], ["stem cell", "CELL", 72, 81], ["patient", "ORGANISM", 110, 117], ["female", "ORGANISM", 149, 155], ["abdominal", "ORGANISM_SUBDIVISION", 268, 277], ["skin", "ORGAN", 355, 359], ["eyes", "ORGAN", 364, 368], ["patient", "SPECIES", 110, 117], ["isolated pancreatic MS", "PROBLEM", 30, 52], ["stem cell transplant", "TREATMENT", 72, 92], ["progressive generalized weakness", "PROBLEM", 223, 255], ["epigastric abdominal pain", "PROBLEM", 257, 282], ["a progressively worsening yellow tint to the skin and eyes", "PROBLEM", 310, 368], ["pancreatic", "ANATOMY", 39, 49], ["stem cell transplant", "OBSERVATION", 72, 92], ["progressive", "OBSERVATION_MODIFIER", 223, 234], ["generalized", "OBSERVATION_MODIFIER", 235, 246], ["weakness", "OBSERVATION", 247, 255], ["epigastric", "ANATOMY_MODIFIER", 257, 267], ["abdominal", "ANATOMY", 268, 277], ["pain", "OBSERVATION", 278, 282], ["back", "ANATOMY", 300, 304], ["progressively", "OBSERVATION_MODIFIER", 312, 325], ["worsening", "OBSERVATION_MODIFIER", 326, 335], ["yellow tint", "OBSERVATION", 336, 347], ["skin", "ANATOMY", 355, 359], ["eyes", "ANATOMY", 364, 368]]], ["The onset of her complaints reportedly occurred seven days prior to her initial presentation.", [["her complaints", "PROBLEM", 13, 27]]], ["Eight years prior she was diagnosed with MDS, for which she underwent successful allogenic bone marrow transplantation that was complicated by subsequent chronic graft versus host disease.", [["bone marrow", "ANATOMY", 91, 102], ["graft", "ANATOMY", 162, 167], ["MDS", "DISEASE", 41, 44], ["chronic graft versus host disease", "DISEASE", 154, 187], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 91, 102], ["graft", "TISSUE", 162, 167], ["MDS", "PROBLEM", 41, 44], ["successful allogenic bone marrow transplantation", "TREATMENT", 70, 118], ["subsequent chronic graft versus host disease", "PROBLEM", 143, 187], ["MDS", "OBSERVATION", 41, 44], ["allogenic bone marrow transplantation", "OBSERVATION", 81, 118], ["chronic", "OBSERVATION_MODIFIER", 154, 161], ["graft versus host disease", "OBSERVATION", 162, 187]]], ["Complete remission of her MDS and graft versus host disease were achieved by allogenic bone marrow transplant and chronic ruxolitinib therapy, respectively.", [["graft", "ANATOMY", 34, 39], ["bone marrow", "ANATOMY", 87, 98], ["MDS", "DISEASE", 26, 29], ["graft versus host disease", "DISEASE", 34, 59], ["ruxolitinib", "CHEMICAL", 122, 133], ["ruxolitinib", "CHEMICAL", 122, 133], ["graft", "TISSUE", 34, 39], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 87, 98], ["ruxolitinib", "SIMPLE_CHEMICAL", 122, 133], ["her MDS", "PROBLEM", 22, 29], ["graft versus host disease", "PROBLEM", 34, 59], ["allogenic bone marrow transplant", "TREATMENT", 77, 109], ["chronic ruxolitinib therapy", "TREATMENT", 114, 141], ["MDS", "OBSERVATION", 26, 29], ["graft versus host disease", "OBSERVATION", 34, 59], ["allogenic bone marrow transplant", "OBSERVATION", 77, 109], ["chronic", "OBSERVATION_MODIFIER", 114, 121], ["ruxolitinib therapy", "OBSERVATION", 122, 141]]], ["Other noteworthy information included a chronic history of tobacco smoking, alcohol dependence, non-intravenous use of methamphetamines, cholecystectomy, and pancreatic cancer in her father.Case presentationPhysical examination was remarkable only for icteric sclera and mild, generalized abdominal tenderness.", [["pancreatic cancer", "ANATOMY", 158, 175], ["sclera", "ANATOMY", 260, 266], ["abdominal", "ANATOMY", 289, 298], ["smoking", "CHEMICAL", 67, 74], ["alcohol dependence", "DISEASE", 76, 94], ["methamphetamines", "CHEMICAL", 119, 135], ["pancreatic cancer", "DISEASE", 158, 175], ["abdominal tenderness", "DISEASE", 289, 309], ["alcohol", "CHEMICAL", 76, 83], ["tobacco", "ORGANISM", 59, 66], ["alcohol", "SIMPLE_CHEMICAL", 76, 83], ["pancreatic cancer", "CANCER", 158, 175], ["abdominal", "ORGANISM_SUBDIVISION", 289, 298], ["tobacco", "SPECIES", 59, 66], ["methamphetamines", "TREATMENT", 119, 135], ["cholecystectomy", "TREATMENT", 137, 152], ["pancreatic cancer", "PROBLEM", 158, 175], ["Physical examination", "TEST", 207, 227], ["icteric sclera", "PROBLEM", 252, 266], ["mild, generalized abdominal tenderness", "PROBLEM", 271, 309], ["cholecystectomy", "OBSERVATION", 137, 152], ["pancreatic", "ANATOMY", 158, 168], ["cancer", "OBSERVATION", 169, 175], ["sclera", "ANATOMY", 260, 266], ["mild", "OBSERVATION_MODIFIER", 271, 275], ["generalized", "OBSERVATION_MODIFIER", 277, 288], ["abdominal", "ANATOMY", 289, 298], ["tenderness", "OBSERVATION", 299, 309]]], ["Vital sign measurements were unremarkable.", [["Vital sign measurements", "TEST", 0, 23], ["unremarkable", "OBSERVATION", 29, 41]]], ["Laboratory testing showed primarily biochemical evidence of cholestatic and hepatocellular liver injury, as well as pancreatic islet cell dysfunction (Table 1).", [["hepatocellular liver", "ANATOMY", 76, 96], ["pancreatic islet cell", "ANATOMY", 116, 137], ["cholestatic and hepatocellular liver injury", "DISEASE", 60, 103], ["pancreatic islet cell dysfunction", "DISEASE", 116, 149], ["hepatocellular", "PATHOLOGICAL_FORMATION", 76, 90], ["liver", "ORGAN", 91, 96], ["pancreatic islet cell", "CELL", 116, 137], ["Laboratory testing", "TEST", 0, 18], ["cholestatic and hepatocellular liver injury", "PROBLEM", 60, 103], ["pancreatic islet cell dysfunction", "PROBLEM", 116, 149], ["evidence of", "UNCERTAINTY", 48, 59], ["cholestatic", "OBSERVATION", 60, 71], ["hepatocellular", "OBSERVATION", 76, 90], ["liver", "ANATOMY", 91, 96], ["injury", "OBSERVATION", 97, 103], ["pancreatic", "ANATOMY", 116, 126], ["islet cell dysfunction", "OBSERVATION", 127, 149]]], ["Abdominopelvic computed tomography (CT) scans obtained in the emergency department showed a hypo-enhancing lesion within the pancreatic head causing secondary intra- and extrahepatic biliary ductal dilatation (Figure 1).", [["lesion", "ANATOMY", 107, 113], ["pancreatic head", "ANATOMY", 125, 140], ["extrahepatic biliary ductal", "ANATOMY", 170, 197], ["intra- and extrahepatic biliary ductal dilatation", "DISEASE", 159, 208], ["pancreatic head", "ORGAN", 125, 140], ["extrahepatic biliary ductal", "PATHOLOGICAL_FORMATION", 170, 197], ["Abdominopelvic computed tomography (CT) scans", "TEST", 0, 45], ["a hypo-enhancing lesion within the pancreatic head", "PROBLEM", 90, 140], ["secondary intra- and extrahepatic biliary ductal dilatation", "PROBLEM", 149, 208], ["hypo-enhancing", "OBSERVATION_MODIFIER", 92, 106], ["lesion", "OBSERVATION", 107, 113], ["pancreatic", "ANATOMY", 125, 135], ["head", "ANATOMY_MODIFIER", 136, 140], ["secondary", "OBSERVATION_MODIFIER", 149, 158], ["intra", "ANATOMY_MODIFIER", 159, 164], ["extrahepatic", "ANATOMY_MODIFIER", 170, 182], ["biliary ductal", "ANATOMY", 183, 197], ["dilatation", "OBSERVATION", 198, 208]]], ["She was admitted for obstructive jaundice, as well as further evaluation and management of her problems.Case presentationShe underwent a CT scan of the chest to evaluate for metastatic disease, which was unremarkable for any lesions or lymphadenopathy.", [["chest", "ANATOMY", 152, 157], ["metastatic disease", "ANATOMY", 174, 192], ["lesions", "ANATOMY", 225, 232], ["obstructive jaundice", "DISEASE", 21, 41], ["lymphadenopathy", "DISEASE", 236, 251], ["chest", "ORGAN", 152, 157], ["lesions", "PATHOLOGICAL_FORMATION", 225, 232], ["obstructive jaundice", "PROBLEM", 21, 41], ["further evaluation", "TEST", 54, 72], ["management", "TREATMENT", 77, 87], ["her problems", "PROBLEM", 91, 103], ["a CT scan of the chest", "TEST", 135, 157], ["metastatic disease", "PROBLEM", 174, 192], ["any lesions", "PROBLEM", 221, 232], ["lymphadenopathy", "PROBLEM", 236, 251], ["obstructive", "OBSERVATION_MODIFIER", 21, 32], ["jaundice", "OBSERVATION", 33, 41], ["chest", "ANATOMY", 152, 157], ["metastatic", "OBSERVATION", 174, 184], ["lesions", "OBSERVATION", 225, 232], ["lymphadenopathy", "OBSERVATION", 236, 251]]], ["Pancreaticoduodenectomy (Whipple procedure) was performed for symptom management, mass resection, and diagnosis.", [["Pancreaticoduodenectomy (Whipple procedure", "TREATMENT", 0, 42], ["symptom management", "TREATMENT", 62, 80], ["mass resection", "TREATMENT", 82, 96], ["mass resection", "OBSERVATION", 82, 96]]], ["Grossly, a 3.5 x 3.0 x 2.5 cm ill-defined mass was observed to be intruding on the ampulla and common bile duct.", [["mass", "ANATOMY", 42, 46], ["ampulla", "ANATOMY", 83, 90], ["bile duct", "ANATOMY", 102, 111], ["ampulla", "MULTI-TISSUE_STRUCTURE", 83, 90], ["bile duct", "MULTI-TISSUE_STRUCTURE", 102, 111], ["a 3.5 x 3.0 x 2.5 cm ill-defined mass", "PROBLEM", 9, 46], ["3.5 x 3.0 x 2.5 cm", "OBSERVATION_MODIFIER", 11, 29], ["ill-defined", "OBSERVATION_MODIFIER", 30, 41], ["mass", "OBSERVATION", 42, 46], ["ampulla", "ANATOMY_MODIFIER", 83, 90], ["common", "ANATOMY_MODIFIER", 95, 101], ["bile duct", "ANATOMY", 102, 111]]], ["On light microscopy, diffuse sheets of atypical cells with scant cytoplasm, irregular nuclei, and prominent nucleoli were evident.", [["cells", "ANATOMY", 48, 53], ["cytoplasm", "ANATOMY", 65, 74], ["nuclei", "ANATOMY", 86, 92], ["nucleoli", "ANATOMY", 108, 116], ["cells", "CELL", 48, 53], ["cytoplasm", "ORGANISM_SUBSTANCE", 65, 74], ["nuclei", "CELLULAR_COMPONENT", 86, 92], ["nucleoli", "CELLULAR_COMPONENT", 108, 116], ["atypical cells", "CELL_TYPE", 39, 53], ["light microscopy", "TEST", 3, 19], ["diffuse sheets of atypical cells", "PROBLEM", 21, 53], ["scant cytoplasm", "PROBLEM", 59, 74], ["irregular nuclei", "PROBLEM", 76, 92], ["prominent nucleoli", "PROBLEM", 98, 116], ["diffuse", "OBSERVATION_MODIFIER", 21, 28], ["atypical cells", "OBSERVATION", 39, 53], ["scant cytoplasm", "OBSERVATION", 59, 74], ["irregular nuclei", "OBSERVATION", 76, 92], ["prominent", "OBSERVATION_MODIFIER", 98, 107], ["nucleoli", "OBSERVATION", 108, 116]]], ["These cells infiltrated between and through benign pancreatic ducts and acini.", [["cells", "ANATOMY", 6, 11], ["benign pancreatic ducts", "ANATOMY", 44, 67], ["acini", "ANATOMY", 72, 77], ["cells", "CELL", 6, 11], ["pancreatic ducts", "MULTI-TISSUE_STRUCTURE", 51, 67], ["acini", "MULTI-TISSUE_STRUCTURE", 72, 77], ["benign pancreatic ducts and acini", "PROBLEM", 44, 77], ["benign", "OBSERVATION_MODIFIER", 44, 50], ["pancreatic ducts", "ANATOMY", 51, 67], ["acini", "ANATOMY", 72, 77]]], ["Immunohistochemical (IHC) staining on the resected pancreatic tissue revealed the tumor cells were strongly positive with CD43 and CD68 (Figure 2) but only minimally immunoreactive with CD45 and CD117.", [["pancreatic tissue", "ANATOMY", 51, 68], ["tumor cells", "ANATOMY", 82, 93], ["tumor", "DISEASE", 82, 87], ["pancreatic tissue", "TISSUE", 51, 68], ["tumor cells", "CELL", 82, 93], ["CD43", "GENE_OR_GENE_PRODUCT", 122, 126], ["CD68", "GENE_OR_GENE_PRODUCT", 131, 135], ["Figure 2", "GENE_OR_GENE_PRODUCT", 137, 145], ["CD45", "GENE_OR_GENE_PRODUCT", 186, 190], ["CD117", "GENE_OR_GENE_PRODUCT", 195, 200], ["tumor cells", "CELL_TYPE", 82, 93], ["CD43", "PROTEIN", 122, 126], ["CD68", "PROTEIN", 131, 135], ["CD45", "PROTEIN", 186, 190], ["CD117", "PROTEIN", 195, 200], ["Immunohistochemical (IHC) staining", "TEST", 0, 34], ["the resected pancreatic tissue", "TEST", 38, 68], ["the tumor cells", "TEST", 78, 93], ["CD43", "TEST", 122, 126], ["CD68", "TEST", 131, 135], ["Figure", "TEST", 137, 143], ["minimally immunoreactive", "PROBLEM", 156, 180], ["CD45", "TEST", 186, 190], ["CD117", "TEST", 195, 200], ["pancreatic tissue", "ANATOMY", 51, 68], ["tumor", "OBSERVATION", 82, 87], ["minimally", "OBSERVATION_MODIFIER", 156, 165], ["immunoreactive", "OBSERVATION", 166, 180], ["CD117", "OBSERVATION", 195, 200]]], ["The tumors cells were negative for CD3, CD20, and CD34.", [["tumors cells", "ANATOMY", 4, 16], ["tumors", "DISEASE", 4, 10], ["tumors cells", "CELL", 4, 16], ["CD3", "GENE_OR_GENE_PRODUCT", 35, 38], ["CD20", "GENE_OR_GENE_PRODUCT", 40, 44], ["CD34", "GENE_OR_GENE_PRODUCT", 50, 54], ["tumors cells", "CELL_TYPE", 4, 16], ["CD3", "PROTEIN", 35, 38], ["CD20", "PROTEIN", 40, 44], ["CD34", "PROTEIN", 50, 54], ["The tumors cells", "TEST", 0, 16], ["CD3", "TEST", 35, 38], ["CD20", "TEST", 40, 44], ["CD34", "TEST", 50, 54], ["tumors cells", "OBSERVATION", 4, 16], ["negative for", "UNCERTAINTY", 22, 34]]], ["Histochemistry together with this IHC profile supported the diagnosis of pancreatic MS rather than epithelial malignancy.", [["pancreatic MS", "ANATOMY", 73, 86], ["epithelial malignancy", "ANATOMY", 99, 120], ["pancreatic MS", "DISEASE", 73, 86], ["epithelial malignancy", "DISEASE", 99, 120], ["pancreatic MS", "CANCER", 73, 86], ["epithelial malignancy", "CANCER", 99, 120], ["Histochemistry", "TEST", 0, 14], ["this IHC profile", "TEST", 29, 45], ["pancreatic MS", "PROBLEM", 73, 86], ["epithelial malignancy", "PROBLEM", 99, 120], ["pancreatic", "ANATOMY", 73, 83], ["MS", "OBSERVATION", 84, 86], ["epithelial", "ANATOMY_MODIFIER", 99, 109], ["malignancy", "OBSERVATION", 110, 120]]], ["Given the patient\u2019s new diagnosis of an extramedullary myeloid tumor, blood and bone marrow involvement was evaluated by serum analysis and bone marrow aspiration and biopsy.", [["extramedullary myeloid tumor", "ANATOMY", 40, 68], ["blood", "ANATOMY", 70, 75], ["bone marrow", "ANATOMY", 80, 91], ["serum", "ANATOMY", 121, 126], ["bone marrow", "ANATOMY", 140, 151], ["extramedullary myeloid tumor", "DISEASE", 40, 68], ["patient", "ORGANISM", 10, 17], ["extramedullary myeloid tumor", "CANCER", 40, 68], ["blood", "ORGANISM_SUBSTANCE", 70, 75], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 80, 91], ["serum", "ORGANISM_SUBSTANCE", 121, 126], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 140, 151], ["patient", "SPECIES", 10, 17], ["an extramedullary myeloid tumor", "PROBLEM", 37, 68], ["blood and bone marrow involvement", "PROBLEM", 70, 103], ["serum analysis", "TEST", 121, 135], ["bone marrow aspiration", "TEST", 140, 162], ["biopsy", "TEST", 167, 173], ["extramedullary myeloid tumor", "OBSERVATION", 40, 68], ["bone", "ANATOMY", 80, 84], ["marrow involvement", "OBSERVATION", 85, 103], ["bone", "ANATOMY", 140, 144], ["marrow", "ANATOMY", 145, 151], ["aspiration", "OBSERVATION", 152, 162]]], ["Peripheral blood smear as well as bone marrow aspiration and biopsy were negative for an increase in blast cells.", [["Peripheral blood", "ANATOMY", 0, 16], ["bone marrow", "ANATOMY", 34, 45], ["blast cells", "ANATOMY", 101, 112], ["Peripheral blood smear", "ORGANISM_SUBSTANCE", 0, 22], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 34, 45], ["blast cells", "CELL", 101, 112], ["blast cells", "CELL_TYPE", 101, 112], ["Peripheral blood smear", "TEST", 0, 22], ["bone marrow aspiration", "TEST", 34, 56], ["biopsy", "TEST", 61, 67], ["an increase in blast cells", "PROBLEM", 86, 112], ["blood", "ANATOMY", 11, 16], ["smear", "OBSERVATION", 17, 22], ["bone", "ANATOMY", 34, 38], ["marrow", "ANATOMY", 39, 45], ["aspiration", "OBSERVATION", 46, 56], ["negative for", "UNCERTAINTY", 73, 85], ["increase", "OBSERVATION_MODIFIER", 89, 97], ["blast cells", "OBSERVATION", 101, 112]]], ["Bone marrow aspirate was subjected to 17-gene next-generation sequencing assays for AML.", [["Bone marrow aspirate", "ANATOMY", 0, 20], ["AML", "ANATOMY", 84, 87], ["AML", "DISEASE", 84, 87], ["Bone marrow", "MULTI-TISSUE_STRUCTURE", 0, 11], ["AML", "CANCER", 84, 87], ["Bone marrow aspirate", "TEST", 0, 20], ["AML", "PROBLEM", 84, 87], ["marrow", "ANATOMY", 5, 11], ["aspirate", "OBSERVATION", 12, 20]]], ["No mutations were identified (Table 2).Case presentationThe patient tolerated her hospital admission well and was dismissed with instructions to follow up with her local oncologist.", [["patient", "ORGANISM", 60, 67], ["patient", "SPECIES", 60, 67], ["mutations", "PROBLEM", 3, 12], ["mutations", "OBSERVATION", 3, 12]]], ["She remains alive and positron emission tomography (PET)/CT scans will be performed for staging and help guide therapy.", [["positron emission tomography", "TEST", 22, 50], ["PET)/CT scans", "TEST", 52, 65], ["staging", "TEST", 88, 95], ["therapy", "TREATMENT", 111, 118]]], ["Induction chemotherapy is planned following improvement in the coronavirus (COVID-19) pandemic.DiscussionMS is an extramedullary blast cell proliferation of one or more of the myeloid lineages, resulting in disruption of the normal architecture of the tissue in which it originates [5].", [["extramedullary blast cell", "ANATOMY", 114, 139], ["myeloid lineages", "ANATOMY", 176, 192], ["tissue", "ANATOMY", 252, 258], ["coronavirus", "DISEASE", 63, 74], ["coronavirus", "ORGANISM", 63, 74], ["extramedullary blast cell", "CELL", 114, 139], ["myeloid lineages", "CELL", 176, 192], ["tissue", "TISSUE", 252, 258], ["myeloid lineages", "CELL_TYPE", 176, 192], ["Induction chemotherapy", "TREATMENT", 0, 22], ["the coronavirus", "PROBLEM", 59, 74], ["COVID", "TEST", 76, 81], ["pandemic", "PROBLEM", 86, 94], ["an extramedullary blast cell proliferation", "PROBLEM", 111, 153], ["the myeloid lineages", "PROBLEM", 172, 192], ["extramedullary blast cell proliferation", "OBSERVATION", 114, 153], ["myeloid lineages", "OBSERVATION", 176, 192], ["disruption", "OBSERVATION", 207, 217], ["normal", "OBSERVATION", 225, 231], ["architecture", "OBSERVATION_MODIFIER", 232, 244], ["tissue", "ANATOMY", 252, 258]]], ["While MS is listed in the World Health Organization (WHO) as a subtype of AML, in reality it is a distinct entity that warrants further pathological and genetic analysis in an attempt to define its own WHO subclassification [6].", [["AML", "ANATOMY", 74, 77], ["MS", "DISEASE", 6, 8], ["AML", "DISEASE", 74, 77], ["AML", "CANCER", 74, 77], ["AML", "PROBLEM", 74, 77], ["genetic analysis", "TEST", 153, 169], ["AML", "OBSERVATION", 74, 77]]], ["Primarily, MS precedes AML, or both pathologies are discovered simultaneously.", [["AML", "ANATOMY", 23, 26], ["MS", "DISEASE", 11, 13], ["AML", "DISEASE", 23, 26], ["AML", "CANCER", 23, 26], ["AML", "PROBLEM", 23, 26], ["both pathologies", "PROBLEM", 31, 47], ["AML", "OBSERVATION", 23, 26], ["pathologies", "OBSERVATION", 36, 47]]], ["MS may also present de novo, as a relapse of AML, or as a progression of a prior MDS, chronic myeloid leukemia, and other myeloproliferative neoplasms [3,5,6].", [["AML", "ANATOMY", 45, 48], ["chronic myeloid leukemia", "ANATOMY", 86, 110], ["myeloproliferative neoplasms", "ANATOMY", 122, 150], ["MS", "DISEASE", 0, 2], ["AML", "DISEASE", 45, 48], ["MDS", "DISEASE", 81, 84], ["chronic myeloid leukemia", "DISEASE", 86, 110], ["myeloproliferative neoplasms", "DISEASE", 122, 150], ["AML", "CANCER", 45, 48], ["chronic myeloid leukemia", "CANCER", 86, 110], ["myeloproliferative neoplasms", "CANCER", 122, 150], ["AML", "PROBLEM", 45, 48], ["a prior MDS", "PROBLEM", 73, 84], ["chronic myeloid leukemia", "PROBLEM", 86, 110], ["other myeloproliferative neoplasms", "PROBLEM", 116, 150], ["AML", "OBSERVATION", 45, 48], ["chronic", "OBSERVATION_MODIFIER", 86, 93], ["myeloid leukemia", "OBSERVATION", 94, 110], ["myeloproliferative neoplasms", "OBSERVATION", 122, 150]]], ["Isolated MS is extremely rare, with an overall incidence of less than 1% as compared with 2.5-9% in patients with AML [7].", [["AML", "ANATOMY", 114, 117], ["MS", "DISEASE", 9, 11], ["AML", "DISEASE", 114, 117], ["patients", "ORGANISM", 100, 108], ["AML", "CANCER", 114, 117], ["patients", "SPECIES", 100, 108], ["Isolated MS", "PROBLEM", 0, 11], ["AML", "PROBLEM", 114, 117], ["MS", "OBSERVATION", 9, 11], ["rare", "OBSERVATION_MODIFIER", 25, 29], ["AML", "OBSERVATION", 114, 117]]], ["Unlike our patient who had allogenic bone marrow transplant for MDS, the reported incidence of MS following allogenic bone marrow transplant for AML is 5-12% with or without bone marrow involvement [8,9].DiscussionGiven the low incidence of MS, epidemiologic data remain sparse.", [["bone marrow", "ANATOMY", 37, 48], ["bone marrow", "ANATOMY", 118, 129], ["AML", "ANATOMY", 145, 148], ["bone marrow", "ANATOMY", 174, 185], ["MDS", "DISEASE", 64, 67], ["MS", "DISEASE", 95, 97], ["AML", "DISEASE", 145, 148], ["bone marrow involvement", "DISEASE", 174, 197], ["MS", "DISEASE", 241, 243], ["patient", "ORGANISM", 11, 18], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 37, 48], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 118, 129], ["AML", "CANCER", 145, 148], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 174, 185], ["patient", "SPECIES", 11, 18], ["allogenic bone marrow transplant", "TREATMENT", 27, 59], ["MDS", "PROBLEM", 64, 67], ["MS", "PROBLEM", 95, 97], ["allogenic bone marrow transplant", "TREATMENT", 108, 140], ["AML", "PROBLEM", 145, 148], ["bone marrow involvement", "PROBLEM", 174, 197], ["MS", "PROBLEM", 241, 243], ["epidemiologic data", "TEST", 245, 263], ["bone", "ANATOMY", 37, 41], ["marrow transplant", "OBSERVATION", 42, 59], ["bone", "ANATOMY", 118, 122], ["marrow transplant", "OBSERVATION", 123, 140], ["without", "UNCERTAINTY", 166, 173], ["bone", "ANATOMY", 174, 178]]], ["Based on the limited number of large retrospective studies that have reviewed U.S. cases of MS, Caucasian males at an average age of 60 years are at an increased risk of developing this rare condition.", [["MS", "DISEASE", 92, 94], ["males", "ORGANISM", 106, 111], ["large retrospective studies", "TEST", 31, 58], ["MS", "PROBLEM", 92, 94], ["this rare condition", "PROBLEM", 181, 200]]], ["Connective tissue, breasts, integumentary, and digestive system are the most common primary sites [7].", [["Connective tissue", "ANATOMY", 0, 17], ["breasts", "ANATOMY", 19, 26], ["integumentary", "ANATOMY", 28, 41], ["digestive system", "ANATOMY", 47, 63], ["primary sites", "ANATOMY", 84, 97], ["Connective tissue", "TISSUE", 0, 17], ["breasts", "MULTI-TISSUE_STRUCTURE", 19, 26], ["digestive", "ORGAN", 47, 56], ["system", "ANATOMICAL_SYSTEM", 57, 63], ["Connective tissue, breasts, integumentary, and digestive system", "PROBLEM", 0, 63], ["tissue", "OBSERVATION", 11, 17], ["breasts", "ANATOMY", 19, 26], ["integumentary", "ANATOMY", 28, 41], ["digestive system", "ANATOMY", 47, 63]]], ["Ultimately, positive predictors for improved survival are the absence of AML, and MS arising from genitourinary, gastrointestinal, and ocular tissue [10].DiscussionIn the absence of bone marrow involvement, the diagnosis of isolated MS is challenging.", [["AML", "ANATOMY", 73, 76], ["genitourinary", "ANATOMY", 98, 111], ["gastrointestinal", "ANATOMY", 113, 129], ["ocular tissue", "ANATOMY", 135, 148], ["bone marrow", "ANATOMY", 182, 193], ["AML", "DISEASE", 73, 76], ["MS", "DISEASE", 82, 84], ["genitourinary, gastrointestinal, and ocular tissue", "DISEASE", 98, 148], ["MS", "DISEASE", 233, 235], ["AML", "CANCER", 73, 76], ["genitourinary", "ORGAN", 98, 111], ["gastrointestinal", "ORGAN", 113, 129], ["ocular tissue", "TISSUE", 135, 148], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 182, 193], ["AML", "PROBLEM", 73, 76], ["MS arising from genitourinary, gastrointestinal, and ocular tissue", "PROBLEM", 82, 148], ["bone marrow involvement", "PROBLEM", 182, 205], ["isolated MS", "PROBLEM", 224, 235], ["AML", "OBSERVATION", 73, 76], ["genitourinary", "ANATOMY", 98, 111], ["gastrointestinal", "ANATOMY", 113, 129], ["ocular tissue", "ANATOMY", 135, 148], ["bone marrow", "ANATOMY", 182, 193], ["MS", "OBSERVATION", 233, 235]]], ["It is frequently misidentified as one of the more common hematological neoplasms, especially in the setting of conventional light microscopy.", [["hematological neoplasms", "ANATOMY", 57, 80], ["neoplasms", "DISEASE", 71, 80], ["hematological neoplasms", "CANCER", 57, 80], ["the more common hematological neoplasms", "PROBLEM", 41, 80], ["conventional light microscopy", "TEST", 111, 140], ["more", "OBSERVATION_MODIFIER", 45, 49], ["common", "OBSERVATION_MODIFIER", 50, 56], ["hematological", "ANATOMY", 57, 70], ["neoplasms", "OBSERVATION", 71, 80]]], ["Based on the advances in imaging and diagnostic methods, the rate of misdiagnosis has decreased from 75% to 25-50% [4,11].DiscussionTo our knowledge, we report the eighth case of pancreatic MS in a patient without a coexisting or primary hematological malignancy that has been described in the literature [12-14].DiscussionThe presentation of MS can be highly variable.", [["pancreatic MS", "ANATOMY", 179, 192], ["primary hematological malignancy", "ANATOMY", 230, 262], ["misdiagnosis", "DISEASE", 69, 81], ["pancreatic MS", "DISEASE", 179, 192], ["hematological malignancy", "DISEASE", 238, 262], ["MS", "DISEASE", 343, 345], ["pancreatic MS", "CANCER", 179, 192], ["patient", "ORGANISM", 198, 205], ["hematological malignancy", "CANCER", 238, 262], ["patient", "SPECIES", 198, 205], ["imaging", "TEST", 25, 32], ["diagnostic methods", "TEST", 37, 55], ["the rate", "TEST", 57, 65], ["misdiagnosis", "TEST", 69, 81], ["pancreatic MS", "PROBLEM", 179, 192], ["primary hematological malignancy", "PROBLEM", 230, 262], ["MS", "PROBLEM", 343, 345], ["decreased", "OBSERVATION_MODIFIER", 86, 95], ["pancreatic", "ANATOMY", 179, 189], ["MS", "OBSERVATION", 190, 192], ["hematological", "ANATOMY", 238, 251], ["malignancy", "OBSERVATION", 252, 262]]], ["Patients can be asymptomatic or complain of symptoms secondary to tumor mass effect.", [["tumor", "ANATOMY", 66, 71], ["tumor", "DISEASE", 66, 71], ["Patients", "ORGANISM", 0, 8], ["tumor", "CANCER", 66, 71], ["Patients", "SPECIES", 0, 8], ["asymptomatic", "PROBLEM", 16, 28], ["symptoms", "PROBLEM", 44, 52], ["tumor mass effect", "PROBLEM", 66, 83], ["tumor", "OBSERVATION", 66, 71]]], ["Abdominal imaging can be useful but ultimately is not diagnostic due to its inability to distinguish isolated MS from other pathologies, such as pancreatitis.", [["Abdominal", "ANATOMY", 0, 9], ["MS", "DISEASE", 110, 112], ["pancreatitis", "DISEASE", 145, 157], ["Abdominal imaging", "TEST", 0, 17], ["isolated MS", "PROBLEM", 101, 112], ["other pathologies", "PROBLEM", 118, 135], ["pancreatitis", "PROBLEM", 145, 157], ["pathologies", "OBSERVATION", 124, 135], ["pancreatitis", "OBSERVATION", 145, 157]]], ["No tumor markers have been established for this entity, making the diagnosis even more challenging.", [["tumor", "ANATOMY", 3, 8], ["tumor", "DISEASE", 3, 8], ["tumor", "CANCER", 3, 8], ["tumor markers", "TEST", 3, 16], ["tumor", "OBSERVATION", 3, 8]]], ["The gold standards for diagnosing isolated MS are tissue biopsy, histopathological investigation, and IHC staining [1].", [["tissue", "ANATOMY", 50, 56], ["MS", "DISEASE", 43, 45], ["tissue biopsy", "MULTI-TISSUE_STRUCTURE", 50, 63], ["tissue biopsy", "TEST", 50, 63], ["histopathological investigation", "TEST", 65, 96], ["IHC staining", "TEST", 102, 114]]], ["Histologically, MS consists of diffusely infiltrative myeloblasts with granulocytic or monocytic differentiation.", [["diffusely infiltrative myeloblasts", "ANATOMY", 31, 65], ["granulocytic", "ANATOMY", 71, 83], ["monocytic", "ANATOMY", 87, 96], ["MS", "DISEASE", 16, 18], ["myeloblasts", "CELL", 54, 65], ["granulocytic", "CELL", 71, 83], ["monocytic", "CELL", 87, 96], ["diffusely infiltrative myeloblasts", "CELL_TYPE", 31, 65], ["diffusely infiltrative myeloblasts", "PROBLEM", 31, 65], ["granulocytic or monocytic differentiation", "PROBLEM", 71, 112], ["diffusely", "OBSERVATION_MODIFIER", 31, 40], ["infiltrative", "OBSERVATION_MODIFIER", 41, 53], ["myeloblasts", "OBSERVATION", 54, 65], ["granulocytic", "OBSERVATION_MODIFIER", 71, 83], ["monocytic differentiation", "OBSERVATION", 87, 112]]], ["These cells are typically large, have abundant cytoplasm, have large nuclei, and tend to partially or totally efface the tissue architecture.", [["cells", "ANATOMY", 6, 11], ["cytoplasm", "ANATOMY", 47, 56], ["nuclei", "ANATOMY", 69, 75], ["tissue", "ANATOMY", 121, 127], ["cells", "CELL", 6, 11], ["cytoplasm", "ORGANISM_SUBSTANCE", 47, 56], ["nuclei", "CELLULAR_COMPONENT", 69, 75], ["tissue", "TISSUE", 121, 127], ["abundant cytoplasm", "PROBLEM", 38, 56], ["large nuclei", "PROBLEM", 63, 75], ["typically", "OBSERVATION_MODIFIER", 16, 25], ["large", "OBSERVATION_MODIFIER", 26, 31], ["abundant", "OBSERVATION_MODIFIER", 38, 46], ["cytoplasm", "OBSERVATION", 47, 56], ["large", "OBSERVATION_MODIFIER", 63, 68], ["nuclei", "OBSERVATION_MODIFIER", 69, 75], ["tissue", "OBSERVATION", 121, 127]]], ["The presence of eosinophilic metamyelocytes may hint more toward granulocytic differentiation, whereas monocytic neoplasms are more difficult to recognize.", [["eosinophilic metamyelocytes", "ANATOMY", 16, 43], ["granulocytic", "ANATOMY", 65, 77], ["monocytic neoplasms", "ANATOMY", 103, 122], ["monocytic neoplasms", "DISEASE", 103, 122], ["eosinophilic metamyelocytes", "CANCER", 16, 43], ["granulocytic", "CELL", 65, 77], ["monocytic neoplasms", "CANCER", 103, 122], ["eosinophilic metamyelocytes", "PROBLEM", 16, 43], ["monocytic neoplasms", "PROBLEM", 103, 122], ["eosinophilic metamyelocytes", "OBSERVATION", 16, 43], ["more toward", "OBSERVATION_MODIFIER", 53, 64], ["granulocytic differentiation", "OBSERVATION", 65, 93], ["monocytic neoplasms", "OBSERVATION", 103, 122]]], ["In either case, cytochemistry, immunophenotyping, cytogenetics, and molecular studies are imperative [5,15,16].", [["immunophenotyping", "TEST", 31, 48], ["cytogenetics", "TEST", 50, 62], ["molecular studies", "TEST", 68, 85]]], ["The most frequently expressed antigens by MS include CD11c, CD13, CD33, CD34, CD43, CD45, CD56, CD68, CD117, lysozyme, and myeloperoxidase.", [["CD11c", "GENE_OR_GENE_PRODUCT", 53, 58], ["CD13", "GENE_OR_GENE_PRODUCT", 60, 64], ["CD33", "GENE_OR_GENE_PRODUCT", 66, 70], ["CD34", "GENE_OR_GENE_PRODUCT", 72, 76], ["CD43", "GENE_OR_GENE_PRODUCT", 78, 82], ["CD45", "GENE_OR_GENE_PRODUCT", 84, 88], ["CD56", "GENE_OR_GENE_PRODUCT", 90, 94], ["CD68", "GENE_OR_GENE_PRODUCT", 96, 100], ["CD117", "GENE_OR_GENE_PRODUCT", 102, 107], ["lysozyme", "GENE_OR_GENE_PRODUCT", 109, 117], ["myeloperoxidase", "GENE_OR_GENE_PRODUCT", 123, 138], ["CD11c", "PROTEIN", 53, 58], ["CD13", "PROTEIN", 60, 64], ["CD33", "PROTEIN", 66, 70], ["CD34", "PROTEIN", 72, 76], ["CD43", "PROTEIN", 78, 82], ["CD45", "PROTEIN", 84, 88], ["CD56", "PROTEIN", 90, 94], ["CD68", "PROTEIN", 96, 100], ["CD117", "PROTEIN", 102, 107], ["lysozyme", "PROTEIN", 109, 117], ["myeloperoxidase", "PROTEIN", 123, 138], ["CD11c", "TEST", 53, 58], ["CD13", "TEST", 60, 64], ["CD33", "TEST", 66, 70], ["CD34", "TEST", 72, 76], ["CD43", "TEST", 78, 82], ["CD45", "TEST", 84, 88], ["CD56", "TEST", 90, 94], ["CD68", "TEST", 96, 100], ["CD117", "TEST", 102, 107], ["lysozyme", "TEST", 109, 117], ["myeloperoxidase", "TEST", 123, 138], ["CD43", "ANATOMY", 78, 82], ["CD45", "ANATOMY", 84, 88]]], ["Aberrant expression of B-cell or T-cell markers may also be observed [17-19].", [["B-cell", "ANATOMY", 23, 29], ["T-cell", "ANATOMY", 33, 39], ["B-cell", "CELL", 23, 29], ["T-cell", "CELL", 33, 39], ["B-cell or T-cell markers", "PROTEIN", 23, 47], ["B-cell", "OBSERVATION_MODIFIER", 23, 29], ["cell markers", "OBSERVATION", 35, 47]]], ["Once diagnosed, it becomes fundamental to determine whether MS is occurring de novo or coinciding with a myeloid neoplasm.", [["myeloid neoplasm", "ANATOMY", 105, 121], ["MS", "DISEASE", 60, 62], ["myeloid neoplasm", "DISEASE", 105, 121], ["myeloid neoplasm", "CANCER", 105, 121], ["MS", "PROBLEM", 60, 62], ["a myeloid neoplasm", "PROBLEM", 103, 121], ["myeloid neoplasm", "OBSERVATION", 105, 121]]], ["Thus, bone marrow biopsy remains paramount due to highly variable outcomes [12,13].DiscussionComplex cytogenetics occur in about 17% of MS in nonleukemic patients compared with 39% of patients with MS arising in the setting of AML.", [["bone marrow", "ANATOMY", 6, 17], ["AML", "ANATOMY", 227, 230], ["MS", "DISEASE", 136, 138], ["MS", "DISEASE", 198, 200], ["AML", "DISEASE", 227, 230], ["bone marrow biopsy", "MULTI-TISSUE_STRUCTURE", 6, 24], ["patients", "ORGANISM", 154, 162], ["patients", "ORGANISM", 184, 192], ["AML", "CANCER", 227, 230], ["patients", "SPECIES", 154, 162], ["patients", "SPECIES", 184, 192], ["bone marrow biopsy", "TEST", 6, 24], ["MS", "PROBLEM", 136, 138], ["MS arising", "PROBLEM", 198, 208], ["AML", "PROBLEM", 227, 230], ["bone", "ANATOMY", 6, 10], ["marrow", "ANATOMY", 11, 17], ["AML", "OBSERVATION", 227, 230]]], ["Common genetic abnormalities include t(8,21) (q22;q22), inv(16), 11q23, t(9;11), t(8;17), t(8;16), t(8;17), t(1;11), monosomy 7, deletion of chromosomes 5q, 16q, and 20q, and trisomy 4, 8, and 11 [18].", [["inv(16)", "GENE_OR_GENE_PRODUCT", 56, 63], ["monosomy 7", "GENE_OR_GENE_PRODUCT", 117, 127], ["chromosomes 5q", "CELLULAR_COMPONENT", 141, 155], ["16q", "CELLULAR_COMPONENT", 157, 160], ["20q", "CELLULAR_COMPONENT", 166, 169], ["t(8,21) (q22;q22)", "DNA", 37, 54], ["t(8;17)", "DNA", 99, 106], ["t(1;11)", "DNA", 108, 115], ["monosomy 7", "DNA", 117, 127], ["chromosomes 5q, 16q, and 20q", "DNA", 141, 169], ["trisomy 4", "DNA", 175, 184], ["Common genetic abnormalities", "PROBLEM", 0, 28], ["t", "TEST", 37, 38], ["t", "TEST", 99, 100], ["monosomy", "TEST", 117, 125], ["deletion of chromosomes 5q", "PROBLEM", 129, 155], ["trisomy", "TEST", 175, 182], ["abnormalities", "OBSERVATION", 15, 28]]], ["Involvement of some particular extramedullary sites is associated with certain abnormalities, such as MS of the abdomen and inv(16) [15-19].DiscussionInitiating treatment in a timely manner is of utmost importance in isolated MS to prevent or reduce the risk of progression to leukemia.", [["extramedullary sites", "ANATOMY", 31, 51], ["abdomen", "ANATOMY", 112, 119], ["leukemia", "ANATOMY", 277, 285], ["MS of the abdomen", "DISEASE", 102, 119], ["MS", "DISEASE", 226, 228], ["leukemia", "DISEASE", 277, 285], ["extramedullary sites", "MULTI-TISSUE_STRUCTURE", 31, 51], ["abdomen", "ORGAN", 112, 119], ["leukemia", "CANCER", 277, 285], ["some particular extramedullary sites", "PROBLEM", 15, 51], ["certain abnormalities", "PROBLEM", 71, 92], ["MS of the abdomen", "TEST", 102, 119], ["treatment", "TREATMENT", 161, 170], ["leukemia", "PROBLEM", 277, 285], ["some", "OBSERVATION_MODIFIER", 15, 19], ["particular", "OBSERVATION_MODIFIER", 20, 30], ["extramedullary sites", "OBSERVATION", 31, 51], ["abdomen", "ANATOMY", 112, 119], ["leukemia", "OBSERVATION", 277, 285]]], ["In most isolated pancreatic cases, a final diagnosis is obtained following surgical resection and histopathology interpretation of the lesion, such as in our patient.", [["pancreatic", "ANATOMY", 17, 27], ["lesion", "ANATOMY", 135, 141], ["pancreatic", "CANCER", 17, 27], ["patient", "ORGANISM", 158, 165], ["patient", "SPECIES", 158, 165], ["surgical resection", "TREATMENT", 75, 93], ["histopathology interpretation", "TEST", 98, 127], ["the lesion", "PROBLEM", 131, 141], ["pancreatic", "ANATOMY", 17, 27], ["cases", "OBSERVATION", 28, 33], ["resection", "OBSERVATION", 84, 93], ["lesion", "OBSERVATION", 135, 141]]], ["However, recently endoscopic ultrasound with fine needle aspiration has determined to be useful or pancreatic mass sampling [12].", [["pancreatic mass", "ANATOMY", 99, 114], ["pancreatic", "ORGAN", 99, 109], ["recently endoscopic ultrasound", "TEST", 9, 39], ["fine needle aspiration", "TEST", 45, 67], ["pancreatic mass sampling", "PROBLEM", 99, 123], ["pancreatic", "ANATOMY", 99, 109], ["mass", "OBSERVATION", 110, 114]]], ["Also, it would avoid unnecessary invasive surgical interventions and complications and subsequently improve prognosis by initiating chemotherapy earlier.DiscussionBased on previous institutional studies, the median time to develop AML from extramedullary MS ranged from 5 to 12 months [11].", [["AML", "ANATOMY", 231, 234], ["AML", "DISEASE", 231, 234], ["MS", "DISEASE", 255, 257], ["AML", "CANCER", 231, 234], ["unnecessary invasive surgical interventions", "TREATMENT", 21, 64], ["complications", "PROBLEM", 69, 82], ["chemotherapy", "TREATMENT", 132, 144], ["previous institutional studies", "TEST", 172, 202], ["AML", "PROBLEM", 231, 234], ["extramedullary MS", "PROBLEM", 240, 257], ["AML", "OBSERVATION", 231, 234], ["extramedullary MS", "OBSERVATION", 240, 257]]], ["Thus, the current National Comprehensive Cancer Network guidelines recommend initially treating extramedullary MS with induction chemotherapy similar to that for patients with overt AML.", [["AML", "ANATOMY", 182, 185], ["Cancer", "DISEASE", 41, 47], ["MS", "DISEASE", 111, 113], ["AML", "DISEASE", 182, 185], ["patients", "ORGANISM", 162, 170], ["overt AML", "CANCER", 176, 185], ["patients", "SPECIES", 162, 170], ["extramedullary MS", "PROBLEM", 96, 113], ["induction chemotherapy", "TREATMENT", 119, 141], ["overt AML", "PROBLEM", 176, 185], ["AML", "OBSERVATION", 182, 185]]], ["This also applies to MS cases with concurrent bone marrow involvement.", [["bone marrow", "ANATOMY", 46, 57], ["MS", "DISEASE", 21, 23], ["bone marrow involvement", "DISEASE", 46, 69], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 46, 57], ["MS cases", "PROBLEM", 21, 29], ["concurrent bone marrow involvement", "PROBLEM", 35, 69], ["bone", "ANATOMY", 46, 50], ["marrow involvement", "OBSERVATION", 51, 69]]], ["Despite the fact that isolated pancreatic MS can be treated with radiotherapy or surgical resection, AML-type remission induction chemotherapy is mandatory after resection of the isolated MS lesion.", [["pancreatic MS", "ANATOMY", 31, 44], ["AML", "ANATOMY", 101, 104], ["MS lesion", "ANATOMY", 188, 197], ["pancreatic MS", "DISEASE", 31, 44], ["AML", "DISEASE", 101, 104], ["MS", "DISEASE", 188, 190], ["pancreatic MS", "CANCER", 31, 44], ["AML", "CANCER", 101, 104], ["isolated pancreatic MS", "PROBLEM", 22, 44], ["radiotherapy", "TREATMENT", 65, 77], ["surgical resection", "TREATMENT", 81, 99], ["AML-type remission induction chemotherapy", "TREATMENT", 101, 142], ["resection", "TREATMENT", 162, 171], ["the isolated MS lesion", "PROBLEM", 175, 197], ["pancreatic", "ANATOMY", 31, 41], ["MS", "OBSERVATION", 42, 44], ["resection", "OBSERVATION", 90, 99], ["isolated", "OBSERVATION_MODIFIER", 179, 187], ["MS", "OBSERVATION_MODIFIER", 188, 190], ["lesion", "OBSERVATION", 191, 197]]], ["Otherwise, MS would recur [12,15-19].", [["MS", "DISEASE", 11, 13]]], ["In addition, time to progression to acute leukemia has been shown to be longer in those treated with systemic chemotherapy as opposed to local radiotherapy or surgery [11].", [["acute leukemia", "ANATOMY", 36, 50], ["acute leukemia", "DISEASE", 36, 50], ["acute leukemia", "CANCER", 36, 50], ["acute leukemia", "PROBLEM", 36, 50], ["systemic chemotherapy", "TREATMENT", 101, 122], ["local radiotherapy", "TREATMENT", 137, 155], ["surgery", "TREATMENT", 159, 166], ["acute", "OBSERVATION_MODIFIER", 36, 41], ["leukemia", "OBSERVATION", 42, 50]]], ["Several retrospective studies have demonstrated the efficacy of allogenic stem cell transplant in isolated MS cases, especially after inducing remission.", [["stem cell", "ANATOMY", 74, 83], ["MS", "DISEASE", 107, 109], ["allogenic stem cell", "CELL", 64, 83], ["Several retrospective studies", "TEST", 0, 29], ["allogenic stem cell transplant", "TREATMENT", 64, 94], ["isolated MS cases", "PROBLEM", 98, 115], ["allogenic stem cell transplant", "OBSERVATION", 64, 94]]], ["However, there are no controlled clinical trials to evaluate the role of this mode of therapy in this setting [1,4].ConclusionsIsolated MS is a rare condition and may occur at any site, leading to widely variable clinical presentations based on the tumor site, size, and extent of tissue involvement.", [["tumor", "ANATOMY", 249, 254], ["tissue", "ANATOMY", 281, 287], ["MS", "DISEASE", 136, 138], ["tumor", "DISEASE", 249, 254], ["tumor", "CANCER", 249, 254], ["tissue", "TISSUE", 281, 287], ["therapy", "TREATMENT", 86, 93], ["a rare condition", "PROBLEM", 142, 158], ["the tumor site", "PROBLEM", 245, 259], ["tissue involvement", "PROBLEM", 281, 299], ["no", "UNCERTAINTY", 19, 21], ["widely", "OBSERVATION_MODIFIER", 197, 203], ["variable", "OBSERVATION_MODIFIER", 204, 212], ["tumor", "OBSERVATION", 249, 254], ["size", "OBSERVATION_MODIFIER", 261, 265], ["extent", "OBSERVATION_MODIFIER", 271, 277], ["tissue involvement", "OBSERVATION", 281, 299]]], ["It should, therefore, be considered as a differential diagnosis of any atypical cellular infiltrate.", [["cellular", "ANATOMY", 80, 88], ["cellular", "CELL", 80, 88], ["any atypical cellular infiltrate", "PROBLEM", 67, 99], ["atypical", "OBSERVATION_MODIFIER", 71, 79], ["cellular", "OBSERVATION_MODIFIER", 80, 88], ["infiltrate", "OBSERVATION", 89, 99]]], ["The use of auxiliary studies (cytochemistry, cytogenetics, and molecular analysis) is essential for diagnosis.", [["auxiliary studies", "TEST", 11, 28], ["cytogenetics", "TEST", 45, 57], ["molecular analysis", "TEST", 63, 81]]], ["Additionally, bone marrow sampling is necessary to exclude morrow involvement.", [["bone marrow", "ANATOMY", 14, 25], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 14, 25], ["bone marrow sampling", "TEST", 14, 34], ["morrow involvement", "PROBLEM", 59, 77], ["bone", "ANATOMY", 14, 18]]], ["As for management, AML-type chemotherapy for remission induction should be used for MS (whether isolated or co-occurring with bone marrow involvement).", [["AML", "ANATOMY", 19, 22], ["bone marrow", "ANATOMY", 126, 137], ["AML", "DISEASE", 19, 22], ["MS", "DISEASE", 84, 86], ["bone marrow involvement", "DISEASE", 126, 149], ["AML", "CANCER", 19, 22], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 126, 137], ["management", "TREATMENT", 7, 17], ["AML-type chemotherapy", "TREATMENT", 19, 40], ["remission induction", "TREATMENT", 45, 64], ["MS", "PROBLEM", 84, 86], ["bone marrow involvement", "PROBLEM", 126, 149]]], ["Moreover, relapsing MS should be treated similar to relapsed AML.", [["AML", "ANATOMY", 61, 64], ["MS", "DISEASE", 20, 22], ["AML", "DISEASE", 61, 64], ["AML", "CANCER", 61, 64], ["relapsing MS", "PROBLEM", 10, 22], ["relapsed AML", "PROBLEM", 52, 64], ["relapsed AML", "OBSERVATION", 52, 64]]], ["Post-remission therapy includes radiotherapy and chemotherapy depending on the extent of involvement, performance status, and risk profile.", [["Post-remission therapy", "TREATMENT", 0, 22], ["radiotherapy", "TREATMENT", 32, 44], ["chemotherapy", "TREATMENT", 49, 61]]], ["Randomized controlled trials are needed to elucidate the role of allogenic stem cell transplant and to further refine management protocols.", [["stem cell", "ANATOMY", 75, 84], ["allogenic stem cell", "CELL", 65, 84], ["Randomized controlled trials", "TREATMENT", 0, 28], ["allogenic stem cell transplant", "TREATMENT", 65, 95], ["management protocols", "TREATMENT", 118, 138], ["allogenic stem cell transplant", "OBSERVATION", 65, 95]]], ["Recent advances in genetic profiling may enable the development of novel targeted therapies.", [["genetic profiling", "TEST", 19, 36], ["novel targeted therapies", "TREATMENT", 67, 91]]], ["The prognostic factors and outcomes of extramedullary MS, apart from relapse and AML transformation, remain poorly understood.", [["AML", "ANATOMY", 81, 84], ["MS", "DISEASE", 54, 56], ["AML", "DISEASE", 81, 84], ["extramedullary MS", "CANCER", 39, 56], ["AML", "CANCER", 81, 84], ["The prognostic factors", "PROBLEM", 0, 22], ["extramedullary MS", "PROBLEM", 39, 56], ["relapse", "PROBLEM", 69, 76], ["AML transformation", "PROBLEM", 81, 99], ["extramedullary MS", "OBSERVATION", 39, 56], ["AML transformation", "OBSERVATION", 81, 99]]]], "PMC7102055": [["IntroductionAdvances in therapy for malignancies, autoimmune disorders, and end-stage organ diseases have lead to improved survival, but also to an increase in the number of immunosuppressed patients (ISP).", [["malignancies", "ANATOMY", 36, 48], ["organ", "ANATOMY", 86, 91], ["malignancies", "DISEASE", 36, 48], ["autoimmune disorders", "DISEASE", 50, 70], ["end-stage organ diseases", "DISEASE", 76, 100], ["immunosuppressed", "DISEASE", 174, 190], ["malignancies", "CANCER", 36, 48], ["organ", "ORGAN", 86, 91], ["patients", "ORGANISM", 191, 199], ["patients", "SPECIES", 191, 199], ["Advances in therapy", "TREATMENT", 12, 31], ["malignancies", "PROBLEM", 36, 48], ["autoimmune disorders", "PROBLEM", 50, 70], ["end-stage organ diseases", "PROBLEM", 76, 100], ["organ", "ANATOMY", 86, 91], ["diseases", "OBSERVATION", 92, 100], ["increase", "OBSERVATION_MODIFIER", 148, 156]]], ["These patients are at risk for opportunistic infections and also for community-acquired infections, such as respiratory virus infections, with considerable related morbidity and mortality [1\u20133].IntroductionIn April 2009, a novel influenza A (H1N1) virus was identified and propragated throughout the world [4].", [["opportunistic infections", "DISEASE", 31, 55], ["infections", "DISEASE", 88, 98], ["respiratory virus infections", "DISEASE", 108, 136], ["influenza A (H1N1) virus", "DISEASE", 229, 253], ["patients", "ORGANISM", 6, 14], ["influenza A (H1N1) virus", "ORGANISM", 229, 253], ["patients", "SPECIES", 6, 14], ["influenza A (H1N1) virus", "SPECIES", 229, 253], ["influenza A (H1N1) virus", "SPECIES", 229, 253], ["opportunistic infections", "PROBLEM", 31, 55], ["community-acquired infections", "PROBLEM", 69, 98], ["respiratory virus infections", "PROBLEM", 108, 136], ["considerable related morbidity", "PROBLEM", 143, 173], ["a novel influenza A (H1N1) virus", "PROBLEM", 221, 253], ["opportunistic", "OBSERVATION_MODIFIER", 31, 44], ["infections", "OBSERVATION", 45, 55], ["infections", "OBSERVATION", 88, 98], ["respiratory virus", "OBSERVATION", 108, 125]]], ["Clinical findings of influenza A 2009 (H1N1) virus infection were similar to those of seasonal influenza, with many patients having mild illness [5].", [["influenza A 2009 (H1N1) virus infection", "DISEASE", 21, 60], ["influenza", "DISEASE", 95, 104], ["illness", "DISEASE", 137, 144], ["influenza A 2009 (H1N1) virus", "ORGANISM", 21, 50], ["patients", "ORGANISM", 116, 124], ["H1N1) virus", "SPECIES", 39, 50], ["patients", "SPECIES", 116, 124], ["influenza A 2009 (H1N1) virus", "SPECIES", 21, 50], ["influenza A", "PROBLEM", 21, 32], ["H1N1) virus infection", "PROBLEM", 39, 60], ["seasonal influenza", "PROBLEM", 86, 104], ["mild illness", "PROBLEM", 132, 144], ["influenza", "OBSERVATION", 21, 30], ["influenza", "OBSERVATION", 95, 104], ["mild", "OBSERVATION_MODIFIER", 132, 136], ["illness", "OBSERVATION", 137, 144]]], ["However, severe cases occurred, with over 18,000 patients dying throughout the world.", [["patients", "ORGANISM", 49, 57], ["patients", "SPECIES", 49, 57], ["severe cases", "PROBLEM", 9, 21], ["severe", "OBSERVATION_MODIFIER", 9, 15], ["cases", "OBSERVATION", 16, 21]]], ["Among hospitalized patients with severe influenza A 2009 (H1N1), 15\u201320% were immunosuppressed [6, 7].", [["patients", "ORGANISM", 19, 27], ["patients", "SPECIES", 19, 27], ["severe influenza A", "PROBLEM", 33, 51]]], ["Given the behavior of seasonal flu in ISP, a higher number of influenza-related complications in this population could be expected [3, 6, 8, 9].", [["influenza", "DISEASE", 62, 71], ["seasonal flu in ISP", "PROBLEM", 22, 41], ["influenza", "PROBLEM", 62, 71], ["seasonal", "OBSERVATION_MODIFIER", 22, 30], ["flu", "OBSERVATION", 31, 34], ["influenza", "OBSERVATION", 62, 71]]], ["However, data regarding clinical features and outcomes in non-human immunodeficiency virus (HIV) ISP are needed.", [["non-human immunodeficiency virus (HIV) ISP", "DISEASE", 58, 100], ["non-human immunodeficiency virus", "ORGANISM", 58, 90], ["non-human immunodeficiency virus", "SPECIES", 58, 90], ["non-human immunodeficiency virus", "SPECIES", 58, 90], ["HIV", "SPECIES", 92, 95], ["clinical features", "PROBLEM", 24, 41], ["non-human immunodeficiency virus", "PROBLEM", 58, 90]]], ["The objective of this investigation was to prospectively characterize the clinical manifestations and outcomes of influenza A 2009 (H1N1) virus infection in ISP.Setting, study subjects, and study design ::: MethodsThis prospective cohorts observational study was conducted at 13 teaching hospitals belonging to the Spanish Network for Research in Infectious Diseases (REIPI).", [["influenza A 2009 (H1N1) virus infection", "DISEASE", 114, 153], ["Infectious Diseases", "DISEASE", 347, 366], ["influenza A 2009 (H1N1) virus", "ORGANISM", 114, 143], ["H1N1) virus", "SPECIES", 132, 143], ["influenza A 2009 (H1N1) virus", "SPECIES", 114, 143], ["this investigation", "TEST", 17, 35], ["the clinical manifestations", "PROBLEM", 70, 97], ["influenza A 2009 (H1N1) virus infection in ISP", "PROBLEM", 114, 160], ["Methods", "TREATMENT", 207, 214], ["observational study", "TEST", 239, 258]]], ["All patients older than 16 years of age admitted to the hospital with confirmed pandemic influenza A 2009 (H1N1) virus infection from June 12, 2009 to November 11, 2009 were included.", [["influenza A 2009 (H1N1) virus infection", "DISEASE", 89, 128], ["patients", "ORGANISM", 4, 12], ["influenza A 2009 (H1N1) virus", "ORGANISM", 89, 118], ["patients", "SPECIES", 4, 12], ["H1N1) virus", "SPECIES", 107, 118], ["pandemic influenza A 2009 (H1N1) virus", "SPECIES", 80, 118], ["pandemic influenza A", "PROBLEM", 80, 100], ["H1N1) virus infection", "PROBLEM", 107, 128], ["influenza", "OBSERVATION", 89, 98]]], ["A confirmed case was defined in the presence of influenza-like illness with laboratory-confirmed pandemic influenza A 2009 (H1N1) virus infection.", [["influenza-like illness", "DISEASE", 48, 70], ["influenza A 2009 (H1N1) virus infection", "DISEASE", 106, 145], ["influenza A 2009 (H1N1) virus", "ORGANISM", 106, 135], ["H1N1) virus", "SPECIES", 124, 135], ["pandemic influenza A 2009 (H1N1) virus", "SPECIES", 97, 135], ["influenza", "PROBLEM", 48, 57], ["pandemic influenza A", "PROBLEM", 97, 117], ["H1N1) virus infection", "PROBLEM", 124, 145], ["influenza", "OBSERVATION", 48, 57]]], ["Pandemic influenza A 2009 (H1N1) virus testing was performed in each institution.", [["Pandemic influenza A 2009 (H1N1) virus", "ORGANISM", 0, 38], ["H1N1) virus", "SPECIES", 27, 38], ["Pandemic influenza A 2009 (H1N1) virus", "SPECIES", 0, 38], ["Pandemic influenza A", "PROBLEM", 0, 20], ["virus testing", "TEST", 33, 46]]], ["The study was approved by the coordinator local ethics committee and informed consent was obtained from all subjects.Clinical assessment and follow up ::: MethodsMicrobiological studies, hospital and intensive care unit (ICU) admission criteria, and treatment decisions were not standardized and were made by attending physicians at each study center.", [["The study", "TEST", 0, 9], ["Clinical assessment", "TEST", 117, 136]]], ["Patients were seen during their hospital stay by one or more of the investigators at each participating hospital, who recorded the clinical data in a standardized, computer-assisted protocol.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["computer-assisted protocol", "TREATMENT", 164, 190]]], ["Data were collected on demographic characteristics, co-morbidities, body mass index (BMI), previous vaccination, clinical signs and symptoms, laboratory analysis, chest X-ray findings, antiviral and antibacterial therapy, concomitant and/or secondary infection, time to clinical stability, and outcomes, including readmissions (<30 days) and mortality.", [["body", "ANATOMY", 68, 72], ["infection", "DISEASE", 251, 260], ["body", "ORGANISM_SUBDIVISION", 68, 72], ["demographic characteristics", "TEST", 23, 50], ["co-morbidities", "PROBLEM", 52, 66], ["body mass index", "TEST", 68, 83], ["previous vaccination", "TREATMENT", 91, 111], ["clinical signs", "TEST", 113, 127], ["symptoms", "PROBLEM", 132, 140], ["laboratory analysis", "TEST", 142, 161], ["chest X-ray findings", "TEST", 163, 183], ["antiviral", "TREATMENT", 185, 194], ["antibacterial therapy", "TREATMENT", 199, 220], ["secondary infection", "PROBLEM", 241, 260], ["chest", "ANATOMY", 163, 168], ["antibacterial therapy", "OBSERVATION", 199, 220], ["secondary", "OBSERVATION_MODIFIER", 241, 250], ["infection", "OBSERVATION", 251, 260]]], ["A senior investigator validated all data.Definitions ::: Methods", [["Methods", "TREATMENT", 57, 64]]]]}